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Abstract 
 
Sequential use of targeted therapies has significantly improved overall survival in 
metastatic clear cell renal cell carcinoma (ccRCC) but durable responses remain rare. 
Improved prognostic and predictive algorithms are required.  
 
3p loss is near ubiquitous in ccRCC. Functions of LIMD1 include regulation of 
hypoxia-inducible factors and microRNA-mediated gene silencing.  LIMD1 
loss/deregulation contributes to lung tumour formation and is associated with poor 
prognosis in breast cancer. The closely related family members, WTIP and Ajuba also 
regulate the hypoxic response and mediate micro-RNA silencing.  Ajuba regulates the 
Hippo signaling pathway, controlling cell cycle and proliferation.  
 
In vivo, loss of LIMD1 was observed in 49% of ccRCC samples.  76% of ccRCC 
tumours demonstrated reduced Ajuba staining and nuclear WTIP staining was reduced 
in 73% of tumours compared to matched control.  Co-loss of LIMD1/Ajuba/WTIP 
was common.  Using patient-derived tumour tissue from two prospective clinical trials, 
LIMD1, Ajuba and WTIP staining was correlated with clinico-pathological outcome 
data. With the exception of loss of Ajuba staining and tumour stage, staining and 
outcome data did not correlate.  
 
The effects of LIMD1 loss on tumourigenesis were investigated using a paired lentiviral 
transduction system in ccRCC lines. LIMD1 loss did not affect cell migration, or cell 
cycle, however loss of LIMD1 was associated with greater hypoxic deregulation. A 
CRISPR-Cas-9 gene editing system was used to successfully knockout LIMD1 and 
Ajuba in a renal primary cell line.   
 
Using a drug-screening platform, the topoisomerase-I inhibitor irinotecan was identified 
as a potentially synthetically lethal drug in association with LIMD1 loss. This was 
validated in a further ccRCC line and in non-renal lines.  
  
Exploiting synthetic lethal approaches in ccRCC treatment has not been widely 
explored.  Our data suggests that loss of LIMD1/Ajuba/WTIP is common and could 
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represent a predictive biomarker such that tumours with loss/low expression could be 
selectively targeted.  
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PRISMA  Preferred reporting items for systematic review 
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RISC  RNA silencing construct 
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siRNA  Short interfering RNA 
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TCGA  The Cancer Genome Atlas 
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TRAF  TNF-receptor associated factors 
TSG  Tumour suppressor gene 
TSP  Tumour suppressor protein 
UISS  University of California Los Angeles Integrated Staging  
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1.1 LIM proteins 
 
The LIM domain is a tandem zinc-finger structure that functions as a modular protein-
binding interface (Kadrmas and Beckerle 2004). Rich in cysteine and histidine residues, 
and common to a small group of homeo-domain transcription factors, the LIM domain 
is known to be critical in mediating protein-protein interactions and is present in a wide 
variety of eukaryotic proteins with diverse biological functions (Feuerstein, Wang et al. 
1994, Pawson and Nash 2003). Specificity of binding of target proteins enables LIM 
proteins to fulfil a wide array of biological functions (Wu, Durick et al. 1996).  
 
Individual LIM domains are made up of approximately 55 amino acids with 8 highly 
conserved predominantly cysteine and histidine residues located at defined intervals 
(Kadrmas and Beckerle 2004). Several LIM proteins are localised only in the nucleus 
and have clear transcriptional roles during development, most however can interact with 
the actin cytoskeleton and shuttle between the nucleus and the cytoplasm modulating 
communication between cytoplasmic and nuclear compartments (Nix, Fradelizi et al. 
2001, Kadrmas and Beckerle 2004).   
 
LIMD1, Wilms tumour-1 interacting protein (WTIP) and Ajuba are members of the 
Zyxin family of LIM-domain containing proteins, proteins with both nuclear and 
cytosolic localisation domains that function as important scaffold proteins (Kadrmas 
and Beckerle 2004).   
 
1.2 The Zyxin family of LIM domain containing proteins 
 
There are seven members of the Zyxin family of LIM-domain containing proteins.  
Phylogenetic analysis sub-divides the family into the Ajuba sub-family, comprising 
LIMD1, Ajuba and WTIP, and the Zyxin sub-family, LPP, Trip6, Zyxin and migfilin 
Proteins in each sub-family have differential roles, with members of the Zyxin family 
preferentially localising to sites of cell adhesion, where they play a critical role in 
mediating cytoskeletal arrangements (Kadrmas and Beckerle 2004). Members of the 
Ajuba family localise to both the cytoplasm and the nucleus (Kadrmas and Beckerle 
2004).  
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1.2.1 LIMD1, Ajuba and WTIP 
 
Located on chromosome 3p21.3, LIMD1 has eight exons, encoding a 676 amino-acid 
protein with a pre-LIM and LIM domain-containing region.  The proline/serine rich 
pre-LIM region contains a nuclear export signal (NES), whilst the LIM domain region 
retains conserved LIM domain regions required for nuclear localisation properties 
(Figure 1.1).  (Sharp, Munoz et al. 2004, Sharp, Al-Attar et al. 2008). 
 
 LIMD1, like other LIM domain containing proteins shuttles between the nucleus and 
cytoplasm, the equilibrium of which is towards nuclear export (Kadrmas and Beckerle 
2004). Its stable structural core helps facilitate high-affinity binding to specific protein 
partners, facilitating its role as an adapter protein (Kadrmas and Beckerle 2004).  
 
Ajuba, located on chromosome 14q11.2, encodes a 538-amino acid protein, which 
shares considerable homology with LIMD1. Ajuba contains the characteristic tandemly 
arranged LIM domains in the C-terminus and has both a pre-LIM encoded NES and a 
LIM domain encoded nuclear localisation signal (NLS) critical for its role in signal 
transduction (Figure 1.1).  
 
The 430 amino acid protein WTIP is 19q13.1 encoded and acts as a binding partner of 
the Wilms tumour protein (WT1), a transcription factor essential for normal nephron 
formation. Again, WTIP contains both NES and NLS and shuttles between the nucleus 
and cytoplasm, the C terminal PDZ domain, plays a key role in the formation and 
function of signal transduction complexes (Figure 1.1).  Within the nucleus, WTIP 
represses WT1 activated transcription (Srichai, Konieczkowski et al. 2004).    
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Figure 1.1: Schemata of LIMD1, Ajuba and WTIP structure. The pre-LIM region is 
proline/serine rich and encodes a nuclear export signal (NES). The LIM domain region contains a NLS 
and tandem zinc-finger motifs critical in mediating protein-protein interactions.  WTIP contains a PDZ 
domain, a common structural domain that plays a key role in the formation and function of signal 
transduction complexes.   
1.3. Loss of chromosome 3 commonly eliminated region (C3CER1) in 
tumourigenesis 
Imrie et al used an elimination test assay to demonstrate that 3p21.3 chromosomal loss 
is frequent through loss of heterozygosity (LOH), driving malignant growth in severe 
combined immuno-deficiency (SCID) mice. After four passages in SCID mice, 
microcell hybrids originally containing an intact chromosome 3 generated from two 
alternative donors were analysed by comparative chromosome painting, reverse painting 
and polymerase chain reaction (PCR) marker analysis. Analysis demonstrated frequent 
loss of 3p with associated preservation of 3q (Kholodnyuk, Kost-Alimova et al. 1997).  
 
 More recent studies have demonstrated that the 3p21.3 region is frequently lost by 
LOH in many human tumours, in particular breast, lung, gastric, colorectal, ovarian, 
renal and head and neck carcinomas and it has consequently become known as the 
chromosome 3, commonly eliminated region 1 (C3CER1) (Lerman and Minna 2000, 
Yang, Yoshimura et al. 2002, Chakraborty, Dasgupta et al. 2003, Petursdottir, 
Thorsteinsdottir et al. 2004). The C3CER1 spans approximately 2.4 Mega bases and 
contains 32 genes, including the tumour suppressor gene LIMD1 (Kost-Alimova and 
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Imreh 2007). Although a number of roles for LIMD1 have been characterised, relatively 
little is known about how loss/deregulation contributes to cellular transformation and 
tumourigenesis.  
 
1.4 LIMD1 loss/deregulation is associated with tumourigenesis in a number of 
solid malignancies 
 
1.4.1 LIMD1 loss in lung carcinoma 
 
In lung carcinoma, LIMD1 loss has been characterised as playing a critical role in 
tumourigenesis (Sharp, Al-Attar et al. 2008). In a panel of 100 human lung squamous 
cell carcinomas (SCCs), the majority of tumours stained immunohistochemically for 
LIMD1 had reduced LIMD1 staining compared to matched non-cancerous, control 
tissue (Sharp, Al-Attar et al. 2008). In lung adenocarcinoma (ADC), comparison of 
LIMD1 mRNA levels between ADC and adjacent normal alveolar epithelium 
demonstrated lower levels of LIMD1 mRNA in tumour compared to the matched, 
control tissue (Sharp, Munoz et al. 2004).  
 
 Limd1-/- mice challenged with the carcinogen urethane developed more tumours, which 
were also of increased size compared to wild type Limd1 proficient mice (Sharp, Al-
Attar et al. 2008). When Limd1-/- mice were bred with mice expressing oncogenic K-
RasG12D, mice heterozygous for K-RasG12D developed a greatly increased tumour number 
and tumour volume compared to control Limd1+/+ mice heterozygous for K-RasG12D 
when exposed to the carcinogen urethane. Loss of Limd1 in these mice increased 
mortality: at 12 months K-RasG12D/Limd1-/- mice had a 90% mortality rate compared to 
30% in the K-RasG12D/Limd1+/+ mice (Sharp, Al-Attar et al. 2008) (Figure 1.2).  
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Figure 1.2 Deletion of Limd1  increases mortality in K-RasG12D mice. Limd1-/- mice 
heterozygous for K-RasG12D developed more tumours than Limd1+/+ mice expressing oncogenic K-RasG12D 
after urethane challenge. Limd1 deficient mice had a significantly shorter OS compared to Limd1 
proficient control. Taken from (Sharp, Al-Attar et al. 2008) 
 
In lung ADC, interrogation of the National Human Genome Research Institute 
(NHGRI) sponsored tumour sequencing project revealed that copy number alterations 
of LIMD1 were common, with LIMD1 deletions occurring in 32% of tumours 
compared to matched control tissue.  However, sequencing of all 8 exons and intron-
exon boundaries revealed no LIMD1 mutations in the 188 ADC samples. Deletion of 
LIMD1 was observed more commonly than for some other frequently deleted genes in 
the C3CER1 region and occurred more commonly than that observed for known lung 
tumour suppressor genes e.g. p53 (Figure 1.3) (Sharp, Al-Attar et al. 2008). 
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        C3CER1 
    (3p21.3 genes) 
 
Figure 1.3 LIMD1  gene deletion and surrounding 3p21.3 genes in human lung 
adenocarcinomas 
 Histogram demonstrating the percentage gene deletion for the indicated C3CER1 gene cluster as 
determined by interrogation of the NHGRI-sponsored tumour suppressor protein (TSP) dataset of lung 
adenocarcinoma tumour compared to matched, normal tissue. Indicated genes are arranged relative to 
their 3p21.3 spatial location. For reference, other known tumour suppressor genes (TSGs) (p53 and Rb) 
and putative 3p TSG deletions are shown. Taken from (Sharp, Al-Attar et al. 2008).  
 
Recent as yet, unpublished work by our group in lung adenocarcinoma, re-analysing 
data from the TCGA Research Network using new data available via cBioportal 
suggests that LIMD1 deletion is much more common than previously described.  
cBioportal (http://cbioportal.org) is web resource that helps facilitate the analysis and 
visualisation of cancer genomic data (Gao, Aksoy et al. 2013). 
  
The cBioportal platform now allows the interrogation of gene copy number at an 
individual sample level, enabling the investigation of both deep and shallow gene 
deletions, rather than deep deletion data only as was previously available. Copy number 
analysis assigns a predicted copy number value according to the following key: 
 
-2 Deep deletion. Possibly a homozygous deletion 
-1 Shallow deletion. Possibly a heterozygous 
deletion 
0 Diploid 
1 Low-level gain 
2 High-level amplification. 
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Analysis of 516-lung adenocarcinoma samples and 501 lung squamous cell carcinomas 
identified shallow and deep combined LIMD1 deletions and this combined analysis 
demonstrated that gene deletion was much higher than previously identified and 
comparable to known highly mutated driver mutations (Figure 1.4).  Both shallow and 
deep LIMD1 deletions are likely to contribute to loss of gene expression, albeit to 
different degrees.  
!
Figure 1.4. cBioPortal analysis of LIMD1 loss in adenocarcinoma and squamous 
cell carcinoma of the lung. Genes are ordered by percentage loss from greatest to smallest. (A) In 
lung adenocarcinoma, 0.2% of tumours contain a deep LIMD1 deletion and 46.9% contain a shallow 
LIMD1 deletion. (B) In squamous cell carcinoma, 0.8% of tumours contain a deep LIMD1 deletion and 
84.6% contain a shallow LIMD1 deletion. Graphs generated by Dr John Foster (2017, unpublished). 
   Chapter 1: Introduction      
!28!
1.4.2 LIMD1 loss in breast carcinoma 
 
Using a tissue microarray (TMA) containing breast cancer tissue and self-matched 
adjacent normal and distal normal tissue, Spendlove et al demonstrated that intense 
LIMD1 staining was observed in the epithelial cells of terminal duct lobular units and 
that reduced LIMD1 staining was common in breast tumour (Spendlove, Al-Attar et al. 
2008).  Using TMAs constructed using tissue obtained from patients with operable 
breast carcinoma, LIMD1 immunohistochemistry (IHC) was correlated with clinico-
pathological data with 495 histospots valid for analysis. Interestingly, subcellular 
localisation of LIMD1 appeared important in driving breast cancer tumourigenesis. 
Absence of nuclear LIMD1 staining strongly correlated with reduced patient survival, 
increased tumour size, higher histological grade and worse Nottingham Prognostic 
Index (NPI) score, a classification that stratifies tumours from excellent prognosis type 
to poor prognosis type. The authors hypothesised that this was related to reduced 
overall total LIMD1 staining (Sharp, Munoz et al. 2004, Spendlove, Al-Attar et al. 2008).  
 
1.4.3 LIMD1 loss in head and neck carcinoma 
 
Chakraborty et al had previously identified that LOH at 3p21.3 was common in head 
and neck carcinomas (Chakraborty, Dasgupta et al. 2003) and that LIMD1 
deletion/changes in methylation patterns were significantly associated with the 
development of dysplastic head and neck lesions (Ghosh, Ghosh et al. 2008). Analysis 
of 25 dysplastic head and neck lesions and 58 head and neck squamous cell carcinomas 
(SCCs) revealed that 94% of samples contained LIMD1 alterations, predominantly 
deletions and changes in methylation patterns, with mutations more commonly 
observed in the SCC samples than the dysplastic lesions. Most of the mutations were 
present in and around the retinoblastoma protein (pRb)-binding domain of exon 1 and 
most resulted in truncated, non-functional LIMD1 (Ghosh, Ghosh et al. 2008). 
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1.4.4 LIMD1 expression in Diffuse Large B-Cell lymphoma (DLBCL) 
 
Gene expression profiling has enabled the division of DLBCL into two major cell- of 
origin phenotypes, germinal centre B (GCB) cell like, which typically have a favourable 
prognosis and poorer prognosis, activated B cell (ABC) like (Wright, Tan et al. 2003).  
 
Use of such gene expression based subtype analysis in the routine clinical setting is 
however expensive, time consuming and rarely practical. Xu et al identified a two-gene 
signature the LIMD1-MYBL1 index, which they compared against the gold standard 
Affymetrix-based standard. MYBL1 belongs to the Myb oncogene family of 
transcription factors, which regulate the proliferation and differentiation of different 
haematopoeitic cells (Golay, Basilico et al. 1996).  
 
Xu et al demonstrated that ABC tumours typically demonstrated high LIMD1 
expression, and GCB tumours high MYBL1 expression. Tested against the gold 
standard Affymetrix method, the Index achieved excellent sensitivity for both ABC and 
GCB subgroups and Overall Survival (OS) rates were significantly different between the 
two groups stratified using this index, with highly expressing LIMD1 tumours 
demonstrating poor prognosis as expected. This simple analysis platform stratifies 
tumours into two prognosis groups, without the need for a gene expression based 
platform, which may not be routinely practical in clinical practice. The author 
hypothesised that given LIMD1’s role as a positive regulator of Nuclear Factor-kappa-
light chain enhancer of activated B cells (NF-κB) in osteoclast differentiation that over-
expression of LIMD1 may contribute to the upregulation of the NF-κB pathway in 
ABC-DLBCL (Xu, Tan et al. 2015).  !
1.5 Ajuba deregulation in tumourigenesis 
  
1.5.1 Ajuba loss in malignant mesothelioma 
 
In a panel of 24 malignant mesothelioma cell lines, Tanaka et al demonstrated by 
Western blotting that 18 of the 24 cell lines (75%) demonstrated significant reduction in 
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Ajuba expression compared to an immortalised control mesothelial cell line, with 15 cell 
lines demonstrating no Ajuba expression. The immunohistochemical analysis of 20 
malignant mesothelial specimens also demonstrated frequent reduction in staining for 
Ajuba with 5 samples (25%), demonstrating no Ajuba staining and 11 (55%), 
demonstrating little staining for Ajuba (Tanaka, Osada et al. 2015).  
1.5.2. Ajuba expression in oesophageal squamous cell carcinoma  
 
Ajuba overexpression has been associated with tumourigenesis in oesophageal SCC. 
Analysis of 179 oesophageal SCC samples compared to matched adjacent tissue (MAT), 
demonstrated significant Ajuba overexpression within the tumour samples, with mean 
expression levels 2.15 times greater than those in the MAT (p<0.001). Analysis of 
immunohistochemical (IHC) staining for Ajuba in 81 tumour samples from the same 
cohort compared to corresponding non-tumour, demonstrated high Ajuba staining in 
70% of tumour samples compared to only 20% of non-tumour samples (p<0.001). 
Associated in vitro experiments demonstrated that Ajuba overexpression promoted 
oesophageal SCC colony formation and cell growth as well as cell migration (Shi, Chen 
et al. 2016).   
  
1.5.3 Ajuba deregulation in colorectal carcinoma 
 
A similar observation of Ajuba upregulation was noted in colorectal cancer specimens 
and cell lines. Analysis of Ajuba levels in a high-throughput microarray dataset of 34, 
tumour samples demonstrated significant Ajuba up-regulation compared to non-tumour 
control. In vitro, Western blot analysis of 7 colorectal cancer cell lines compared to non-
tumour control demonstrated Ajuba overexpression in all cancer cell lines, with an 
associated upregulation of Ajuba mRNA levels.  In this cohort, no significant 
differences in LIMD1 or WTIP levels were observed compared to control (Liang, 
Zhang et al. 2014).  
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1.6. WTIP loss in human disease  
 
No studies to data have demonstrated a clear role for WTIP deregulation in 
tumourigenesis. 19q13.11 deletion syndrome is associated with developmental delay and 
intellectual disabilities, speech disturbance, growth retardation and hypospadias with 
WTIP identified as the most likely candidate gene (Gana, Veggiotti et al. 2012).  
1.7 Characterised functions of LIM-domain containing proteins 
 
1.7.1 LIMD1 is required for microRNA-mediated gene silencing  
 
MicroRNAs (miRNAs) are small, non-coding RNA molecules, of approximately 22 
nucleotides that function as post-transcriptional silencers of gene expression by forming 
base pair interactions with messenger RNA (mRNA) (Filipowicz, Bhattacharyya et al. 
2008).  
 
MiRNAs are critical in the temporal regulation of development (He and Hannon 2004) 
and in addition changes in miRNA expression patterns are implicated in driving 
tumourigenesis in a range of human malignancies with both over-expression and down-
regulation contributing to malignant transformation (Cummins, He et al. 2006, Roldo, 
Missiaglia et al. 2006). In ccRCC for example miR-16, miR-452 and miR-224 are 
frequently up regulated (Jung, Mollenkopf et al. 2009).  
 
MiRNAs are generated in a two-step pathway. Most reside in inter-genic or intronic 
gene regions and are transcribed into primary-miRNA (pri-miRNA) transcripts by RNA 
polymerase II (James, Wong et al. 2012). These pri-miRNA transcripts are then 
processed into hairpin precursor miRNA molecules (pre-miRNA) 70-100 nucleotides in 
length by a complex containing the Drosha RNase and the double strand RNA-binding 
protein DGCR8 (Han, Lee et al. 2006) (James, Wong et al. 2012). The pre-miRNA then 
translocates to the cytoplasm in an exportin-5 dependent manner and the complex is 
processed by DICER into ~20 nucleotide duplexes with 2 nucleotide 3’ overhangs. One 
strand of the duplex is selected as the mature miRNA and the remaining strand 
degraded (James, Wong et al. 2012).  
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Specifically, miRNAs regulate gene expression by assembling alongside the Argonaute 
(Ago) protein into miRNA induced silencing complexes (miRISCs). The specific 
miRNA, guides the bound Ago protein to complementary mRNA target sequences, 
which results in post-transcriptional mRNA silencing and/or degradation of the mRNA 
sequence (Filipowicz, Bhattacharyya et al. 2008). The microRNA-induced silencing 
complex (miRISC) is a large multi-subunit complex, in which AGO drives the 
recruitment of GW182/TNRC6 proteins, scaffold proteins critical for the formation of 
the miRISC and their downstream effector complexes (Braun, Huntzinger et al. 2013) . 
In turn, translational repression, mRNA destabilisation and degradation of target 
mRNAs is achieved by the recruitment of effector proteins to the miRISC such as those 
involved in de-capping, DCP1/2, RNA unwinding, DDX6, and de-adenylation, CCR4-
NOT (Figure 1.5) (Chekulaeva, Parker et al. 2010, Chekulaeva, Mathys et al. 2011, 
Chen, Boland et al. 2014).  
 
There are four human AGO proteins (AGO1-4) which appear to demonstrate a degree 
of functional redundancy with respect to miRNA loading/target recognition with the 
functionally dominant AGO determined by protein expression levels (Dueck, Ziegler et 
al. 2012). Recent work however suggests that differential regulation of the AGOs by 
signalling pathways is important and that the AGOs are not fully interchangeable.  
 
 LIMD1, Ajuba and WTIP localise to cytoplasmic P-bodies, sites of miRNA/mRNA 
interaction where mRNAs accumulate and are subjected to degradation or storage 
(James, Wong et al. 2012). These LIM-domain proteins facilitate miRNA-mediated 
silencing through their interaction with components of the miRISC (James, Zhang et al. 
2010) (Bridge, Shah et al. 2017).  
 
James et al identified LIMD1, Ajuba and WTIP co-localisation in cytoplasmic P-bodies 
alongside components of the miRISC, specifically eIF4E, DCP-2 and RCK/p54, AGO2 
and GW182. Subsequent immunoprecipitation (IP) experiments demonstrated that all 
three proteins interact with components of the miRISC: AGO2, RCK, DCP2 and 
eIF4E (James, Zhang et al. 2010).   
 
Using LIMD1 short hairpin (shRNA)-directed knockdown and rescue lines, James et al 
demonstrated that LIMD1, Ajuba and WTIP are critical effectors of miRNA-mediated 
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gene silencing, with siRNA-targeted depletion resulting in significant de-repression of 
miRNA mediated silencing.  In addition, all three proteins were able to bind to the 
mRNA 5’ m7GTP cap structure and could be co-purified with endogenous eIF4E using 
m7GTP-Sepharose beads, leading them to propose that all three proteins act as a 
molecular scaffold protein, facilitating an association between the core miRISC and the 
eIF4E/m7GTP-cap structure of the mRNA (James, Zhang et al. 2010)  
 
Recent work by Bridge et al has updated this model with the demonstration that the 
Akt3-mediated phosphorylation of AGO2 (S387) promotes an interaction with LIMD1, 
which acts as a molecular ‘clamp’ facilitating the interaction of AGO2 with TNRC6A 
and the miRISC (Figure 1.5) ((Bridge, Shah et al. 2017).  
 
Using a Renilla luciferase reporter construct with five targeted or non-targeted miR-
99/100 binding sites in the 3’ UTR, siRNA-mediated knockdown of AGO2, TRNC6A 
or LIMD1 all resulted in significant de-repression of the reporter construct whereas 
knockdown of AGO1, 3 or 4 did not. Interestingly, by using a CRISPR-Cas-9 system to 
genetically ablate LIMD1 in HELA cells, repression of the miR99/100 reporter was 
equivalent in the paired LIMD1 proficient and deficient cells. Further analysis 
demonstrated that there was a switch in AGO utilisation in the LIMD1-/- line to AGO-
3, and that AGO-3 depletion produced an equivalent de-repression in this reporter in 
the LIMD1 deficient compared to proficient line. In the LIMD1 deficient HELA cell 
line, AGO3 interaction with GWI82 was achieved through a switch in LIM protein to 
WTIP (Bridge, Shah et al. 2017).  A diagram of the proposed interaction of 
LIMD1/WTIP with components of the miRISC is shown in Figure 1.5.  
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Figure 1.5. Proposed model for the formation of an inhibitory closed-loop 
complex mediating miRNA mediated silencing. In LIMD1 proficient cells, LIMD1 
phosphorylation at S387 by Akt3 facilitates the interaction of AGO2 with TNRC6A and the downstream 
effector DDX6.  In the absence of LIMD1, there is a switch in LIM protein and AGO, with WTIP 
forming a complex with AGO3 and TNRC6A. Taken from (Bridge, Shah et al. 2017) 
miRNA downregulation can drive tumourigenesis in multiple tumour types including 
ccRCC, through the deregulation of gene expression (He and Hannon 2004, Huang, Dai 
et al. 2009). Loss of LIMD1/WTIP with consequent deregulation of the miRISC and 
reduced miRNA induced post-transcriptional gene silencing, could be an important 
mechanism for driving tumourigenesis in ccRCC.  
   Chapter 1: Introduction      
!35!
1.7.2 LIMD1 regulation of hypoxia inducible factors (HIF) !
Hypoxia is a common consequence of the rapid growth of many solid tumours 
including ccRCC and functions as a critical driver and regulator of a network of gene 
expression, at both translational and post-translational levels (Hockel and Vaupel 2001) 
(Schito and Semenza 2016). HIFs are transcriptional regulators that regulate oxygen-
dependent gene expression resulting in the expression of genes that are critical for the 
regulation of cell survival and angiogenesis (Carroll and Ashcroft 2005) (Poon, Harris et 
al. 2009, Schito and Semenza 2016).  
 
 
Figure 1.6 Activation of the HIF pathway in renal cell carcinoma.  
Micro-environmental changes such as hypoxia, changes in pH and nutrient deprivation, changes in 
growth factors and genetic changes can lead to a loss of function of tumour suppressors and oncogenic 
activation in turn driving tumourigenesis. Increased HIFα translocates to the nucleus, heterodimerises 
with HIFβ and recruits co-activators e.g. p300/CBP, which in turn activate the transcription of multiple 
genes involved in angiogenesis, metabolic adaptation, cell survival and metastases. Adapted from (Poon, 
Harris et al. 2009).    
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There are three prolyl hydroxylases PHD1, 2 and 3 that regulate HIF. A further critical 
oxygen dependent regulator of HIF-α is factor inhibiting HIF (FIH-1), which acts 
independently of the HIF regulation by PHDs (Webb, Coleman et al. 2009). 
   
In normoxia, the PHDs hydroxylate two conserved proline residues on HIF-α, which 
leads to the binding of the von Hippel-Lindau (VHL) tumour suppressor and 
subsequent VHL mediated poly-ubiquitylation and degradation of HIF-α via the 
proteasome (Figure 1.7) (Jaakkola, Mole et al. 2001). Of the three PHDs, PHD2 is 
thought to represent the more critical oxygen sensor in the regulation of HIFα 
(Appelhoff, Tian et al. 2004). Work by the Sharp group has demonstrated that LIMD1 
is a critical regulator of the hypoxic response through HIF1α regulation (Foxler, Bridge 
et al. 2012).  
 
Co-immunoprecipitation (IP) assays with X-press tagged LIMD1, Ajuba and WTIP 
proteins and PHDs 1, 2 and 3 demonstrated that LIMD1 bound to all three of the 
PHDs, with WTIP and Ajuba binding only to PHD1 and 3.  In a direct binding assay, 
recombinant LIMD1 was found to bind directly to glutathione-S-transferase (GST)-
PHD-2. Hypothesising that LIMD1 formed a PHD-LIMD1-VHL active complex to 
regulate HIF-1α, the group demonstrated that endogenous LIMD1 co-
immunoprecipitated with PHD2 whilst IP of endogenous VHL resulted in co-
immunoprecipitation of elongin B and cullin 2, (adapter proteins that help facilitate 
proteasomal degradation via VHL), as well as co-immunoprecipitation of LIMD1 and 
PHD2. In vivo co-immunoprecipitation studies with the pre-LIM region of LIMD1 
(LIMD1Δ472-676) and LIM-domain region LIMD1Δ1-467) revealed PHD2 bound to 
the pre-LIM region and VHL to the LIM-domain region.   
 
As predicted, overexpression of LIMD1 resulted in significantly reduced hypoxic 
response element (HRE) driven luciferase reporter assay and this was further increased 
with co-expression of exogenous PHD2. In hypoxia, LIMD1-depleted cells exhibited an 
exaggerated increase in HIF1α protein levels.  
 
Given that in normoxia degradation of HIF1α is the result of hydroxylation and 
ubiquitylation within the oxygen-dependent degradation domain (ODD) of HIF1α, the 
relationship between increased LIMD1 expression and levels of ODD were investigated 
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and as predicted, increased LIMD1 expression resulted in reduced levels of ODD whilst 
LIMD1 depletion resulted in increased ODD expression.  
 
Given the PHD2-LIMD1-VHL binding model hypothesis, PHD2/VHL non-binding 
LIMD1 mutants would be expected to be unable to induce ODD or HIF degradation 
and this was confirmed in vitro, confirming that associated PHD hydroxylase and/or 
VHL ubiquitin-ligase is required for functional LIMD1 regulation of this pathway 
(Foxler, Bridge et al. 2012).   
 
An overview of the role of LIMD1 in this pathway in both normoxia and hypoxia is 
shown in Figure 1.7.   
 
Figure 1.7 LIMD1 forms a molecular scaffold to simultaneously bind VHL and 
PHD to form a VHL-LIMD1-PHD complex that targets HIF1α for degradation 
via the proteasome A In normoxia, a significant proportion of HIF1α is hydroxylated and LIMD1 
interacts with PHD2 through its pre-LIM region and with VHL through the LIM domain to link the 
proteins into one complex and promote significant HIF1α degradation via the proteasome. B In hypoxia, 
LIMD1 still engages an active pool of PHD2 and VHL to enable a degree of HIF1α modification and 
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degradation but there is a significant increase in HIF1α, a proportion of which becomes phosphorylated 
and transcriptionally active. Adapted from (Foxler, Bridge et al. 2012) 
1.7.3 LIMD1 interacts with the retinoblastoma protein and represses E2F-driven 
transcription 
 
The retinoblastoma 1 gene RB1 is an archetypal tumour suppressor (Knudson 1971). 
pRb binds to the E2F family of transcription factors and upon binding acts as a critical 
negative regulator of the cell cycle, controlling entry into S-phase through the regulation 
of the G1/S checkpoint (Dimova and Dyson 2005). In addition, E2F family members 
play a critical role in the regulation of genes with other cell cycle functions, notably 
DNA repair and recombination, differentiation and development, and the regulation of 
apoptosis (Dimova and Dyson 2005).  
 
LIMD1 has been characterised as a binding partner for pRb leading in turn to the 
repression of E2F-driven transcription (Sharp, Munoz et al. 2004). Sharp et al performed 
a yeast two-hybrid screen to identify binding partners of pRb using full-length pRb 
fused to the GAL4 DNA binding domain. This interaction was confirmed with the use 
of an in vitro pull-down assay with [S35] methionine-labelled LIMD1, confirming that 
amino acids 326-628 of LIMD1 interact with amino acids 763-928 in the C-terminus of 
pRb. E2F luciferase reporter assays were then undertaken in HEK-293-T cells to assess 
LIMD1 regulation of E2F1-driven transcription. This demonstrated that LIMD1 
represses E2F1 driven transcription in a LIMD1 concentration-dependent manner. 
LIMD1 deletion mutants were then examined for their ability to repress E2F driven 
transcription.  Deletion of the pRb-binding domain resulted in a greater than 50% 
reduction in the ability of LIMD1 to repress E2F mediated transcription (Figure 1.8) 
(Sharp, Munoz et al. 2004).  
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Figure 1.8. LIMD1 represses E2F driven transcription. A. HEK-293 cells were transiently 
transfected with an empty vector or LIMD1 expression vector and luciferase activity determined 48 hours 
later in the presence of the E2F luciferase reporter.  Western blotting for LIMD1 was undertaken.  B. 
The ability of LIMD1 to repress E2F-luciferase driven transcription depends on the presence of the pRB-
binding domain. Adapted from (Sharp, Munoz et al. 2004),  
1.7.4 LIMD1 is a regulator of bone remodelling 
 
Bone homeostasis is maintained by the balance between osteoclast mediated bone 
resorption and osteoblast mediated bone formation (Tanaka, Nakayamada et al. 2005). 
Crosstalk between these two processes is critical for maintaining this homeostatic 
relationship.  Both osteoblasts and osteoclast progenitors are localised in the bone 
marrow: osteoblasts derive from the mesenchymal bone marrow stromal cell lineage 
and osteoclasts from bone marrow derived macrophages (Tanaka, Nakayamada et al. 
2005). Osteoclast differentiation is regulated by a number of proteins: in particular by 
the receptor activator of NF-kB ligand RANK-L. Activation of NF-kB through the 
binding of RANK-L facilitates the association with TNF-receptor associated factors 
(TRAFs) in particular TRAF6 which in turn bind to proteins within a multiprotein 
complex known as the sequestrome which includes the protein p62, leading to the 
activation of a signalling cascade which activates genes critical for osteoclast 
development (Feng, Zhao et al. 2007). LIMD1 can bind to both p62 and TRAF6 and in 
addition during osteoclast differentiation LIMD1 levels are induced (Feng, Zhao et al. 
2007)(Figure 1.9). Work by Luderer et al has also demonstrated that LIMD1 influences 
osteoblast progenitor numbers, differentiation and function with LIMD1-/- osteoblasts 
displaying increased mineralisation and differentiation (Luderer, Bai et al. 2008).  
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Figure 1.9 RANK-L mediated osteoclast differentiation is regulated by LIMD1. 
RANK-L binding to its receptor, results in receptor activation and trimerisation. In turn this facilitates an 
association with TRAF proteins, in turn facilitating the formation of a sequestrome, a multiprotein 
complex including p62 and atypical protein kinase C (aPKc). Activation of the enzyme IκB kinase (IKK) 
phosphorylates IκBα, which leads to its dissocation from NFκB and degradation via the proteasome. The 
activated NFκB translocates to the nucleus and binds and activates DNA response elements. MAPK 
pathway activation activates Activator protein-1 (API)/Fos, and influences downstream transcription and 
osteoclast differentiation. LIMD1 can bind TRAF6 and p62 and acts as a positive regulator of AP1.  
 
1.7.5 LIMD1 and Latent membrane protein 1 (LMP-1) in EBV latency 
 
The Epstein Barr virus (EBV) is a powerful driver of malignancy, particularly in HIV-
associated cancers and head and neck cancers (Boshoff and Weiss 2002). The EBV 
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Latent membrane protein 1 (LMP-1) is a pleiotrophic growth factor that promotes cell 
growth and transformation in vitro and in transgenic mice (Thornburg, Kulwichit et al. 
2006). This oncogenicity is in part mediated through the activation of NFkB pathways 
and LIMD1 as outlined is known to bind TRAF6 and enhances the ability of TRAF6 to 
activate AP1 in osteoblasts (Feng, Zhao et al. 2007). The oncogenic transcription factor 
Interferon regulatory factor 4 (IRF4), is a transcription factor essential for the 
development of T cells and is a marker of the ABC subtype of DLBCL-considered to 
be of poorer prognosis. IRF4 and LIMD1 levels have been shown to correlate in a 
range of haematological malignancies, including EBV-driven ones (Wang, Yao et al. 
2014). Wang et al demonstrated that IRF-4 and NFkB bind to the LIMD1 promoter in 
EBV transformed cells, and that LIMD1 expression is up-regulated by IRF-4 and NFkB 
downstream of LMP1. In EBV transformed cells, co-immunoprecipitation assays with 
LMP1 deletion mutants confirmed that the cytoplasmic activating domains, CTAR1 and 
CTAR2 of LMP-1 interact with LIMD1 and as expected with TRAF-6 and that deletion 
of both domains ablated its ability to interact with LIMD1. Interestingly, over-
expresison of full length LMP1 resulted in significantly lower levels of LIMD1, which 
occurred at the post-translational level, thought to result in LIMD1 degradation through 
a proteasome dependent pathway. Knockdown of LIMD1 resulted in reduced activity 
of NFkB and AP1 indicating that LIMD1 is required for LMP1/TRAF6-mediated 
signal transduction and also resulted in the downregulation of the LMP1 target genes, 
IRF4, IRF7 and Bcl-6. Finally, LIMD1 depletion increased DNA damage associated cell 
death and inhibited autophagy, suggesting that LIMD1 protects EBV-transformed cells 
from DNA damage but makes them more susceptible to autophagy (Wang, Howell et 
al. 2018). 
1.7.6 Ajuba regulates the Hippo signalling pathway 
 
The Hippo signalling pathway controls organ size, through the regulation of the cell 
cycle, proliferation and apoptosis (Huang, Wu et al. 2005). A number of mammalian 
regulators of this pathway have been characterised including the serine/threonine kinase 
large tumour suppressor 1 and 2 (LATS1/2) (Zeng and Hong 2008). Increasing 
evidence is emerging that deregulation of the Hippo pathway occurs in a broad range of 
human carcinomas including colorectal, lung, liver and ovarian cancer (Harvey, Zhang 
et al. 2013). Interestingly, somatic or germline mutations in genes that regulate the 
Hippo signalling pathway are uncommon: mutations in neurofibromin 2 (NF2) encoding 
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merlin are described, but mutations in other pathway genes are rare (Harvey, Zhang et 
al. 2013).  
 
In Drosophila Djub is the sole orthologue of the Ajuba subfamily of LIM proteins 
(Renfranz, Siegrist et al. 2003) functioning as an essential negative regulator of the 
conserved Hippo signalling pathway (Das Thakur, Feng et al. 2010). In mammalian 
cells, activation of the Hippo signalling pathway induces the activation of LATS1/2 
which phosphorylates and inactivates the transcriptional co-activator Yes-associated 
protein (YAP) and its paralogue TAZ, excluding YAP/TAZ from the nucleus with 
consequent down-regulation of genes driving cell growth (Zhao, Tumaneng et al. 2011). 
Ajuba LIM proteins are important negative regulators of the Hippo signalling pathway. 
In mammalian cells, Ajuba, LIMD1 and WTIP strongly associate with LATS1/2, 
preventing LATS1/2 mediated YAP/TAZ phosphorylation therefore functioning as 
negative regulators of YAP activity (Figure 1.10).  (Das Thakur, Feng et al. 2010) 
(Tanaka, Osada et al. 2015)  
 
Zhao et al have demonstrated that in sub-confluent non-contacted cells, Ajuba LIM 
proteins are predominantly cytosolic, resulting in the inhibition of LATS1/2 mediated 
YAP phosphorylation and activated YAP therefore accumulates in the nucleus and cells 
proliferate, but once confluent, Ajuba proteins are recruited to adherens junctions in 
turn releasing LATS1/2 resulting in YAP phosphorylation and subsequent cell 
inactivation and growth arrest (Zhao, Wei et al. 2007).   
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Figure 1.10 Ajuba proteins regulate the Hippo signalling pathway. A In confluent 
cells in the absence of growth factors, PDK1 forms a complex with Hippo pathway components (Lats, 
Mst, PDK1 and Sav1) and the Hippo pathway is active, YAP remains phosphorylated and excluded from 
the nucleus resulting in cell growth arrest. B Activation of the Ras/MAPK pathways through growth 
factor activation results in phosphorylation of Ajuba and disassociation of the PDK1/Hippo complex. 
Growth factors can also activate PI3K and recruit PDK1 to the cell membrane, resulting in further 
disassociation of the PDK1-Hippo complex. This results in YAP de-phosphorylation, which accumulates 
in the nucleus, driving transcription of pro-proliferative genes.  Adapted from (Gumbiner and Kim 2014).   
1.7.7 Ajuba regulates epithelial-mesenchymal transition (EMT) 
 
EMT is fundamental for tumour invasion and metastasis (Thiery 2003).  During EMT, 
epithelial cells lose contact with their neighbours and gain mesenchymal properties, 
enabling them to break through the basement membrane: a critical component of this 
pathway is the functional loss of E-cadherin (Onder, Gupta et al. 2008). Snail proteins 
contain conserved SNAG (Snail/Gfi) domains, essential for the binding of 
transcriptional co-repressor complexes, and in turn target the downregulation of E-
cadherin expression, thereby driving EMT (Onder, Gupta et al. 2008). !
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In Xenopus, Ajuba can act as a transcriptional co-repressor alongside Snail by binding 
the SNAG transcriptional repressor domain on E-cadherin, in turn repressing E-cadherin 
transcription (Langer, Feng et al. 2008).  
 
In colorectal cell lines, the ectopic expression of Ajuba induces EMT, enhancing cell 
motility and invasiveness through Snail upregulation (Wang, Shi et al. 2013). In clinical 
colorectal specimens, an inverse correlation between Ajuba and E-cadherin expression 
is observed (Wang, Shi et al. 2013).   
 
1.7.8 Ajuba proteins stabilise adherens junctions 
 
The regulation of stable cadherin-dependent junctions between neighbouring cells is 
fundamental to ensure epithelial cell differentiation; deregulation of such interactions 
can promote tumour growth and metastasis (Onder, Gupta et al. 2008). The small 
GTPase Rac1 (Rac) is a critical signalling pathway co-ordinating cadherin-F actin 
association at the plasma membrane and therefore mediating the recruitment of actin to 
clustered cadherin complexes (Ratheesh, Priya et al. 2013). Upon cell-cell contact, Ajuba 
and Rac are both recruited independently to cell junctions, and upon Rac activation, the 
Rac effector PAK1 is activated by auto-phosphorylation, in turn phosphorylating Ajuba 
and increasing its affinity to activate Rac; essentially Ajuba acts as a scaffold to 
concentrate active Rac. In the absence of Ajuba, Rac can still be recruited and activated 
by junction assembly, but cannot resist mechanical stress (Nola, Daigaku et al. 2011).  
 
1.7.9 Ajuba proteins localise to centrosomes and are required for mitotic 
commitment 
 
Aurora family kinases are critical regulators of mitosis (Goldenson and Crispino 2015) . 
Aurora-A is required for mitotic entry with activation of Aurora-A in late G2 phase 
essential for the recruitment of the cyclin B1-Cdk1 complex to centrosomes and upon 
activation of this complex, cells are committed to mitosis (Hirota, Kunitoku et al. 2003). 
In a two-hybrid screen Ajuba has been characterised as binding Aurora-A and Ajuba 
induces the auto-phosphorylation and consequent activation of Aurora-A (Hirota, 
   Chapter 1: Introduction      
!45!
Kunitoku et al. 2003).  Depletion of Ajuba prevents the activation of Aurora-A at 
centrosomes in late G2 phase and associated entry into mitosis is inhibited (Hirota, 
Kunitoku et al. 2003). 
1.7.10 WTIP regulates podocyte function 
 
Podocytes are highly specialised glomerular epithelial cells that help maintain the normal 
function of the glomerular filtration barrier in the kidney. WTIP has been shown to 
regulate podocyte-actin dynamics and therefore maintain stable cell contact (Sedor, 
Madhavan et al. 2011). After glomerular injury, WTIP shuttles to the podocyte nucleus 
and effects changes in gene transcription that enable podocyte remodelling (Sedor, 
Madhavan et al. 2011). WTIP also interacts with additional sex comb-like (ASXL) family 
proteins; chromatin factors that are involved in transcriptional activation and repression 
and in combination with ASXL proteins play an important role in kidney podocyte 
development (Moon, Um et al. 2015).  
 
1.7.11 WTIP inhibits Wnt signalling  
 
Deregulated Wnt signalling is common in cancer pathways (Polakis 2012) . Ror2 is a 
receptor tyrosine kinase, involved in the development of multiple tissue types including 
skeletal and heart muscle, lung and kidney formation.  In mice, Wtip and Ror2 have 
been shown to interact with Ror2 recruiting Wtip to the cell membrane with both genes 
and proteins demonstrating overlapping expression in the mouse embryo (van Wijk, 
Witte et al. 2009). Wtip can inhibit Wnt signalling in both mammalian cells and 
Xenopus embryos, through an interaction with the receptor tyrosine kinase Ror2 (van 
Wijk, Witte et al. 2009).  
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1.8. Summary of the function of the Ajuba proteins 
 
The mammalian Ajuba proteins LIMD1, Ajuba and WTIP participate in a diverse array 
of cellular processes (Kadrmas and Beckerle 2004). All three proteins contain the 
characteristic C-terminal LIM domains, which facilitate protein-protein interactions and 
can shuttle between the nucleus and the cytoplasm, functioning as important signalling 
transducers relaying signals between the cell surface and the nucleus (Kadrmas and 
Beckerle 2004), playing for example a critical role in the regulation of EMT via E-
cadherin expression (Wang, Shi et al. 2013). Ajuba proteins are negative regulators of 
the Hippo signalling pathway (Das Thakur, Feng et al. 2010), upregulation of which is 
implicated in driving tumourigenesis in multiple tumour types.  Other roles include the 
stabilisation of adherens junctions (Nola, Daigaku et al. 2011). LIMD1 is a regulator of 
pRb, in turn repressing E2-F mediated transcription and acts as an important regulator 
of bone remodelling through its effects on osteoclast differentiation (Luderer, Bai et al. 
2008). 
 
Ajuba proteins are essential components of the miRISC, facilitating miRNA mediated 
gene silencing (Bridge, Shah et al. 2017). Acting as scaffold proteins, all three proteins 
regulate the hypoxic response, targeting HIFα for VHL mediated polyubiquitylation and 
degradation via the proteasome (Foxler, Bridge et al. 2012).  
 
Deregulation of the pathways described is frequently implicated in driving 
tumourigenesis and metastasis. LIMD1, Ajuba and WTIP demonstrate considerable 
functional redundancy as demonstrated for example in the regulation of the hypoxic 
response and in miRNA silencing via the miRISCs.  
 
A number of studies have implicated Ajuba protein deregulation as important in driving 
tumourigenesis in vivo. LIMD1 loss is common in lung carcinoma and drives 
tumourigenesis in a mouse model, whilst in breast cancer LIMD1 loss contributes to 
tumourigenesis and is associated with worse prognosis disease (Sharp, Al-Attar et al. 
2008, Spendlove, Al-Attar et al. 2008). LIMD1 expression levels are also associated with 
subtypes of DLBCL (Li, Wang et al. 2015). Ajuba upregulation has also been associated 
with colorectal carcinoma and oesophageal squamous cell carcinoma (Liang, Zhang et 
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al. 2014, Shi, Chen et al. 2016).  Ajuba loss in malignant mesothelioma has been 
described and is related to deregulation of the Hippo signalling pathway (Tanaka, Osada 
et al. 2015).  
 
To date, LIMD1, Ajuba and WTIP have not been characterised in ccRCC. Hypoxic 
deregulation is a critical driver of tumourigenesis in ccRCC and deregulation of miRNA 
mediated silencing is commonly observed (Biswas, Troy et al. 2010). Dysfunctional 
Hippo signalling can mediate proliferation, invasiveness and the metastatic potential of 
ccRCC (Schutte, Bisht et al. 2014). It was therefore hypothesised that deregulation of 
the LIM domain containing proteins LIMD1, Ajuba and WTIP may contribute to 
tumourigenesis in ccRCC.  
1.9 Overview of Clear cell renal cell carcinoma  
 
Renal cell carcinoma (RCC) accounts for 3.8% of adult malignancies globally and is the 
eighth leading cause of cancer-related death (Rathmell and Godley 2010). The 
commonest RCC, clear cell renal cell carcinoma  (ccRCC), accounts for 70-80% of cases 
and has the greatest potential for recurrence and distant metastatic spread (Escudier, 
Szczylik et al. 2012). 
 
Patients with organ-confined RCC may be cured with nephrectomy, however 
approximately 30% of patients have metastatic disease at the time of initial presentation 
and 40% of patients with localised disease, will recur post nephrectomy (Koul, Huh et 
al. 2011). Metastatic RCC will progress in almost all patients and is often accompanied 
by significant morbidity (Escudier, Porta et al. 2014).  
 
Since 2007, the prognosis of metastatic RCC has improved dramatically with the 
development of targeted agents which target complex pathways regulating RCC 
tumourigenesis (Escudier, Szczylik et al. 2012). In addition, the use of immune 
checkpoint inhibitors to enhance anti-tumour immunity offers a promising novel 
therapeutic approach (Massari, Santoni et al. 2015).  
 
Currently with sequential and repeated use of targeted agents, patients with 
intermediate-prognosis disease have an overall survival of 25-30 months compared to 
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10 months in the pre-targeted therapy era (Motzer, Mazumdar et al. 1999, Heng, Xie et 
al. 2009) and this may increase further with the use of novel therapeutic options. 
Nonetheless, the natural history of ccRCC can be highly unpredictable, between 4.2% 
and 7.1% of patients with small tumours less than 4cm in diameter have metastatic 
disease at presentation (Lughezzani, Jeldres et al. 2009), and conversely up to 40% of 
patients with lymph node metastases diagnosed at nephrectomy are alive five years after 
surgery (Mekhail, Abou-Jawde et al. 2005).   
1.10 Epidemiology of ccRCC  
 
Incidence of ccRCC is highest in North America and Northern Europe and the disease 
is over-represented in men, with a male to female ratio of 1.5-2:1 (Levi, Ferlay et al. 
2008). Incidence of RCC is substantially lower amongst Asians, both within Asian 
countries and in Western countries (Ljungberg, Campbell et al. 2011). Prevalence 
increases with increasing age and most tumours are diagnosed in those aged 60-64; 
nonetheless 7% of sporadic tumours are diagnosed in patients under the age of 40 
(Rodriguez, Patard et al. 2002). The incidence of all stages continues to increase and 
although there has been a decrease in overall mortality rates for RCC in many Western 
countries, this is not true globally (Levi, Ferlay et al. 2008) (Figure 1.11).  
 
 
Figure 1.11 Number of new cases of RCC and deaths per 100,000 of the 
population in the USA. The number of age-adjusted new cases per 100,000 has continued to 
increase between 1992 and 2013 whilst the number of deaths per 100,000 has remained constant, likely 
representing an increase in early tumour diagnosis in combination with increasing all stage incidence 
related to environmental factors with improved outcomes for patients with metastatic disease. Adapted 
from Surveillance, epidemiology, and end results (SEER) program.  
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A number of identified risk factors contribute to a significantly increased risk of 
sporadic ccRCC and the environmental factors best characterised are obesity and 
smoking (Ljungberg, Campbell et al. 2011). Hypertension and advanced kidney disease 
necessitating dialysis also increase risk (Ljungberg, Campbell et al. 2011). Dietary habits, 
particularly red meat intake and occupational exposure to specific carcinogens have 
been implicated, although evidence for this in the literature is inconclusive (Daniel, 
Schwartz et al. 2011). Moderate alcohol consumption appears to have a protective effect 
and reasons for this are unknown (Bellocco, Pasquali et al. 2012). In up to 50% of cases, 
renal masses are diagnosed incidentally on ultrasound (US) or computed tomography 
(CT) conducted for other medical reasons (Gill, Aron et al. 2010). This has increased 
the incidence of small renal masses, defined as contrast enhancing masses with a 
maximum dimension of 4cm or less (Gill, Aron et al. 2010).  
 
In 1-5% of cases, ccRCC may arise as part of a hereditary syndrome, the most common 
of which is Von-Hippel Lindau syndrome, characterised by germ-line mutations in the 
tumour suppressor gene Von-Hippel Lindau (VHL) (Sudarshan and Linehan 2006). 
Associated focal lesions arise from the inactivation or silencing of the remaining wild 
type allele (Latif, Tory et al. 1993).  
 
For a first-degree relative of a patient with RCC the increased risk of RCC is roughly 
two-fold (Ljungberg, Campbell et al. 2011). Genetic susceptibility and its interaction 
with environmental exposure is thought to influence renal cell cancer risk but limited 
studies identifying candidate genes have thus far proved inconclusive (Chow, Dong et 
al. 2010). However, a large genome-wide association study (GWAS) led by the 
International Agency for Research on Cancer (IARC) and the US National Cancer 
Institute has provided stronger evidence of the association between genetic variants and 
risk of sporadic RCC, identifying for example an association between genetic variants of 
the gene encoding hypoxia-inducible factor-2α (HIF2α) and increased risk of renal 
carcinoma (Purdue, Johansson et al. 2011).   
   Chapter 1: Introduction      
!50!
1.11 Pathology of clear cell renal cell carcinoma 
 
Clear cell renal cell carcinoma (ccRCC) is the commonest RCC, identified in 75-80% of 
cases (Frew and Moch 2015). ccRCCs are renal cortical tumours characterised by 
malignant epithelial cells with clear or eosinophilic cytoplasm and a compact-alveolar or 
acinar growth pattern: tumours are typically highly vascular (Aydin and Zhou 2008). The 
name ‘Clear Cell’ reflects the finding that the cytoplasm is commonly filled with 
glycogen and lipids which are lost upon tissue fixation (Frew and Moch 2015) (Figure 
1.12). In the main, the literature supports the view that most ccRCCs arise from the 
renal proximal tubules with most tumours staining positively for proximal tubule 
markers including CD10 and villin, however some ccRCC can also express distal tubule 
and collecting duct markers such as cytokeratin 19 and CD24 (Frew and Moch 2015).   
 
 
Figure 1.12 Typical histological appearance of clear cell renal cell carcinoma.  
Haematoxylin and eosin staining is demonstrated with nests of epithelial cells with clear cytoplasm and a 
distinct cell membrane, separated by a delicate branching network of vascular tissue. Taken from 
Medscape. 
 
1.12 Genetics of clear cell renal cell carcinoma 
 
1.12.1 Clear cell renal cell carcinoma is a disease of 3p loss 
 
Hereditary ccRCC typically occurs in patients with germline mutations in the tumour 
suppressor gene VHL, a classic tumour suppressor and regulator of HIF1α, located on 
the short arm of chromosome 3 (3p25.3) (Latif, Tory et al. 1993, Crossey, Foster et al. 
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1994). For decades, sporadic ccRCC was defined by the biallelic loss of function of 
VHL, which occurs through a combination of 3p loss and VHL mutation or changes 
in promoter methylation status with such changes observed in over 90% of ccRCC 
tumours Such an early event is designated a trunk event, with loss/mutation, an early 
driver of tumourigenesis.  (Zbar, Brauch et al. 1987, Gnarra, Tory et al. 1994, Kaelin 
2007, Sato, Yoshizato et al. 2013).  
  
However, it is clear that biallelic loss of VHL function is not sufficient for ccRCC 
formation. The study of kidneys of patients with VHL disease, i.e. germline mutations in 
one copy of VHL, has demonstrated that these patients probably have hundreds of 
thousands of functional VHL null single cells or multi-centre clusters of cells, despite no 
evidence of ccRCC (Montani, Heinimann et al. 2010).  
 
Comprehensive large-scale sequencing projects using highly integrative analysis of The 
Cancer Genome Atlas (TCGA) and work undertaken by Sato et al analysed over 400 and 
240 cases of ccRCC respectively.  In the ccRCC samples, whole-genome and/or whole 
exome expression was undertaken, RNA sequencing and array-based gene expression 
was analysed as well as gene copy number and methylation status (Cancer Genome 
Atlas Research 2013, Sato, Yoshizato et al. 2013).  
 
Work by the TCGA Research Network identified that recurrent arm-level and focal 
somatic copy number alterations (SCNAs) occurred at fewer sites than observed for 
other cancers. The SCNAs that did occur, however, more commonly involved entire 
chromosomes or chromosome arms compared to focal events: in 17% of cases 
compared to 0.4% of cases respectively (Cancer Genome Atlas Research 2013). In over 
90% of cases, this chromosomal loss involved loss of chromosome 3p, which 
incorporates VHL, PBRM1, SETD2 and BAP1 genes (Cancer Genome Atlas Research 
2013)  (Figure 1.12). Sato et al observed similar levels of 3p LOH in 94% of ccRCC 
specimens analysed, with 77.6% occurring through simple 3p loss or copy neutral LOH 
(uniparental disomy in 22.4%) (Hakimi, Pham et al. 2013, Sato, Yoshizato et al. 2013).   
 
Intriguingly, when whole-exome sequencing and large-scale targeted sequencing studies 
of these tumours were undertaken, four of the top five significantly mutated genes were 
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located between 3p21 and 3p25 in VHL, PBRMI, SETD2 and BAP1 genes (Hakimi, 
Pham et al. 2013, Sato, Yoshizato et al. 2013) (Figure 1.13).  
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Figure 1.13 Frequency of mutated genes identified in studies by both 
interrogation of the TCGA and by Sato e t  a l . The relationship between the VHL, PBRM1, 
SETD2 and BAP-1 loci on 3p is outlined and the frequency of mutation of commonly mutated genes in 
ccRCC tumours identified by the TCGA investigators and by Sato et al indicated.  Asterisks indicate 
selective deep sequencing of frequently mutated tumour suppressors in addition to samples in the study 
by Sato et al (n=240). Adapted from (Hakimi, Pham et al. 2013) 
 
 PBRM1, SETD2 and BAP1 all function as chromatin and/or histone modifiers. 
(Dalgliesh, Furge et al. 2010, Varela, Tarpey et al. 2011). PBRM1 encodes the 
Polybromo1 (BAF180) protein, which functions as the chromatin targeting subunit of 
the Polybromo complex SW1/SNF (Gossage, Murtaza et al. 2014). SETD2 encodes a 
protein responsible for methylation/demethylation of histone residues whilst BAP1 
encodes a nuclear de-ubiquitylase, which mediates de-ubiquitylation of histones 
(Gossage, Murtaza et al. 2014).  
 
Given that 3p LOH is so commonly observed in ccRCC, loss of function mutations of 
any of these four genes is highly likely to result in complete inactivation of one of four 
tumour suppressors that may be functionally linked. Interestingly, Sato et al 
demonstrated that almost all mutations involving PBRMI, SETD2 and BAP1 occurred 
in a subset of VHL inactivated cases.  In addition, the allelic frequency of mutations of 
SETD2 and BAP1 was significantly less than that for VHL. This indicates that SETD2 
and BAP1 mutations are acquired and selected for from within pre-existing VHL 
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mutated clones and/or PBRM1 mutated clones, in turn potentially contributing to 
further tumour progression.  BAP-1 mutations were also mutually exclusive with 
PBRM1 mutations (Sato, Yoshizato et al. 2013).  
 
There is emerging evidence that these genes function as important tumour suppressors 
in a range of malignancies, with BAP1 for example implicated in mesothelioma 
tumourigenesis (Bott, Brevet et al. 2011) and SETD2 in breast carcinoma 
tumourigenesis (Al Sarakbi, Sasi et al. 2009). In addition, Hakimi et al have demonstrated 
that BAP1 mutations are associated with worse cancer specific survival in ccRCC, 
(Section 1.20) (Hakimi, Pham et al. 2013)   
 
1.12.2 Copy number alterations at other loci in ccRCC 
 
Sato et al and the TCGA Research Network investigators observed frequent copy 
number alterations at other chromosome loci, often involving large chromosome 
segments. Gain of 5q was observed in 67% of samples tested by the TCGA network, 
and further analysis refined this area to the 5q35 region (Cancer Genome Atlas Research 
2013). Sato et al observed gain of 5q in 65% of samples (Sato, Yoshizato et al. 2013). 
The relevant target(s) of this amplification are not known, although 5q amplification 
does lead to overexpression of the SQSTM1 oncogene, also known as the ubiquitin-
binding protein p62, an autophagosome carrier protein that can target proteins that bind 
to it for selective autophagy (Cassidy and Narita 2015) and known to promote resistance 
to redox stress in vitro (Li, Shen et al. 2013). Interestingly as outlined in Section 1.7.4, 
LIMD1 can bind to p62, and in osteoclasts leads to the activation of a signalling cascade 
activating genes critical in normal bone development (Feng, Zhao et al. 2007).    
 
Gain of 7q (41%), loss of 8p and or 8q (20%) and loss of heterozygosity at 9p were all 
commonly observed in samples tested by Sato et al (Sato, Yoshizato et al. 2013). Arm 
level losses on chromosome 14q were also common, seen in 45% of samples tested by 
the TCGA research network (Cancer Genome Atlas Research 2013).  
 
Loss of 14q has been described in other studies.  Kroeger et al analysed 288 ccRCC 
tumours and identified loss of 14q in 28% of tumours. Of note HIF1α is 14q encoded 
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and Kroeger et al hypothesised that 14q loss was a surrogate marker for HIF1α loss 
(Kroeger, Klatte et al. 2013).  
 
In ccRCC with intact VHL, Sato et al observed mutations in TCEBI in 36-42% of cases 
(Sato, Yoshizato et al. 2013). TCEB1, located on chromosome 8q21, encodes Elongin 
C, a subunit of the heterotrimeric RNA polymerase II elongation factor and a vital 
component of the VHL complex, important in accomplishing ubiquitylation of VHL-
bound HIF proteins (Aso, Lane et al. 1995). Sato et al demonstrated that mutations in 
TCEBI were always accompanied by LOH at 8q21. In addition, there were no 
significant differences in the clinico-pathological characteristics of cases with VHL 
mutations and those with mutations in TCEB1 (Sato, Yoshizato et al. 2013), suggesting 
that loss of functional TCEB1 or VHL have an equivalent role in driving ccRCC 
tumourigenesis.  
Other frequently identified mutational targets in ccRCC include TET2 (mutated or 
deleted in 16% of tumours), KEAP1 and MTOR. TET2 is believed to play a critical step 
in DNA demethylation (Tahiliani, Koh et al. 2009) whilst KEAP1 is a key component 
of a cullin-RING ubiquitin ligase complex involved in the oxidative stress response 
(Kansanen, Kuosmanen et al. 2013).  Sato et al identified that including MTOR, 26% of 
tumours had mutations that involved the PI3K-AKT-mTOR signalling pathway 
(Hakimi, Pham et al. 2013, Sato, Yoshizato et al. 2013) and this closely correlates with 
the figure of 28% observed by the TCGA investigators (Cancer Genome Atlas Research 
2013). 
 
1.13 Hypoxia inducible factors in ccRCC  
 
Rapid tumour cell proliferation often results in tumour outgrowth of vascular supply 
and disorganised neo-angiogenesis with resultant areas of tumour hypoxia (Carroll and 
Ashcroft 2005, Pal and Figlin 2011).  
Such hypoxia results in tumour adaptations with consequent pro-tumourigenic effects. 
The transcription factor and regulator of tumour oxygen homeostasis HIF, is the major 
protein up-regulated by tumour hypoxia (Schito and Semenza 2016). Tumour hypoxia 
also results in relative resistance to apoptosis through for example loss of functional p53 
(Graeber, Osmanian et al. 1996). In addition mechanisms that include NFκB and 
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activator protein 1 (AP-1) up-regulation initiate pro-survival mechanisms that increase 
cell proliferation, migration and invasion (Dong, Venkatachalam et al. 2001, 
Pennacchietti, Michieli et al. 2003, Eales, Hollinshead et al. 2016). Deregulation of such 
pathways drives tumourigenesis and thus pathogenesis of cancer (Pantuck, Zeng et al. 
2003, Pouyssegur, Dayan et al. 2006, Koul, Huh et al. 2011, Eales, Hollinshead et al. 
2016).  
1.13.1 Overview of hypoxia inducible factors 
 
 Heterodimeric HIFs are DNA binding complexes that direct the transcription of genes 
with HREs. There are three isoforms of the HIF-α subunit, HIF1-α, HIF-2α and HIF-
3α that form heterodimers with a constitutively expressed, stable β subunit (Figure 
1.14) (Loboda, Jozkowicz et al. 2010). The HIFα/β heterodimer binds HREs in the 
promoters of target genes. HIF-1α and HIF-2α are critical mediators of the hypoxic 
response, whilst the role of HIF-3α is less well characterised (Loboda, Jozkowicz et al. 
2010).  Both HIF1α and HIF2α are closely related at a protein level with a similar 
domain structure and activate a similar broad pattern of genes, although there are some 
critical differences (Hu, Wang et al. 2003, Hu, Sataur et al. 2007, Webb, Coleman et al. 
2009).  HIF3α, has six splice variants, one of which can function in a dominant negative 
role to impair the induction of hypoxia inducible genes and when co-expressed with 
HIF1α, prevents HIF1α DNA/HRE interaction (Loboda, Jozkowicz et al. 2010). In 
addition HIF3α lacks a C-terminal activation domain and therefore cannot function as 
an effective transcriptional activator (Pasanen, Heikkila et al. 2010) (Figure 1.14).  
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Figure 1.14 HIFα and HIFβ subunits. 
HIFs consist of an α and a β subunit which share considerable homology. There are three human 
isoforms of the α subunit and two of the β-subunit. The functional domains include a basic helix-loop-
helix (bHLH) domain that mediate DNA binding and two per-ARNT-pas (PAS) domains that mediate 
interaction with the HIFα/β subunit. The α-subunits contain an ODDD domain that is required for 
oxygen dependent hydroxylation and subsequent degradation via the proteasome. Proline hydroxylase 
proteins (PHDs) facilitate hydroxylation of the ODDD and this in turn can be inhibited by factor 
inhibiting HIF (FIH).  C and N-terminal transactivation domains (TADs) are identified in both HIF-1α 
and HIF-2α and facilitate interaction with the p300/DBP transcriptional co-activator. HIF3α lacks a 
CTAD.  Nuclear localisation signals (NLS) target HIF proteins to the nucleus. Adapted from (Brahimi-
Horn and Pouyssegur 2007) 
1.13.3 The von Hippel-Lindau (VHL) protein 
Loss of and mutations in the VHL gene in both hereditary and sporadic ccRCC have 
been described. The VHL gene encodes two isoforms of pVHL, one a 213-amino acid, 
30kDa isoform (pVHL30) and the second a 160-amino acid 19kDa form (pVHL19) 
(Blankenship, Naglich et al. 1999) pVHL19 is the isoform that predominates in many 
tissues and lacks a 53 amino-acid terminal pentameric acid repeat domain (Gossage, 
Eisen et al. 2015). Functional studies suggest that both forms have broadly equivalent 
effects in driving tumourigenesis in vitro and tumour suppressor activity in vivo 
(Iliopoulos, Ohh et al. 1998) (Schoenfeld, Davidowitz et al. 1998) although some 
differences are apparent with only one isoform, regulating microtubule function 
(Ratcliffe 2003).   
 
pVHL is composed of an α and β domain which are closely coupled, with the α-domain 
consisting of three α helices and the β-domain, two β-sheets with an α-helix on top 
(Gossage, Eisen et al. 2015).  Work in VHL deficient RCC lines demonstrated 
constitutively high expression of genes containing HRE elements including VEGF and 
GLUT1 and following re-expression of function VHL, expression levels were 
significantly downregulated. VHL was shown to bind to HIF1α and decrease protein 
levels without affecting its mRNA expression suggesting that it played a critical role in 
the regulation of HIFα (Gnarra, Zhou et al. 1996, Iliopoulos, Levy et al. 1996) 
 
Work in the 1990s, demonstrated that the VHL complex forms a ternary complex by 
binding to transcription elongation factors C and B to form the VCB complex, a 
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functional E3 ligase critical for pVHL function (Kibel, Iliopoulos et al. 1995). The VCB 
complex in turn nucleates a complex containing cullin 2 (CUL2) and the RING finger 
protein (RBX1), to form the VCB-CR complex (Stebbins, Kaelin et al. 1999).  Elongin 
B and C act as adapters that link pVHL in the VCB-CR complex to heterodimers of 
CUL2 and RBX1 and this interaction stabilises pVHL and elongin B and C, with the 
resultant complex resistant to degradation via the proteasome (Schoenfeld, Davidowitz 
et al. 2000). By contrast, pVHLs that harbour mutations disrupting elongin binding 
undergo rapid proteasome mediated degradation (Stebbins, Kaelin et al. 1999).  
 
1.13.4 Prolyl hydroxylases (PHDs) 
 
Subsequent work demonstrated that the HIFα domain bound exclusively to the β-
domain of pVHL and that this binding is dependent on the hydroxylation of two, 
conserved proline resides within HIFα by PHD1, PHD2 or PHD3.  Mutational 
mapping identified the proline residues 402 and 564 within HIF1α as the targets for 
PHD hydroxylation with mutation of either residue leading to a stabilisation of HIF1α 
protein levels (Brahimi-Horn and Pouyssegur 2007). PHD mediated hydroxylation of 
HIFα requires oxygen as a co-substrate and PHDs are therefore normally only active in 
normoxia and PHD proteins are the major oxygen sensors of the cell (Brahimi-Horn 
and Pouyssegur 2007).  
 
Prolyl hydroxylation of HIFα by PHD leads to HIF recognition and ubiquitylation by 
the VCB-CR complex and in turn polyubiquitylated HIFs are recognised and degraded 
by the cellular proteasome. However, under hypoxic conditions, or in the absence of 
functional pVHL, HIFα accumulates and transcriptional regulation of genes with HIF-
responsive elements result (Figure 1.14) (Pantuck, Zeng et al. 2003, Brahimi-Horn and 
Pouyssegur 2007). 
 
1.13.5 HIF-1 and HIF2 regulation 
 
In hypoxia or where hypoxic deregulation has occurred, HIF1α/2α heterodimerises 
with HIFβ and the complex in turn recognises a conserved DNA consensus sequence 
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within the promoters of target gene HREs. In turn the HIFα/β complex recruits the 
transcriptional co-activators p300 and CREB-binding protein (CBP). HIF1α contains 
two transcriptional co-activator domains, the N-terminal transactivation domain 
(NTAD) and C-terminal transactivation domain (CTAD), linked by an inhibitory 
domain. The NTAD overlaps with the oxygen-dependent degradation domain (ODD) 
(Brahimi-Horn and Pouyssegur 2007)).  
 
Hydroxylation of conserved proline residues in the ODD domain and lysine acetylation 
confers recognition by the VHL-ubiquitin E3 ligase complex under normal oxygen 
tension (Ke and Costa 2006).  In hypoxia, however inhibition of hydroxylation by the 
PHDs results in stabilisation of HIFα/β and subsequent transcriptional activation of 
target genes.  
 
Factor inhibiting HIF (FIH-1) 
 
 Asparaginyl hydroxylation of HIF-α by FIH-1 prevents the interaction of the C-TAD 
with the transcriptional co-activator CBP/p300 (Webb, Coleman et al. 2009) and 
provides a further oxygen-dependent mechanism in the control of HIF that is 
independent of HIF-α stability regulation by HIF PHDs (Figure 1.15). FIH-1 and the 
PHDs belong to the same superfamily of dioxygenases and in general require the same 
set of cofactors (oxygen, 2-oxoglutarate and ferrous iron), but there are differences 
between these enzymes. Firstly, FIH-1 has a higher affinity for molecular oxygen 
relative to the PHDs, and this suggests that in mild hypoxia FIH-1 can remain active 
while the PHDs are inactivated (Figure 1.15) (Webb, Coleman et al. 2009). This is 
potentially important because not all HIF target genes are equally dependent on the 
function of the C-TAD (Ke and Costa 2006)  
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Figure 1.15 HIF-1α regulation by proline hydroxylation. In normoxia, HIF1α is 
hydroxylated by PHDs 1, 2 and 3 in the presence of O2, Fe2+, 2-oxoglutarate (2-OG) and ascorbate. 
Consequently hydroxylated HIF-1α is inactivated through its interaction with the VHL-ubiquitin E3-
containing complex that ubiquitinates HIF1α targeting it for degradation via the proteasome and 
abrogating interaction with the co-activator p300/CBP. In hypoxia or in the absence of a function VHL 
complex, HIF1α is stabilised and interacts with HIF1β leading to transcriptional activation of genes 
containing HRE elements. Adapted from (Brahimi-Horn and Pouyssegur 2007)  
 
1.14 HIF1α and HIF2α regulate the transcription of different genes 
 
HIF1α and HIF2α can regulate the expression of many of the same hypoxia-induced 
genes but also have unique transcriptional targets.  This transcriptional specificity 
resides in differences in the N-TAD domain, and subsequent differential interactions 
with transcriptional co-factors (Hu, Sataur et al. 2007, Loboda, Jozkowicz et al. 2010, 
LaGory and Giaccia 2016). For example SLC2A1, which encodes GLUT1 and CA12 
which encodes CAXII are target genes of both HIF1α and HIF2α, whilst genes that 
play an important role in mediating glycolysis such as PFK (encoding 
phosphofructokinase), and HK1/2 (encoding hexokinase 1 and 2) are solely HIF1α 
target genes. In contrast, EPO, encoding erythropoeitin and POU5F1 encoding the stem 
cell identify factor OCT4 are predominantly regulated by HIF2α (Keith, Johnson et al. 
2012).  
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There are also clear differences in the patterns of expression of HIF-1α and HIF-2α.  In 
normal tissue, HIF-1α is ubiquitously expressed whilst HIF-2α expression is less 
ubiquitous, predominating in the kidney, lung, heart, and small intestine (Gordan, 
Bertout et al. 2007, LaGory and Giaccia 2016). Differential expression of HIF-1α and 
HIF-2α are also key in driving key development processes with HIF-1α for example 
playing a key central role in early vascular and bone development, a role that is 
subsequently assumed by HIF-2α as oxygen tension increases (Koh and Powis 2012).  
HIF-1α and HIF-2α additionally have play different roles in the regulation of myeloid 
gene function with HIF-1α upregulation associated with anti-microbial effector function 
of myeloid cells and the pathophysiology of sepsis. HIF-1 drives the upregulation of 
macrophage derived VEGF, whilst HIF-2α drives macrophage production of soluble 
VEGFR-1, suggesting specific and independent roles for HIF-1α and HIF-2α (Eubank, 
Roda et al. 2011).  
HIF-1α and HIF-2α levels are regulated by differential post-transcription and post-
translational modulation. For example, hypoxia-associated factor (HAF), an ubiquitin 
ligase that functions in an oxygen independent fashion, targets HIF1α but not HIF2α 
for proteolytic degradation (Koh and Powis 2009), HAF can bind HIF-2α, but at a 
different site to HIF-1α, increasing HIF-2α transactivation without causing its 
degradation (Koh and Powis 2009). In addition, specific PHD enzymes have differential 
effects on HIF-1α/HIF-2α with for example PHD3 preferentially hydroxylating HIF-2α 
in multiple cell lines (Appelhoff, Tian et al. 2004) 
1.14.1 HIF1α and HIF2α in tumourigenesis 
 
Increased HIF-1α and HIF-2α expression has been observed in a broad range of human 
cancer cell types including bladder, breast, gastric, head and neck, ovarian and renal cell 
carcinomas (Keith, Johnson et al. 2012). For most tumour types both HIF-1α and HIF-
2α over-expression appear to result in worse prognosis although this is not the case for 
some tumour types.  In neuroblastoma for example HIF-1α overexpression is 
associated with a better prognosis and HIF-2α over-expression with a worse prognosis 
(Keith, Johnson et al. 2012). 
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Comparison of HIF1α and HIF2α functions in a KRAS driven mouse model of lung 
tumourigenesis demonstrated that Hif1a deletion had little effect on tumour burden and 
tumourigenesis whilst overexpression of a stabilised HIF-2α protein promoted tumour 
angiogenesis and invasion through the expression of VEGFA and SNAIL (Kim, Perera 
et al. 2009).  !
In ccRCC, VHL inactivation is observed in over 90% of tumours. In tumours with wild 
type pVHL, biallelic inactivation of TCEB1, (which encodes elongin C), is observed in 
42% of tumours. This in turn leads to constitutive HIF-α activity, suggesting that there 
is a strong selective pressure to inactivate the normal controls that result in HIF-α 
degradation (Sato, Yoshizato et al. 2013, Frew and Moch 2015).  
 
HIF-1α and HIF-2α are not equivalent in driving ccRCC tumourigenesis and increasing 
evidence supports the observation that HIF-2α plays a more critical pro-tumourigenic 
role: HIF-1α may in fact function as a tumour suppressor (Raval, Lau et al. 2005). Raval 
et al demonstrated that in VHL-defective RCC cells, enhanced expression of HIF-2α 
resulted in reduced HIF-1α expression and the reverse was also observed:  this may be 
related to a reverse hypoxia response element in the HIF1A promoter region resulting 
in epigenetic silencing of HIF1A mRNA expression.  Raval et al also demonstrated that 
in VHL-defective RCC lines, HIF-1α and HIF-2α have contrasting effects on the 
biology of RCC with HIF2α but not HIF-1α driving the expression of cyclin D1, TGFα 
and VEGF, whilst the pro-apoptotic gene encoding BNip3 is promoted positively by 
HIF-1α and negatively in HIF-2α (Raval, Lau et al. 2005).  
The balance between HIF1-α and HIF2-α activation also appears important in ccRCC 
tumourigenesis. In an RCC tumourigraft model, HIF-1α overexpression retarded 
tumour growth whilst HIF-2α overexpression enhanced growth (Raval, Lau et al. 2005), 
similar results were also observed by Biswas et al in 786-0 xenografts (Biswas, Troy et al. 
2010).  
 
HIF-1α can oppose the activity of the cell cycle promoting protein MYC through direct 
binding to MYC (Koshiji, Kageyama et al. 2004) and by the upregulation of 
proteasome-dependent MYC degradation (Zhang, Gao et al. 2007). HIF-2α on the 
other hand enhances MYC activity resulting in cell cycle progression through the 
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upregulation of cell-cycle promoting genes such as CYCLIN D1 and CYCLIN D2 
(Gordan, Bertout et al. 2007). In sporadic ccRCC cases that express both HIF-1α and 
HIF-2α, MYC activity is reduced with lower frequencies of proliferating tumour cells in 
comparison to tumours that express only HIF-2α (Frew and Moch 2015).  
In ccRCC cell lines, HIF-1α and HIF-2α expression levels are differentially dependent 
on the activities of the mammalian target of rapamycin complex 1 (mTORC1) and 
mTORC2 as well as the AKT-1, AKT2 and AKT3 kinases (Toschi, Lee et al. 2008). 
Since mutational activation of the PI3K-mTOR pathways is common in ccRCC, it may 
be that deregulation of this pathway contributes to the differential expression of HIF1α 
and HIF-2α (Frew and Moch 2015).  
In addition, HAF can regulate the differential expression of HIF-1α and HIF-2α driven 
genes, trans-activating HIF-2α and targeting HIF-1α for degradation. This is turn up-
regulates HIF-2α mediated gene expression with upregulation of genes involved in 
invasion such as MMP9, PAI-1 and the stem cell factor OCT-3/4 and also promoting 
EMT. Chronic hypoxia up-regulates HAF transcription, potentially further driving a 
switch from a HIF-1α to HIF-2α dependent response to hypoxia (Koh, Lemos et al. 
2011).  
In patients with VHL-disease where tumour cells are VHL-null, early kidney lesions 
tend to express more HIF-1α and more advanced lesions more HIF-2α (Raval, Lau et 
al. 2005).  This may result from chromosomal changes that occur during ccRCC 
progression. Single copy loss of 14q, which harbours the HIF1A locus predicts worse 
outcome and biallelic loss of function of HIF-1α is common (Shen, Beroukhim et al. 
2011).  Certainly in vivo analysis of HIF-1α overexpression in some series has correlated 
with both favourable and unfavourable prognostic features (Lidgren, Hedberg et al. 
2005, Klatte, Seligson et al. 2007), whilst HIF-2α overexpression has generally 
correlated with worse clinico-pathological parameters, with subcellular localisation 
implicated in prognosis (Kroeger, Seligson et al. 2014). 
  
1.14.2 Activation of the PI3K-AKT-mTORC1 signalling pathway in ccRCC 
through HIF activation  
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 The HIFα/β complex drives the transcription of growth factors such as VEGF, 
platelet derived growth factor (PDGF) and transforming growth factor-α (TGF-α) 
(Oosterwijk, Rathmell et al. 2011). VEGF binds and activates the VEGF receptors 1 
and 2 (VEGF-R1 and 2), which stimulates angiogenesis through the downstream 
activation of the PI3K-AKT-mTORC1 signalling pathway (de Vries, Escobedo et al. 
1992, Millauer, Wizigmann-Voos et al. 1993) (Figure 1.16).   VEGFR-2 activation 
promotes endothelial cell proliferation, migration and vascular permeability whilst 
activation of VEGFR-1 results in neo-vascularisation through the organisation of new 
capillaries, and the recruitment of vascular smooth muscle cells and pericytes (de Vries, 
Escobedo et al. 1992, Millauer, Wizigmann-Voos et al. 1993, Sakamoto, Ryan et al. 
2008). Tyrosine-kinase inhibitors (TKIs) used in the treatment of metastatic ccRCC 
effect responses through the targeting of VEGF receptor tyrosine kinases, whilst the 
monoclonal antibody bevacizumab targets the VEGF-R preventing VEGF binding 
(Oosterwijk, Rathmell et al. 2011) (Figure 1.16).  
 
VEGF, PDGF and TGF-β activation in addition activate the mTOR pathway, which in 
turn generates a positive feedback loop to increase cellular HIFα levels (Cho, Signoretti 
et al. 2007). mTOR, forms a complex with a regulatory-associated protein to form 
mTORC1 and with a separate complex to form mTORC2 (Faivre, Kroemer et al. 2006, 
Koul, Huh et al. 2011). Downstream activation of mTORC1 results in upregulation of 
protein synthesis, entrance into the G1 phase of the cell cycle and down-regulation of 
proteins that regulate apoptosis (Faivre, Kroemer et al. 2006). mTOR inhibitors such as 
everolimus predominantly mediate their effects through the downregulation of anti-
angiogenic pathways and in particular effects on endothelial cells and pericytes (Le 
Tourneau, Faivre et al. 2008) (Figure 1.16) 
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Figure 1.16 Schematic overview of hypoxic deregulation in ccRCC and the 
mechanism of action of targeted therapies. Sunitinib, sorafenib, axitinb and pazopanib are 
small molecular inhibitors of multiple receptor tyrosine kinase receptors including VEGF-R and PDGF-
R. Temsirolimus and everolimus inhibit the kinase activity of the mTOR complex 1. Bevacizumab is a 
VEGF ligand-binding monoclonal antibody. Adapted from (Oosterwijk, Rathmell et al. 2011)  
 
Additional genomic mutations of genes that regulate the PI3K-mTORC1 signalling 
cascade are common and observed in approximately 20% of all ccRCC cases and such 
mutations often occur in a mutually exclusive fashion.  Such mutations include ‘loss of 
function’ mutations of negative regulators of the pathway such as PTEN, and TSC1 and 
activation mutations of positive regulators such as PIK3CA, PIK3CB, and AKT1/2/3 
(Cancer Genome Atlas Research 2013). In a subset of ccRCCs, in addition to loss of 
function mutations of VHL, it appears that there is a selective advantage obtained from 
additional co-operating mutations that generate further deregulation of the PI3K 
signalling pathways (Frew and Moch 2015).   
 
1.14.3 HIF-1α and HIF-2α as central metabolic regulators in ccRCC 
 
HIF-α activation results in the upregulation of the expression of glucose transporters 
and almost all glycolytic enzymes and also induces pyruvate dehydrogenase kinase 1 and 
lactate dehydrogenase A (Iyer, Kotch et al. 1998), causing a Warburg-like metabolic 
shift, driving pyruvate away from mitochondrial oxidation. Reactive oxygen species play 
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an important role in signalling cascades that stimulate malignant cell growth. Cells that 
are VHL-deficient have increased level of NOX4 and NADPH-dependent superoxide. 
Reactive oxygen species in turn regulate hypoxia-dependent and hypoxia-independent 
activation of HIF-2α (Block, Gorin et al. 2007). In addition, alterations in other genes 
such as p53, MYC and PI3K-mTORC1 pathway components will result in significant 
changes in cellular metabolism (Frew and Moch 2015).  
 
1.14.4 Hypoxic deregulation affects cell cycle regulation in ccRCC 
 
Loss of VHL function in primary mouse cells appears to engage cell cycle checkpoint 
and/or senescence pathways and impair cellular proliferation. In sporadic ccRCC in 
around 40% of tumours, mutations or copy number deletions of genes that encode 
components of cell-cycle and senescence regulatory networks such as CDKN2A, TP53, 
RB1 and ATM, or copy number gains of chromosomal regions that span MYC or 
MDM4 are observed (Cancer Genome Atlas Research 2013, Sato, Yoshizato et al. 
2013). HIF-α activation also induces the expression of transforming growth factor alpha 
(TGF-α), which results in activation of an EGF-R/PI3K/AKT/IκB-kinase-α/NFκB 
signalling cascade (An and Rettig 2005). NFκB activation increases cell cycle transition 
through the induction of cyclin D1, driving cell transition from G1 to S, in addition, 
upregulation is association with an increase in cell proliferation, tissue invasion, 
angiogenesis and apoptosis inhibition (Guttridge, Albanese et al. 1999).  
 
1.14.5 Loss of pVHL affects microtubule function  !
pVHL regulates the orientation of mitotic cell division and ensures the fidelity of the 
mitosis spindle checkpoint in a HIF-α independent fashion. Loss of pVHL leads to 
reduced MAD2 expression (Thoma, Toso et al. 2009), a key component of the mitotic 
spindle checkpoint that prevents onset of anaphase until all chromosomes are correctly 
aligned (Thoma, Toso et al. 2009).  Microtubules are crucial for the maintenance of cell 
shape and polarity, and in addition critical for cilia maintenance: pVHL plays an 
important role in cilia maintenance and in human cells lacking pVHL, cilia formation 
does not occur which in adult kidney cells results in the formation of pre-cancerous 
renal cysts (Schermer, Ghenoiu et al. 2006).   
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1.14.6 Mitogen-activated protein kinase (MAP-K) deregulation in ccRCC 
 
Mitogen-activated protein kinase (MAPK) pathway kinases (MKK) play a critical role in 
the regulation of cell differentiation, survival and proliferation (Pearson, Robinson et al. 
2001). Upon activation, MKKs phosphorylate MAPKs such as the extracellular signal-
regulated protein kinase (ERK), c-Jun-NH2 kinase (JNK) and p38 MAP-K (Robinson 
and Cobb 1997). Sustained activation of ERK is an established requirement for 
angiogenesis and overexpression of MKK has been described in RCC (Oka, Chatani et 
al. 1995).  
 
1.15 MiRNA deregulation in ccRCC 
 
The role of LIMD1, Ajuba and WTIP in the regulation of miRNA mediated mRNA 
silencing has been outlined (James, Zhang et al. 2010, Bridge, Shah et al. 2017). Chen et 
al performed systematic and integrative analysis of 5 public miRNA expression datasets 
in ccRCC comparing expression profiles with that of normal renal tissue. This identified 
eleven deregulated miRNAs shared by five independent datasets that could distinguish 
normal kidney from ccRCC. Differentially enriched miRNA target genes played a 
critical role in cell cycle and transcription regulation, particularly the G1/S transition. 
Other pathways that demonstrated differential enrichment were involved in receptor 
mediated HIF regulation, as well as PTEN, TGF, and WNT pathways and the control 
of cytoskeletal remodelling (Chen, Zhang et al. 2013).   
 
Increasing evidence supports the role of miRNAs in the regulation of the VHL/HIF 
axis with for example miR-17-5p and miR-224 acting as direct targets of both VHL and 
HIF1α. miR-138 was identified as a negative regulator of HIF1α with upregulation 
associated with increased apoptosis and migration of ccRCC cells (Song, Zhang et al. 
2011). miR-210 has been shown to be expressed at higher levels in tumours with VHL 
mutations and is strongly regulated by both HIF-1α and to a lesser extent HIF-2α 
(McCormick, Blick et al. 2013)  Overexpression of miR-210 has been shown to correlate 
with better clinico-pathological features, low tumour grade, stage and Ki-67 levels. 
Patients undergoing nephrectomy for localised RCC with tumours expressing high miR-
210 had significantly longer OS than those with tumours with low miR-210 levels 
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(McCormick, Blick et al. 2013, Samaan, Khella et al. 2015). miR-122 upregulation has 
also been shown to play an important role in RCC progression by activating the 
PI3K/Akt signalling pathways. Numerous miRNAs are also downregulated in ccRCC 
with for example miR-187, miR215, miR-217, miR-155 and miR1826 associated with 
poorer prognosis (shorter survival or early recurrence) (Li, Wang et al. 2015).  
 
In an analysis of 316 patients with RCC, genetic variations in microRNA-related genes 
notably DICER and DROSHA have been shown to associate with worse survival and 
increased risk of tumour recurrence. Interestingly in this same cohort, cumulative effects 
of multiple SNPs impacted on RCC survival, with patients carrying six or more 
unfavourable SNPs demonstrating a 6.66 fold increased risk of death compared to those 
with two or fewer unfavourable SNPs (95% confidence interval (CI) 2.49-17.86) (Lin, 
Horikawa et al. 2010).  
 
1.16 Hippo pathway deregulation in ccRCC !
Schütte et al have demonstrated that aberrant Hippo signaling is important in driving 
ccRCC proliferation and invasiveness. Immunohistochemical staining of 31 ccRCC 
tumours demonstrated nuclear overexpression of the Hippo target YAP, which was 
particularly prominent at the tumour edge suggesting that overexpression was driving 
tumour invasion. In vitro, shRNA mediated knockdown of YAP significantly inhibited 
the proliferation and migration of ccRCC cells in soft agar assays, whilst in a mouse 
xenograft ccRCC model, YAP knockdown significantly reduced tumour growth. 
Microarray analysis of YAP knockdown versus mock-transduced ccRCC cells 
demonstrated the down-regulation of endothelin 1 and 2 and the angiogenic inducer 
CYR61 as well up-regulation of the cell adhesion molecule cadherin 6 and c-myc 
(Schutte, Bisht et al. 2014).    
1.17 Presentation of renal cell carcinoma 
 
Historically a classic triad of haematuria, palpable abdominal mass and flank pain has 
been described, however fewer than 10% of patients now present in this manner and 
such symptoms are associated with advanced disease and consequent poor prognosis 
(Patard, Leray et al. 2003). Up to 50% of patients are diagnosed incidentally on imaging 
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for other medical reasons (Gill, Aron et al. 2010). Paraneoplastic syndromes are 
common and occur in approximately 30% of patients and are related to tumour-
mediated cytokine release, in particular interleukin-6 (IL-6), erythropoietin (EPO), 
parathyroid related peptide (PTH-RP) and nitric oxide (NO) production and can result 
in constitutional syndromes such as weight loss, fever and malaise.  Other 
paraneoplastic syndromes results in specific metabolic and biochemical abnormalities, 
such as hypercalcaemia as a result of PTH-RP production and erythrocytosis related to 
EPO production (Palapattu, Kristo et al. 2002).  
 
1.18 Diagnosis of renal cell carcinoma 
 
US and CT are commonly undertaken to detect and evaluate renal masses with CT 
playing an important role in the staging of RCC (Israel and Bosniak 2005). The presence 
of a contrast enhancing mass on CT is highly suggestive of malignancy (Israel and 
Bosniak 2005). Renal ultrasonography can be useful for the further evaluation of 
questionable cystic renal masses if CT imaging is inconclusive but large papillary 
tumours may be overlooked by renal ultrasonography (Israel and Bosniak 2005). 
Positron emission tomography (PET) is not a standard imaging modality of choice 
(Ljungberg, Bensalah et al. 2015). Further characterisation of possible lung metastases or 
enlarged mediastinal lymph nodes should be undertaken with contrast enhanced CT 
scan of the chest (Ljungberg, Bensalah et al. 2015). Most individuals with bone or brain 
metastases are symptomatic and in such patients further appropriate targeted imaging 
should be undertaken with for example bone scan or MRI of the brain (Ljungberg, 
Bensalah et al. 2015).  
 
Following the identification of a renal mass, most renal masses will be further evaluated 
with a percutaneous renal biopsy. At least two quality cores (non-fragmented and 
>10mm in length) should be taken and peripheral biopsies are preferable to central to 
avoid the issue of central necrosis (Ljungberg, Bensalah et al. 2015).    
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1.19 Treatment of clear cell renal cell carcinoma 
 
1.19.1 Treatment of organ-confined ccRCC 
 
Treatment of organ-confined disease is typically with partial nephrectomy (PN) or 
radical nephrectomy (RN): this is the only curative treatment with associated high-
quality evidence. Smaller T1a-b tumours should be managed by PN if technically 
feasible as there is no difference in cancer-specific relapse between a PN or RN 
approach, but all-cause mortality is increased in patients undergoing RN where tumours 
are less than four centimetres (MacLennan, Imamura et al. 2012). PN can be performed 
using an open or laparoscopic or robot-assisted laparoscopic approach (Ljungberg, 
Bensalah et al. 2015). For larger tumours, lower morbidity is associated with a 
laparoscopic, compared to open RN approach and this approach is therefore preferable 
where technically possible (Ljungberg, Bensalah et al. 2015).  
 
Radiofrequency ablation or cryo-ablation remain alternative validated approaches in 
patients with small tumours; particularly in those not fit enough to undergo surgery 
(Escudier, Porta et al. 2014). Microwave ablation, laser ablation and high intensity 
focused US ablation are considered experimental approaches and are not routinely 
recommended (Ljungberg, Bensalah et al. 2015).  
1.19.2 Treatment of metastatic ccRCC (mccRCC) !
1.19.2.1 Surgery in mccRCC 
 
Cytoreductive nephrectomy is recommended in patients with good PS and a large 
primary tumour with limited volume of metastatic disease and in those with a 
symptomatic primary tumour, for example causing significant pain or haematuria 
(Escudier, Porta et al. 2014). Two large multi-centre phase III trials, the CARMENA 
and Surtime EORTC-GU 30073 evaluated the role of upfront nephrectomy versus TKI 
treatment with Overall Survival (OS) and Progression Free rate at 28 weeks as their 
respective primary endpoints. The CARMENA trial, a randomised multi-centre trial of 
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patients with synchronous mRCC randomised patients 1:1 to either 12 weeks of neo-
adjuvant suntinib prior to nephrectomy or sunitinib alone without nephrectomy. This 
non-inferiority trial demonstrated no statistically significant difference in OS for 
sunitinib along compared to sunitinib prior to nephrectomy (Hazard ratio (HR) for 
death 0.89, 95% CI 0.71-1.10)) (Mejean, Ravaud et al. 2018). The EORTC-GU 30073 
study (SURTIME) randomised patients with resectable, synchronous metastatic ccRCC 
to either immediate nephrectomy followed by sunitinib or deferred nephrectomy with 
neo-adjuvant sunitinib for twelve weeks.  Results demonstrated that there was no 
difference in progression free rate at 28 weeks between the two arms but strikingly, 
although the sample size was small, OS stratified by the intention to treat population 
was significantly increased in the deferred nephrectomy group at 32.4 months (95% 
confidence interval (CI) 14.5-63.5 months) versus 15.1 months (95% CI 14.5-63.5 
months). In addition, there were fewer surgical complications in the deferred arm at 
27.5%, versus 43.5% (Bex, Mulders et al. 2017). Such practice changing clinical trials are 
redefining the role of upfront nephrectomy in this patient group.  
 
Metastatectomy with resection of metastatic lesions can play in role in fit patients with a 
limited burden of disease, e.g. solitary or easily accessible pulmonary metastases and 
tumour characteristics suggesting reasonably indolent disease (Ljungberg, Bensalah et al. 
2015).  Resection of solitary lung metastases may provide a survival benefit in a 
subgroup of patients without aggressive tumour characteristics (Karam, Rini et al. 2011).  
 
1.19.2.2 Chemotherapy and radiotherapy in mccRCC !
Chemotherapy and radiotherapy play a limited role in the treatment of metastatic 
ccRCC. Most ccRCC tumours demonstrate a degree of chemotherapy resistance, in part 
related to tumour production of large amounts of a multi-drug resistance protein, 
leading to cellular cytotoxic drug efflux (Tobe, Noble-Topham et al. 1995). Relative 
tumour hypoxia and disorganised angiogenesis, impairing tumour-associated drug 
delivery are also likely to contribute (Karakashev and Reginato 2015).  Combination 
chemotherapy with irinotecan, cisplatin and mitomycin-C (IPM) does for example 
demonstrate some efficacy: in a retrospective analysis of 62 patients, 64% of patients 
derived some benefit following the failure of cytokine therapy (Shamash, Powles et al. 
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2005). The role of chemotherapy is however increasingly diminishing since the 
introduction of effective targeted therapy.   
 
RCCs have traditionally been considered relatively radioresistant, defined as a poor 
clinical response to conventional radiotherapy doses. The radiobiologic characteristics 
of in vitro survival curves are considered important determinants of tumour response to 
conventional radiotherapy with the classic measure of radiosensitivity defined as the 
survival fraction of cells in a clonogenic survival curve after a 2 Gy radiation exposure 
(Ning, Trisler et al. 1997). In vitro assays demonstrate that RCC lines are relatively 
insensitive to 2 Gy radiation, although they do show sensitivity to higher doses of 
radiotherapy, particularly doses of over 6 Gy (Ning, Trisler et al. 1997).  
 
Given the relative tumour insensitivity to conventional RT doses and inherent limited 
radiation tolerance of the normal kidneys and surrounding tissues, fractionated 
radiotherapy is rarely used to treat primary renal tumours. Several clinical studies have 
however reported excellent control of brain metastases in patients treated with >10 Gy 
fractions delivered through stereotactic radiosurgery (Sheehan, Sun et al. 2003) and 
good control of spinal metastases and pain relief in patients treated with a 20 Gy single 
RT fraction (Gerszten, Burton et al. 2007).  
 
1.19.2.3 Interleukin-2 (IL-2) and interferon-α (IFN-α) in mRCC 
 
Prior to the introduction of TKIs, IFN-α and high dose IL-2 were the mainstay of 
treatment, associated with a modest at best response. High dose IL-2 is only appropriate 
in a small subset of very fit patients with good prognosis disease and since the 
introduction of checkpoint inhibition has become increasingly redundant. In patients 
with good prognosis disease, response rates to IFNα are in the region of 10-20% with 
an associated survival benefit of only a few months (Coppin, Porzsolt et al. 2005). In the 
SELECT trial, high dose IL-2 was associated with a durable complete response in less 
than 10% of cases, however most patients do not benefit and the median PFS of 
patients in the study was short at only 4.4 months (Clement and McDermott 2009).  
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1.19.2.4 Targeted therapy for metastatic RCC 
 
Angiogenesis is a critical step in ccRCC tumour progression with multiple kinases such 
as VEGF-receptor tyrosine kinases (VEGF-R-TKs) and PDGF-receptor-tyrosine 
kinases (PDGF-RTK) up-regulating angiogenesis and maintaining tumour growth 
(Gotink and Verheul 2010) (Figure 1.15) 
 
Currently eight targeted drugs are approved in the USA and Europe for treating 
metastatic ccRCC and with sequential and recurrent use of such drugs, median OS is 
around 27 months in patients with Memorial Sloan-Kettering Cancer Cancer (MSKCC) 
intermediate prognosis disease compared to 9 months in the pre-TKI era (this is a 
prognostic scoring system that stratifies patients according to clinico-pathological 
parameters) (Motzer, Hutson et al. 2013) and immune checkpoint inhibitors may extend 
this figure further.  Most targeted agents target VEGF/PDGF-mediated angiogenesis 
either directly blocking VEGF/VEGFR interaction, as in the case of the humanised 
monoclonal antibody bevacizumab, or indirectly, as multi-tyrosine kinase inhibitors in 
the case of sunitinib, pazopanib, sorafenib, axitinib and cabozantinib (Gotink and 
Verheul 2010, Tannir, Schwab et al. 2017) (Figure 1.15). Temsirolimus and everolimus 
are analogues of rapamycin that inhibit the kinase activity of the mTOR complex 1 
(mTORC1) resulting in reduced translation of cell-cycle regulatory proteins and 
suppressed angiogenesis (Rini 2011) (Figure 1.15). 
 
Multi-targeted TKIs have conventionally been used as first-line agents, and most are 
small-molecule kinase inhibitors that compete with ATP to prevent ATP binding and 
kinase activation. Their dominant molecular targets are the VEGF receptor TK, in 
particular, VEGFR-1, 2, and 3 TKs but other pro-angiogenic pathways are also affected, 
particularly the PDGF-R and c-KIT pathways (Gotink and Verheul 2010, Rini 2011).  
Sunitinib for example targets VEGFR, PDGFR, FLT-3 and c-KIT and off-target effects 
can contribute to drug-associated side effects (O'Farrell, Abrams et al. 2003).  
 
Pivotal phase III randomised controlled trials had established the use of sunitinib and 
pazopanib as first-line treatment in mccRCC although novel immunotherapy agents are 
changing the treatment paradigm (Motzer, Hutson et al. 2007, Sternberg, Davis et al. 
2010, Escudier, Porta et al. 2014). Bevacizumab in combination with IFN-α has a role in 
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favourable and intermediate prognostic groups, although it is not generally used in the 
United Kingdom (Rini, Halabi et al. 2010).  
 
The potent, orally available TKI axitinib is not recommended as first line therapy in 
metastatic ccRCC as the primary end-point of PFS was not met in the pivotal trial 
evaluating the role of axitinib in this setting (Hutson, Lesovoy et al. 2013).  
 
mTOR inhibitors have conventionally been used after the failure of VEGF-targeted 
therapy. In the phase III randomised controlled trial RECORD-1, patients who had 
progressed after first line VEGF-targeted therapy were randomised 2:1 to everolimus or 
placebo with crossover to everolimus permitted upon progression. In the intention to 
treat analysis, the PFS was significantly improved in the everolimus arm at 5.4 versus 1.9 
months (Stein, Bellmunt et al. 2013).  
 
The majority of patients will initially obtain clinical benefit with VEGF-targeted therapy, 
however acquired resistance invariably develops, variable both in timing and clinical 
pattern. Some mechanisms such as angiogenic escape are described, whereby with time 
the initial targeted therapy becomes ineffective at blocking the VEGF axis, but 
switching to a more potent VEGF targeted agent may result in a further response 
(Motzer, Escudier et al. 2013). In addition, the restoration of angiogenesis may result 
through the activation of VEGF-independent pathways, for example FGF-2, 
tie2/Ang2, IL8 and Src upregulation (Powles, Chowdhury et al. 2011). MET and AXL 
up-regulation are also increasingly implicated in resistance to VEGF-TKI. MET is a 
receptor tyrosine kinase which after binding to its ligand, hepatocyte growth factor, 
activates pro-tumourigenic pathways, which regulate cell proliferation, motility, 
migration and invasion, MET upregulation in ccRCC is a poor prognostic indicator. 
AXL is another RTK, which binds to the ligand GAS6, in turn stimulating multiple pro-
tumourigenic signalling cascades (Zhou, Liu et al. 2016). AXL upregulation is associated 
with worse outcome in ccRCC and upregulation is also an established mechanism for 
resistance to VEGF TKIs (Zhou, Liu et al. 2016).  
 
Cabozantanib is on oral TKI that targets the VEGF-TKI as well as the MET and AXL 
signalling pathways. In the metastatic RCC phase III study evaluating cabozantinib 
versus everolimus (METEOR) study, patients who had received at least one prior 
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VEGFR-TKI and had progressed within 6 months of the most recent dose of VEGFR-
TKI were randomised to either cabozantinib or everolimus. The PFS in patients 
receiving cabozantinib was 7.4 months versus 3.8 months in those receiving everolimus, 
(HR 0.58, 95% CI 0.51-0.89) (Choueiri, Escudier et al. 2016).  
 
More recently the role of cabozantinib in patients with poor and intermediate prognosis 
mRCC has been evaluated in the first line setting. In a multi-centre phase III trial, 
patients were randomised either to receive sunitinib or cabozantinib with crossover not 
permitted.  A significant improvement in PFS was observed in association with 
cabozantinib treatment of 8.2 versus 5.6 months for sunitinib, median OS was also 
improved, at 30.3 months versus 21.8 months although this did not meet statistical 
significance (Choueiri, Halabi et al. 2017).  
 
The multi-tyrosine kinase inhibitor lenvatinib, is a potent VEGF-R TKI, and also acts 
on the FGF-R pathways, a common mechanism for tumour escape and TKI resistance. 
In a randomised phase II study, patients randomised to the combination treatment 
compared to everolimus alone, demonstrated a 9-month improvement in PFS (O'Reilly 
and Larkin 2017).  
 
Studies such as the phase II study of axitinib in patients with metastatic RCC unsuitable 
for nephrectomy (A-PREDICT) are making use of sequential tissue before and after 
VEGF-targeted therapy to help improve our understanding of possible mechanisms of 
tumour escape. Predictive biomarkers that establish the likely therapeutic benefit of 
targeted agents are being evaluated and are discussed further in section 1.21. Single 
nucleotide polymorphisms (SNPs) appear particularly promising, however intra-
tumoural heterogeneity undoubtedly has hampered biomarker identification (Section 
1.22).   
1.19.2.5 Novel immune therapy in metastatic ccRCC 
 
The natural history of RCC suggests that the immune system can play a powerful role in 
controlling tumour growth, as disease regression can occur in the absence of treatment. 
RCC typically has a prominent immune cell infiltrate with high levels of T cells, natural 
killer (NK) cells, dendritic cells (DCs) and macrophages, but often demonstrates a high 
level of immune dysfunction. This ultimately promotes cell growth and immune evasion 
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(Porta, Bonomi et al. 2007).  Mechanisms for immune escape include T-cell down-
regulation through anergy-associated gene upregulation (Noessner, Brech et al. 2012) 
and disturbance of the circulating lymphocyte and dendritic cell subpopulations (Porta, 
Bonomi et al. 2007).  
 
Novel immune modulating agents act predominantly as immune checkpoint blocking 
antibodies, blocking in particular the cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) and programmed death receptor-1 (PD-1)/programmed death receptor 
ligand-1 (PDL1) (Mataraza and Gotwals 2016). CTLA-4 inhibits T-cell activation during 
the priming phase of T-cell activation whilst PD-1, expressed on B, T and NK cells, 
exerts its inhibitory activity predominantly during the effector phase of T-cell activation 
within the tumour microenvironment (Topalian, Drake et al. 2015). PD-1 and PD-L1 
are also both expressed on regulatory T-cells (Tregs) and Treg upregulation can 
promote a pro-angiogenic RCC phenotype (Facciabene, Motz et al. 2012).  
 
Multiple trials have evaluated anti-PD-1 and anti PDL-1 therapy in RCC. In the phase 
III Checkmate-025 trial, patients with advanced metastatic ccRCC who had received 
previous targeted therapy, were randomised to either the PD-1 blocking drug 
nivolumab, or the mTOR inhibitor everolimus until progression or unacceptable 
toxicity. Nivolumab improved OS, with a median OS of 25 months compared to 19.6 
months in patients receiving everolimus (Motzer, Rini et al. 2015).  Studies have also 
demonstrated that blocking PDL-1 in mRCC is also effective. In a phase 1a study of the 
humanised anti-PDL-1 antibody atezolizumab, a reduction in tumour burden was 
observed in 46% of patients with an associated manageable safety profile (McDermott, 
Sosman et al. 2016).  
 
CTLA-4 blockade in metastatic RCC has also been evaluated.  In a phase II study, 5 out 
of 40 patients receiving high dose ipilumimab responded compared to 1 response out of 
20 patients in the low dose group (Yang, Hughes et al. 2007).  
 
In the Checkmate-214 trial presented at ESMO in September 2017, treatment naïve 
patients with mRCC were randomised to combination therapy with nivolumab and 
ipilumimab versus sunitinib monotherapy (Rexer 2015).  Overall there was an 
improvement in both objective response rate (ORR) and PFS in association with the 
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combination of nivolumab and ipilumimab: 41.6% versus 26.5% (p<0.0001) for ORR 
and a PFS of 11.6 versus 8.2 months (HR 0.82, p=0.03). More striking however was the 
subgroup analysis of patients with poor and intermediate prognosis disease with 
tumours demonstrating positivity for PDL-1 expression (≥1%). In these patients the 
ORR was 58.5% versus 25% and median PFS was 22.8 months versus 5.9 months (HR 
0.48, p=0.0003). In patients with good prognosis disease however, the reverse 
association was seen irrespective of tumour PDL-1 expression.  The ORR was 29% 
with nivolumab/ipilimumab versus 52% with sunitinib (p = 0.0002) and median PFS 
was 15.3 months versus 25.1 months, respectively, HR 2.17, p < 0.0001. This study is 
therefore potentially practice changing (Rexer 2015, Rexer, Steiner et al. 2017).  
1.20 Prognostic factors in clear cell renal cell carcinoma  
 
An on-going challenge in an era of personalised and molecularly targeted medicine is to 
identify biomarkers that assist diagnosis, determine prognosis and predict how patients 
will respond to treatment. Such a targeted approach can result in a stratified patient- 
centred focus, with the aim of maximising therapeutic efficacy for that individual.   
 
Prognostic factors are objectively measurable clinical or biological characteristics that 
provide information on the likely outcome for that patient based on the factor 
identified. This can provide important patient-relevant information, such as giving an 
estimate of OS, which in turn may dictate how that patient is treated. For example, 
active surveillance may be inappropriate in a patient with a tumour with poor prognostic 
features. A predictive factor is a clinical or biological characteristic that provides 
information on the likely benefit of treatment i.e. whether a patient will respond to a 
particular treatment.  
 
For ccRCC, a number of clinical prognostic algorithms exist and numerous prognostic 
biomarkers have been identified.  Few of these however have been externally validated 
and currently there are no validated predictive biomarkers (Gulati, Martinez et al. 2014).  
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1.20.1 TNM stage classification 
 
The tumour/node/metastasis (TNM) staging is a validated prognostic scoring system, 
first described in 2001, which should be used for clinical and scientific staging purposes. 
Updated in 2010, accurate staging is crucial to aid decision-making related to for 
example the surgical management of localised disease. In addition this classification 
provides important prognostic information on the likelihood of local recurrence and 
long-term overall survival. The 2010 TNM staging classification is prognostic and has 
undergone validation in both single institution and multi-institution analyses (Zisman, 
Pantuck et al. 2001, Edge and Compton 2010, Kim, Alt et al. 2011, Ljungberg, Bensalah 
et al. 2015).  
1.20.2 Grading of ccRCC 
 
The pathological grading of ccRCC is based on the microscopic morphology after 
haematoxylin and eosin (H and E) staining.  The most popular grading system was 
described in 1982 by Fuhrman et al (Fuhrman, Lasky et al. 1982). This system defines 
four nuclear grades on the basis of increasing nuclear size, irregularity and nucleolar 
prominence. In patients with localised disease, Fuhrman grade is strongly predictive of 
the likelihood of distant metastases following nephrectomy (Fuhrman, Lasky et al. 
1982). Recently a simplified nuclear grading system has been proposed based solely on 
nucleoli size and shape: this correlates with prognosis and demonstrates good inter-
observer reproducibility and increasingly is recommended as the grading system of 
choice (Srigley, Delahunt et al. 2013, Escudier, Porta et al. 2014).  
 
1.20.3 Clinical prognostic factors in ccRCC 
 
There are several prognostic, validated scoring systems in routine use in both localised 
and metastatic ccRCC.  Whilst giving an indication of likely prognosis within the 
population as a whole, the accuracy of outcome-prediction is limited at an individual 
patient level (Motzer, Mazumdar et al. 1999, Frank, Blute et al. 2002, Heng, Xie et al. 
2009, Tang, Vickers et al. 2011).  
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The SSIGN score incorporates the stage, size, grade and presence/absence of necrosis 
and generates a score of between 0 and 15, which correlates well with 5-year metastasis-
free survival. Patients designated 0-2 are considered low risk with a 97.1% 5 year-
metastasis-free survival whilst those scoring ≥6 are considered high risk with a 31.2% 5 
year-metastasis-free survival (Leibovich, Blute et al. 2003). The SSIGN score has 
subsequently undergone validation in a European single centre cohort of >1800 patients 
with scores found to correlate with Cancer- Specific Survival (CSS). Combining scores 
into five categories improved discrimination with respect to CSS (Zigeuner, Hutterer et 
al. 2010).   
 
The University of California Los Angeles Integrated Staging System (UISS) incorporates 
prognostic models for both localised and metastatic RCC and has been validated in an 
international multi-centre study of over 4000 patients in the pre-TKI era (Figure 1.17) 
(Patard, Kim et al. 2004). The original UISS score was modified into an algorithm that 
stratified patient survival into low (LR), intermediate (IR) and high risk (HR) groups for 
both localised and metastatic disease based on the 1997 TNM stage, Fuhrman grade and 
Eastern Cooperative Oncology Group (ECOG) performance status (PS). In the cohort 
described, significant differences in 3-year OS were observed in patients with localised 
disease depending on their risk group with 3-year OS of 92%, 67% and 44% for LR, IR 
and HR groups respectively. In patients with metastatic disease, the 3-year survival rates 
were 37%, 23% and 12% for LR, IR and HR groups respectively (Figure 1.17) (Patard, 
Kim et al. 2004).  
 
  
Figure 1.17 Kaplan-Meier survival estimates according to University of California 
Los Angeles Integrated Staging System in 3,119 patients with localised disease 
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(left panel), and 1,083 patients with metastatic disease (right panel). LR, low-risk; IR, 
intermediate-risk; HR, high-risk. Adapted from (Patard, Kim et al. 2004) 
In the metastatic setting, one of the most widely used predictive models to predict OS is 
the MSKCC tool developed by Motzer et al. This was developed in patients receiving 
IFN-α (Motzer, Bacik et al. 2002) and independently validated in 2005 in patients 
receiving a variety of single and combination agents (Mekhail, Abou-Jawde et al. 2005) 
before undergoing validation in patients receiving targeted therapy (sunitinib) (Motzer, 
Hutson et al. 2009). The components of the MSKCC score are (1) KPS less than 80%, 
(2) time from diagnosis of RCC to treatment of less than one year, (3) serum lactate 
dehydrogenase greater than 1.5x upper limit of normal (ULN), (4) corrected serum 
calcium greater than 10mg/dL and (5) haemoglobin concentration less than the lower 
limit of normal (LLN).  
 
Favourable prognosis is defined as no poor prognostic factors, intermediate as one or 
two poor prognostic factors and poor, as more than two poor prognostic factors 
(Motzer, Bacik et al. 2002). In the validation study by Mekhail et al, median OS stratified 
for the three prognostic groups was 28.6, 14.6, and 4.5 months respectively (P<0.0001)  
(Figure 1.18) (Mekhail, Abou-Jawde et al. 2005).  
 
 
 
Figure 1.18 Kaplan-Meier survival estimates by MSKCC risk groups in the cohort 
of 353 previously untreated patients with mRCC. Patients were stratified in to high, 
intermediate and low risk groups on the basis of their pre-treatment MSKCC score. Adapted from 
(Mekhail, Abou-Jawde et al. 2005) 
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Heng et al identified prognostic factors predictive of OS in 645 patients with mRCC 
receiving 1st line VEGF-targeted therapy. Four of the five adverse prognostic factors 
form part of the MSKCC score: (1) haemoglobin less than lower limit of normal (LLN), 
(2) corrected calcium > upper limit of normal (ULN), (3) KPS<80%, and (4) time from 
diagnosis to treatment of <1 year.  In addition neutrophil count >ULN and platelet 
count >ULN were identified as independent adverse prognostic factors. Patients were 
stratified in to three-risk groups, favourable, (0 risk factors), intermediate, (1-2 risk 
factors) and poor risk  (3 or greater risk factors).  Median OS strongly corresponded 
with prognostic group at 43, 27 and 8 months respectively (Figure 1.19) (Heng, Xie et 
al. 2009).  
 
 
Figure 1.19 Kaplan-Meier survival estimates stratified according to Heng risk 
group with proportion of patients in each group alive at 24 months post therapy 
initiation. Adapted from (Heng, Xie et al. 2009) 
 
1.20.4 Molecular biomarkers for ccRCC 
 
Molecular biomarkers may be prognostic and, or predictive in nature and can be 
grouped according to their physiological location, defined as either circulating or tissue 
based.  
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1.20.4.1 Circulating ccRCC biomarkers 
 
VEGF and VEGF related proteins 
 
VEGF is a potent mediator of angiogenesis in ccRCC, facilitating tumour growth and 
metastases. Expression is regulated by HIFα and enhanced VEGF concentration 
correlates with VHL gene inactivation (Gnarra, Zhou et al. 1996). Jacobsen et al, found 
that elevated serum VEGF levels were prognostic and associated with a shorter survival 
time in the pre-TKI era (Jacobsen, Rasmuson et al. 2000). Other studies have however 
demonstrated opposite associations, correlating high baseline VEGF-A concentrations 
with shorter OS and PFS (Tran, Liu et al. 2012).  
 
Escudier et al found that higher serum VEGF levels were predictive and correlated with 
a better response to sorafenib (Escudier, Eisen et al. 2009).  Studies have however also 
demonstrated that low baseline levels of soluble VEGFR-3 and VEGF-C levels are 
associated with longer PFS in patients receiving sunitinib treatment compared to IFN-α 
(Deprimo, Bello et al. 2007).  
 
Cytokine and angiogenic factors (CAFs) 
 
Other circulating cytokine and angiogenic factors have been evaluated as potential 
prognostic and predictive indicators. In a phase III trial Tran et al found that higher 
baseline plasma interleukin-8, HGF and osteopontin levels were associated with shorter 
PFS in patients receiving pazopanib and that high concentrations of six CAF signatures, 
IL-6, IL-8, HGF, osteopontin, VEGF-A and TIMP-1 correlated with shorter PFS whilst 
higher baseline IL-6 levels were prognostic for OS (Tran, Liu et al. 2012). 
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1.20.4.2 Tissue based ccRCC biomarkers 
 
VHL 
 
Multiple biomarkers for ccRCC have been identified and many are hypoxically 
regulated. Most studies correlating VHL gene status and common clinical prognostic 
factors have not found an association: this may be related to the near universality of 
VHL-inactivation (Kondo, Yao et al. 2002, Gimenez-Bachs, Salinas-Sanchez et al. 
2006) (Maroto and Rini 2014).   
 
HIF 
 
HIF1α is frequently over-expressed in ccRCC. Klatte et al found that in patients with 
metastatic ccRCC, high HIF-1α expression was independently associated with shorter 
OS (Klatte, Seligson et al. 2007). However other groups have not observed the same 
association. Lidgren et al for example reported no survival difference between patients 
with high and low HIF-1α expression (Lidgren, Hedberg et al. 2005). 
 
 HIF1α and HIF2α have some overlapping functions but can regulate distinct sets of 
genes with increasing evidence that HIF2α plays a more critical role in mediating 
tumourigenesis in ccRCC (Biswas, Troy et al. 2010). In addition, some reports have 
suggested that HIF1α acts as a tumour suppressor in ccRCC with overexpression 
associated with better prognostic outcomes (Gossage, Eisen et al. 2015). There is also 
conflicting evidence as to the prognostic effects of the overexpression of genes 
regulated downstream of HIF1α such as VEGF and CAIX.  
 
Fan et al undertook a Preferred Reporting Items for Systematic Review (PRISMA)-
compliant systematic review and meta-analysis of the prognostic significant of HIF1α 
and HIF2α immunohistochemical expression in renal cell carcinoma. In view of studies 
that have demonstrated that sub-cellular HIF localisation may be important in driving 
ccRCC tumourigenesis (Kroeger, Seligson et al. 2014), analysis was undertaken both for 
total HIF and with stratification according to sub-cellular localisation. 14 studies were 
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included. Total HIF1α and HIF2α expression did not correlate with PFS or OS, 
however sub-cellular HIF localisation was prognostic with high nuclear HIF1α 
expression correlating with worse OS and high cytoplasmic HIF2α with worse CSS 
(Fan, Li et al. 2015).  
 
Increasing evidence is emerging that ccRCC can be subdivided into tumours with (1) 
wild type (WT) VHL, (2) VHL-deficient tumours that overexpress both HIF1α and 
HIF2α and (3) VHL-deficient tumours that only overexpress HIF2α and that such sub-
classification may be prognostic. It has been suggested that this last subtype of tumours 
are particularly aggressive with enhanced c-MYC activity and enhanced activation of the 
MAPK/ERK pathway resulting in increased cell proliferation and metastases (Gordan, 
Lal et al. 2008). 
 
 Kroeger et al undertook cytogenetic analysis on 345 ccRCC tumours with abnormal 
karyotype, sub-classifying tumours according to the loss of the VHL gene (3p loss), 
HIF1-α (14q loss) and HIF2α overexpression. They concluded that tumours that 
demonstrated loss of 3p i.e. those with loss of VHL had more favourable clinico-
pathological features and patients with such tumours had improved CSS compared to 
those with VHL-proficient tumours. In addition, loss of 14q (HIF1α) was associated 
with worse relapse-free survival (RFS) and CSS. In tumours that overexpressed HIF2α 
and had lost 3p (VHL), 14q loss (HIF1α) was the most important predictor of RFS 
(Kroeger, Klatte et al. 2013).  
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Carbonic anhydrase IX (CAIX) 
 
CAIX is a HIF1α regulated protein involved in regulating intracellular and extracellular 
pH in response to hypoxic stress (Dorai, Sawczuk et al. 2006) and is up-regulated in 
approximately 70% of ccRCCs (Choueiri, Regan et al. 2010). In both localised and 
metastatic ccRCC, low CAIX staining has been shown in several series to serve as an 
independent poor prognostic factor for survival (Bui, Visapaa et al. 2004, Phuoc, Ehara 
et al. 2008). However, data from the treatment approaches in renal cancer global 
evaluation (TARGET) trial, evaluated CAIX expression in patients with mRCC treated 
with either sorafenib or placebo and demonstrated neither prognostic nor predictive 
value for CAIX staining (Jonasch, Corn et al. 2010). Similarly no association was 
observed between CAIX staining and clinical outcomes in patients receiving treatment 
with temsirolimus (Cho, Signoretti et al. 2007).  
 
VEGF and VEGF-related proteins 
 
In some studies, elevated VEGF has been shown to correlate with increasing tumour 
size, Fuhrman grade, tumour necrosis and tumour stage (Paradis, Lagha et al. 2000) 
(Yildiz, Gokce et al. 2004). VEGF-A overexpression has also been associated with 
shorter OS in patients receiving first line sunitinib (Garcia-Donas, Leandro-Garcia et al. 
2013). This same study also found that VEGFR-3 overexpression was associated with a 
longer PFS and that VEGFR3 overexpression demonstrated a negative correlation with 
the VEGFR3 polymorphism RS307826, a predictor of sunitinib resistance (Garcia-
Donas, Leandro-Garcia et al. 2013). 
 
Chromatin remodelling genes 
 
Loss of, and mutations in the newly identified chromatin remodelling genes PBRM1, 
SETD2 and BAP1 in ccRCC has been described (Sato, Yoshizato et al. 2013) (Cancer 
Genome Atlas Research 2013). Sato et al investigated the effects of these mutations on 
survival and tumour recurrence and found that PBRMI mutations had no impact on OS 
or disease-free survival (DFS), but that BAP1 mutations were associated with a 
significantly shorter OS (p=0.0203). Tumours with SETD2 mutations demonstrated a 
very high relapse rate (HR=3.38, p=6x10-4) compared to SETD2 proficient tumours but 
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this did not correlate with OS (Sato, Yoshizato et al. 2013).  Hakimi et al described the 
outcome associated with BAP1 and SETD2 mutations in 609 patients with ccRCC from 
two distinct cohorts (an MSKCC and TCGA cohort). They observed that BAP1 
mutations were associated with worse CSS in both cohorts. SETD2 mutations were 
associated with worse CSS in the TCGA cohort but not in the MSKCC cohort, whilst 
PBRM1 mutations, observed with the highest frequency of the three TS, had no impact 
on CSS (Hakimi, Pham et al. 2013).   
 
Single nucleotide polymorphisms 
 
SNPs are the commonest type of genetic variation.  Genome-wide association studies 
(GWAS) can be used to identify germline polymorphisms associated with clinical 
outcome. There is increasing evidence that SNPs may function as useful predictive 
biomarkers in ccRCC. Several studies have investigated SNPs as predictors of drug 
efficacy, with certain polymorphisms predicting sunitinib efficacy e.g. SNPs in the 
CYP3A5, NR1/3 and ABCB1 genes. Patients with favourable polymorphisms in these 
genes had a significantly improved median PFS when treated with sunitinib compared 
to those without (13.1 versus 7.5 months, p=0.009) (van der Veldt, Eechoute et al. 
2011). 
  
Genetic analysis from the comparison of pazopanib versus sunitinib in metastatic renal 
cell carcinoma (COMPARZ) trial, comparing upfront pazopanib versus sunitinib 
demonstrated a significant association between IL-8 polymorphisms in patients treated 
solely with sunitinib but not pazopanib with respect to both PFS and OS (Maroto and 
Rini 2014).  
 
1.20.5 Clear cell type A (ccA) and clear cell type B (ccB) subtypes 
 
In the past few years, gene expression microarray data has been analysed using software 
that uses iterative consensus clustering algorithms to identify distinct subtypes of 
ccRCC. Most previous prognostic stratification approaches relied on preselected 
molecular features or clinical outcomes to distinguish tumour types but with this 
approach there is no inherent pre-selection, and tumours are classified based on their 
underlying tumour biology.  
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By applying consensus clustering to the gene expression data of ccRCC tumours 
without first applying clinical or biological information, two subtypes of ccRCC 
designated ccA and ccB were identified. Analysis of these subsets identified a small core 
of highly predictive genes that can be used to classify tumours individually. The 
investigators found that several of the pathway genes overexpressed in ccA tumours, 
were strongly correlated with VHL inactivation and the overexpression of HIF 
signalling components such as EPAS1, EGNL3, PDGFC, HIG2 and CA9. However, 
VHL inactivation in both ccA and ccB tumours occurred with similar frequency. Other 
pathways deregulated in ccA tumours are involved in fatty acid and organic acid 
metabolism. For ccB tumours, pathway analysis demonstrated that genes that regulate 
EMT, the cell cycle and wound healing were overexpressed. A third group of tumours 
that shared pattern features with both ccA and ccB tumours was identified, and 
Brannon et al speculated that this group may represent an intermediate group 
undergoing progress from one subtype to the other, or share common characteristics of 
both groups (Brannon, Reddy et al. 2010).   
 
Notably when analysis of CSS and OS was undertaken for the two groups and subtype 
correlated with the covariates in the UISS score (Fuhrman grade, tumour size and PS), 
there was a significant difference.  Patients with ccA tumours had a median survival of 
8.6 years versus 2 years in those with ccB tumours. In addition, molecular classification 
strongly correlated with tumour stage and grade, with ccA tumours demonstrating lower 
stage and grade (Brannon, Reddy et al. 2010).  
 
Despite attempts to stratify patient risk on the basis of biomarkers, most molecular 
ccRCC biomarkers have not been independently validated and validated biomarkers 
have not entered clinical practice. In a recent study by Gulati et al, ccRCC prognostic 
biomarkers validation was undertaken in an independent patient cohort and intra-
tumour heterogeneity of the most promising biomarkers also assessed. A total of 17 out 
of 28 biomarkers were validated as predictors of poor CSS on univariate analysis, but 
only tumour stage and the ccB signature were independent predictors in multivariate 
analysis (Gulati, Martinez et al. 2014).    
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The group identified a number of somatic copy number alterations (SCNAs) as poor 
prognostic markers on univariate analysis, e.g. chromosome 8q and 12 amplification and 
chromosome 9p and 22q deletions. Given these findings the group asked whether the 
ccB expression signature reflected the transcriptomic impact of these poor risk genetic 
alterations and identified that several of these SCNAs were over-represented in the ccB 
samples. By calculating the weighted Genomic Instability (wGII) a measure of overall 
copy number aberrations, they found that ccB samples had significantly higher wGIIs 
compared to ccA samples. They therefore hypothesised that the ccB phenotype is 
partially driven by these poor prognosis SCNAs in association with a cancer genomic 
background of elevated chromosomal instability (Gulati, Martinez et al. 2014).  
 
1.20.6 Biomarkers in ccRCC for predicting response to immunotherapy  
 
Programmed death ligand-1 (PDL-1) 
 
Drugs that enhance anti-tumour immune responses through the targeting of the PDL1-
/PD1 pathways have demonstrated promising results in RCC resulting in durable 
responses in a subset of patients (McDermott, Sosman et al. 2016) (Herbst, Soria et al. 
2014).  
 
PDL1 is expressed on both tumour cells and also tumour-infiltrating immune cells 
within the tumour microenvironment where it acts as a negative regulator of T-cell 
proliferation and function and therefore facilitates tumour evasion of immune 
surveillance. Higher PDL-1 expression in tumour-infiltrating immune cells has been 
associated with worse outcome in RCC (Thompson, Dong et al. 2007). It appears 
increasingly that PDL-1 expression on tumour-infiltrating immune cells may be more 
important than on tumour cells.  
 
McDermott et al undertook subgroup analysis for PFS and OS in patients with 
metastatic RCC receiving the PDL-1 inhibitor atezolizumab and found a trend towards 
lower anti-tumour activity in patients with tumours with low PDL1 expression 
compared to patients with tumours with higher PDL1 expression(McDermott, Sosman 
et al. 2016). In addition, a number of immunologic correlates were observed which were 
associated with response, such as a fall in plasma VEGFA and on-treatment falls in the 
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acute-phase proteins ferritin and macrophage inflammatory protein-1α. McDermott et al 
also found that a higher ratio of effector T cells to regulatory T cells as represented by 
FOXP3 expression was associated with atezolizumab response (McDermott, Sosman et 
al. 2016). 
1.21 Tumour heterogeneity in ccRCC 
 
As outlined, the clinical behaviour of both localised and metastatic ccRCC is highly 
variable.  A major difficulty in the identification of effective biomarkers is that 
individual tumours are often genetically heterogeneous both within the primary tumour 
and in metastases from the same patient (Gerlinger, Rowan et al. 2012, Gulati, Martinez 
et al. 2014). Such tumour heterogeneity may be of particular relevance in the 
development of drug resistance, where drug-selection pressures facilitate the faster 
growth of drug-resistant clones, which may ultimately result in treatment failure 
(Campbell, Yachida et al. 2010).  
 
Gerlinger et al analysed multiple samples of primary ccRCC tumours and metastatic 
deposits in four patients with metastatic RCC, undertaking exome sequencing, 
chromosome aberration analysis and ploidy profiling on multiple spatially separated 
samples. Biopsy samples were obtained before the initiation of six weeks of everolimus, 
after which period a nephrectomy was undertaken and everolimus then restarted until 
tumour progression. Mutations were sub-classified into those that were ubiquitous, 
those that were shared by several but not all regions and mutations that were unique to 
specific regions (designated private mutations).   
 
For patient 1, mutational intra-tumour heterogeneity was observed in multiple driver 
tumour-suppressor genes in particular in, SETD2, PTEN and KDM5C with only VHL 
mutated ubiquitously in all analysed regions.  Mutations were distinct and spatially 
separated, suggesting convergent phenotypic evolution with ‘Darwinian selection’ for 
mutations conferring a phenotypic advantage. Ploidy profiling and allelic analysis 
revealed extensive divergent allelic-imbalance profiles and ploidy heterogeneity 
(Gerlinger, Rowan et al. 2012) (Figure 1.20). Interestingly the metastatic sites and one 
region of the primary tumour segregated together and were enriched for genes in the 
ccA subgroup in contrast to the remaining tumour regions that enriched for the ccB 
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subgroup. This highlights a significant issue associated with biomarker prediction, 
whereby samples obtained from a single biopsy may not be predictive of the tumour as 
a whole (Gerlinger, Rowan et al. 2012).  
  
(i) (ii)
(iii)
 
Figure 1.20 ccRCC demonstrates significant tumour heterogeneity both within 
the primary tumour and in metastatic deposits.  Multiple samples of a primary ccRCC 
tumour and metastatic deposits in a patient were analysed by exome sequencing, chromosome aberration 
analysis and ploidy profiling on multiple spatially separated samples as indicated in (i) and (ii). This 
revealed a trunk-branch model of tumour heterogeneity for this patient, with ubiquitous driver events 
common to all components of the tumour, and heterogeneous passenger mutations, driving further 
tumour evolution and metastases (iii) Adapted from (Gerlinger, Rowan et al. 2012) 
 
Gulati et al analysed 63 tumour regions from ten ccRCCs and found that only two 
tumours homogeneously expressed the ccA signature with the eight other tumours 
expressing both ccA and ccB signatures within different tumour regions (Gulati, 
Martinez et al. 2014).  This highlights the need to sample multiple tumour regions in 
order to draw meaningful conclusions as to ccRCC tumour behaviour 
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Epigenetic events are also likely to be heterogeneous within a tumour.  For example, 
changes in DNA methylation and repressive chromatin modifications have been found 
to restrict the expression of HIFα-targeted genes driving metastasis. In a ccRCC line, a 
subpopulation of cells were found to have a metastatic expression programme, 
supporting the idea that epigenetic modification of gene expression in a subset of cells 
drives metastasis (Vanharanta, Shu et al. 2013). It is unclear whether such changes arise 
stochastically or as a consequence of changes in the expression of genes that control 
cellular epigenetic status such as PBRM1, SETD2 and BAP1. It is perhaps not 
coincidental that mutations in such genes occur so frequently in ccRCC with BAP-1 
mutations for example associated with worse clinico-pathological indices (Gossage, 
Murtaza et al. 2014).  
 
Circulating blood biomarkers such as circulating tumour cells and cell-free plasma DNA 
may provide a non-invasive real-time surrogate for tissue based biomarkers and 
overcome some of the issues associated with tumour heterogeneity. 
1.22 The concept of synthetic lethality and exploiting synthetically lethal 
relationships to target ccRCC 
 
ccRCC displays limited chemotherapy and radiotherapy sensitivity and therefore 
conventional anti-cancer therapies used in many tumour types have limited efficacy. 
Current targeted treatments have improved OS and novel immune checkpoint therapies 
offer a promising new approach.  
 
Nonetheless, most patients eventually develop resistance to targeted therapy and the 
identification of novel drugs or the use of existing drugs either alone or in combination 
with existing therapy is critical for improving patient outcome. Increased knowledge of 
the genetic drivers of ccRCC in particular can be exploited to specifically target tumours 
with such mutations.  
 
The concept of synthetic lethality is being successfully exploited in oncology to identify 
drugs that specifically target cancer cells but spare healthy non-cancer cells. Synthetic 
lethality arises when a combination of mutations in two or more genes leads to cell 
death, whereas a mutation in only one of these genes does not and the cell remains 
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viable. In cancer cells where a particular cancer-specific gene inactivation has occurred, 
targeting a second gene may result in cancer-specific cell death whilst sparing non-
cancerous cells (Nijman 2011).  This principle is shown in Figure 1.21.  
Rehman, F. L. et al. (2010) Synthetic lethal approaches to breast cancer therapy 
Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2010.172 
Loss of either gene A or gene B in normal cells is compensated by the action of the remaining gene. In tumor cells, however, a mutation in one of these genes leaves the cell 
vulnerable to loss of the other gene by drug inhibition. This approach is the basis of drugs that target synthetic lethal relationships. By contrast, normal tissues are spared any toxic 
effects.
 
Figure 1.21 Schematic representation of synthetic lethality.  
Two genes are synthetically lethal when their simultaneous inactivation results in cell death. Here, 
inactivation of gene A or gene B alone does not affect cell viability whereas inactivation of both genes 
results in cell death. Taken from Rehman et al. Synthetic lethal approaches to breast cancer, Nat Rev Clin 
Oncol 2010.  
 
Probably the best known example of a synthetic lethal approach has come from the 
treatment of BRCA1/2 mutated breast and ovarian cancer with PolyADP-ribose 
polymerase (PARP) inhibitors (Yap, Sandhu et al. 2011). Here the BRCA1/2 mutation 
results in deficiency in the homologous recombination (HR) DNA repair pathway, 
leading to a dependency on error-prone DNA repair mechanisms and consequent 
genomic instability. PARP activation is largely driven by DNA damage and by targeting 
the BRCA1/2 mutated cancer cells and their error-prone DNA repair mechanisms, 
PARP inhibitors are largely selective only for cancer cells since non-cancer cells still 
have one functioning BRCA1/2 copy and therefore intact homologous recombination 
pathways (Livraghi and Garber 2015).   
 
For many tumours, multiple anti-cancer drugs exist that effectively kill cancer cells but 
are not therapeutically useful due to toxic side effects in non-cancerous cells. Most 
chemotherapeutic drugs have very low therapeutic indices and windows. The 
therapeutic index is defined as the dose required for toxic effects divided by the dose 
required for therapeutic effect, whilst the therapeutic window refers to the 
concentration range over which therapeutic effects can be expected (Kaelin 2005). The 
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therapeutic window is affected by ‘on target’ pharmacokinetic properties that relate to 
the intended biological effect of the drug on its intended target and by ‘off target’ effects 
i.e. the propensity of the drug to affect unintended targets. This has significant 
implications as one of the most important factors limiting effective anti-cancer 
treatment relates to drug toxicity in normal cells, in particular those that are rapidly 
dividing such as bone-marrow haematopoietic precursors (Kaelin 2005). Synthetic 
lethality therefore provides a conceptual framework, by which cancer cells can be 
selectively targeted. 
 
There are a number of approaches by which this can be achieved. 1) A target-driven 
approach such as that seen for PARP-I in BRAC1/2 mutated cancers where the target 
is uniquely present in cancer cells or (2) a context driven approach, related to for 
example epigenetic gene silencing in different tissues (Reddy and Kaelin 2002).   
 
A number of approaches to targeting renal cell carcinoma using a synthetic lethal 
approach have been tried particularly through the targeting of pathways associated with 
VHL deficiency. Targeting VHL loss represents a particularly attractive approach as it 
represents a ‘trunk mutation/ ‘trunk event’ where loss/mutation occurs at an early stage 
of tumour formation and is therefore present in all cells, therefore overcoming some of 
the issues associated with tumour heterogeneity.  However, targeting ‘non-trunk’ 
mutations may also be important as these non-ubiquitous mutations may function as 
powerful drivers of tumour progression and metastasis and contribute to the emergence 
of clonal populations of drug-resistant cells (Gerlinger, Catto et al. 2015).  
 
Chan et al made use of a synthetic lethal approach to target VHL mutated RCC, 
targeting VHL-deficient RCC cells through their reliance on the high-affinity glucose 
transporter 1 and aerobic glycolysis (the Warburg effect).  They screened ~64,000 small 
molecules using a RCC cell line with a naturally occurring VHL mutation and a 
genetically matched cell line with reintroduced wild-type VHL. This identified two 
groups of drugs, one the pyridyl aniline thiazoles (e.g. STF-62247), previously 
characterised as demonstrating autophagic cell death in VHL-deficient RCCs (Turcotte, 
Chan et al. 2008) and a second class of drugs the ‘3-series’ typified by the drug STF-31 
that selectively target VHL deficient RCCs by targeting glucose uptake through GLUT1 
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and exploiting the dependence of VHL deficient RCCs on this mechanism for glucose 
uptake for survival (Chan, Sutphin et al. 2011).  
Targeting ccRCC tumours in association with loss of a tumour suppressor, using a 
synthetically lethal approach therefore represents an attractive strategy, potentially 
maximising therapeutic effect in ccRCC cells whilst minimising toxicity in non-tumour 
cells where the tumour suppressor of interest is still expressed. 
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1.23 Summary 
 
LIMD1, Ajuba and WTIP (LAW) are Zyxin family members, characterised by tandem 
zinc-finger motifs that facilitate protein-protein interactions enabling them to act as 
adaptor proteins. The LAW proteins have both nuclear and cytoplasmic localisation 
domains and shuttle between the nucleus and cytoplasm functioning as important 
signalling transducers, relaying signals between the cell surface and the nucleus 
(Kadrmas and Beckerle 2004). This for example facilitates a critical role in the regulation 
of EMT via E-cadherin expression (Wang, Shi et al. 2013). Ajuba proteins are negative 
regulators of the Hippo signalling pathway (Das Thakur, Feng et al. 2010), and are 
essential components of the miRISC, facilitating miRNA mediated gene silencing 
(Bridge, Shah et al. 2017). Acting as scaffold proteins, they regulate the hypoxic 
response targeting HIFα for VHL mediated polyubiquitylation and degradation via the 
proteasome (Foxler, Bridge et al. 2012). All three proteins demonstrate considerable 
homology (Kadrmas and Beckerle 2004).  
 
A number of studies have implicated Ajuba proteins in tumourigenesis. LIMD1 loss is 
common in lung carcinoma and drives tumourigenesis in a mouse model (Sharp, Al-
Attar et al. 2008), whilst in breast cancer, LIMD1 loss contributes to tumourigenesis and 
is associated with worse prognosis disease (Spendlove, Al-Attar et al. 2008). In head and 
neck cancer, LIMD1 deletion and changes in methlylation patterns are common 
(Chakraborty, Dasgupta et al. 2003). Studies have also demonstrated LIMD1 up-
regulation in association with DLBCL subtypes (Xu, Tan et al. 2015) and in oesophageal 
squamous cell carcinoma and in colorectal carcinoma Ajuba upregulation has been 
described (Liang, Zhang et al. 2014, Xu, Tan et al. 2015, Shi, Chen et al. 2016). Ajuba 
loss in malignant mesothelioma has been characterised and is related to deregulation of 
the Hippo signalling pathway (Tanaka, Osada et al. 2015).  
 
To date, LIMD1, Ajuba and WTIP have not been characterised in ccRCC. Hypoxic 
deregulation is a critical driver of tumourigenesis in ccRCC and deregulation of miRNA-
mediated silencing commonly observed (Biswas, Troy et al. 2010). Dysfunctional Hippo 
signalling can also mediate proliferation, invasiveness and increase the metastatic 
potential of ccRCC (Schutte, Bisht et al. 2014).  
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ccRCC is a complex tumour type that is increasing in incidence: approximately 1.6% of 
the population will be diagnosed with kidney cancer at some point in their lifetime 
(Ljungberg, Campbell et al. 2011). The genetics of ccRCC are complex.  Although 
biallelic loss of VHL function occurs as a tumour initiating event in over 90% of 
ccRCC causing resultant hypoxic deregulation through HIFα upregulation (Frew and 
Moch 2015), recent genetic analysis has identified that other 3p locus genes play an 
important role in driving tumourigenesis, in particular the chromatin remodelling genes 
PBRM1, SETD2 and BAP1 (Sato, Yoshizato et al. 2013). Further underscoring the 
importance of hypoxic deregulation as a critical driver of tumourigenesis in ccRCC is 
the observation that the deregulation of downstream targets of HIFα such as 
components of the PI3K-mTORC1 pathway is also common (Sato, Yoshizato et al. 
2013).  
 
Non-metastatic ccRCC is potentially curable with nephrectomy but metastatic disease is 
considerably harder to control. Although novel targeted agents that act as multi-tyrosine 
kinase inhibitors targeting VEGF pathways and inhibitors of mTOR have significantly 
improved overall survival, individual prognosis remains variable and reasons for this are 
not fully understood (Ljungberg, Bensalah et al. 2015). Immune checkpoint inhibition 
offers the possibility of a durable response in a sub-set of patients, although clinical trial 
readouts of long-term survival are not yet mature.  
 
Clinical outcomes remain very difficult to predict and although clinical prognostic 
indicators can help stratify patients, most prognostic and predictive biomarkers have not 
been independently validated with the exception of the ccA/ccB tumour subgrouping 
and tumour stage and grade (Gulati, Martinez et al. 2014). Undoubtedly the 
development of prognostic and predictive biomarkers is hampered by intra-tumoural 
heterogeneity and there is currently insufficient knowledge of the effects of different 
combinations of mutations on the initiation and progression of ccRCC (Gerlinger, 
Rowan et al. 2012). Intra-tumoural heterogeneity also potentially contributes to 
resistance to targeted therapy with the selection of drug-resistant clones driving tumour 
progression and metastases (Gerlinger, Rowan et al. 2012).  
 
Targeting tumour suppressors, which are associated with a loss of function phenotype is 
difficult. Using a synthetic lethal approach to selectively target another gene in a 
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pathway upon which the tumour cells are dependent can overcome this. Importantly 
such an approach can result in tumour-selective cell death with relative sparing of non-
cancerous cells (Chan and Giaccia 2011, Nijman 2011).  
 
LIMD1, WTIP and Ajuba remain uncharacterised in ccRCC. The three proteins 
demonstrate considerable homology and functional redundancy as shown for example 
in the regulation of the hypoxic response and in miRNA silencing via the miRISCs.  
 
 Given their role in multiple pathways that can drive tumourigenesis in ccRCC, 
particularly the regulation of the hypoxic response, miRNA silencing and Hippo 
signalling and the association between their loss and tumourigenesis in several tumour 
types it was hypothesised that loss/deregulation could drive tumourigenesis in ccRCC 
and, that the three proteins were likely to demonstrate a degree of functional 
redundancy in this tumour type.  
 
It was also hypothesised that a synthetically lethal approach could represent an attractive 
therapeutic approach and be used to target ccRCC tumours that had demonstrated loss 
of these proteins.  
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1.24 Thesis aims and objectives 
 
1. Characterisation of LIMD1, Ajuba and WTIP (LAW) expression in ccRCC and 
matched adjacent tissue (MAT) 
2. Correlation of the relationship between expression levels of LAW proteins in 
ccRCC and MAT 
3. Correlation of expression of LAW proteins with other hypoxically regulated 
proteins in ccRCC and MAT 
4. Investigation of the relationship between LAW expression and clinico-
pathological data in ccRCC 
 
5. Characterisation of the effects of LIMD1 loss on cellular 
transformation/tumourigenesis in ccRCC in vitro.  
 
6. The use of CRISPR-Cas-9 gene editing system to achieve knockout of Ajuba 
proteins in Renal proximal tubular epithelial cells (RPTEC) 
 
7. Identification of anti-cancer drugs demonstrating synthetic lethality in 
association with LIMD1 loss in ccRCC using a drug-screening platform 
 
8. Investigation of the effects of LIMD1 loss on the sensitivity to drugs commonly 
used to treat metastatic ccRCC !
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2  Materials and Methods 
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2. 1 Immunohistochemistry !
2.1.1 Human tumour Samples 
 
The GSK TMAs were constructed from archived biopsy tissue or nephrectomy 
specimens obtained from a prospective randomised clinical trial of the tyrosine kinase 
inhibitor lapatinib versus placebo (Ravaud, Hawkins et al. 2008): 145, paraffin-
embedded RCC histospots of 0.6mm diameter and 4µm thickness were represented on 
the TMAs in triplicate with placenta and healthy kidney tissue included as control.  
 
 Further ccRCC TMAs were made by Dr Daniel Worth at Barts Cancer Institute. TMA 
histospots were generated from core biopsies and nephrectomy samples from a study 
evaluating the role of the TKI pazopanib prior to nephrectomy (Powles, Sarwar et al. 
2016). Samples were represented at least in duplicate and tumours from a total of 104 
patients included on the TMAs with samples taken from both baseline biopsy and 
nephrectomy samples (63 patients underwent nephrectomy). Histospots were paraffin-
embedded, 2mm in diameter and 4µm in thickness. Both TMAs were obtained from the 
Orchid tissue bank and Barts Cancer Institute.  
 
In addition, commercially available TMAs containing 75 ccRCC histospots with 
matched adjacent tissue were purchased from US Biomax (H-Kid-CRCC150C2-02s). A 
single histospot from each tumour was represented on the array with a corresponding 
matched adjacent tissue sample from each patient. Histospots were paraffin embedded, 
1.5mm in diameter and 4µm in thickness.  
 
Control tissue for antibody optimisation was obtained from Mr George Elia and Dr 
Andrew Clear at Barts Cancer Institute.   Full ethical approval for the use of the tissue 
for non-diagnostic purposes had previously been obtained where appropriate.  
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2.1.2 Solutions for Immunohistochemistry 
 
Endogenous peroxide blocking solution: 3% H2O2 (w/v) or 2% H2O2 (w/v) was 
added to 100% methanol (MeOH). The solution was made up freshly each time.  
 
Antibody dilution buffer: 1% BSA (w/v) and 0.1% Sodium Azide (w/v) was added to 
PBS and allowed to fully dissolve prior to storage at 4oC.  
 
Blocking horse serum: Four drops of horse serum in 5 mls PBS  
 
Avidin/Biotinylated enzyme complex (ABC): Two drops of reagent A and 2 drops 
of reagent B (Universal ABC horseradish peroxidase (HRP) Kit, Vectastain PK-6200) 
were added to 5mls PBS and allowed to equilibrate at room temperature for at least 30 
minutes prior to incubation.  
 
3,3’-Diaminobenzidine (DAB): 1 drop of DAB chromogen was added to each ml of 
DAB buffer (Biogenex HK542-XAK).  
 
1% acid alcohol: 10mls of 10mM HCL was added to 990mls of 70% ethanol (EtOH) 
and stored at room temperature. 
 
TBS-T (0.05%): Pre-mixed 10x TBS buffer pH 7.4 (Severn Biotech Ltd, 20-730-10) 
was diluted to 1x with distilled water and stored at room temperature. 500µl of 
Tween®-20 (Sigma-Aldrich-P9416) was added to 1 litre of 1xTris-buffered saline (TBS)  
 
PBS-T (0.05%): 10x PBS powder pH 7.4 (Severn Biotech Ltd, 20-730-10) was diluted 
to 1x with distilled water and stored at room temperature. 500µl of Tween®-20 (Sigma-
Aldrich-P9416) was added to 1 litre of 1xTBS. 
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2.1.3 Antibodies used for Immunohistochemistry 
 
Antigen Catalogue 
Number 
Dilution for IHC Primary Species 
LIMD1 (Sharp et al, 2004, 
2008, 2009) 
1:40-1:200 Mouse 
HIF2α Novus Biologicals 
NB100-122 
1:50-1:200 Mouse 
HIF1α Novus Biologicals 
NB100-105 
1:50-1:200 Mouse 
VHL BD Biosciences 
556347 
1:50-1:200 Mouse 
 
Ajuba Sigma Aldrich 
HPA006171 
 
1:50-1:100 Rabbit 
WTIP LS Bio C160645 1:50-1:100 Rabbit 
CD34 DAKO M7165 1:50 Rabbit 
VEGFA Thermoscientific 
RB-9031-P1 
1:300 Rabbit 
 
Table 2.1: Antibodies used for immunohistochemistry. Catalogue number, dilution 
and primary species detailed.  
2.1.4 Manual Immunohistochemistry for LIMD1 
 
Cut sections were dried overnight at 60°C to help section adhesion. Slides were de-
paraffinised in xylene for 2x5-minutes and immersed in 70% industrial methanol 
solution (IMS) (Sigma-458600) for 2 minutes prior to blocking endogenous peroxidase 
activity with 2% H2O2 for 2x5-minute incubations. Slides were transferred to 70% IMS 
for a further 2 minutes and rinsed in running tap water for 2 minutes. Epitope retrieval 
was performed using a pressure cooker at maximum temperature and pressure for 10 
minutes in 1% Tris based low pH antigen unmasking solution (pH 6) (Vector Labs-
H3300). Once the pressure cooker had cooled in running tap water, the slides were 
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further cooled in running tap water for 5 minutes. Slides were washed briefly with TBS-
T (0.05%) and dried briefly. Primary antibody diluted at least 30 minutes prior to 
application in Zytomed antibody diluent (ZUC025-100) was applied for 40 minutes, 
slides washed for 2 minutes with TBS-T (0.05%) and primary antibody staining detected 
using the Biogenex-SuperSensitiveTM polymer-HRP system (QD440-XAKE): the super-
enhancer was applied for 20 minutes, washed with TBS-T (0.05%) and the SS-label then 
applied for 30 minutes.  
 
Slides were then washed in TBS-T (0.05%) for 2 minutes and the peroxidase reaction 
detected by incubation with the DAB chromogen solution for 10 minutes (Biogenex-
HK542-XAK). Slides were then washed in running tap water for 2 minutes, 
counterstained in haematoxylin (Gill’s No 2 Haematoxylin solution, (Sigma GH-S216) 
for 5 minutes and then rinsed in tap water for 2 minutes. Slides were differentiated in 
1% Acid Alcohol with four, one-second washes and rinsed in tap water for 2 minutes. 
Slides were then rinsed in 1x Scott’s tap water substitute (Sigma S-5134) for 3 minutes, 
rinsed in tap water for 2 minutes prior to dehydration through three, 2-minute changes 
of IMS prior to clearing in xylene for two, 2-minute washes. Slides were mounted with a 
DPX-xylene based permanent mount (Sigma 06522).  
 
2.1.5 Manual Immunohistochemistry for HIF1α 
 
Sections were de-paraffinised in xylene for two, 5-minute incubations and then in 70% 
ethanol for two-five minute incubations prior to blocking endogenous peroxide activity 
with 3% hydrogen peroxide (H2O2) in methanol for 10 minutes.  Antigen retrieval was 
performed by microwave heating in pre-heated 1% Tris based low pH antigen 
unmasking solution (pH 6) (Vector Labs-H3300) prior to passive cooling for 10 minutes 
and active cooling in running water for 5 minutes.  
 
Slides were washed with TBS for two, 3-minute washes and non-specific binding 
blocked with 400µl diluted horse serum per slide for thirty minutes (Universal ABC 
HRP Kit-Vectastain).  
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Slides were washed for two, 2-minutes with TBS prior to the addition of 400µl of 
Avidin blocking solution (Vector Laboratories SP-2001) for 15 minutes, the wash 
repeated and Biotin blocking solution (Vector Laboratories SP-2001) added for 15 
minutes. After washing with two, 2-minute TBS washes: slides were incubated with 
200µl of the diluted primary HIF1α antibody (Novus Biologicals NB-100-105) 
overnight in a moist humidity chamber at 4oC.  
 
The following morning, slides were allowed to equilibrate to room temperature for 30 
minutes, then washed with two, 2-minute TBS washes prior to incubation with the 
Universal biotinylated Secondary antibody for 30 minutes (Universal ABC Kit, 
Vectastain). The TBS wash was repeated and the slides incubated with 350µl of the 
ABC complex for 30 minutes (Universal ABC HRP Kit, Vectastain). After washing with 
TBS for three, 2-minute washes, 350µl of diluted DAB chromogen (Biogenex HK542-
XAK) was added to each slide for 10 minutes, the slides washed with TBS (two, 2-
minute washes).  
 
Slides were counterstained with haematoxylin for 2 minutes, washed in tap water for 1 
minute prior to differentiation for 1 second in 1% acid alcohol and rewashing in tap 
water for 1 minute. Dehydration was undertaken in increasing ethanol concentrations (2 
minutes in 70% EtOH, 2 minutes in 90% EtOH, two, 3-minutes incubations in 100% 
EtOH) prior to clearing in xylene (two, 3-minute incubations) and mounting with DPX 
mountant (Sigma 06522).   
 
2.1.6 Manual Immunohistochemistry for Ajuba and WTIP and VEGFa  
 
Antigen retrieval was performed as described for HIF1α. Slides were then washed with 
three, 3-minute TBS washes and non-specific binding blocked with 5% goat serum in 
PBS (DAKO-X0907) for one hour. The antibody was diluted to the correct dilution in 
antibody dilution buffer at least 30 minutes prior to using, slides dried briefly and then 
incubated with the primary antibody for one hour.  
 
Samples were washed with TBS for 5 minutes and primary antibody staining detected 
using the Envision Plus Detection System (K4002) with application of the labelled 
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polymer-HRP directly to the slide for 30 minutes. After washing with TBS for 5 
minutes, 350µl of diluted DAB chromogen (Biogenex HK542-XAK) was added to each 
slide for 10 minutes to detect the peroxidase reaction.  Slides were washed with 1xTBS 
(three, 2- minute washes) prior to counterstaining, clearing and mounting as for HIF1α.  
 
2.1.7 Automated immunohistochemistry for LIMD1, VHL, HIF2α and CD34  
 
An automated IHC system using the Ventana Discovery system was employed 
according to the manufacturer’s specifications. Staining was undertaken with LIMD1 
antibody at dilutions of between 1:40 and 1:100.  Non-specific binding was blocked with 
an avidin and a biotin-blocking step. The primary antibody was visualised using an ABC 
system with a universal mouse/rabbit secondary antibody prior to incubation with an 
avidin/biotin complex and visualisation with a DAB chromogen. This same protocol 
was utilised for VHL staining, with an antibody concentration of between 1:50 and 
1:400, and for HIF2α with an antibody concentration of between 1:50 and 1:400. For 
CD34, an antibody concentration of between 1:25 and 1:50 was utilised.  
 
2.1.8 Manual scoring of immunohistochemistry 
 
IHC of control and tumour samples were reviewed by either Professor Michael Sheaff 
of Barts Health NHS Trust, or Dr Georgia Trevisan of University College London 
Hospital, both experienced consultant histopathologists, in order to establish antibody 
specificity, help define appropriate positive and negative controls and to agree on 
appropriate antibody concentrations after IHC optimisation and on manual scoring 
systems where appropriate. All TMA histospots were only scored if the core was intact 
and where appropriate tumour present.  
 
All TMAs were double scored, either by Professor Sheaff or Dr Trevisan and myself or 
Dr Scott Shepherd of Royal Free Hospital, an oncology specialist registrar. Intra-class 
correlation coefficient analysis was undertaken using SPSS-16 to assess inter-observer 
scoring agreement.  
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2.1.9 ARIOL Imaging of immunohistochemistry 
 
Antibody staining of the commercially available TMAs was quantified using the ARIOL 
imaging system (Genetix, San Jose, CA). The slides were loaded in the automated slide 
loader (Applied Imaging SL50) prior to scanning at low resolution (1.25x) and at high 
resolution (20x) using the Olympus Bx61 microscope with an automated platform. 
After high resolution scanning, the images were reviewed for training and quantification 
purposes to differentiate the stained and the unstained cells by the colour of staining 
and the shape of the nuclei whereby brown staining was considered positive and blue 
staining negative. For the tumour histospots, areas of tumour were manually identified 
with masking of the stroma and of the normal/benign tissue from image analysis. 
Scores were generated using a modified automated scoring system: this generates an 
output score based on the combined score for the average staining intensity of the 
protein of interest throughout the analysed area within the histospot as a function of the 
area of positive staining throughout the analysed area of each histospot.  
 
2.2 Cell Culture Techniques 
 
2.2.1 Renal cell carcinoma cell lines 
 
The human renal cell carcinoma lines were provided by Dr Jong-Jie Lu of Barts Cancer 
Institute and had been derived from patient tumours at Barts and the London NHS 
Trust or were commercially available. All cell lines were routinely tested for mycoplasma 
infection and the commercially available lines had previously undergone genetic 
profiling using polymorphic short tandem repeat loci analysis.  
 
Renal cell carcinoma 
line 
Renal cell carcinoma 
subtype 
Wild type VHL 
present? 
RCC4 (Va) ccRCC X 
RCC4 (VHL) ccRCC X 
RCC7 ccRCC √ 
RCC10 ccRCC X 
RCC11 ccRCC X 
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RCC12 ccRCC X 
RCC17 Papillary X 
RCC29 ccRCC X 
RCC45 ccRCC X 
RCC48 ccRCC X 
RCC59 ccRCC X 
RCC88 ccRCC X 
RCC912 ccRCC X 
CAKI1 ccRCC X 
CAKI2 ccRCC X 
ACHN ccRCC X 
786-0 ccRCC X 
 
Table 2.2: RCC lines used in assays with detail of RCC subtype and wild type 
VHL status 
 
2.2.2 Cell maintenance and passaging of adherent cancer cells 
 
Adherent monolayer human cancer cell lines were cultured in Roswell Park Memorial 
Institute-1640 medium (RPMI-1640) (Sigma) or Dulbecco’s Modified Eagle Medium 
(DMEM) (Sigma), supplemented with 10% heat inactivated foetal bovine serum (FBS) 
(Gibco) and 1% penicillin/streptomycin (PAA Laboratories) and maintained at 37oC in 
a humidified atmosphere with 5% CO2 or where appropriate serum starved with culture 
in 1-2% FBS. When cells reached 80% confluency, they were passaged through 
trypsinisation (1xTrypsin-EDTA, Sigma). Lentiviral-transduced renal cell lines 
expressing a puromycin resistance construct, were grown in media supplemented with 
puromycin 0.5-3ug/ml (Invivogen (ant-pr-1)). Penicillin/streptomycin was omitted 
from the media in cells undergoing transfection or transduction.  
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2.2.3 Cell freezing of cancer cells 
 
For long-term storage, cells of a low passage number were trypsinised and re-suspended 
in media, then re-pelleted by centrifugation (1200rpm, for 3 minutes) and washed with 
phosphate-buffered saline (PBS) before re-pelleting. The washed cell pellet was re-
suspended in freezing mix (90% FBS and 10% (v/v) dimethyl sulphoxide (DMSO)) and 
aliquots transferred to cryovials for storage.  The cryovials were stored at -80oC for 24 
hours prior to transfer to liquid nitrogen for long-term storage.  
 
2.2.4 Renal proximal tubular epithelial cells (RPTEC) and cell culture 
Healthy renal proximal tubular epithelial cells obtained from Lonza (CC-2553) were 
cultured in renal basal epithelial growth medium (BEGM) supplemented with human 
epidermal growth factor 0.1%, hydrocortisone 0.1%, epinephrine 0.1%, insulin 0.1%, 
tri-iodothyronine 0.1%, transferrin 0.1%, fetal calf serum 0.5%, gentamicin 30µg/ml 
and amphotericin 15ng/ml (CloneticsTM REGMTM BulletKitTM Lonza CC-3190). Cells 
were maintained at 37oC in a humidified atmosphere with 5% CO2. When cells had 
reached 70-80% confluency they were passaged by trypsinisation. For a 25cm2 flask, 
cells were washed with 5mls of room temperature HEPES-buffered saline solution 
(HEPES-BSS) (Lonza-CC5022), the HEPES-BSS aspirated and cells gently trypsinised 
with 2mls of trypsin/EDTA solution (Lonza-CC5012). Cells were examined 
microscopically until 90% of the cells were rounded up, the cells gently detached and 
the trypsin/EDTA solution neutralised with 4mls of room temperature trypsin 
neutralising solution (TNS) (Lonza-CC5022). The cells were pelleted by centrifugation 
at 220g for 5 minutes and re-suspended in an appropriate volume of media.  
2.2.5 Cell counting and cell seeding  
 
Cells were counted using the automated TC20TM Biorad cell counter. Cells were 
trypsinised as described and 10µl of the carefully mixed cell suspension pipetted in to 
the haemocytometer slide. Each slide was read twice and a mean cell count per ml of 
cell suspension calculated.  
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Cells were seeded into sterile tissue culture plates or dishes. Lentiviral-transduced cells 
expressing a puromycin-resistance construct were taken out of selection 24 hours prior 
to seeding. Cells were plated such that they would be at the desired density at the 
relevant time-point as required by the protocol. 
 
2.2.6 Hypoxic treatment of cells 
 
Cells were exposed to 1% oxygen and maintained at 37°C and at 5% CO2 within a 
hypoxic workstation for the time period required by the particular experiment.  
 
2.2.7 Lentiviral-transduction of renal cell carcinoma cell lines 
 
The ccRCC lines RCC11 and RCC48 were transduced with lentivirus constructs 
containing either knockdown LIMD1 (shLIMD1), rrLIMD1 (LIMD1 knockdown with 
concomitant rescue) or control, non-targeting siRNA (scr), in order to generate lines 
with 1) effective LIMD1 knockdown 2) effective knockdown with concomitant rescue 
of LIMD1 and 3) control cells transduced with non-targeting siRNA.   
 
The lentivirus was obtained from Dr John Foster of Barts Cancer Institute who had 
packaged the expression vector of interest into an attenuated second-generation 
lentivirus with a puromycin resistance construct in HEK293T cells using the packaging 
plasmids pCMVO2.4 and pMDE2. The vector expresses a Flag-His tag (Figure 2.1). 
The viral supernatant was collected at 48 hours and 72 hours and kept frozen at -80oC.  
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Figure 2.1. shRNA expression vector demonstrating shRNA cassette cloning site in to 
which the scr (control, non-targeting siRNA), short hairpin LIMD1 (shLIMD1) and  
rrLIMD1 (LIMD1 knockdown with concomitant rescue) were cloned. The vector 
expresses a Flag-His tag and a puromycin resistance construct.  
 
RCC11 and RCC48 cell lines were seeded in to 6-well plates at different seeding 
densities to assess optimal seeding density for viral transduction: seeding 1x105 
cells/well resulted in 50% confluency at 24 hours, considered optimal for lentiviral 
transduction. 24 hours post seeding, a puromycin kill curve was established with cells in 
separate wells treated with varying puromycin concentrations: 0, 0.5, 1, 3, 5, 7.5 and 10 
µg/ml (Invivogen anti-pr-1) for 48 hours, in order to identify a puromycin 
concentration to use to subsequently select for RCC cells that had undergone lentiviral 
transduction 
  
RCC11 and RCC48 cells were seeded in to 6-well plates at 1x105 cells/well. At 24 hours, 
the media was changed and 1ml of the appropriate thawed viral supernatant added to 
each 6-well plate. The virus was removed from the cells after 24 hours and fresh media 
added. Cells were puromycin selected from 72 hours after the addition of virus and cells 
used in assays after 2-3 passages. All viral waste and virally contaminated equipment was 
carefully decontaminated by soaking in 1% Virkon for at least 12 hours.  
 
2.2.8 Polycomb complex protein-1 (BMI-1) immortalisation of RPTEC  
 
Prior to BMI-1 transduction of RPTECs a puromycin-kill curve was undertaken to 
determine an appropriate puromycin concentration to use for selection of the BMI-1 
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transduced RPTECs: the lentiviral construct contains a puromycin resistance antibiotic 
selection marker.  
 
RPTEC were seeded in to a 6-well plate at a seeding density of 1x105 cells per well. After 
24 hours, cells in separate wells were treated with varying puromycin concentrations, 0, 
0.5, 1, 3 and 5µg/ml (Invivogen anti-pr-1) for 48 hours, to select an appropriate 
puromycin concentration to select for the lentiviral transduced RPTECs.  
 
pFLRu and pLVX multifunctional lentivirus systems into which BMI-1 had been cloned 
were utilised. RPTECs were seeded into a 6-well plate at 1x105 cells/well and 24 hours 
after seeding, 10 or 20µl of concentrated pFLRu-BMI-1 virus or, 10 or 20µl of 
concentrated pLVX-BMI-1 virus added to separate wells within the plate. Two control 
wells, where no virus was added were included. 72 hours after seeding, puromycin 
selection at 0.5µg/ml was started and media containing no puromycin added to one of 
the control wells.  
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2.3 CRISPR (Clustered regularly interspaced palindromic repeat)-Cas-9 system 
for gene editing in RPTEC (renal proximal tubular epithelial cells) 
 
2.3.1 Edit-R DharmaFECTTM Duo gene engineering CRISPR-Cas-9 Transfection 
system in RPTEC 
 
Cleavage of the complementary target for LIMD1 and Ajuba in the BMI-1 transduced 
RPTEC cells was undertaken using the DharmaFECTTM Duo Transfection system. 
 
Three 20-nucleotide target CRISPR RNAs (crRNAs), complementary to the genomic 
target sequence for LIMD1, and three for Ajuba, were selected by Dr Daniel Foxler 
(Figures 2.2 and 2.3). Dharmacon manufactured custom crRNAs through the addition 
of the required S.pyogenes repeat sequence to the 3’ end of the target sequence resulting 
in a custom 42-nucleotide crRNA.  
 
1. CTTCCAAGATCAAACTC 
 
2. CCGAGTTTGAGGAAACTCGC  
 
3. ATGGATAAGTATGACGACCT 
 
Figure 2.2 gRNAs selected for LIMD1 CRISPR using the DharmaFECTTM Duo 
Transfection system. 20-nucleotide target guide RNAs (gRNAs) complementary to the genomic 
target sequence for LIMD1 were selected. All contained protospace adjacent motif (PAM) sequences and 
were complementary to coding sequences in exon 1 of LIMD1. 
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1. GGACGGCTTGCTCGCGTCGC 
 
2. GCAAAGCTGTTAGCTCGTCC  
 
3. GTTGCCCCCCGATTTTCGGC 
 
 
Figure 2.3 gRNAs selected for Ajuba CRISPR using the DharmaFECTTM Duo 
Transfection system. 20-nucleotide target gRNAs complementary to the genomic target sequence 
for Ajuba were selected. All contained PAM sequences and were complementary to coding sequences in 
exon 1 of Ajuba.  
 
Figure 2.4. mKate2 and Cas-9 plasmids. A plasmid with an mKate2 fluorescent reporter, 
blasticidin resistance marker and hCMV promoter element was used to assess transfection efficiency. A 
Cas9 Nuclease Expression plasmid, with a Blasticidin resistance antibiotic selection marker and hCMV 
promoter element was used for transfection. Taken from DharmaconTM Edit-RTM CRISPR-Cas9 
Gene Engineering with Cas9 Nuclease Expression Plasmids and synthetic RNAs. 
 
Since the BMI-1transduced cells expressed a puromycin-resistance construct, a Cas9 
Nuclease Expression plasmid with a blasticidin resistance antibiotic selection marker 
was used to ensure that transfected cells could be selected. An mKate2 fluorescent 
reporter with a blasticidin resistance marker and an hCMV promoter element was used 
to assess transfection efficiency (Evrogen, Moscow, Russia, DharmaFECTTM)  (Figure 
2.4) 
 
BMI-1 transduced RPTEC were seeded in to a 24-well plate at a seeding density at both 
5x104 cells/well and 7.5x104 cells/well. At 24 hours blasticidin selection in separate wells 
was started at 0, 2, 5, 7.5, 10, 12.5, 15 and 20µg/ml and continued for 72 hours, in order 
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to identify a blasticidin concentration to use to select RPTEC that had undergone 
transfection. 
Transfection efficiency was optimised using the EditR mKATE2 optimisation plasmid, 
with blasticidin resistance marker. BMI-1 transduced RPTEC cells were taken out of 
puromycin selection 24 hours prior to seeding and seeded in to 24 well plates in growth 
factor-supplemented REGM at a seeding density of either 5x104 and 7.5x104 cells/well.  
A 10µM crRNA working solution was prepared by adding 2mls of nuclease-free10mM 
Tris pH 7.4 buffer to 20nmol crRNA and a 10µM tracr RNA working solution by 
adding 500µl of nuclease-free, 10mM Tris pH 7.4 butter to 5nM of tracr RNA. A 
100ng/µl SMART Cas9 plasmid working solution was prepared by adding 1.2mls of 
nuclease-free, 10mM Tris pH 7.4 buffer to 120µg of plasmid.   
 
2.3.2 Transfection protocol for the DharmaFECTTM Duo CRISPR Transfection 
system in RPTEC 
  
Optimem® reduced serum medium was warmed at 37°C. A mastermix of Optimem® 
and Dharmafect DuoTM transfection reagent was made in an autoclaved 1.5ml 
eppendorf tube by adding 38.4µl of Dharmafect DuoTM transfection reagent to 601.6µl 
of Optimem® reduced serum medium, mixing well and then aliquoting 50µl in to 12 
sterile 1.5ml eppendorf tubes and leaving for five minutes. This resulted in a final 
Dharmafect DuoTM concentration of 3µl/500µl.  
 
For the knockout transfection mix: 
 
Cas-9 plasmid     1µg (10µl)  
 tracrRNA     2.5µl  
gRNA1    0.8µl 
gRNA2    0.8µl 
gRNA3    0.8µl 
Optimem® reduced serum medium  37.5µl 
      50µl 
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 This resulted in a 50nm final concentration of the crRNA: tracrRNA mix. 
 
For the control transfection mix: 
 
 Cas-9 plasmid     1µg (10µl)  
 tracrRNA     2.5µl  
Optimem® reduced serum medium   37.5µl 
     50µl 
 
For the efficiency transfection mix: 
 
mKATE2 plasmid               1µg (10µl)  
 tracrRNA    2.5µl  
gRNA1    0.8µl 
gRNA2    0.8µl 
gRNA3    0.8µl 
Optimem® reduced serum medium  37.5µl 
     50µl 
 
 This resulted in a 50nm final concentration of the crRNA: tracrRNA mix. 
 
Each of the transfection mixes was added to the 50µl dharmafect duoTM/Optimem 
reduced serum medium, mixed well, and left for 20 minutes before adding in a drop-
wise fashion to 400µl of fresh media in each well of RPTECs in a 24 well plate.  
 
At 48 hours, the cells were examined microscopically to determine which cells had the 
highest fluorescent intensity and thus best transfection efficiency. The transfection mix 
was removed and cells transiently selected with blasticidin at 12.5µg/ml for 72 hours 
and then allowed to recover in antibiotic free media until confluency was reached prior 
to passaging. Two control un-transfected wells were also included: blasticidin at 
12.5µg/ml was added to one well and antibiotic free media to the other well. All 
RPTEC cells in the untransfected, blasticidin treated well were dead after 72 hours in 
selection.  
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2.4 Migration as assessed through scratch assays 
 
The lentiviral-transduced RCC cell lines were plated in to 6-well plates with seeding 
density of 2x105/well in RPMI supplemented with 10% FCS and 1% 
penicillin/streptomycin.  
 
Once 100% confluent a horizontal and vertical cross was made to transect and bisect 
each well using a p200 tip. Plates were then carefully washed with five changes of PBS 
to remove any floating cells and cells serum starved with RPMI supplemented with 2% 
FCS and 1% penicillin/streptomycin to encourage cell migration. Puromycin selection 
was maintained throughout the assay with media changed every 24 hours.  
 
Images were taken immediately after creation of the scratch and at 24 hours and 48 
hours. The size of the remaining scratch was calculated using Image-J software.  
2.5 Clonogenic assays 
 
The lentiviral transduced RCC cell lines were plated in to 6-well plates with a seeding 
density of 100 or 200 cells/well. Media was changed every 72 hours and puromycin 
selection maintained throughout. Once clear colonies were visible (approximately 14-20 
days post seeding), cells were washed three times with ice cold PBS prior to fixation 
with ice cold 100% Methanol overnight. Cells were then counterstained with crystal 
violet (0.5% w/v) for 20 minutes with gentle rocking. Excess crystal violet was washed 
from the plates and the plates allowed to air dry. Colony number was counted manually.  
In order to read the absorbance of the crystal violet, crystal violet was solubilised in 2% 
Triton (v/v) in PBS prior to incubation on a rocker overnight at room temperature. 
Absorbance was then read at 540nm using the Wallac 1420 Multilabel counter plate 
reader.  
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2.6 Hypoxic response element (HRE) assay 
 
2.6.1 HIF1α HRE-reporter assay principle 
 
Luciferase dual-reporter assays are widely used to study transcriptional activation. The 
two different types of luciferase used commonly have distinct substrate requirements, 
which produce different wavelengths of fluorescence, thus enabling quantification from 
a single sample. In this assay, cells were simultaneously transfected with a thymidine 
kinase-Renilla (TK-Renilla) luciferase reporter  (thymidine kinase is constitutively 
expressed) and a pGL3-(6x) HRE-firefly luciferase plasmid (whereby the promoter 
response element for HIF1-α had been cloned upstream of the pGL3 basic firefly 
luciferase plasmid). Differences in transfection efficiency could then be accounted for 
by normalising the luminescence obtained for the experimental reporter (Renilla) to the 
luminescence obtained for the constitutive reporter (Firefly). The normalised reporter 
luminescence in the experimental cell line of interest/experimental condition can then 
be normalised to the control.  
 
2.6.2 HIF1α HRE-reporter plasmid construct 
 
The pGL3-(6x)HRE-firefly luciferase plasmid was obtained from Dr Daniel Foxler who 
had cloned six copies of the promoter response element for HIF1α upstream of the 
pGL3 basic firefly luciferase plasmid (Figure 2.5) (Promega-E1751), pGL3Vo plasmid 
lacking the HRE construct was used as vector only control and the thymidine kinase-
Renilla (TK-Renilla) luciferase reporter used as an internal control value to enable 
normalisation of the experimental firefly luciferase activity and to account for 
differences in transfection efficiency.  
 
   Chapter 2: Materials and Methods   
!118!
 
Figure 2.5. Schemata of the pGL3-Basic Vector. 6 copies of the promoter response element 
for HIF1α were cloned upstream of the pGL3 basic firefly luciferase plasmid. Adapted from pGL3 
Luciferase Reporter Vectors www.promega.com. 
 
2.6.3  Optimisation of transfection efficiency for the HIF-1α HRE-reporter 
system 
 
Optimisation of the transfection conditions for the HRE reporter assay was undertaken 
in RCC11 and RCC45 cell lines. 3.5x105 of each cell line in 500µl of RPMI were seeded 
in to 24 well plates. Each transfection was done in triplicate with incubation in both 
normoxia (20% O2) and hypoxia (1% O2). Cells were co-transfected in triplicate with 
either the pGL3-(6x)HRE-firefly luciferase or pGL3Vo firefly luciferase in combination 
with the TK-Renilla luciferase reporters. Transfection was undertaken 24 hours after the 
cells were seeded. Using autoclaved eppendorfs, a mastermix of the pGL3-(6x)HRE-
firefly DNA or pGL3 Vo-firefly DNA in combination with the TK-Renilla luciferase 
DNA was made, adding the DNA to 50µl per well transfected of pre-warmed reduced 
serum media (Opti-MEM®), and mixing gently with a pipette. Viafect transfection 
reagent™, equilibrated to room temperature, was added to the mix at a ratio of 3:1 
relative to the total amount of DNA added and mixed well by pipetting. The 
transfection mix was left to incubate at 20 minutes at room temperature, prior to adding 
50µl of the mix dropwise directly to the media.  The following combinations of pGL3-
(6x)HRE or pGL3Vo in combination with the TK-Renilla luciferase were transfected.  
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TK-Reni l la  Luciferase (ng) pGL3Vo (ng) pGL3-(6x)HRE (ng) 
30 50 50 
30 100 100 
30 200 200 
   
50 50 50 
50 100 100 
50 200 200 
 
Table 2.3: Optimisation of transfection for HIF-1α HRE-reporter system 
protocol.  
 
Seven hours after transfection, one plate was incubated in the hypoxic workstation (1% 
O2 at 37°C in a humidified atmosphere with 5% CO2) for 16 hours and the second plate 
left for 16 hours in normoxia (20% O2 at 37
oC in a humidified atmosphere with 5% 
CO2).  
2.6.3.1 HIF1α Dual luciferase reporter assay reagent preparation 
 
1. Passive Lysis Buffer (PLB):  1 volume of 5x PLB (Promega-E1941) was 
added to 4 volumes of distilled water, mixed well and stored at 4°C 
2. Luciferase Assay Reagent (LAR): The lyophilised Luciferase Assay Substrate 
was re-suspended in Luciferase Assay Buffer II (Promega E1910) and stored at -
20°C 
3. Stop and Glo Reagent ®: 0.2 mls of 50x Stop and Glo substrate (Promega 
E2920) was added to 10 mls of Stop and Glo Buffer®  (Promega E2920) and 
vortexed for 10 seconds 
 
2.6.3.2 Cell lysis for HIF1α dual luciferase reporter assay system 
 
Cells were lysed in 80µl 1x passive lysis buffer 24 hours post transfection and snap 
frozen on dry ice. Samples were thawed and allowed to equilibrate at room temperature, 
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with gentle rocking for fifteen minutes prior to assessing luciferase activity using the 
dual luciferase reporter assay system. 
 
2.6.3.3 Protocol for readout of Luciferase reporter assay  
 
10µl of each lysate was pipetted in triplicate in to a white-bottomed 96-well plate. 100µl 
of the luciferase assay reagent was added to each sample prior to gentle mixing on an 
orbital plate shaker for two minutes. Firefly luminescence was then read using the 
Wallac 1420 Multilabel Counter Plate reader. 100µl of diluted room temperature Stop 
and Glo® was then added to each well to quench firefly activity and the Renilla 
luciferase activity read using the Wallac 1420 Multilabel Counter Plate reader. The 
luminescence for the Renilla reporter was then normalised to the Firefly reporter for 
each reading and the normalised shLIMD1 values then normalised to the scr control 
values in both normoxia and hypoxia.  
 
2.7 Synthetic lethality Drug screen 
 
2.7.1 Synthetic lethality Drug screen background 
A cancer-therapeutic drug library containing five hundred and eighty four Federal Drug 
Agency (FDA) approved, cancer-therapeutic drugs was obtained from the Institute of 
Cancer Research. All drugs included in the screen are either already in clinical use as 
cancer-therapeutic drugs, or have been evaluated within a clinical trial setting as showing 
potential cancer-therapeutic effects. The drug library incorporated five, 96-well plates 
and included empty wells in row 7 and further empty rows on plate five for the addition 
of further controls.  
 
2.7.2 Optimisation of RCC11 seeding density prior to drug screen 
 
RCC11 scr and RCC11 shLIMD1 cells of early and identical passage were taken out of 
puromycin selection 24 hours prior to seeding. Cells were seeded in to 96-well plates in 
100µl of media with six replicates for each seeding density at a range of different 
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seeding densities: 800,100,1200 and 1500 cells/well for both cell lines. The media was 
changed at 24 and 48 hours to replicate the conditions of the drug screen and the plates 
manually inspected on day 6 to determine cell confluency. A seeding density that 
resulted in 90-95% cell confluency on day 6, considered optimal for 2-dimensional drug 
screens was selected for each cell line: this was 1000 cells/well and 1200 cells/well for 
RCC11 scr and RCC11 shLIMD1 cells respectively.  
2.7.3 Seeding of RCC11 scr and RCC11 shLIMD1 cells for the drug screen !
RCC11 scr and RCC11 shLIMD1 cells of early and identical passage were taken out of 
puromycin selection 24 hours prior to seeding. Seeding of the RCC11 scr cells was at 
1000 cells/well and the RCC11 shLIMD1 cells at 1200 cells/well. 6, 96 well plates for 
RCC11 scr and 6, 96-well plates for RCC11 shLIMD1 cells were seeded.  
2.7.4 Preparation of the drug plates 
 
The drug library was stored in the -20°C freezer. For all five 96-well plates row 7 was 
empty and for the fifth plate, there were no drug compounds in rows 8-12, allowing the 
incorporation of additional control wells.  A number of controls were added to these 
rows. For row 6 for all wells, a media only control was added to the top three wells (7A, 
B and C) and 5µl of DMSO to the 3 wells underneath (7D, E and F). We had observed 
activity with the tyrosine kinase inhibitor sunitinib in these cell lines and 5µl of sunitinib 
at a concentration of 20µM was added to well 7G and H on each plate. In addition, on 
the 6th plate, 5µl of sunitinib at a concentration of 20µM was added to rows 8A-E and 
5µl of sunitinib at a concentration of 40µM to rows 9A-E and 5µl of sunitinib at a 
concentration of 60µM to rows 10A-E.  Using fresh RPMI, supplemented with 10% 
FCS, (but containing no penicillin/streptomycin), 95µl of media was carefully aliquoted 
in to each well of each drug plate  
Dilution of the drug library was carried out on the day drugging of the cells was 
undertaken.  
2.7.5 Drugging of the RCC11 scr and RCC11 shLIMD1 plates 
 
24 hours after seeding, media was aspirated from the RCC11 scr and RCC11 shLIMD1 
cells and replaced with 95µl of RPMI supplemented with 10% FCS but containing no 
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antibiotics and plates carefully labelled.  5µl of each compound from the compound 
library/control wells was carefully transferred to the corresponding RCC11scr/RCC11 
shLIMD1 plate using a p20 multichannel pipette and the drug carefully mixed with the 
media by pipetting up and down 5 times. This resulted in a final drug concentration of 
1µM for all compounds in the drug library, with 0.5% DMSO control and between 1µM 
and 3µM of sunitinib control.  
48 hours after the first drugging, the media was carefully aspirated from the 96 well 
plates and replaced with 95µl of RPMI supplemented with 10% FCS. The drugging 
process described above was repeated.  
On day 6, 48 hours after the second drugging, drug assays were read using a Cell-Titer-
Glo® luminescence cell viability assay. 
A further drug screen was undertaken, with drugging of the cells with 2µM of the drug 
library. The protocol was as described, but 90µl of media was added to each well prior 
to drugging with 10µl of the drug library.  
2.7.6 Cell-Titer-Glo® Luminescence cell viability assay 
 
The Cell-Titer-Glo® Luminescence cell viability assay is an ATP based assay where the 
luminescence signal is directly proportional to the amount of ATP present, which in 
turn is directly proportional to the number of viable cells present in culture.  
 
The Cell-Titer-Glo® reagents were prepared by reconstituting the lyophilised 
enzyme/substrate mixture according to the manufacturers instructions, and mixing well 
to obtain a homogenous solution prior to aliquoting and storing at -20oC. Stored, 
thawed aliquots were diluted 1 in 4 with PBS prior to use.  
 
Media was aspirated from the 96 well plates, and 100µl of diluted Cell-Titer-Glo® 
reagent pipetted in to each plate prior to mixing on an orbital shaker for 2 minutes: 
plates were then incubated at room temperature in the dark for 10 minutes to stabilise 
luminescent signal. Luminescence was read using the Wallac 1420 Multilabel counter 
plate reader.  
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2.7.7 Drug screen output analysis 
 
The ‘Z score’ method was used to compare the relative cell killing for each drug 
between the scr and shLIMD1 plates. This method excludes control measurements 
altogether under the assumption that most compounds are inactive and can serve as 
controls. The scoring system rescales the output of the Cell-Titre GloTM assay relative to 
the within plate variation by subtracting the median of the plate values from each drug 
assay result and dividing the difference by the median absolute deviation calculated from 
all measurements within the plate. This generates a readout whereby the more negative 
the Z-score the greater the degree of cell killing relative to the plate as a whole and the 
more positive the Z-score the greater the cell viability relative to the plate as a whole 
(Malo, Hanley et al. 2006). The outputs of the Z-scores were then plotted graphically 
using Prism 6. Drug ‘hits’ from the screen were subsequently validated using short-term 
cell-viability assays.  
 
2.8 Drug-sensitivity assays 
 
2.8.1 Drugs used in the drug sensitivity assays 
 
All drugs were diluted to a stock concentration of 10mM in DMSO, prior to dilution to 
the relevant drug concentration in RPMI/DMEM media as appropriate, supplemented 
with 10% FCS.  
Drug Name Drug concentration 
range 
Company/Catalogue 
Number 
Sunitinib 0.1µM-10µM Santa Crusz Biotechnology, 
220177 
Temsirolimus 0.5µM-30µM Cambridge Bioscience, 
CAY11590 
Irinotecan 0.1µM-60µM LKT Laboratories, I6932 
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Pazopanib 0.1µM-60µM Cambridge Bioscience, 
1916-5 
Dorzolamide 0.1µM-60µM Sigma-Aldrich, SML0468 
Selumetinib 0.1µM-60µM Santa Crusz Biotechnology, 
sc-364613 
 
Table 2.4: Drugs used in drug sensitivity assays. Drug name, drug concentration 
range and catalogue number detailed.  
 
2.8.2 Seeding density for different cell lines for drug sensitivity assay 
 
Early passage cells were taken out of puromycin selection 24-hours prior to plating. 
Seeding optimisation was undertaken such that confluency when assessed manually was 
at between 90-95% on day 6 (Table 2.5). Cell lines e.g. scr and shLIMD1 were seeded 
on to the same 96-well plate and each cell line dosed at each drug concentration in 
triplicate. At 24 and 72 hours, the media was aspirated and replaced with media 
containing the appropriate concentration of drug.  
 
Cell line Seeding density in 96 well 
plate (cells/well) 
RCC11 scr 1000 
RCC11 shLIMD1 1200 
RCC48 scr 800 
RCC48 shLIMD1 1000 
HEK-293T 2000 
A549 1500 
HELA 1500 
 
Table 2.5 Optimal seeding densities for a range of cell lines in a 96 well plate. 
Cells were seeded at a range of seeding densities in a 96 well plate and a seeding density associated with 
90-95% confluency on day 6 selected. 
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2.8.3 Drug-sensitivity protocol 
 
24 hours post cell seeding cells were drugged with increasing doses of the drugs listed in 
Table 2.4. Drugs were diluted in the appropriate media for optimal cell growth (RPMI 
or DMEM) supplemented with 10% FCS just prior to cell drugging. The dose range was 
chosen to give a dose response with cell death of between 0 and 95% where possible 
and all drugging at each dose concentration was undertaken in triplicate. Media was 
aspirated using a multichannel aspirator and replaced with the appropriate drug 
concentration. Drugging of cells in the outer wells was avoided to overcome the effects 
of ‘edge effects’, whereby evaporation of media is more likely to occur in the outermost 
wells. 
 
 48 hours after the first drugging, the media was carefully aspirated from the 96-well 
plates and the drugging process described above was repeated.  
On day 6, 48 hours after the second drugging, drug assays were read using the Cell-
Titer-Glo® luminescence cell viability assay described in section 2.7.6. The 
Luminescence was read using the Wallac 1420 Multilabel counter plate reader and the 
mean for each reading for each drug concentration normalised to the DMSO control 
and a drug dose-response curve constructed using Prism 6.  
2.9. Fluorescent associated cell-sorting (FACS) protocol for the analysis of cell 
viability using propidium iodide (PI) staining 
 
PI staining and FACS analysis of paired RCC11 scr/shLIMD1 and RCC48 
scr/shLIMD1 cells was undertaken to assess differences in cell cycle associated with 
LIMD1 proficiency/deficiency.  
 
2.9.1 Preparation of cells for FACS analysis and propidium iodide (PI) staining 
 
RCC11 scr/shLIMD1 and RCC48 scr/shLIMD1 cells were seeded in to 6-well plates 
such that cell confluency was approximately 70% 24 hours post seeding. Cells were 
lysed and cell number counted as described in Section 2.2. 5x105 cells of each cell type 
and a further 5x105 cells (as an unstained control) were pelleted by centrifugation (300g 
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for five minutes at 4°C). The pellet was washed once with ice cold PBS prior to 
permeabilisation/fixation in 700µl of ice cold 70%-ethanol. Cells were incubated on ice 
for 30 minutes prior to re-pelleting (13,000g for one minute at 4°C). Cells were further 
permeabilised by re-suspending the pellet in 700µl of 0.1% Triton X100 in PBS on ice 
for five minutes prior to re-centrifugation (13,000g for one minute at 4°C). RNA was 
cleaved by re-suspending the pellet in 50µl of a 100µg/ml RNAse solution in PBS and 
shaking at 37°C at 100rpm for one hour prior to re-centrifugation (300xg for 8 minutes 
at 4°C). Cells were stained with 200µl of a 50µg/ml solution of propidium iodide in 
PBS and incubated on ice for 30 minutes. 800µl of Hank’s buffered saline solution/2% 
FCS was added prior.  
 
2.9.2 FACS analysis of PI staining 
 
Fluorescence was read using a Fluorescence Activated Cell Sorter (FACS Caliber B) 
using the YG-610/20 excitation-emission filters with the appropriate gates set around 
the G0/G1, S and T2/M phase peaks. Results were analysed using Flowjo 7.6.5 
software.  
2.10 Enzyme linked immuno-absorbant assay (ELISA) of RCC11 and RCC48 
proficient/deficient cells 
 
2.10.1 Quantikine ELISA background 
 
A Quantikine VEGF ELISA kit (R&D Systems) was used to measure levels of VEGFA 
in the supernatant. This is a sandwich immunoassay, using a prepared 96-well plate, pre-
coated with capture antibody. Samples/standard are added to the plate, with analyte 
bound by the immobilised antibody with unbound material washed away. The substrate 
solution tetramethylbenzidine (TMB) is added to the well, with a blue colour developing 
in proportion to the amount of analyte added. Colour development is then stopped and 
absorbance read at 450nm. 
2.10.2 Cell Preparation of RCC11 and RCC48 for ELISA 
 
Paired RCC11 scr/shLIMD1 and RCC48 scr/shLIMD1 cells were taken out of 
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puromycin selection 24 hours prior to seeding in to 12-well plates at a density to ensure 
50-60% confluency at 24 hours. Media was supplemented with 10% FBS but 
penicillin/streptomycin omitted. Plates were seeded for incubation in both normoxia 
(20% O2 at 37
oC in a humidified atmosphere with 5% CO2) and in a hypoxic 
workstation (1% O2 at 37
oC in a humidified atmosphere with 5% CO2). 24 hours post-
seeding, cells were either transferred to the hypoxic workstation or left to remain in a 
normoxic environment. Cell culture media was then aliquoted 16 hours later.    
2.10.3 Reagent preparation and VEGFa assay procedure 
 
 All reagents were allowed to equilibrate to room temperature prior to use. Cell culture 
media was pipetted in to an autoclaved eppendorf and spun at 13,000rpm for one 
minute before aliquoting in to a clean eppendorf. VEGF controls of known 
concentration supplied in the Quantikine ELISA kit were also included. The ELISA was 
performed in duplicate for each sample/control. 50µl of assay diluent RD1W was added 
to each microplate well and 200µl of the standard or sample added to the assay diluent. 
The microplates were then covered with an adhesive strip and incubated for two hours 
at room temperature. Each well was aspirated and washed three times with 400µl of 
wash buffer and any remaining wash buffer removed by inverting the plate and blotting 
against clean paper towels. 200µl of VEGF conjugate was then added to each well, 
covered with an adhesive strip and incubating for two hours at room temperature. Each 
well was then aspirated and the wash with wash buffer repeated as detailed above. The 
substrate solution was then made up by mixing equal quantities of colour reagent A and 
B and adding 200µl of the substrate solution to each well prior to incubation at room 
temperature for 25 minutes. 50µl of stop solution was added to each well and the 
optical density read using the Wallac 1420 Multilabel counter plate reader with 
absorbance read at both 450nm and at 540nm to account for background absorbance. 
Background absorbance was subtracted for each sample/control and mean values for 
both controls and samples calculated. Using the readout for the control samples, a 
corrected absorbance/VEGF concentration graph was calculated and the VEGF 
concentrations for the samples determined.  
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2.11 Western blot analysis 
2.11.1. Solutions used for cell lysis 
 
RIPA: 150 mM NaCl, 1% (v/v) IGEPAL-630, 0.5% (w/v) sodium deoxycholate, 0.1% 
(w/v) SDS and 50mM Tris dissolved in distilled water, pH adjusted to 8. 
 
Protease and Phosphatase Inhibitors: (Roche). One CompleteTM Protease Inhibitor 
Cocktail tablet and one PhosStopTM tablet were dissolved in 10mls of lysis buffer and 
stored at -20oC for < 6 weeks.  
 
MG-132 Proteasome Inhibitor: (Cell Signalling). A 10mM stock solution was obtained 
by dissolving the MG-132 powder into sterile DMSO and stored at -20oC for < 2 
months. A working concentration of 10µM was used.  
2.11.2 Preparation of cell lysates for Western blot analysis 
 
Cells were washed three times with ice cold PBS and scraped gently into ice cold RIPA 
lysis buffer containing protease/phosphatase inhibitor and MG132. Samples were 
sonicated three times for 3 seconds and centrifuged at 13,000rpm for 10 minutes at 4oC 
to clear insoluble cellular debris.  The supernatant was transferred to a clean eppendorf 
tube and stored at -80oC 
2.11.3 Protein concentration evaluation 
 
Protein concentration of the cell lysates was measured using either the Bio-Rad or 
Sigma Bradford assay.  
 
2.11.3.1 Bio-Rad DC TM protein assay 
 
Bovine serum albumin (BSA) (20mg/ml) was diluted in distilled water to generate 
protein standard positive controls ranging in concentration from 0.1mg/ml to 
1.5mg/ml.  Reagent A’ was prepared by adding 20µl of Bio-Rad DCTM reagent S to 1ml 
of Bio-Rad DCTM reagent A (Bio-Rad 500-0116).  
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5µl aliquots of the control samples, a dH20 control, and the thawed lysate samples were 
pipetted in triplicate in a 96-well plate.  25µl of A’ and 200µl of Reagent B was then 
added to each sample, the plate incubated at room temperature for 10 minutes and 
absorbance measured at 630nm using the Wallac 1420 Multilabel counter plate reader.  
 
2.11.3.2 Sigma Bradford Assay 
 
Dilutions of protein standard positive controls, ranging from 0.15625mg/ml to 5mg/ml 
were made by diluting BSA in distilled water. 2µl of each control (including a distilled 
water sample as background control) and lysate sample were added in triplicate to a 96 
well plate. 8µl of distilled water was added to each well to reduce the concentration of 
the RIPA buffer, followed by 250µl of the Bradford reagent. The plate was incubated at 
room temperature for 15 minutes and absorbance measured at 530nm using the Wallac 
1420 Multilabel counter plate reader.  
 
For both assays, the absorbance of the protein standards was used to construct a 
standard curve, using Prism 6 and the equation for this curve used to determine the 
sample concentrations.  
2.11.4.  Solutions for sodium dodecyl sulphate polyacrylamide gel electrophoresis  
(SDS-PAGE) and Immunoblotting 
 
5x SDS-PAGE Sample buffer: (50% (v/v) glycerol, 250mM Tris-HCL pH 6.8, 5% 
(w/v) SDS, 5% (v/v), β-Mercaptoethanol and 0.05% (w/v) Bromophenol Blue) were 
dissolved in distilled water and stored at -20oC 
 
Transfer buffer: Blocking Solution: 5% (w/v) dried skimmed milk powder was 
dissolved in 1x PBS-Tween (0.05% v/v) or 5% (w/v) dried skimmed milk powder was 
dissolved in 1x-TBS-Tween (0.05% v/v). 
 
Resolving gel: ddH2O was added to bis-acrylamide (30% stock solution, National 
Diagnostics EC890) of the desired volume to achieve the correct percentage gel prior to 
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the addition of resolving buffer (0.375M Tris pH 8.8 and 0.1% SDS) (National 
Diagnostics). 0.1% ammonium persulphate (APS) was added to crosslink the 
acrylamide, catalysed by the addition of 0.01% N,N,N’,N’-tetramethylethylenediamine 
(TEMED) immediately prior to pouring. 100% ethanol was added immediately after 
pouring to achieve a straight horizontal gel during resolving.  
 
Stacking gel: Stacking buffer (0.125M Tris pH 6.8, 0.1% SDS) was added to 4% bis-
acrylamide (National Diagnostics). Crosslinking of the acrylamide was achieved with the 
addition of 0.1% APS and 0.01% TEMED. Gel combs were inserted straight after 
pouring the stacking gel.  
 
2.11.5 Western Blot protocol 
 
Samples were run on poured 8% to 12% polyacrylamide gels.  Generally 8% gels were 
used to resolve proteins between 50 and 150 kDa and 10% gels for proteins between 30 
and 50 kDa. 
 
Cell lysates were denatured in 1x SDS-PAGE Sample buffer by heating at 95oC for 5 
minutes. Samples were cooled on ice and centrifuged briefly prior to loading. 5µl of 
molecular weight marker was loaded alongside the protein samples to enable band size 
estimation. Typically 15-20µg of protein sample was loaded with 5µg for the β-actin 
control.   
 
Proteins were resolved by SDS-PAGE at 80 Volts for 20 minutes and then at 120 Volts 
until fully resolved. Gels were transferred on to methanol permeabilised, Polyvinylidene 
fluoride (PVDF) membranes using the Trans-Blot TurboTM system (Bio-Rad) for 20 
minutes at 25 Volts and 2.5 Amps. Membranes were blocked in blocking buffer for 1 
hour and then incubated with the required primary antibody diluted in blocking buffer 
at 4oC overnight with gentle agitation. 
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Antigen Company (Catalogue Number) Dilution for 
immunoblotting 
Host 
species 
Primary 
Antibodies 
   
LIMD1 (Sharp et al, 2004, 2008, 2009) 1:500 Mouse 
HIF1α BD Transduction Laboratories 
610959 
1:500 Mouse 
HIF2α Novus Biologicals NB100-132 1:500 Rabbit 
Ajuba Cell Signaling 4897 1:500 Mouse 
WTIP Santa Crusz SC241737 1:500 Goat 
β-Actin Sigma-Aldrich A5316 1:50,000 Mouse 
    
Secondary 
Antibodies 
   
    
Mouse Dako 2019-10 1:2,500 Goat 
Rabbit Dako 2019-03 1:2,500 Goat 
Goat Dako 2018-11 1:2,500 Rabbit 
 
Table 2.6: Antibodies used for Immunoblot analysis. Primary antibody, catalogue 
number, antibody dilution, and host species listed.  
 
Membranes were then washed with three, 5-minute washes in PBS-Tween 0.05% prior 
to incubation with secondary antibody (horse-radish peroxidase conjugated, diluted in 
blocking buffer to concentration 1:2,500) for 1 hour at room temperature with gentle 
agitation. Membranes were washed with three, 5-minute washes in PBS-Tween 0.05%, 
prior to incubation with Enhanced Chemiluminescence (ECL) Plus Western Blotting 
Detection Reagent (Thermo Scientific 80196) at room temperature for 5 minutes to 
initiate an HRP-catalysed luminescent reaction. Membranes were exposed to 
chemiluminescent detection film (UltraCruz autoradiography film) for between 5 
seconds and up to 2 hours and the film developed in a Curix 60 Developer (Agfa, 
Middlesex, UK). 
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     Chapter 3.      
     
LIMD1, WTIP and Ajuba (LAW) expression is reduced in clear cell 
renal cell carcinoma 
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3.1 Introduction 
 
Sharp et al demonstrated that LIMD1 is downregulated and contributes to 
tumourigenesis in lung carcinoma (Sharp, Al-Attar et al. 2008). In breast carcinoma, 
Spendlove et al showed not only frequent loss of LIMD1 expression in tumour 
compared to normal adjacent and distant tissue but that absence/loss of nuclear staining 
strongly correlated with worse patient survival and a more aggressive tumour phenotype 
(Spendlove, Al-Attar et al. 2008).  
 
LIMD1, Ajuba and WTIP (LAW) are closely homologous members of the larger Zyxin 
family, characterised by triple tandem C-terminal zinc finger motifs which facilitate 
protein-protein interactions (Kadrmas and Beckerle 2004). Tanaka et al have recently 
demonstrated that in malignant mesothelioma cells, Ajuba downregulation is common 
and that Ajuba re-expression abrogated some aspects of tumourigenesis (Tanaka, Osada 
et al. 2015). In addition, Ajuba is 14q expressed and work by Kroeger et al has 
demonstrated a strong association between 14q loss and worse clinical outcome in 
ccRCC. Kroeger et al hypothesised that this could be related to HIF1α loss, which is 14q 
expressed, although this has not been established and other candidate genes remain 
uncharacterised (Kroeger, Klatte et al. 2013). Conversely, work by Shi et al, has 
demonstrated that Ajuba is frequently up-regulated in oesophageal SCC compared to 
non-cancerous tissue at both the mRNA and protein level (Shi, Chen et al. 2016).  
 
All three LIM-domain proteins interact with components of the RISC and the mRNA 
m7 GTP cap-protein complex required for miRNA-mediated silencing (Bridge, Shah et 
al. 2017). Of note, alterations in a number of hypoxically regulated miRNAs are 
implicated in ccRCC tumourigenesis and miRNAs are often aberrantly expressed in 
carcinomas with consequent oncogenic and loss of tumour suppressive functions (Li, 
Wang et al. 2015).  In addition, all three proteins play a critical role in the regulation of 
the hypoxic response functioning as a molecular scaffold simultaneously binding VHL 
and PHDs to regulate HIF-1α (Foxler, Bridge et al. 2012).  Ajuba LIM proteins are 
negative regulators of the Hippo signalling pathway, a critical regulator of epithelial 
organ size (Zeng and Hong 2008), deregulation of which is implicated in driving 
tumourigenesis in multiple tumour types including ccRCC (Harvey, Zhang et al. 2013) .   
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All three family members remain uncharacterised in ccRCC. It was hypothesised that 
loss of LAW is common in ccRCC and could contribute to tumourigenesis: given the 
close homology of the three proteins and their overlapping functionality, a degree of 
functional redundancy may also exist such that a second LAW protein could 
compensate in part for the loss of a first LAW protein.  It was also hypothesised that 
loss of several LAW proteins may coexist and further contribute to tumourigenesis  
 
To this end, LAW levels were characterised in vitro in a panel of ccRCC lines prior to 
assessing immunohistochemical staining in a range of normal tissues and tumours 
before characterising staining in ccRCC and matched adjacent tissue (MAT). The 
relationship between the levels of the three proteins in ccRCC and MAT was 
investigated:  establishing if tumours that had low levels of LIMD1 for example were 
also more likely to have low Ajuba and or WTIP staining.  
 
In addition, staining for LAW proteins was correlated with staining for VEGFa and 
CD34.  Both VEGFa and CD34 are markers of hypoxic deregulation, a critical driver of 
ccRCC (Pouyssegur, Dayan et al. 2006) and validated prognostic indicators in ccRCC. In 
some studies, VEGF-A overexpression is associated with a more aggressive ccRCC 
subtype (Patard, Rioux-Leclercq et al. 2009) and targeted therapy with tyrosine-kinase 
inhibitors down-regulates angiogenesis predominantly through VEGF-R and PDGF-R 
pathways (Dorevic, Matusan-Ilijas et al. 2009). CD34 is an established marker for 
capillary endothelia and hence micro-vascular density (MVD). Tumour MVD has been 
shown to correlate with the aggressiveness of renal cell carcinoma: in an analysis of 57 
RCC tumours, adjusted MVD was associated with shorter disease-free survival on 
univariate and multivariate analysis (Iakovlev, Gabril et al. 2012) (Yao, Qian et al. 2007). 
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3.2 Aims and Objectives 
 
The aims and objectives of this chapter are: 
 
1. To assess the protein levels of LAW family members in a panel of ccRCC cell 
lines in vitro by immunoblot 
2. To optimise immunohistochemical staining for LAW family members in a range 
of normal and tumour tissues  
3. To characterise the expression and relationship between LAW family members 
immunohistochemically in ccRCC and matched adjacent tissue (MAT) 
4. To characterise the relationship between LAW family members and established 
markers of hypoxic deregulation in ccRCC 
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3.3 Expression of LIMD1 and its family members Ajuba and WTIP is 
reduced/absent in a significant proportion of ccRCC lines 
 
Firstly the expression of LIMD1, Ajuba and WTIP was characterised in a panel of 
ccRCC lines relative to expression in renal proximal tubular epithelial cells (RPTEC), 
the cells from which ccRCC is thought to derive (Frew and Moch 2015) (Figure 3.1).  
Western blot analysis demonstrated good specificity of the antibodies in vitro with band 
sizes corresponding to that predicted. The Sharp lab had also used siRNA directed 
against the proteins of interest to knock down LAW expression, with consequent 
abrogation of the Western blot signal thus further confirming antibody specificity.  
 
Blots were not run with an RPTEC-BMI-1 control included concurrently as this was not 
available at the time. Protein levels were analysed using Image-J and normalised to the 
β-actin control. A separate blot was run for Ajuba, LIMD1 and WTIP, which included 
lysate from RPTEC cells, BMI-1-transduced RPTEC and RCC45 (Figure 3.1). This 
enabled the levels of Ajuba, LIMD1 and WTIP in the RPTEC line to be normalised to 
the RCC45 line, and LAW levels in the panel of ccRCC line could then be normalised to 
this figure, allowing the comparison of LAW expression in the ccRCC lines compared 
to RPTEC control.  
 
LIMD1 expression was reduced or absent in ten out of the twelve cell lines 
characterised (88%). Eleven of the twelve lines (92%) demonstrated low or absent 
Ajuba expression and for WTIP, four out of the twelve lines (33%) demonstrated low 
or absent WTIP expression, with the remaining eight lines (67%) demonstrating 
increased expression. Some lines showed high levels of expression of all three family 
members e.g. RCC11, whilst others had low levels of two family members e.g. RCC38, 
which expressed very low Ajuba and reduced LIMD1 with increased WTIP compared 
to the RPTEC-BMI-1 control. RCC12 was the only ccRCC line tested that expressed 
low levels of all three family members, although some signal was present for all three 
proteins (Figure 3.1).  
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(iii)
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Figure 3.1 Expression of LIMD1 and family members WTIP and Ajuba is 
lost/reduced in ccRCC lines in v i tro .  
Immunoblots of whole cell ccRCC extracts showing the protein expression of (i) HIF2α, LIMD1, Ajuba, 
WTIP, VHL and β-actin as loading control. Loading protein concentrations were normalised after 
determination of lysate protein concentration using a Bradford assay. (ii)  Whole cell extract 
immunoblots to show the protein expression of LIMD1, Ajuba and WTIP in RPTEC and BMI-1 
transduced RPTEC with the ccRCC line RCC45 for comparison. Loading protein concentrations were 
normalised after determination of lysate protein concentration using a Bradford assay and β-actin 
included as a loading control. (iii) Western blot signal for LIMD1, Ajuba and WTIP was compared in the 
ccRCC lines with expression levels in RPTEC. Analysis was undertaken using Image J.  
3.4 LIMD1 staining in tumours and pre-invasive tissue is specific and 
demonstrates predominantly cytoplasmic staining patterns 
 
LIMD1 expression has not been characterised in most normal human tissues or 
carcinomas. Work by Sharp et al and Spendlove et al, characterising LIMD1 staining in 
breast and lung carcinoma demonstrated predominant cytoplasmic staining with some 
nuclear staining in breast tissue, and in both tissues little stromal staining (Sharp, Al-
Attar et al. 2008, Spendlove, Al-Attar et al. 2008).  
 
Firstly TMAs containing a range of tumour samples and pre-invasive tissue were 
stained, in order to demonstrate IHC antibody specificity and identify positive and 
negative control tissue for use when staining the ccRCC samples. Optimal staining was 
obtained with a manual staining protocol (LIMD1 antibody concentration 1:50). 
Professor Mike Sheaff of Barts Health NHS Trust reviewed all staining to define 
appropriate antibody concentrations, confirm that staining appeared specific and 
identify appropriate controls. Staining patterns were heterogeneous with a variety of 
cytoplasmic expression patterns in different tissues, little nuclear staining and little 
stromal staining. Staining was felt to be specific with little background staining observed 
in a range of normal and malignant tissues (Figure 3.2). 
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Figure 3.2: IHC staining using an optimised manual staining protocol 
demonstrates specific and heterogeneous LIMD1 staining in a range of tumour 
types.  
TMAs printed with histospots from a range of tumour types were stained using an optimised manual 
staining protocol with LIMD1 antibody concentration 1:50, and visualisation using the Avidin-biotin 
peroxidase method with haematoxylin counterstaining. (A) Testis teratoma (strong cytoplasmic epithelial 
staining but little stromal staining),  (B) thymoma (strong tumour cytoplasmic LIMD1 staining), (C) 
thyroid papillary carcinoma (strong cytoplasmic tumour staining with little stromal staining), (D) 
phylloides breast carcinoma (no LIMD1 staining). Scale bars corresponding to 200µm are shown for size 
comparison. 
 
In addition, healthy breast tissue and lung tissue, where staining patterns for LIMD1 
had previously been published were stained (Sharp, Al-Attar et al. 2008, Spendlove, Al-
Attar et al. 2008). The antibody used for this IHC was derived from the same 
hybridoma used by Sharp et al and Spendlove et al (Sharp, Al-Attar et al. 2008, 
Spendlove, Al-Attar et al. 2008).  Sharp et al had described the staining pattern in lung 
tissue, demonstrating high level, predominantly cytoplasmic expression in ciliated 
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pseudostriated epithelia of bronchial epithelial tissue with weaker staining in distal 
alveolar epithelia, and this correlated with Western blot analysis of protein extracts from 
these cells (Sharp, Al-Attar et al. 2008). IHC staining patterns in lung tissue were similar 
to that described by Sharp et al (Sharp, Al-Attar et al. 2008) (Figure 3.3).  In breast 
tissue Spendlove et al had found that LIMD1 was specifically expressed in the epithelial 
cells of terminal duct lobular units (Spendlove, Al-Attar et al. 2008), a staining pattern 
we also identified, although less nuclear staining was noted (Figure 3.3). The control 
TMA described, containing a range of pre-invasive and tumour histospots was included 
as a positive/negative control when other tissue types were stained. For all staining, an 
additional negative control was included, where the primary antibody was omitted to 
account for non-specific antibody binding. 
  
A (i) A (ii)
A(iii)
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Figure 3.3: IHC staining using an optimised manual staining protocol in lung 
tissue and breast tissue demonstrates specific LIMD1 staining that corresponds 
to the pattern observed previously by Sharp e t  a l .  
Paraffin embedded lung tissue and breast tissue was stained using an optimised manual staining protocol 
with LIMD1 antibody concentration 1:50, and visualisation using the Avidin-biotin peroxidase method 
with haematoxylin counter staining. (Ai) Staining of bronchial epithelial tissue with staining of the ciliated 
pseudostratified epithelium (Aii) Staining of the distal alveolar epithelium (Aiii) Magnified image of the 
distal alveolar epithelium (Bi) Staining of breast tissue demonstrates staining of epithelial cells only with 
no stromal staining. A scale bar corresponding to 200µm is shown (Bii) Magnified image of breast tissue 
staining.  
3.5 LIMD1 staining in kidney tissue 
 
Prior to staining the ccRCC TMA histospots, the specificity of the LIMD1 antibody for 
kidney tissue was established and the expected staining patterns defined. Staining 
patterns had not previously been characterised in ccRCC or healthy renal tissue.  IHC 
for LIMD1 in healthy renal tissue demonstrated specific staining of the proximal and 
distal convoluted tubules with very little staining of the glomeruli. Staining was 
cytoplasmic with no nuclear staining observed (Figure 3.4). 
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Figure 3.4: IHC in health kidney tissue is specific with staining of the proximal 
and distal convoluted tubules but not the glomeruli.  
Healthy paraffin embedded kidney tissue was stained using an optimised manual staining protocol with 
LIMD1 antibody concentration 1:50, and visualisation using the Avidin-biotin peroxidase method with 
haematoxylin counterstaining. A scale bar corresponding to 200µm is shown for size comparison.  
3.6 Ajuba and WTIP staining in a range of normal tissues 
 
The normal staining patterns for Ajuba and WTIP are largely uncharacterised. Data 
sheets for the Ajuba antibody and the Protein Atlas website demonstrate strong staining 
of tissues of the gastrointestinal tract and this has also been described in the literature 
(Shi, Chen et al. 2016).  Tanaka et al stained malignant mesothelioma tissue for Ajuba 
and demonstrated variable expression patterns with both cytoplasmic and nuclear 
staining patterns (Tanaka, Osada et al. 2015). Given that neither protein has been 
extensively evaluated, TMAs with histospots derived from a range of normal tissues 
were stained, in order to define normal staining patterns and identify positive and 
negative controls to include when staining our ccRCC cohort. All staining was reviewed 
by Professor Mike Sheaff and once optimised felt to be specific.  An optimal antibody 
concentration of 1:50 was identified for Ajuba following review of staining in normal 
stomach and renal tissue using a range of antibody concentrations. Staining was strongly 
positive in tissue of the gastrointestinal tract in both cytoplasmic and nuclear 
compartments: healthy stomach tissue was subsequently used as a positive control. 
Optimal staining of stomach tissue for Ajuba is shown in Figure 3.5, and optimal 
staining of renal tissue in Figures 3.7, 3.8 and 3.9.  
   Chapter 3: Results   
!143!
 
Figure 3.5. Representative staining for Ajuba in normal stomach tissue 
Staining was undertaken using an optimised, manual staining protocol with visualisation using the avidin-
biotin peroxidase method and haematoxylin counterstaining. Representative images of healthy stomach 
stained with Ajuba antibody at 1:50 are shown above at 10x and 20x magnification with both cytoplasmic 
and nuclear staining demonstrated (Figures (i-ii). Scale bars corresponding to 200µm are shown 
 
For the normal renal tissue and ccRCC samples, Ajuba staining was predominantly 
nuclear with little cytoplasmic staining (Figures 3.7, 3.8 and 3.9). Professor Sheaff felt 
that only the nuclear Ajuba staining should be characterised in the ccRCC and MAT 
histospots and this staining pattern was consistent with that described on Protein Atlas. 
Review of the literature did not identify any studies characterising Ajuba staining in 
ccRCC.  
  
WTIP staining was both cytoplasmic and nuclear in ccRCC and MAT histospots and 
staining in both compartments felt by Professor Sheaff to be a true result and scorable.  
Optimised WTIP staining is demonstrated in small bowel and placenta in Figure 3.6 
and in ccRCC/MAT in Figures 3.7, 3.8 and 3.9.  Review of the literature did not 
identify any WTIP staining in ccRCC for comparison. For all staining a negative control 
was included where the primary antibody was omitted to account for non-specific 
binding for both the WTIP and Ajuba antibodies. 
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Figure 3.6 Representative images of staining for WITP in small bowel and 
placenta 
Staining was undertaken using an optimised, manual staining protocol with visualisation using the avidin-
biotin peroxidase method and haematoxylin counterstaining. (i-ii) Representative images of small bowel 
stained with WTIP antibody at 1:50 are shown above demonstrating predominantly nuclear staining 
patterns at 10x and 20x magnification respectively. (iii and iv) Representative images of lymph node 
tissue stained with WTIP antibody at 1:50 are shown above demonstrating lower levels of nuclear and 
cytoplasmic staining at 10x and 20x magnification.  Scale bars corresponding to 200µm are shown for size 
comparison 
3.7 Immunohistochemistry demonstrates loss of LAW family members in over 
50% of ccRCC histospots 
 
Having established the specificity of staining for LIMD1, WTIP and Ajuba in a range of 
tissue samples/tumours, immunohistochemical staining for LAW was undertaken, using 
a commercially available TMA purchased from US Biomax incorporating 75 ccRCC 
histospots, each with a MAT histospot.  
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Tissue micro-arrays allow for the immunohistochemical analysis of large number of 
tumour samples in a high-throughput manner, a particular advantage in a clinical trial 
setting and for research methodological studies where a large number of samples need 
to be analysed to identify a relationship, for example correlating tumour 
suppressor/oncogene expression with clinico-pathological data (Fiore, Bailey et al. 
2012). It can however be difficult to set an appropriate quantitative scale that can 
accurately be followed by the observer, particularly when staining for proteins 
previously uncharacterised (Hsi 2001). Correlating staining manually between ccRCC 
samples and MAT using a TMA where MAT is adjacent to each ccRCC sample may 
also be associated with an unconscious observer bias. In addition, when attempting to 
identify a correlation between levels of two different proteins, scoring manually using a 
quantitative scale, which may only have three or four values, may make evaluation of 
correlation patterns difficult and a small but nonetheless significant correlation may be 
overlooked (Matos, Trufelli et al. 2010).  
 
 Images were therefore acquired and analysed using an automated image 
acquisition/analysis system.  High-resolution images were obtained of each histospot 
and areas of tumour/normal tissue quantitatively scored using the Ariol SL-50 system 
(Genetix). Areas of tumour were manually identified with masking of the stroma and of 
the normal/benign tissue from image analysis in the ccRCC samples. Stroma was also 
excluded with masking in the MAT samples. Scores were generated using a modified 
automated scoring system: this generates an output score as a function of the average 
staining intensity and the area of positive staining of the protein of interest throughout 
the tissue. This is a validated method for the assessment of IHC staining (Yaziji and 
Barry 2006) (Rizzardi, Johnson et al. 2012).  
 
Tumours were separated in to those showing a reduction in IHC staining (Figure 3.7), 
similar levels of staining (Figure 3.8) and increased staining (Figure 3.9) in the ccRCC 
histospots compared to MAT for each of the LAW proteins.  
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Figure 3.7 Representative images of Immunohistochemical staining in ccRCC 
demonstrating reduction in staining of LAW family members compared to 
matched adjacent tissue (MAT) 
Commercially available TMAs with 75 ccRCC histospots and contiguous MAT were stained for LIMD1, 
Ajuba and WTIP. Staining was undertaken using an optimised, manual staining protocol with visualisation 
using the avidin-biotin peroxidase method and haematoxylin counterstaining.  LIMD1 antibody 
concentration of 1:50, Ajuba antibody concentration of 1:50 and WTIP antibody concentration of 1:100 
were utilised. Images demonstrate reduced staining for LIMD1, Ajuba and WTIP in the matched ccRCC 
samples compared to matched-adjacent tissue control. Scale bars corresponding to 150µm are shown for 
size comparison.  
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Figure 3.8 Representative images of Immunohistochemical staining in ccRCC 
demonstrating similar levels of staining of LAW family members compared to 
matched adjacent tissue (MAT) 
Commercially available TMAs with 75ccRCC histospots and contiguous MAT were stained for LIMD1, Ajuba and 
WTIP. Staining was undertaken using an optimised, manual staining protocol with visualisation using the avidin-
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biotin peroxidase method with haematoxylin counterstaining. LIMD1 antibody concentration of 1:50, Ajuba antibody 
concentration of 1:50 and WTIP antibody concentration of 1:100 were utilised. Images demonstrate similar levels of 
staining for LIMD1, Ajuba and WTIP in the matched ccRCC histospots, compared to matched-adjacent tissue 
control. Scale bars corresponding to 150µm is shown for size comparison.   
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Figure 3.9 Representative images of immunohistochemical staining 
demonstrating increased levels of staining for LAW family members compared 
to matched adjacent tissue (MAT) 
Commercially available TMAs with 75ccRCC histospots and contiguous MAT were stained for LIMD1, 
Ajuba and WTIP. Staining was undertaken using an optimised, manual staining protocol with visualisation 
using the avidin-biotin peroxidase method with haematoxylin counterstaining. LIMD1 antibody 
concentration of 1:50, Ajuba antibody concentration of 1:50 and WTIP antibody concentration of 1:100 
were utilised. Images demonstrate increased levels of staining for LIMD1, Ajuba and WTIP in the 
matched ccRCC histospots, compared to matched-adjacent tissue control. Scale bars corresponding to 
150µm are shown for size comparison.    
 
For the Ariol SL-50 analysis, a 10% increase or decrease in combined modified 
automated score was deemed to represent a significant difference in staining. This 
cutoff was chosen, as there was little difference in the proportion of tumours in each 
category when this cutoff was increased to 20%.  TMA histospots were also manually 
scored and differences in scoring between the automated and manual scoring correlated.  
 
The manual tumour scoring system for the LAW family members was adapted from 
one used by Spendlove et al in the analysis of breast carcinoma (Spendlove, Al-Attar et 
al. 2008). A four-point scoring system was adopted where zero represented no staining, 
one weakly positive staining, two, moderately positive staining and three, strongly 
positive staining. Good concordance in identifying tumours with reduced, similar and 
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increased staining for LAW family members was seen when the manual and automated 
image acquisition/analysis system scores were compared particularly where loss of 
staining was observed (data not shown). Given the increased objectivity of the Ariol SL-
50 scoring and the increased potential for discrimination between variable levels of 
staining, the automated modified staining score was predominantly used for subsequent 
comparison of staining within this TMA.  
 
3p loss of heterozygosity is an early event in renal cell carcinoma (Clifford, Prowse et al. 
1998). In a study by Kanu et al, 98.8% of RCC tumours that demonstrated LOH at the 
3p25.3 VHL locus also displayed LOH at the SETD2 locus, a 3p21.3 encoded gene 
(Figure 3.10) (Kanu, Gronroos et al. 2015).  
 
 
Figure 3.10. Proportion of samples showing LOH along chromosome 3 using 
SNP 6.0 array data in 450 RCCs from TCGA. Taken from (Kanu, Gronroos et al. 
2015).  
 
Ajuba is 14q encoded and 14q deletions are commonly seen in ccRCC. In a study by 
Kroger et al, 81/288 (28%) of tumours demonstrated loss of 14q: this was hypothesised 
to be associated with HIF1α loss but other candidate genes which could include Ajuba 
have not been characterised (Kroeger, Klatte et al. 2013).  
 
Given that biallelic inactivation of a tumour suppressor is necessary to drive 
tumourigenesis, reduced expression of both 3p (e.g. LIMD1) and 14q-encoded genes 
(e.g. Ajuba) may be seen in tissue adjacent to a ccRCC tumour compared to that 
observed in tissue taken from a healthy kidney without evidence of ccRCC. WTIP is 
19q13.11 encoded and 19q loss has not been implicated in ccRCC. Therefore it might 
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be expected that there would be some reduction in staining for the 3p encoded LIMD1 
and the 14q encoded Ajuba in ccRCC histospots compared to MAT but that an absence 
staining would be rare in the MAT samples. Therefore comparison of staining in both 
ccRCC and MAT histospots was undertaken and the number of histospots with no 
staining for each of the three proteins also characterised. Manual scoring was used to 
identify tumours/MAT that demonstrated no LAW staining, as it was difficult to 
establish an appropriate cut off for no staining using the modified ARIOL scoring 
system. 
 
49.3% of ccRCC tumours demonstrated reduced LIMD1 staining compared to MAT as 
assessed using the modified automated staining score (Figures 3.7 and 3.10), with 
13/75 (17%), of the ccRCC histospots demonstrating no LIMD1 staining when scored 
manually, compared to 2/75 (3%) of the MAT histospots (Χ2 test=13.891, p=0.0002**). 
76% of tumour histospots demonstrated less Ajuba staining compared to MAT as 
assessed using the modified automated staining score (Figures 3.7 and 3.10).  26/75 
(35%) ccRCC histospots demonstrating no Ajuba staining compared to 6/75 (8%) of 
the MAT histospots when scored manually (Χ2 test=91.848, p<0.0001***).  
 
IHC staining for WTIP demonstrated both significant cytoplasmic and nuclear staining 
(Figure 3.7). For WTIP, using the modified automated staining score, only 20% of 
tumours had reduced total WTIP staining compared to MAT with 63% of tumours 
showing increased total WTIP staining compared to MAT (Figures 3.7 and 3.10).  
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Figure 3.10 Relative differences in staining for LAW family members in ccRCC 
compared to MAT as assessed using the Ariol SL-50 scanning system 
Antibody staining of the commercially available TMAs was quantified using the ARIOL imaging system 
(Genetix, San Jose, CA). After high resolution scanning, the images were reviewed for training and 
quantification purposes to differentiate the stained and the unstained cells by the colour of staining and 
the shape of the nuclei whereby brown staining was considered positive and blue staining negative). Areas 
of tumour were manually identified with masking of the stroma and normal/benign tissue from image 
analysis of the ccRCC samples and masking of the stroma in the MAT. Scores were generated using a 
modified automated scoring system: this generates an output score based on the combined score for the 
average staining intensity for the protein of interest throughout the histospot and the area of positive 
staining of each histospot. Tumours were divided in to three groups on the basis of differences in staining 
patterns between ccRCC tumours and MAT for all three family members using the Ariol output scoring 
system. A reduction in staining was defined as <10% reduction in ccRCC staining compared to MAT, 
similar staining as between ≤10% and ≥10% difference between ccRCC and MAT and increased staining 
as >10% staining in ccRCC compared to MAT. 
(i) Pie chart to illustrate the relative differences in staining between ccRCC and MAT for LIMD1, (ii) Pie chart to 
illustrate the relative differences in staining between ccRCC and MAT for Ajuba, (iii) Pie chart to illustrate the 
relative differences in staining between ccRCC and MAT for WTIP 
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One disadvantage of using the automated image analysis described is that it was not 
possible to discriminate between nuclear and cytoplasmic staining using this system: 
staining for WTIP was strongly positive in both compartments. Manual scoring 
however allowed for the separate scoring and evaluation of nuclear and cytoplasmic 
staining. This demonstrated a significant reduction in nuclear staining for WTIP in over 
73% of tumours with 31% of tumours demonstrating reduced cytoplasmic staining 
(Figure 3.11). 43/75 (58%) of tumours demonstrated no nuclear staining compared to 
7/75 (9%) of MAT histospots, (Χ2 test=293.16, p=<0.0001***). 3/75 (4%) of tumours 
demonstrated no cytoplasmic staining compared to 3% of MAT (Χ2 test=0.344, 
p=0.577). This would imply that although loss of total WTIP staining was not 
commonly observed in ccRCC compared to MAT histospots, sub-cellular WTIP 
localisation differed between tumours and MAT, with significantly less nuclear staining 
observed in the ccRCC samples.  
 
 
 
Figure 3.11 Relative differences in staining patterns for WTIP compared to MAT 
between ccRCC and MAT as assessed using a manual scoring system 
Scoring was undertaken using a 4-point scoring system from 0-3 for both cytoplasmic and nuclear 
components by an experienced urology histopathologist and counter scored by myself blinded to the 
initial scoring: tumour only was scored in the ccRCC histospots and stroma excluded in the MAT and 
ccRCC histospots. (i) Pie chart to illustrate differences in nuclear WTIP between ccRCC and MAT. (ii) 
Pie chart to illustrate differences in cytoplasmic WTIP between ccRCC and MAT 
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3.8 Correlation of the relationship between LAW levels assessed 
immunohistochemically in ccRCC 
 
Given the close structural homology between LAW family members and the 
characterised overlapping functions, particularly with respect to the regulation of 
HIF1α, microRNA function, and regulation of the Hippo pathway, it was hypothesised 
that a degree of functional redundancy may exist between LAW family members. 
Expression of at least one family member is likely to be a requirement for cell viability 
and this was observed when immunoblotting a panel of ccRCC lines (Figure 3.1). It 
was also hypothesised that loss of more than one family member may contribute to 
increased tumourigenesis compared to the loss of one family member alone. The 
relationship between staining levels for LAW in both the ccRCC and MAT was 
therefore characterised.    
3.8.1 Levels of LIMD1 and Ajuba expression closely correlate in ccRCC but not 
in matched adjacent tissue (MAT)  
Levels of staining for Ajuba and LIMD1 strongly associated in the ccRCC samples 
(Spearman-Rank correlation coefficient p=0.0012**) but not in the MAT  (Spearman-
Rank correlation coefficient p=0.335) (Figure 3.12). This suggests that in ccRCC 
tumours, Ajuba and LIMD1 loss frequently co-exists.  Given that LIMD1 and Ajuba 
levels in MAT do not correlate, this would imply that the correlation in ccRCC is not 
simply the result of an association whereby tumours with more LIMD1 staining also 
have more Ajuba staining but could suggest co-loss of both tumour suppressors, 
potentially functioning as a mechanism for increased tumourigenesis. 
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Figure 3.12. Levels of LIMD1 and Ajuba expression closely correlate in ccRCC 
but not MAT 
The relationship between modified automated ARIOL score for Ajuba and LIMD1 were plotted 
graphically using Prism 6 and correlation calculated using the Spearman-Rank correlation coefficient. A 
ccRCC and MAT, B. ccRCC and C. MAT  
 
3.8.2 Levels of LIMD1 and WTIP expression closely correlate in ccRCC and 
MAT 
 
The correlation of total WTIP and LIMD1 showed a strong positive association in both 
ccRCC and MAT histospots as assessed using the modified automated ARIOL scoring 
system (Spearman-Rank correlation coefficient p<0.0001***) i.e. respective high or low 
   Chapter 3: Results   
!154!
WTIP is associated with respective high or low LIMD1 expression in both tissues 
(Figure 3.13). Given that WTIP staining is observed in both the cytoplasm and nucleus 
and the automated scoring system did not allow for the discrimination of differences in 
localisation of staining, manual LIMD1 staining was correlated with manual nuclear and 
manual cytoplasmic WTIP scoring. This was felt to be of particular relevance as 73% of 
tumours demonstrated reduced nuclear WTIP staining compared to MAT (Figure 
3.11).  
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Figure 3.13 Levels of LIMD1 and WTIP expression closely correlate in ccRCC 
and MAT 
The relationship between automated ARIOL score for LIMD1 and WTIP was plotted graphically using 
Prism 6 and correlation calculated using the Spearman-Rank correlation coefficient. A ccRCC and MAT, 
B. ccRCC and C. MAT  
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A strong positive correlation between cytoplasmic WTIP staining and LIMD1 staining 
in both ccRCC and MAT was observed (Spearman-Rank correlation coefficient 
p=0.0016** and p<0.0001*** respectively) (Figure 3.14). For nuclear WTIP staining, a 
strong positive correlation was observed with manual LIMD1 staining in the MAT but 
not ccRCC histospots (Spearman-Rank correlation coefficient p=0.0044** and 
p=0.3366 respectively) (Figure 3.14).  
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Figure 3.14 LIMD1 and WTIP correlation in ccRCC and MAT with manual 
scoring 
The relationship between manual LIMD1 score and manual WTIP score was plotted graphically using 
Prism 6 and correlation calculated using the Spearman-Rank correlation coefficient. A correlation 
cytoplasmic WTIP and LIMD1 in ccRCC, B correlation cytoplasmic WTIP and LIMD1 in MAT, C 
correlation nuclear WTIP and LIMD1 in ccRCC, D correlation nuclear WTIP and LIMD1 in MAT 
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The strong positive correlation between LIMD1 and total WTIP in ccRCC and MAT 
may represent a simple association whereby tissue with more LIMD1 also express more 
WTIP, however the correlation between nuclear and cytoplasmic WTIP staining with 
LIMD1 staining suggests that the association is more complex. MAT histospots with 
high nuclear WTIP also have increased LIMD1 staining, and this may be a simple 
reflection of increased total WTIP within the tissue. In the ccRCC histospots however 
where 73% of the tumour samples demonstrate reduced nuclear WTIP staining 
compared to MAT and no association between nuclear WTIP and LIMD1 staining is 
observed and it was hypothesised that changes in sub-cellular WTIP localisation could 
be occurring independently of LIMD1 loss potentially contributing to tumourigenesis.  
 
3.8.3 Levels of Ajuba and WTIP expression closely correlate in ccRCC but not in 
MAT 
 
Staining for Ajuba and WTIP strongly associated in the ccRCC (p=0.0317*) but not in 
the MAT histospots (p=0.4166) (Figure 3.15).  
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Figure 3.15 Levels of Ajuba and WTIP expression closely correlate in ccRCC but 
not MAT 
The relationship between modified automated ARIOL score for WTIP and Ajuba was plotted graphically 
using Prism 6 and correlation calculated using the Spearman-Rank correlation coefficient. A. ccRCC and 
MAT, B. ccRCC and C. MAT  
 
Again, this suggests that there is not a simple correlation whereby MAT or tumours 
with more Ajuba also express more WTIP and vice versa. In ccRCC, loss of expression of 
both tumour suppressors may co-exist and may function a mechanism for promoting 
tumourigenesis. Given the association between subcellular WTIP localisation and 
LIMD1 observed (Figure 3.14), subcellular WTIP and Ajuba staining as assessed using 
a manual scoring system was characterised. This demonstrated a strong correlation 
between cytoplasmic WTIP and Ajuba staining in both ccRCC and MAT tissue 
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(Spearman-Rank correlation coefficient p=0.0097** and p=0.041* respectively (Figure 
3.16). When nuclear WTIP and Ajuba staining was correlated, a positive correlation in 
the ccRCC histospots (p=0.0405*) but not MAT histospots (p=0.5889) was observed 
(Figure 3.16). This again could imply that sub-cellular WTIP localisation may be 
important in driving tumourigenesis in ccRCC with a frequent reduction in Ajuba and 
reduced nuclear WTIP staining co-existing.  
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Figure 3.16 WTIP and Ajuba correlation in ccRCC and MAT with manual 
scoring 
The relationship between manual score for WTIP and Ajuba was plotted graphically using Prism 6 and 
correlation calculated using the Spearman-Rank correlation coefficient.  A correlation cytoplasmic WTIP 
and Ajuba in ccRCC, B correlation cytoplasmic WTIP and Ajuba in MAT, C correlation nuclear WTIP 
and Ajuba in ccRCC, D correlation nuclear WTIP and Ajuba in MAT 
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3.9 Immunohistochemical staining for VEGF and CD34  
 
Given our knowledge of the role of LIMD1 in the regulation of the hypoxic response 
and the close homology between different LAW family members/likely overlapping 
functions, the relationship between staining for LAW family members and markers of 
angiogenesis was assessed. The TMA was stained for VEGFA, a critical mediator of 
angiogenesis (E, Cao et al. 2012) and CD34, an established marker for capillary 
endothelia in normal tissue and tumour and marker of microvascular density (MVD) 
(Fina, Molgaard et al. 1990).  
 
3.9.1 Immunohistochemical staining for VEGFa and CD34 in control tissue 
 
Positive staining for VEGFa was defined as membranous and/or cytoplasmic staining 
(Dorevic, Matusan-Ilijas et al. 2009). Staining obtained using an optimised manual IHC 
protocol was reviewed by Professor Sheaff and felt to be specific and scorable (Figures 
3.17 and 3.19).  
 
Figure 3.17 Representative control images for staining for VEGFa 
A TMA printed with a range of histospots derived from normal tissues was stained using an optimised 
manual staining system (Ventana discovery) with visualisation using an Avidin-Biotin method to establish 
antibody specificity and to provide positive/negative control tissue when staining the ccRCC TMAs. 
Representative images of placental tissue stained with VEGFa antibody at 1:50 are shown (Figures (i) and 
(ii)) at 10x and 20x magnification respectively) Scale bars corresponding to 200µm are shown for size 
comparison 
 
CD34 IHC was undertaken using an automated staining system (Ventana Discovery). 
TMAs containing a range of pre-invasive/malignant histospots were included as 
positive/negative controls for both CD34 and VEGFa staining (Figures 3.17 and 3.18), 
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and the primary antibody omitted as a further negative control to account for non-
specific binding. Strongly positive CD34 staining was observed in the fenestrated 
epithelium of glomeruli in healthy renal tissue as previously described (Figure 3.20) 
(Pusztaszeri, Seelentag et al. 2006). Images were scanned and analysed using the 
automated Ariol system as before.  
 
 
Figure 3.18 Representative control images for staining for CD34  
A TMA printed with a range of histospots derived from normal tissues was stained using an automated staining 
system (Ventana discovery) with visualisation using an Avidin-Biotin method to establish antibody specificity and to 
provide positive/negative control tissue when staining the ccRCC TMAs. Representative images of highly 
vascularised adrenal tissue stained with CD34 antibody at 1:50 are shown (Figures (i) and (ii) at 10x and 20x 
magnification respectively) Scale bars corresponding to 200µm are shown  
 
3.9.2 Immunohistochemical staining for VEGFa and CD34 in ccRCC  
 
Having established specific and expected patterns of staining for VEGFa and CD34 in 
control tissue including kidney tissue, staining of the commercially available 
ccRCC/MAT TMA from US Biolabs was undertaken. As before, areas of tumour were 
manually identified with masking of the stroma and of normal/benign tissue from image 
analysis and exclusion of the stroma in the MAT. For VEGFa, scores were generated 
using the modified automated ARIOL scoring system as described. For CD34, image 
analysis training was undertaken using the ARIOL system to correctly identify blood 
vessel staining. Using this automated analysis system, the number of blood vessels 
within each histospot and the mean vessel area and mean lumen area were calculated. 
This enabled calculation of the total cross sectional area of blood vessels within each 
histospot.   
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A (i) A (ii)
B (i) B (ii)
C (i) C (ii)
 
Figure 3.19 Immunohistochemistry for VEGFa and CD34 in kidney tissue and 
ccRCC samples 
Commercially available TMAs with 75 ccRCC histospots and contiguous MAT were stained for VEGFa 
and CD34. Staining for VEGFa is shown in the left panel (i), with CD34 staining in the matched 
histospots in the right panel (ii). VEGFa staining was performed using an optimised manual protocol with 
antibody concentration 1:300 and visualisation using the Avidin-biotin peroxidase method. CD34 staining 
was undertaken using an automated system (Discovery, Ventana Medical Systems, Tucson AZ) with 
CD34 antibody concentration 1:50 and visualisation using the Avidin-biotin peroxidase method.  A (i) 
Representative VEGFa staining in matched adjacent kidney tissue, A (ii) Representative CD34 staining in 
same MAT histospot B (i) Representative low level VEGFa staining in ccRCC histospot, B (ii), CD34 
staining in same MAT histospot C (i) Representative high level VEGFa staining in a ccRCC histospot, 
B(iii) CD34 staining in same matched ccRCC histospot   Scale bars corresponding to 200µm are shown 
for size comparison. 
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3.9.3 Staining for LIMD1, Ajuba and WTIP does not correlate with CD34 
staining  
  
Given the role of LAW proteins in the regulation of the hypoxic response, it was 
hypothesised that reduced staining for LAW would be associated with increased MVD 
staining as assessed by CD34 staining. Comparison of LIMD1 and CD34 staining did 
not show any correlation (p=0.9507 in ccRCC histospots and p=0.8662 in MAT) 
(Figure 3.20), nor was a correlation between Ajuba and CD34 staining observed 
(p=0.5490 in ccRCC histospots and p=0.1388 in MAT) (Figure 3.21). Comparison of 
WTIP and CD34 staining also did not demonstrate a correlation in either ccRCC or 
MAT histospots, (p=0.7362 and p=0.8632 respectively) (Figure 3.22).  
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Figure 3.20 Levels of LIMD1 and CD34 assessed immunohistochemically do not 
correlate in either ccRCC or MAT 
The relationship between modified automated ARIOL score for LIMD1 and CD34 was plotted 
graphically using Prism 6 and correlation calculated using the Spearman-Rank correlation coefficient. A 
ccRCC and MAT, B. ccRCC and C. MAT  
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Figure 3.21 Levels of Ajuba and CD34 assessed immunohistochemically do not 
correlate in either ccRCC or MAT 
The relationship between modified automated ARIOL score for Ajuba and CD34 staining as a measure 
of MVD was plotted graphically using Prism 6 and correlation calculated using the Spearman-Rank 
correlation coefficient. A ccRCC and MAT, B ccRCC and C MAT  
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Figure 3.22 Levels of WTIP and CD34 assessed immunohistochemically do not 
correlate in either ccRCC or MAT 
The relationship between modified automated ARIOL score for WTIP and CD34 was plotted graphically 
using Prism 6 and correlation calculated using the Spearman-Rank correlation coefficient. A ccRCC and 
MAT, B. ccRCC and C. MAT  
 
3.9.4 Correlation of VEGFa staining with LIMD1, WTIP and Ajuba staining 
 
Staining for LAW family members was correlated with that of VEGFa, a potent inducer 
of tumour angiogenesis in ccRCC and downstream target of HIF2α (Keith, Johnson et 
al. 2012). For LIMD1 a positive correlation was observed such that increasing LIMD1 
expression correlated with increasing VEGFa expression in both ccRCC and MAT 
histospots, (Spearman Rank correlation p=0.0010** and p=0.0011** respectively) 
(Figure 3.23). For Ajuba no such correlation was observed for both ccRCC and MAT 
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histospots (Spearman Rank correlation p=0.9731 and p=0.1633 respectively (Figure 
3.24). For total WTIP staining a positive association was again observed, p<0.0001**** 
and p=0.0009*** for ccRCC and MAT histospots respectively (Figure 3.25). In the 
first instance, this correlation may seem surprising: it had been hypothesised that low 
LAW expression might be associated with increasing VEGFa staining.  
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Figure 3.23 Levels of LIMD1 and VEGFa assessed immunohistochemically 
strongly correlate in both ccRCC and MAT 
 The relationship between modified automated ARIOL score for VEGFa and LIMD1 was plotted 
graphically using Prism 6 and correlation calculated using the Spearman-Rank correlation coefficient. A 
Correlation in combined ccRCC and MAT, B. Correlation in ccRCC alone and C Correlation in MAT 
alone 
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Figure 3.24 Levels of Ajuba and VEGFa assessed immunohistochemically are 
strongly positively correlated in both ccRCC and MAT 
The relationship between modified automated ARIOL score for VEGFa and Ajuba was plotted 
graphically using Prism 6 and correlation calculated using the Spearman-Rank correlation coefficient. A 
Correlation in combined ccRCC and MAT, B Correlation in ccRCC alone and C Correlation in MAT 
alone 
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Figure 3.25 Levels of WTIP and VEGFa assessed immunohistochemically are 
strongly positively correlated in both ccRCC and MAT 
The relationship between modified automated ARIOL score for VEGFa and WTIP was plotted 
graphically using Prism 6 and correlation calculated using the Spearman-Rank correlation coefficient. A 
Correlation in combined ccRCC and MAT, B. Correlation in ccRCC alone and C. Correlation in MAT 
alone 
 
3.9.5 Correlation of VEGFa staining with CD34 staining  
 
It was hypothesised that decreased LAW expression was likely to be associated with 
increased neo-angiogenesis and therefore increased VEGFa and CD34 staining but no 
association was observed between levels of LAW and CD34 staining. A positive 
correlation was observed between increasing LIMD1 and VEGFa staining and total 
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WTIP and VEGFa staining in both ccRCC and MAT histospots whilst no such 
correlation was observed between Ajuba and VEGFa staining in either tissue type.  
 
Correlation of the relationship between staining for CD34 and VEGFa was undertaken 
(Figure 3.26). An inverse correlation was observed in ccRCC with increased CD34 
staining associated with decreased VEGFa staining, p=0.0082**: this association was 
not observed in MAT p=0.4138 (Figure 3.26). It was hypothesised that CD34 and 
VEGFa staining would correlate positively in ccRCC, with increased VEGFa expression 
contributing to increased angiogenesis. One possible explanation may be a ‘steal’ effect, 
whereby tumours with higher total VEGFa levels in turn secrete more VEGFa, 
therefore promoting neo-vascularisation and resulting in paradoxically lower VEGFa 
staining within the tumours, but increased neo-angiogenesis. Kluger et al noted a similar 
relationship when they quantitatively assessed the relationship between vessel area and 
expression of VEGFR1/2 in ccRCC tumour cells (Kluger, Siddiqui et al. 2008).  
 
The positive correlation observed between increasing LIMD1 and VEGFa staining and 
increasing total WTIP and VEGFa staining could therefore indicate increasing neo-
angiogenesis in tumours expressing low LIMD1 or low total WTIP.  
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Figure 3.27 Levels of VEGFa and CD34 assessed immunohistochemically do not 
correlate in either ccRCC or MAT 
The relationship between modified automated ARIOL score for VEGFa and CD34 was plotted 
graphically using Prism 6 and correlation calculated using the Spearman-Rank correlation coefficient. A 
Correlation in combined ccRCC and MAT, B. Correlation in ccRCC alone and C. Correlation in MAT 
alone 
 
 
  Chapter 3: Summary   
!171!
 
3.10 Summary 
 
This chapter demonstrates the down-regulation of Ajuba and LIMD1 in most ccRCC 
lines in vitro compared to control RPTEC. WTIP expression was however only reduced 
in four out of twelve lines with some lines demonstrating significantly more WTIP 
expression.   Normal immunohistochemical staining characteristics for LAW proteins 
are described in a range of normal/malignant tissues, and LAW staining characterised in 
both ccRCC samples and MAT.  The relationship between staining for the three 
proteins is correlated in both ccRCC and MAT and staining correlated with established 
markers of hypoxic deregulation (Figure 3.28).  
 
In vivo, loss of LIMD1 was observed in 49.3% of ccRCC tumours, with 17% 
demonstrating no LIMD1 staining compared to 3% of MAT (Χ2 test p=0.0002**). 76% 
of tumours demonstrated loss of Ajuba compared to MAT, with 35% demonstrating no 
Ajuba staining compared to 8% of MAT (Χ2 test p<0.0001***).  Loss of WTIP was 
observed in 20% of tumours compared to MAT, with 63% of tumours actually 
demonstrating an increase in total WTIP staining. The subcellular localisation of WTIP 
appeared important with 73.3% of tumours showing reduced nuclear staining of ccRCC 
compared to MAT histospots and 58% of tumours demonstrated no nuclear staining 
compared to 9% of MAT histospots, (Χ2 p=<0.0001***). For cytoplasmic staining, 4% 
of tumours demonstrated no cytoplasmic staining compared to 3% of MAT, Χ2 
test=0.344, p=0.577). This implies that sub-cellular WTIP localisation differs between 
tumours and MAT, with significantly less nuclear staining observed in the ccRCC 
samples.  
 
Staining for LIMD1 and Ajuba and Ajuba and WTIP correlates strongly in ccRCC 
histospots but not in MAT, implying that co-loss frequently exists and may be relevant 
in tumourigenesis. Staining for LIMD1 and WTIP strongly correlated in both ccRCC 
and MAT histospots, which could imply a simple association whereby tissue with more 
LIMD1 staining also has more WTIP staining. Of note, however when sub-cellular 
WTIP localisation was included in the analysis, cytoplasmic WTIP staining 
demonstrated a strong positive correlation with LIMD1 staining in both ccRCC and 
MAT perhaps indicating increased total WTIP levels, whilst nuclear WTIP and LIMD1 
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staining demonstrated a strong positive correlation in MAT but not ccRCC, suggesting 
that changed in subcellular WTIP localisation may be important in driving 
tumourigenesis. Cytoplasmic WTIP staining positively correlated with Ajuba staining in 
both MAT and ccRCC, however nuclear WTIP staining correlated with Ajuba staining 
in ccRCC but not MAT. This could imply that sub-cellular WTIP localisation is relevant 
in tumourigenesis. An overview of the Spearman-Rank correlation coefficient, 
comparing the modified automated ARIOL score for the different proteins in the 
ccRCC histospots and MAT is summarised in Figure 3.28. 
 
Figure 3.28 Summary overview of the Spearman-Rank correlation coefficient 
comparing the modified automated ARIOL score for the proteins stained 
immunohistochemically. A. ccRCC histospots and B. MAT  
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Given the importance of hypoxic deregulation in driving ccRCC and the pro-
tumourigenic effects of HIF2α in ccRCC particularly through the modulation of 
vascular endothelial cell function, LAW expression was correlated with VEGFa and 
CD34 staining. LAW expression did not correlate with CD34 expression in our samples, 
although a strong positive association was observed between LIMD1/WTIP and 
VEGFa staining but not Ajuba and VEGFa staining (Figure 3.28). It was hypothesised 
that this association could actually reflect increased angiogenesis associated with reduced 
LIMD1/WTIP expression, whereby lower VEGFa staining resulted from increased 
tumour VEGFa secretion, a ‘so called’ steal effect.   
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3.11 Discussion 
 
3.11.1 Overview of immunohistochemistry 
 
Most of the work undertaken in this chapter has relied on the immunohistochemical 
detection of antigens of interest, a powerful tool for antigen identification through the 
visualisation of specific antigen-antibody interactions, enabling both the quantification 
and characterisation of the distribution and sub-cellular localisation of the antigen of 
interest (Yaziji and Barry 2006, Matos, Trufelli et al. 2010). IHC provides a powerful 
tool in diagnostic pathology, prognostication and therapeutic decision-making and given 
that the distribution and localisation of antigens of interest can be characterised, can 
provide putative information about antigen function (Matos, Trufelli et al. 2010).  
 
IHC is a relatively low cost technique where rapid throughput is possible, particularly 
using automated/semi-automated systems. Multiple TMAs/slides can be processed 
simultaneously and more than one antigen detected simultaneously (Matos, Trufelli et al. 
2010, Ramos-Vara and Miller 2014). There are however pitfalls in IHC that must be 
considered carefully and errors minimised (Yaziji and Barry 2006) .  
 
3.11.2 IHC optimisation 
 
Careful optimisation to ensure antigen-antibody specificity, to minimise variability 
between staining repeats and facilitate accurate quantification must be undertaken 
(Ramos-Vara and Miller 2014). Accurate antibody recognition is a critical step with 
specificity mainly dependent on the quality of the primary antibody and the ability of the 
antigen epitope to bind to it (Ramos-Vara and Miller 2014). In the staining protocols 
described some commercially available antibodies were utilised that had been widely 
tested and robustly validated, with suggested IHC protocols defined and positive and 
negative controls determined (Ramos-Vara and Miller 2014). Appropriate controls were 
always included and all staining reviewed by an experienced histopathologist in order to 
determine that staining appeared sensitive and specific, help define expected staining 
patterns and establish optimal antibody concentrations.  
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For LIMD1, Ajuba and WTIP, antibody sensitivity and specificity had been less widely 
evaluated immunohistochemically and had not been characterised in ccRCC. Antibody 
specificity had been established in vitro using Western Blotting techniques with si 
knockdown/re-expression confirming antigen specificity by the Sharp lab. Expected 
staining patterns and antibody specificity had been established in breast and lung tissue 
for LIMD1 and staining of these tissues was similar to that previously characterised 
(Sharp, Al-Attar et al. 2008, Spendlove, Al-Attar et al. 2008). IHC staining for Ajuba was 
similar to that described in online databases such as Protein Atlas and as described in 
the literature (Tanaka, Osada et al. 2015, Shi, Chen et al. 2016).  
 
For all IHC, an indirect two-step method was used, which increases sensitivity since the 
unlabelled primary antibody retains full avidity, hence increasing the reaction intensity 
(Ramos-Vara and Miller 2014).  For the commercially available TMAs and TMAs 
obtained from a clinical trial setting, standardised specimen fixation in paraffin and 
tissue processing was followed (Yaziji and Barry 2006, Howat and Wilson 2014), 
adhering to standardised Good Laboratory Guidelines. An avidin-biotin visualisation 
method was used, which increases sensitivity as a greater number of biotin molecules 
can be attached to a primary antibody (Happerfield, Bobrow et al. 1993, Ramos-Vara 
and Miller 2014). Background staining related to endogenous biotin activity, which is 
common in kidney tissue can however be problematic. Appropriate blocking steps were 
included and kidney tissue was always included as a negative control with omission of 
incubation with the primary antibody: very little staining of this control slide was 
consistently observed. An optimal antibody concentration was defined as the titre 
producing the highest ratio of ‘signal’ i.e. specific binding, to ‘noise’ i.e. minimising 
background labelling (Ramos-Vara and Miller 2014) (Matos, Trufelli et al. 2010). In 
addition, positive and negative control samples were always included which consisted of 
a range of tissue types represented on a TMA.  Internal negative control evaluation 
provided an additional assurance of antibody specificity, for example ensuring that there 
was little stromal staining when staining for LAW proteins (Elias, Gown et al. 1989). 
The use of an automated IHC protocol in some cases has the potential to reduce assay-
to-assay variability introduced by human variation/error and this was utilised for CD34 
staining (Ramos-Vara, Kiupel et al. 2008).  
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3.11.3 Interpretation of IHC staining 
 
The interpretation of IHC staining is generally qualitative and subjective and the 
determination of cut-off values establishing a positive or negative result often arbitrarily 
determined (Matos, Trufelli et al. 2010).  This is particularly difficult when evaluating 
staining for a new antigen/biomarker where the micro-anatomic or subcellular 
distribution may not have been described and appropriate cut-offs for positive/negative 
staining determined (Seidal, Balaton et al. 2001). For example, HIF2α is generally 
considered to act as a nuclear transcription factor, although it is also thought to function 
within a protein translational initiation complex within the cytoplasm (Uniacke, 
Holterman et al. 2012). Kroeger et al demonstrated that high cytoplasmic HIF2α 
expression was associated with a more aggressive ccRCC phenotype (Kroeger, Seligson 
et al. 2014), an observation that would have been lost with conventional staining 
analysis that did not evaluate sub-cellular localisation.  
 
Staining for PD-L1 and PD1 with multiple assays/antibodies within a multitude of 
clinical trial settings undertaken by different pharmaceutical companies has highlighted 
some of the problems of a lack of consistency between different assay protocols and a 
lack of a clear underlying biomarker definition, with different staining 
patterns/intensities considered positive with different IHC protocols (Kerr and Hirsch 
2016).  
 
3.11.4 Scoring systems for immunohistochemistry  
 
A number of scoring systems are commonly used to evaluate IHC staining. The Allred 
quick score, is a combined score based on overall staining intensity, (typically ranging 
from 0-3), and the proportion of neoplastic tissue staining positively, (with grouping in 
to 3 categories, >75%-uniform, 25-75%-variable and 0-25% rare) (Varghese, Bukhari et 
al. 2014). One significant limitation of such an approach is the variability in visual 
perception of staining intensity related to differences in haematoxylin counter-staining 
and the potential for conscious or unconscious bias associated with assessing staining 
on contiguous tumour and matched adjacent tissue samples (Choudhury, Yagle et al. 
2010). A modified version of the Allred quick score was utilised to manually evaluate 
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staining within the ccRCC TMAs, scoring both the staining intensity and proportion of 
tumour cells stained to generate a semi-quantitative score.  Despite the limitations 
associated with manual perception of scoring, such a scoring system is generally 
considered accurate with good inter-observer reliability for staining observed (Zlobec, 
Steele et al. 2006). In addition, given that tumour and MAT tissue was represented 
contiguously on the same slide, no differences in haematoxylin counterstaining should 
have been present.  
 
In order to obtain a more accurate objective measure of expression that better enabled 
comparison of staining intensity, a modified automated quantitative analysis system was 
used, a validated scoring system that can be more accurate than pathologist based 
staining (Camp, Chung et al. 2002) (Rizzardi, Johnson et al. 2012). However, in practice 
the use of automated systems does require significant user input with characterisation of 
the area of interest requiring manual input with for example exclusion of stromal tissue 
at least until adequate image training has been undertaken (Camp, Chung et al. 2002). 
An analysis of automated quantitative analysis of oestrogen receptor expression in 
breast carcinoma using a tissue microarray study of 3,484 cases did not demonstrate a 
significant difference from expert pathologist scoring (Turbin, Leung et al. 2008). 
Differences in staining patterns between tumour samples and the MAT were compared 
using both manual and automated scoring systems and good agreement observed 
suggesting that both methods offered a robust and comparable scoring system.  
 
3.11.5 Changes in expression of LAW proteins in ccRCC 
 
The Ajuba LIM proteins have not been widely characterised in mammalian 
tissues/malignancies although LIMD1 loss has been shown to drive tumourigenesis in 
breast and lung carcinoma (Sharp, Al-Attar et al. 2008, Spendlove, Al-Attar et al. 2008) 
and Ajuba loss implicated in malignant mesothelioma tumourigenesis (Tanaka, Osada et 
al. 2015). Up-regulation of Ajuba expression has been observed in oesophageal SCC 
samples compared to matched control tissue (Shi, Chen et al. 2016).  
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3.11.5. 1 Loss of LIMD1 in ccRCC histospots  
 
Spendlove et al demonstrated that loss of LIMD1 was common in breast carcinoma and 
absent/weak nuclear staining strongly correlated with adverse prognostic indicators: 
worse histological subtype, increasing tumour size and tumour grade and worse 
cumulative-patient survival (Spendlove, Al-Attar et al. 2008). Their model proposed that 
loss of nuclear LIMD1 was a surrogate marker for reduced overall LIMD1 expression. 
Staining of lung carcinoma samples also demonstrated frequent loss of LIMD1 staining 
compared to control matched tissue (Sharp, Al-Attar et al. 2008).  
 
3p LOH is common and loss of at least one LIMD1 allele may therefore occur in many 
ccRCC samples.  Biallelic loss of 3p is however uncommon, in one study characterising 
VHL loss, LOH of one 3p copy was observed in 94% of tumours with inactivation or 
hypermethylation of the remaining allele in 98% of such tumours (Gnarra, Tory et al. 
1994). 
 
In a recent study by Thiesen et al, copy number alterations (CNAs) in 48 ccRCC 
tumours were analysed.  Gene losses on chromosome 3p were observed in all 48 
tumours. Loss of tumour suppressor genes were common at the 3p21.31 locus, with 
CNAs of LIMD1 identified in 28 of the 48 tumours analysed (58.3%): interestingly there 
was a correlation with loss and tumour grade with 21 of the 26 (80%) grade 1 tumours 
demonstrating CNA loss of LIMD1 and only 5 of the 20 (25%) grade 3 tumours 
demonstrating CNA loss of LIMD1.  This suggests that CNA of LIMD1 occur more 
commonly in the lower grade, less aggressive tumour phenotype and also that higher 
grade tumours develop independently from the lower grade ones (Thiesen, Steinbeck et 
al. 2017).   
 
The proportion of other 3p21.31 encoded tumour suppressor genes demonstrating 
CNA alterations was variable with loss of SETD2 identified in 43/48 (89%) of the 
tumours by Thiesen et al. This suggests that loss of 3p21.3 genes is not simply as a result 
of a ‘carrier’ effect, i.e. tumours that have CNAs of SETD2 for example do not 
demonstrate CNAs of LIMD1 simply because they are both 3p21 encoded but that loss 
of genes that map close to one another can occur independently and that chromosomal 
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micro-deletions may be more common than previously thought (Thiesen, Steinbeck et 
al. 2017).  
 
Interestingly, a study of kidneys of patients with VHL disease, i.e. germline mutations in 
one copy of VHL, has demonstrated that these patients probably have hundreds of 
thousands of functional VHL-null single cells or multi-centre clusters of cells, despite 
no evidence of ccRCC (Montani, Heinimann et al. 2010). Given that biallelic 
loss/inactivation of a tumour suppressor is necessary for a loss of function phenotype, 
CNA of 3p encoded tumour suppressors as an early initiator of tumourigenesis may 
occur in tissue adjacent to ccRCC samples, despite there being no evidence of tumour 
formation within this matched, non cancerous tissue. Using MAT as a control tissue has 
a number of significant advantages: staining is undertaken on tissue with the same 
genetic background, and therefore changes in staining for proteins of interest is likely to 
be associated with tumourigenesis.  
 
However, LIMD1 staining may be reduced in such MAT histospots compared to tissue 
obtained from a healthy kidney without evidence of ccRCC and an even better control 
may therefore have consisted of contiguous MAT and distant MAT where LOH was 
less likely to have occurred. It was observed that LIMD1 expression was reduced in ten 
of the twelve (83%) ccRCC lines compared to the control RPTEC line whilst a 
reduction in LIMD1 staining was observed in 49.3% of ccRCC histospots compared to 
MAT, with 17% of the ccRCC histospots demonstrating no LIMD1 staining compared 
to 3% of the MAT (Χ2 p=0.0002).  Given the significant proportion of tumours 
demonstrating no LIMD1 staining, it seems likely that biallelic inactivation of LIMD1 is 
occurring in a significant proportion of ccRCC samples and not MAT, further 
implicating LIMD1 loss in tumourigenesis.  
A recently published study characterised LIMD1 staining in 32 RCC samples and 
demonstrated what was described as a significant reduction in LIMD1 staining 
characterised as low/moderate staining compared to matched control tissue in 15.8% of 
tumours. It is not clear what proportion of tumours demonstrated reduced staining 
compared to control (Sur, Maurya et al. 2017).  
Although numbers of each tumour type were low, the investigators reported that lower 
stage tumours, stage I were more likely to demonstrate reduced staining compared to 
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stage III tumours, 20.2% versus 6% leading them to hypothesise that reduced LIMD1 
expression is more important in driving early disease as also hypothesised by Thiesen et 
al, although in the study by Thiesen et al, gene expression levels and grade were 
correlated (Sur, Maurya et al. 2017, Thiesen, Steinbeck et al. 2017).  
However, in the study by Sur et al no comment is offered regarding the correlation 
between LIMD1 staining and grade and given the small number of tumour samples of 
each stage it is difficult to draw definitive conclusions regarding a correlation between 
more advanced tumours and loss of LIMD1 staining (Sur, Maurya et al. 2017).  
Beyond the LOH of one allele, it is unclear how LIMD1 levels are down-regulated at 
the protein level. Huggins et al demonstrated that LIMD1 mRNA levels were generally 
unchanged compared to control tissue in breast carcinoma (Huggins, Gill et al. 2007), 
and only 0.85% of breast tumours had LIMD1 mutations, suggesting at least in this 
tumour type that LIMD1 protein levels are regulated post-transcriptionally, for example 
by posttranslational modification (Huggins, Gill et al. 2007). Analysis by other 
investigators, using data from the TCGA Research Network analysing a data set of 450 
ccRCC tumours with copy number data and 293 tumours with somatic mutation data 
identified 14 genes that were significantly mutated in the data set, suggestive of driver 
status but LIMD1 was not one of these genes characterised (Sato, Yoshizato et al. 
2013).  
 
However, as described in Chapter 1, recently as yet unpublished work by our group in 
lung adenocarcinoma re-analysing data from the TCGA Research Network using new 
data available via cBioportal suggests that LIMD1 mutation is much more common 
than previously described.   
 
Analysis of 516 lung adenocarcinoma samples and 501 lung squamous cell carcinomas 
identified shallow and deep combined LIMD1 deletions and this combined analysis 
demonstrated that deletion was much higher than previously identified and comparable 
to known highly mutated driver mutations (Figure 3.28).  Both shallow and deep 
LIMD1 deletions are likely to contribute to loss of gene expression, albeit to different 
degrees.  
  Chapter 3: Discussion   
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Figure 3.28 cBioPortal analysis of LIMD1 loss in adenocarcinoma and squamous cell carcinoma 
of the lung. Genes are ordered by percentage loss from greatest to smallest. (A) In lung adenocarcinoma, 
0.2% of tumours contain a deep LIMD1 deletion and 46.9% contain a shallow LIMD1 deletion. (B) In 
squamous cell carcinoma, 0.8% of tumours contain a deep LIMD1 deletion and 84.6% contain a shallow 
LIMD1 deletion. Graphs generated by Dr John Foster (2017, unpublished). 
3.11.5.2 Loss of Ajuba staining in ccRCC 
 
The reported staining of a range of normal tissue types and tumours demonstrated as 
was observed that Ajuba staining is predominantly nuclear in localisation (Tanaka, 
Osada et al. 2015, Shi, Chen et al. 2016).  Staining of twenty cases of malignant 
mesothelioma for Ajuba and the transcriptional co-activator and regulator of the Hippo 
signalling pathway YAP, which drives the transcription of target genes with consequent 
oncogenic transformation, demonstrated that tumours that lacked Ajuba staining had 
strong nuclear localisation of YAP, suggesting that Ajuba inactivation and YAP 
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activation correlated, providing an explanation for potential increased tumourigenesis in 
association with Ajuba loss (Tanaka, Osada et al. 2015).  
 
It appears that patterns of Ajuba expression may differ significantly depending on 
tumour type. Interestingly in a recent study of oesophageal squamous cell carcinoma, 
Ajuba levels were significantly higher in the carcinoma samples, compared to adjacent 
control tissue and Ajuba overexpression acted oncogenically to promote cell growth and 
colony formation, cell migration and invasion (Shi, Chen et al. 2016). When IHC 
patterns were analysed in the study by Shi et al, tumours demonstrated predominantly 
cytoplasmic staining patterns, compared to the predominant nuclear staining pattern 
observed from matched tissue, suggesting that nuclear to cytoplasmic Ajuba transfer 
may drive tumourigenesis in this tumour type. When RNA sequencing was used to 
identify Ajuba related oncogenic pathway activation, up-regulation of MMP10 and 
MMP13 through the activation of ERK1/2 pathways was observed. Therefore in 
oesophageal SCC, Ajuba appeared to be acting as an oncogene through the up-
regulation of ERK1/2 pathways (Shi, Chen et al. 2016). Shi et al also looked at mRNA 
levels of Ajuba, WTIP and LIMD1 and found in 179 paired samples that Ajuba was 
significantly overexpressed in tumour tissues compared to adjacent non-tumour tissue, 
but mRNA levels of WTIP and LIMD1 did not differ significantly (Shi, Chen et al. 
2016), suggesting at least in this tumour type that Ajuba deregulation but not WTIP and 
LIMD1 drives tumourigenesis.   
 
Loss of 14q in ccRCC has been associated with worse recurrence free and cancer 
specific survival: Kroeger et al hypothesised that this may be related to loss of HIF1α 
but other candidate genes including 14q-encoded Ajuba remain uncharacterised 
(Kroeger, Klatte et al. 2013). A significant proportion of tumours in our cohort 
demonstrated a reduction in Ajuba staining compared to MAT (76%), with 35% of 
tumours demonstrating no Ajuba staining compared to 8% of MAT samples (Χ2 
p<0.0001).  
 
Kroeger et al demonstrated 14q LOH in around 45% of ccRCC tumours (Kroeger, 
Klatte et al. 2013). The reduction in Ajuba staining observed in our cohort of ccRCC 
tumour may in part be associated with loss of HIF1a through LOH at 14q with Ajuba 
loss occurring as a carrier effect. However, given that 76% of tumours demonstrated 
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reduced Ajuba staining compared to control, this would suggest that Ajuba 
downregulation occurs very frequently and is not simply a consequence of a carrier 
effect of HIF1a loss, allelic loss of Ajuba may be occurring independently of HIF1a and 
other mechanisms such as post-transcriptional down-regulation of protein expression 
may also contribute to reduced protein expression.  
 
As was hypothesised for LIMD1 loss, loss of one Ajuba allele may also be occurring in 
some of the MAT samples, since it would be expected that inactivation of both tumour 
suppressor gene copies would be required to drive tumourigenesis.  Therefore Ajuba 
expression in MAT may be less than would be expected in healthy tissue in the absence 
of ccRCC. This is supported by the observation that Ajuba expression was reduced in 
eleven of the twelve (92%) ccRCC lines compared to the control RPTEC line (Figure 
3.1), a figure higher than the 76% reduction in staining observed in the ccRCC samples 
compared to control MAT (Figure 3.10).  Given that 35% of tumours demonstrated no 
Ajuba staining, compared to 8% of MAT (Χ2 p<0.0001), this implies that in a significant 
proportion of tumours, there is no or very little protein expression as a consequence of 
biallelic inactivation.  
 
Work by Thiesen et al found that loss of 14q23.3-encoded genes was common and that 
weighted analysis assigned loss more commonly to high grade tumours: CNA loss of 
14q11.2 encoded Ajuba was however only observed in only 4/48 tumours (8%), 
although CNA of other 14q encoded genes was more commonly observed, again 
suggesting that loss is not simply a consequence of a carrier effect. Further 
characterisation of CNA is therefore relevant in our cohort and further suggested 
experimental work described in Section 3.12.  
 
3.11.5.3 Loss of WTIP staining in ccRCC 
 
WTIP is 19q13.11 encoded and 19q loss has not been implicated in ccRCC 
pathogenesis. WTIP staining has not been widely characterised and a literature review 
failed to identify any studies characterising immunohistochemical staining in cancers. 
Immunofluorescence studies in Xenopus demonstrates that WTIP is cytoplasmically 
expressed and regulates ciliogenesis (Chu, Ossipova et al. 2016) 
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WTIP staining patterns were both nuclear and cytoplasmic in nature, which correlates 
with staining patterns described on Protein Atlas. Only 20% of tumours demonstrated 
less total WTIP staining compared to matched adjacent tissue, with 63% showing 
increased staining, a figure that corresponds to the in vitro work where 66% of ccRCC 
lines demonstrated increased WTIP expression compared to RPTEC control. Sub-
cellular localisation however appeared important with 73% of tumours showing reduced 
nuclear staining compared to MAT.  CNA loss of 19q13.1encoded genes including 
WTIP was only observed in a few of the 48 ccRCC samples analysed by Thiesen et al 
(Thiesen, Steinbeck et al. 2017).  
 
It is interesting that for many tumours WTIP expression was increased compared to 
MAT and reasons for this remain unknown.  It remains unclear why reduced nuclear 
WTIP staining could be associated with increased tumourigenesis and it is difficult to 
speculate given that changes in WTIP in malignancies have not been characterised, nor 
are the functions of WTIP fully understood. It could be that reduced nuclear WTIP 
expression in association with increased cytoplasmic expression is associated with 
increased microRNA silencing or could relate to WTIP’s role in mitotic spindle cell 
orientation.  
 
Other studies of other tumour suppressors have also shown that subcellular localisation 
strongly correlates with prognosis and drives tumourigenesis. As outlined, Spendlove et 
al demonstrated that subcellular LIMD1 localisation correlated with clinico-pathological 
outcome data, with loss of nuclear staining associated with worse outcome (Spendlove, 
Al-Attar et al. 2008). In addition, loss of nuclear BRCA1 expression in breast cancers is 
strongly associated with highly proliferative tumour phenotypes (Jarvis, Kirk et al. 1998). 
Kroeger et al characterised HIF2α staining in both cytoplasmic and nuclear 
compartments in ccRCC and found a strong correlation between increased cytoplasmic 
staining and worse clinico-pathological outcome (Kroeger, Seligson et al. 2014).  
 
For WTIP changes in subcellular localisation may be of importance in driving tumour 
pathogenesis and further experiments to characterise this relationship are described in 
Section 3.12.  
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3.11.6 Association between patterns of LAW staining in ccRCC 
 
It was hypothesised that given the close homology of LAW family members and 
characterised overlapping functions, a degree of functional redundancy is likely but that 
loss of all three family members was unlikely to occur, a pattern observed in vitro in a 
panel of ccRCC lines. It was also hypothesised that co-loss of one or more family 
member may increase tumourigenesis. 
 
 In Drosophila there is a single LAW gene orthologue djub and Drosophila cells that do 
not express djub are not viable. Such an association is also observed in mammalian cells, 
where depletion of all 3 LAW proteins in the dog kidney epithelial cell line, MDCK 
results in cell death (Das Thakur, Feng et al. 2010). In an analysis of MDCK cells, all 
three Ajuba subfamily members strongly associated with LATS1/2 suggesting that they 
regulate Hippo signalling in this tissue type. Depletion of both Ajuba and LIMD1 in the 
MDCK cells resulted in a significant increase in phospho-YAP levels, again suggesting 
that Ajuba and LIMD1 play a critical role in the regulation of Hippo signalling in renal 
cells. In the study by Das Thakur et al, co-depletion of Ajuba and WTIP or LIMD1 and 
WTIP was not undertaken (Das Thakur, Feng et al. 2010).  
 
A strong positive correlation between LIMD1 and Ajuba staining in the ccRCC 
histospots but not in the MAT was observed. This suggests that LIMD1 and Ajuba 
down-regulation coexist in ccRCC but not in matched renal tissue and could imply that 
down-regulation contributes to tumourigenesis.  This may in part be as a consequence 
of loss of heterozygosity of both 3p and 14q but as outlined, given the over-
representation of ccRCC samples with no LIMD1 or no Ajuba staining compared to 
MAT samples, further down-regulation of both proteins appears to be occurring in at 
least some tumours. Information on tumour grade and stage was available for the US 
Biomax cohort and was correlated with LIMD1 and Ajuba levels in the ccRCC samples 
but did not correlate (data not shown), although the sample size was small for some of 
the tumour stages/grades.  This does not however mean that loss of such tumour 
suppressors does not drive tumourigenesis, particularly if loss is an early event (Thiesen, 
Steinbeck et al. 2017). VHL loss and tumour grade and stage consistently fail to show 
any association but VHL loss is clearly an important driver of tumourigenesis in ccRCC 
(Frew and Moch 2015).  
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3.11.7 Relationship between LAW staining and markers of hypoxic deregulation 
 
It was hypothesised that loss of LIMD1, Ajuba or WTIP would be associated with 
increased hypoxic deregulation and thus increased CD34 and VEGF staining. No 
correlation was observed between staining for LIMD1, Ajuba or WTIP and CD34 
expression as a marker of MVD. This does not however mean that such an association 
does not exist.  
 
Given the small area of histospots and inherent heterogeneity of ccRCC, analysis of 
MVD on TMAs may not be representative of the tumour vasculature as a whole. To 
date, studies assessing the prognostic value of MVD in ccRCC have shown conflicting 
results, with Sandlund et al for example finding no association with prognosis (Sandlund, 
Hedberg et al. 2007) whilst Iakovlev et al found that higher adjusted MVD was 
associated with shorter disease-free survival but not tumour stage (Iakovlev, Gabril et al. 
2012). In addition, the distinct type of vasculature in ccRCC may be important. Yao et al 
classified intra-tumoural blood vessels based on the differential expression of blood 
vessel markers and identified two distinct types of microvessels: undifferentiated 
CD31+/CD34- and differentiated CD34+ vessels. Undifferentiated CD31+/CD34- MVD 
only, correlated with higher tumour grade and shorter patient survival (Yao, Qian et al. 
2007).  
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3.12 Future work 
 
The use of histospots on TMAs for the analysis of tumour staining and correlation of 
such staining with clinico-pathological data has been assessed in multiple studies as 
valid. Histospots are however small and given the observation of tumour heterogeneity 
in ccRCC, concern remains they may not be representative of the tumour characteristics 
as a whole. The use of tissue from several areas of the same tumour and if possible 
metastatic sites from the same patient would establish if LAW staining is heterogeneous. 
Driver mutations, driving metastatic spread could for example result in similar staining 
characteristics in metastatic deposits but not in samples from the primary tumour.  In 
addition, given that LOH may well be occurring in MAT adjacent to the ccRCC 
histospots, it would be interesting to correlate staining patterns between the ccRCC 
samples and contiguous and distant MAT.   
 
Given the differences in staining for LAW proteins in ccRCC histospots compared to 
MAT observed it would also be interesting to analyse mRNA levels for LAW in both 
the ccRCC and MAT histospots, enabling the comparison of gene expression and 
protein levels.  Huggins et al found that LIMD1 mRNA levels are relatively unchanged 
in breast tumours compared to matched controls despite protein down-regulation 
(Huggins, Gill et al. 2007) and this was also observed by Sharp et al upon interrogation 
of the NHGRI-sponsored tumour sequencing project dataset in lung carcinoma (Sharp, 
Al-Attar et al. 2008). Using the cBioportal platform to interrogate the TCGA research 
network would enable the identification of both shallow and deep deletions of the LAW 
LIMD1 proteins in ccRCC samples and control renal tissue.   
 
Given that 3p LOH is such a common event in ccRCC, and the observations of 
Thiesen et al that CNA loss of LIMD1 was frequent in ccRCC, it would be interesting to 
characterise LIMD1 copy number in our cohort of ccRCC and MAT using Fluorescent 
in situ hybridisation (FISH). LIMD1 LOH may also be occurring in MAT as a precursor 
for tumourigenesis and biallelic LIMD1 loss/inactivation may be observed in some 
tumours. 14q loss is also frequently observed in ccRCC and Ajuba copy number in our 
ccRCC/MAT samples could also be characterised using FISH. Copy number alterations 
in the ccRCC samples could be correlated with contiguous and distant MAT.   
  Chapter 3: Future Work   
! 188!
 
Immunofluorescence (IFA) is widely used in vitro to characterise protein co-localisation 
and protein sub-cellular localisation. LAW proteins, shuttle between the cytoplasm and 
the nucleus with an equilibrium towards the cytoplasm (Kadrmas and Beckerle 2004). 
Dr. Katherine Bridge of the Sharp lab has demonstrated predominantly cytosolic 
LIMD1 staining in a number of ccRCC lines. Given the observation that ccRCC 
tumours frequently have less nuclear WTIP staining compared to MAT, it would be 
particularly interesting to characterise WTIP staining in vitro using IFA in ccRCC lines 
using a non-tumour cell line such as RPTEC as control. Correlation of staining patterns 
for LAW using IFA in such cells would characterise the relationship between sub-
cellular localisation for the three family members. In addition, immunoblot of both the 
nuclear and cytoplasmic components of ccRCC lines could be used to characterise the 
sub-cellular localisation of LAW proteins.   
 
Immunohistochemistry demonstrated no association between CD34+ staining and 
staining for LAW proteins. As outlined however, Yao et al observed two distinct types 
of microvessel in ccRCC, undifferentiated CD31+/CD34- and differentiated CD34+ 
vessels with the undifferentiated CD31+/CD34- MVD correlating with higher tumour 
grade and shorter patient survival in ccRCC (Yao, Qian et al. 2007) It would therefore 
be relevant to stain the TMAs for CD31 in addition to CD34 and correlate both CD31 
and CD34 staining with that for LAW proteins and VEGF.  Other investigators have 
found a strong correlation between VEGF staining and staining for VEGF-R1, 2 and 3 
(Kluger, Siddiqui et al. 2008). Kluger et al found in ccRCC that staining for VEGFR-1 
strongly correlated with tumour grade and VEGFR-2 staining with tumour stage but 
that increasing VEGF staining was neither associated with stage or grade (Kluger, 
Siddiqui et al. 2008). After multi-variate analysis, work by del-Puerto Nevada et al 
demonstrated that expression of phosphorylated, i.e. activated VEGFR-2 in tumour 
stroma might potentially be used as a predictive biomarker in RCC patients treated with 
first line sunitinib, and that staining correlated with both OS and PFS (del Puerto-
Nevado, Rojo et al. 2014). It would therefore be interesting to correlate staining for 
LAW with staining for VEGFRs, in particular VEGFR1 and 2 and phosphorylated 
VEGFR-2. 
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Chapter 4 
Correlation of LIMD1, WTIP and Ajuba (LAW) expression with 
clinico-pathological outcome data in clear cell renal cell carcinoma 
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4.1 Introduction 
 
There is a continuous drive in oncology to generate better patient prognostic/predictive 
algorithms to improve patient outcome and help influence choice of treatment for 
maximum therapeutic effect. Clinical prognostic scoring systems such as the Heng 
scoring system can help predict patient outcome in metastatic ccRCC (Heng, Xie et al. 
2013).  Patient outcome within subgroups however remains highly variable and reasons 
for this are not fully understood. A number of biomarkers have been identified in 
ccRCC but biomarker validation has proved difficult and currently there are no 
validated predictive biomarkers, and no biomarkers used routinely in clinical practice 
(Gulati, Martinez et al. 2014).  
 
In breast carcinoma, Spendlove et al demonstrated frequent loss of LIMD1 in tumour 
tissue compared to matched-control tissue. In a cohort of 459 patients, loss of nuclear 
staining for LIMD1 strongly correlated with reduced patient survival, increased tumour 
size, increased histological grade and worse Nottingham Prognostic Index, an index that 
stratifies patients from excellent to poor prognosis (Spendlove, Al-Attar et al. 2008).  
 
Reduced LIMD1 staining was observed in 49.3% of ccRCC samples compared to MAT, 
with no staining in 17% of ccRCC samples compared to 3% of the control tissue 
samples. For Ajuba, a 76% reduction in staining was observed in the ccRCC samples 
compared to MAT, with 35% of tumour samples demonstrating no staining compared 
to only 8% of the control tissue samples. For WTIP, 20% of ccRCC histospots 
demonstrated less staining compared to control tissue, with 63% of tumours 
demonstrated increased staining. Subcellular WTIP localisation however appeared 
important, with 58% of tumours demonstrating no nuclear staining compared to only 
9% of the MAT histospots. 
  
The Experimental Cancer Medicine Network aims to help facilitate the translation of 
basic scientific discovery into an understanding of what drives tumourigenesis and 
resistance to therapeutics in vivo as well as to develop novel treatments for patients with 
cancer. Access to patient tissue from two prospective clinical trials with detailed five-
year clinico-pathological outcome data represents a valuable resource, enabling the 
investigation of LAW staining in a large panel of tumours in vivo and the correlation of 
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staining patterns with validated clinico-pathological indices. Many studies investigating 
potential biomarkers in various tumour types cannot be validated and often, reporting 
recommendations for tumour marker prognostic studies guidelines, which state that 
univariate and multivariate analysis should be conducted, are not followed (Gulati, 
Martinez et al. 2014).  
 
To this end, TMAs containing archived tumour samples generated from a prospective 
randomised clinical trial of the epidermal growth factor receptor-2 (EGFR-2) tyrosine 
kinase inhibitor lapatinib versus hormone therapy (Ravaud, Hawkins et al. 2008) were 
stained for LIMD1, Ajuba and WTIP. Staining was correlated with clinico-pathological 
outcome data and both univariate and multivariate analysis undertaken. LAW staining 
was also correlated with staining for VHL, HIF1α and HIF2α, known markers of 
hypoxic deregulation in ccRCC. Using TMAs generated from the phase II study 
investigating upfront pazopanib prior to nephrectomy in patients with metastatic ccRCC 
(PANTHER) study, (Powles, Sarwar et al. 2016), staining for LIMD1 was further 
validated immunohistochemically and staining correlated with clinico-pathological 
outcome data.  
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4.2 Aims and Objectives 
 
• To correlate staining for LIMD1, Ajuba and WTIP in ccRCC TMAs generated 
from a prospective clinical trial, with clinico-pathological outcome  
 
• To correlate LIMD1, Ajuba and WTIP staining with staining for VHL, HIF1α 
and HIF2α, known markers of hypoxic deregulation in ccRCC 
 
• To validate the correlation of LIMD1 staining and clinico-pathological outcome 
in ccRCC by staining a further cohort of patients enrolled in a phase II clinical 
trial  
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4.3 Tumour characteristics and clinical trial information 
 
TMAs containing archived tumour samples generated from a prospective randomised 
clinical trial of the epidermal growth factor receptor-2 (EGFR-2) tyrosine kinase 
inhibitor lapatinib versus hormone therapy (Ravaud, Hawkins et al. 2008) were stained.  
 
This trial was published in 2008, prior to the widespread availability of targeted therapy 
in RCC. Eligible patients had progressed through first-line cytokine therapy and had 
tumours that expressed EGFR and/or its co-receptor HER-2 (Ravaud, Hawkins et al. 
2008). Patients were randomised either to the active or placebo arm and stratified by 
Karnofsky performance status (KPS) and number of metastatic sites. Detailed clinico-
pathological and 5-year follow up data was available. The trial included 460 patients but 
only 144 tumour samples archived locally were available for analysis. Many patients had 
advanced disease at the time of tumour archive: 37% had metastatic ccRCC (stage IV) 
and 33% Stage III disease. TMA histospots were paraffin embedded and 0.9mm in 
diameter, with tumours from each patient represented on the TMAs in triplicate.    
 
A further cohort of patient samples was available, generated from a phase II study 
investigating upfront pazopanib prior to nephrectomy in patients with metastatic ccRCC 
(PANTHER) (Powles, Sarwar et al. 2016). A total of 100 patients were assessable for 
clinical benefit for pazopanib, with nephrectomy performed in 63 patients (61%). 82% 
of patients had intermediate MSKCC prognostic risk disease and 18% MSKCC poor 
risk disease. Tissue samples were paraffin embedded and histospots of 2mm diameter 
were represented on the TMAs in duplicate.  
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4.4 LIMD1 staining  
 
A new batch of LIMD1 antibody was used to stain the first set of TMAs designated the 
GSK cohort. This antibody was generated from a new clone from the same mouse 
hybridoma. Over time the initial LIMD1 antibody had degraded when stored in the -
20°C freezer and although it continued to give a good signal when used for 
immunoblotting, IHC staining intensity had diminished considerably and differences in 
staining intensity between histospots could not be accurately quantified using this 
method.  In addition, obtaining consistent IHC staining using the new batch of antibody 
and the optimised manual IHC protocol proved very difficult.  
 
More consistent results were however obtained when staining with this new antibody 
batch was undertaken using an automated staining system  (Discovery System, Ventana 
Medical system). Staining specificity was re-established using control TMAs with 
histospots from a range of normal and malignant tissues. Staining of these TMAs and of 
paraffin embedded healthy renal tissue slides were used to determine an optimum 
antibody concentration and to ensure staining appeared specific. Staining patterns and 
intensity were observed to be consistent between the old and the new batch of antibody 
(Figure 4.1). Dr Giorgia Trevisan, a consultant histopathologist at University College 
London Hospital, reviewed all IHC staining.  
LIMD1 old and new healthy renal 
LIMD1 old and new ccRCC
(i) (ii)
Figure 4.1. Comparison of manual and semi-automated IHC staining for LIMD1 
Paraffin embedded renal tissue was stained immunohistochemically for LIMD1. Staining is cytoplasmic, 
with little staining of the glomeruli but staining of the distal and proximal tubules. (i) Representative IHC 
staining of renal tissue obtained using a manual IHC staining protocol and antibody concentration 1:50.  
(ii) Representative IHC staining of renal tissue obtained using a semi-automated IHC staining protocol 
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with antibody concentration 1:100 and a new batch of the LIMD1 antibody derived from the same 
hybridoma. Scale bar corresponding to 100µm is shown for size comparison.  
 
Using the semi-automated staining system, staining patterns in ccRCC histospots and 
health kidney tissue were very similar to that observed with the manual IHC system with 
LIMD1 staining almost exclusively expressed in the cytoplasm and little stromal staining 
and no staining of the glomerulus observed (Figures 4.1 and 4.2).  
(i) (ii)
LIMD1 GSK TMA for IHC analysis
 
Figure 4.2 IHC staining for LIMD1 in ccRCC histospots 
TMA histospots derived from a phase II clinical trial were stained immunohistochemically for LIMD1 
using a semi-automated staining platform and LIMD1 antibody concentration 1:100. Histospots were 
represented on the TMAs in triplicate. (i) Low level cytoplasmic LIMD1 staining (ii) High level 
cytoplasmic LIMD1 staining.  
 
The tumour scoring system was adapted from the scoring system used by Spendlove et 
al in the analysis of breast carcinoma (Spendlove, Al-Attar et al. 2008). Most positively 
staining tumours had low staining intensity and a four-point scoring system was used 
where zero represented no staining, one, weakly positive staining, two, moderate 
staining, and three, strongly positive staining. A score was generated based on the 
proportion of positively staining tumour cells and the intensity of staining throughout 
the histospot, a modified Allred scoring system (Allred, Bustamante et al. 1990). An 
overall score was then calculated based on the mean staining intensity for the histospots 
derived from the same tumour. For some tumours, samples were missing from the 
TMA or histospots included contained no carcinoma and such tumours were excluded. 
Tumours were then sub-divided into those with absent or low level LIMD1 staining, 
where the mean score as a function of the proportion of positive staining tumour cells 
and staining intensity was less than 100, and those with moderate or high LIMD1 
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staining, where the mean score was greater than 100. Most tumours demonstrated fairly 
homogeneously staining throughout the tumour histospots and this meant that defining 
alternative cutoffs for high versus low staining, e.g. less than the median versus more 
than the median was not possible as scores were too clustered. Given the low number 
of tumours for some staining intensity categories, this grouping was necessary in order 
for there to be sufficient tumours in each group to make statistical analysis meaningful.  
 
This scoring system was used in preference to the score obtained from the automated 
Ariol image acquisition and analysis system as the manual LIMD1 IHC scoring had 
previously been validated as a robust scoring system, correlating with clinico-
pathological data in a large breast carcinoma cohort (Spendlove, Al-Attar et al. 2008). In 
addition, the automated Ariol score did not always seem to correlate accurately with the 
extent of staining and staining intensity when compared to the score obtained manually. 
This was likely related to the small size of the histospots on the GSK TMA staining and 
the staining artefact present for some spots.  
 
As before, positive and negative controls were included with the use of a TMA with 
histospots derived from a range of pre-invasive/invasive tumours and a negative control 
where the primary antibody was omitted when staining the GSK TMA. Staining 
patterns of control tissue and RCC samples corresponded to staining patterns observed 
with the previous batch of LIMD1 antibody (Figures 4.1 and 4.2).  
 
Non-clear cell renal cell carcinoma samples were excluded from analysis, leaving 132 
analysable ccRCC tumours. All staining was double scored by Dr Trevisan and myself, 
blinded to clinico-pathological outcome data and to each others scoring, although 
agreement had been reached as to how different staining intensities should be scored.  
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4.5 LIMD1 IHC of ccRCC histospots 
4.5.1 Intra-class correlation coefficient analysis to assess inter-observer scoring 
agreement for LIMD1 
 
In order for a scoring system to be robust, it needs to be reproducible. The intra-class 
correlation coefficient is the most commonly used method to assess inter-observer 
measurements of scoring for IHC and therefore reproducibility (Shrout and Fleiss 
1979). The closer the agreement is to 1, the better the agreement between observers. 
Generally a score of greater than 0.75 indicates excellent agreement, between 0.4 and 
0.75 good agreement and a score of less than 0.4, poor agreement (Coenraads, Van Der 
Walle et al. 2005, Zlobec, Steele et al. 2006). Intra-class correlation coefficient analysis 
was calculated using SPSS version 24. Very good correlation between scores was seen 
for LIMD1 staining, with an intra-class correlation coefficient of 0.743 for single 
measures, demonstrating that scoring was consistent and valid (Figure 4.3).  
 
Intraclass correlation GSKTMA 
Kate Gio
Case Processing Summary 
 n % 
Cases Valid 130 98.5 
Excluded 2 1.5 
Total 132 100.0 !
Reliability Statistics 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based 
on 
Standardized 
Items n of Items 
.852 .874 2 !
Intra-class Correlation Coefficient 
 
Intra-class 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower 
Bound 
Upper 
Bound Value df1 df2 Sig 
Single Measures .743 .654 .811 6.770 129 129 .000 
 
Average 
Measures 
.852 .791 .896 6.770 129 129 .000 !
(i) (ii)
(iii)
 
Figure 4.3 Very good intra-class correlation is observed for LIMD1 scoring 
LIMD1 histospot staining was double scored by Dr Trevisan and myself. Staining was cytoplasmic. 
Histospots containing no tumour were excluded from analysis and only areas of tumour scored. A score 
for each histospot was generated incorporating overall staining and percentage of tumour staining 
positively. (i) Scoring by myself and Dr Trevisan was correlated with 130 valid cases included. (ii) 
Cronbach’s alpha value was estimated at 0.874 suggesting very good internal consistency. (iii) The intra-
class correlation coefficient for single measures was 0.852 for average measures, indicating very good 
agreement between scoring for each histospot. 
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4.5.2 Correlation of LIMD1 staining with tumour stage and grade 
 
Tumour grade and tumour stage are validated prognostic indicators in ccRCC (Zisman, 
Pantuck et al. 2001). Spendlove et al had found that loss of nuclear LIMD1 staining 
strongly correlated with increasing tumour grade but no correlation with tumour stage 
was observed (Spendlove, Al-Attar et al. 2008). The association between LIMD1 
staining and tumour grade and stage was characterised using the TMAs generated from 
the GSK study (Ravaud, Hawkins et al. 2008).  
4.5.3 Tumour stage and grade do not correlate with LIMD1 staining pattern in 
ccRCC  
 
Tumours were grouped in to those with absent or low LIMD1 staining and those with 
moderate or strong LIMD1 staining. Tumour grade did not correlate with LIMD1 
staining, (Χ2 test for trend p=0.658), and tumour stage did not correlate with LIMD1 
staining (Χ2 test for trend p=0.8492) (Figure 4.4) 
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Figure 4.4 LIMD1 staining does not correlate with tumour stage and grade in 
ccRCC samples obtained from the GSK study 
Tumours were divided in to those with no or low LIMD1 staining and those with moderate or high 
LIMD1 staining based on the mean staining intensity throughout the histospots derived from the same 
tumour. A (i) Bar chart illustrating the relative number of tumours with no/low LIMD1 staining versus 
those with moderate/high LIMD1 staining for each ccRCC tumour grade. A (ii) Table illustrates the 
relative frequency of no/low LIMD1 staining versus moderate/high LIMD1 staining for each ccRCC 
tumour grade. B (i) Bar chart illustrating the relative number of tumours with no/low LIMD1 staining 
versus those with moderate/high LIMD1 staining for each ccRCC tumour stage. B (ii) Table illustrates 
the relative frequency of no/low LIMD1 staining versus moderate/high LIMD1 staining for each ccRCC 
tumour stage. The χ2 test for trend was calculated using Prism version 6 
4.5.4 Low/absentLIMD1 staining does not correlate with overall survival 
 
Next the relationship between LIMD1 staining and overall patient survival in the GSK 
cohort was examined.  28 results were censored, (patients lost to follow up or still alive 
at time of last follow up). Estimated median OS from start of trial commencement was 
379 days with a range of 1 to 1396 days.  Dr Shah Jalal of Barts Cancer Institute 
provided advice regarding the statistical analysis of data.  
 
Absent/low LIMD1 staining did not correlate with OS in this cohort.  The median 
estimated OS in patients with tumours with absent/low LIMD1 staining was 397 days 
compared to 351 days in patients with tumours with moderate/high LIMD1 staining 
(Log-rank p=0.264) (Figure 4.5).  
 
  Chapter 4: Results   
! 200!
Case Processing Summary 
Kate LIMD1 1014 
median 
Total 
No 
No. of 
Events 
Censored 
No. Percent 
.00 43 33 10 23.3% 
1.00 87 69 18 20.7% 
Overall 130 102 28 21.5% !
(i)
(ii)
(iii)
Means and Medians for Survival Time 
KateLIMD1 1014 
median 
Mean Median 
Estimate Std. Error 
95% Confidence Interval 
Estimate Std. Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
.00 534.997 70.618 396.586 673.407 397.000 49.816 299.361 494.639 
1.00 419.128 33.518 353.432 484.824 351.000 57.205 238.877 463.123 
Overall 467.009 36.463 395.542 538.476 379.000 35.832 308.769 449.231 
 !
 
Overall Comparisons 
 
Chi-
Square df Sig. 
Log Rank (Mantel-
Cox) 
1.248 1 .264 
 
Breslow 
(Generalized 
Wilcoxon) 
.783 1 .376 
 
Tarone-Ware 
.902 1 .342 
 !
(iv)
 
 
Figure 4.5 Loss of LIMD1 does not correlate with OS in ccRCC  
 
Kaplan-Meier plot of cumulative OS in patients in the GSK cohort. OS is defined as time from 
randomisation to date of death or last follow up in the case of censored patients.  (i) Summary of cases 
included in the analysis. (ii) Kaplan-Meier plots of cumulative OS in patients with ccRCC tumours with 
no/low total LIMD1 staining versus OS in patients with tumours with LIMD1 staining. (iii) Estimated 
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means and medians for survival time in the two groups. (iv) Comparison of cumulative OS with Log 
Rank, Breslow and Tarone-Ware Chi-Square test in the two groups. All analysis was undertaken using 
SPSS version 24.  
 
4.5.5 Low/absent LIMD1 staining does not correlate with overall survival on 
multi-variate analysis 
 
A Cox regression analysis was performed using SPSS Version 24. The regression model 
was adjusted for the validated MSKCC prognostic criteria, Karnofsky Performance 
status (KPS<80% or ≥80%), number of metastatic sites at screening (≤2 or >2), 
haemoglobin (<normal or ≥ normal), corrected serum calcium (≤10 or >10mg/dl), and 
age and sex which are not MSKCC prognostic criteria. These parameters were included 
as they were included in the initial trial Cox regression analysis (Ravaud, Hawkins et al. 
2008). Information on tissue EGFR status and treatment randomisation to either 
lapatinib or hormone therapy was not available and therefore could not be included in 
the analysis. The adjusted multi-variate analysis demonstrated that absent/low LIMD1 
staining was not associated with reduced OS, HR=0.911 (95% CI 0.561-1.481, 
p=0.708), however the validated prognostic indices of corrected calcium (HR 1.39, 95% 
CI 1.132-2.49, p=0.016*), number of metastatic sites (HR 2.036, 95% CI 1.239, 
p=0.005**) and haemoglobin (HR 1.965, 95% CI 1.218-3.175, p=0.006**) were 
statistically significant and correlated with worse OS as we would predict (Figure 4.6). 
This demonstrates the validity of the multivariate model used and analysis undertaken.  
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Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Event 82 62.1% 
Censored 22 16.7% 
Total 104 78.8% 
Cases dropped Cases with missing 
values 
28 21.2% 
Cases with negative 
time 
0 0.0% 
Censored cases 
before the earliest 
event in a stratum 
0 0.0% 
Total 28 21.2% 
 
Total 
132 100.0% 
 !
Cox&mul<variate&analysis&OS&GSK&cohort&June&2015&
Risk%Factor% Signiﬁcance% Hazard&
Ra<o&(HR)%
95%&CI&for&HR&
(lower)%
95%&CI&for&HR&
(upper)%
KPS&(<80%&versus&>&80%)& 0.052& 1.866& 0.993& 3.506&
No&of&metasta<c&sites&(≤&2versus&>2)& 0.005& 2.036& 1.239& 3.355&
Hb&<&N&versus&Hb>&N& 0.006& 1.965& 1.218& 3.175&
Corrected&Ca&≤10&versus&Ca&>10& 0.016& 1.39& 1.132& 2.49&
Age& 0.070& 1.026& 1.027& 0.998&
Sex& 0.523& 0.840& 0.492& 1.434&
No&LIMD1&staining&versus&LIMD1&
staining&
0.708& 0.911& 0.561& 1.481&
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Event 82 62.1% 
Censored 22 16.7% 
Total 104 78.8% 
Cases dropped Cases with missing 
values 
28 21.2% 
Cases with negative 
time 
0 0.0% 
Censored cases 
before the earliest 
event in a stratum 
0 0.0% 
Total 28 21.2% 
 
Total 
132 100.0% 
 !
Cox&mul<variate&analysis&GSK&TMA&
June&2015&OS&
Omnibus Tests of Model Coefficients 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-square df Sig. Chi-square df Sig. Chi-square df Sig. 
594.278 39.907 7 0.000 35.995 7 0.000 35.995 7 0.000 
 !
(i)
(ii)
(iii)
Correlation OS Cox regression
 
Figure 4.6 Multi-variate Cox-regression analysis demonstrates that no/absent 
LIMD1 staining does not correlate with OS. There is a correlation between OS 
and number of metastatic sites, haemoglobin and corrected calcium.  
Cox-regression analysis of OS in the GSK cohort was undertaken using SPSS version 24 to include 
LIMD1 staining, age, sex, KPS, number of metastatic sites, haemoglobin, and corrected calcium. (i) The 
omnibus test of model co-efficient was significant demonstrating that the new model offered an 
improvement over the old model (ii) Of the 132 patients, 104 had complete data available for all 
parameters and were therefore included in the analysis. (iii) Results of the Cox-regression analysis.  
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4.5.6 Low/absent LIMD1 staining does not correlate with PFS 
 
The relationship between PFS and staining for LIMD1 was examined.   PFS was 
defined as the time from randomisation to radiological or clinical progression as defined 
in the trial protocol (Ravaud, Hawkins et al. 2008). Median PFS for the cohort was 61 
days with a range from 1 to 421 days. Absent/low LIMD1 staining did not correlate 
with PFS: estimated PFS was 67 days for patients with absent/low LIMD1 staining 
versus 61 days for patients with moderate/high LIMD1 staining (Log Rank (Mantel-
Cox) p=0.281) (Figure 4.7). 
Means and Medians for Survival Time 
KateLIMD1 1014 
median 
Mean Median 
Estimate Std. Error 
95% Confidence Interval 
Estimate Std. Error 
95% Confidence Interval 
Lower 
Bound Upper Bound 
Lower 
Bound Upper Bound 
.00 113.488 14.120 85.813 141.164 67.000 31.467 5.324 128.676 
1.00 107.989 10.604 87.205 128.772 61.000 9.845 41.704 80.296 
Overall 109.808 8.467 93.213 126.403 61.000 7.042 47.197 74.803 
 !
Case Processing Summary 
KateLIMD1 1014 
median Total n 
n of 
Events 
Censored 
n Percent 
.00 43 43 0 0.0% 
1.00 87 87 0 0.0% 
Overall 130 130 0 0.0% !
(i)
(ii)
(iii)
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Overall Comparisons 
 
Chi-
Square df Sig. 
Log Rank (Mantel-
Cox) 
.115 1 .734 
Breslow 
(Generalized  
Wilcoxon) 
.437 1 .509 
Tarone-Ware .262 1 .609 !
(iv)
 
 
Figure 4.7 Loss of LIMD1 does not correlate with PFS in ccRCC  
 
Kaplan-Meier plot of cumulative PFS in patients in the GSK cohort. PFS is defined as time from date of 
randomisation to clinical or radiological progression. (i) Summary of cases included in the analysis (ii) 
Kaplan-Meier plots of cumulative PFS in patients with ccRCC tumours with no/low total LIMD1 
staining versus PFS in patients with tumours with LIMD1 staining. (iii) Estimated means and medians 
for PFS in the two groups. (iv) Comparison of cumulative PFS with Log Rank, Breslow and Tarone-
Ware Chi-Square test in the two groups. All analysis was undertaken using SPSS version 24.  
 
4.5.7 Low/absent staining for LIMD1 is not statistically significant for PFS on 
multi-variate analysis 
 
Multivariate Cox Regression analysis for PFS was undertaken.  As before the regression 
model was adjusted for KPS (KPS<80% or ≥80%), number of metastatic sites at 
screening, haemoglobin (< normal or ≥ normal), corrected serum calcium (≤10 or 
>10mg/dl), age and sex. All patients had progressed at the cut off date for PFS analysis 
and 104 patients were included in the analysis with no cases censored. Low/absent 
LIMD1 staining was not associated with differences in PFS on multi-variate analysis 
(HR 1.179, 95% CI 0.765-1.818, p=0.457): increasing age was however associated with 
shorter PFS (HR 1.036, 95% CI 1.010-1.062, p=0.006*), although the other parameters 
included, KPS, corrected calcium, haemoglobin, number of metastatic sites and sex did 
not correlate (Figure 4.8). With the exception of sex and age these parameters, form 
part of the MSKCC score, a predictor of OS but not PFS and are not validated 
prognostic factors for PFS. 
 
  Chapter 4: Results   
! 205!
Cox regression PFS for LIMD1
Omnibus Tests of Model Coefficients 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-square df Sig. Chi-square df Sig. Chi-square df Sig. 
748.826 19.288 7 .007 18.007 7 .012 18.007 7 .012 
 !
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Event 104 78.2% 
Censored 0 0.0% 
Total 104 78.2% 
Cases dropped Cases with missing 
values 
29 21.8% 
Cases with negative 
time 
0 0.0% 
Censored cases 
before the earliest 
event in a stratum 
0 0.0% 
Total 29 21.8% 
Total 133 100.0% 
 !
(i)
(ii)
(iii)
Risk Factor Significance Hazard Ratio 
(HR) 
95% CI for 
HR (lower) 
95% CI for 
HR (upper) 
KPS (<80% versus >80%) 0.154 1.569 0.845 2.913 
No of metastatic sites (≤2 versus>2) 0.598 1.129 0.719 1.773 
Hb <N versus Hb>N 0.379 1.149 1.912 1.353 
Corrected Ca ≤10 versus Ca>10 0.043 1.655 1.015 2.702 
Age 0.006 1.036 1.010 1.062 
Sex 0.435 1.214 0.745 1.972 
No/low LIMD1 staining versus 
moderate/high LIMD1 staining 
0.457 1.179 0.765 1.818 
 
Figure 4.8 Multi-variate Cox-regression analysis demonstrates that no/absent 
LIMD1 staining does not correlate with PFS. There is a correlation between age 
and PFS 
Cox-regression analysis of PFS in the GSK cohort was undertaken using SPSS version 24 to include 
LIMD1 staining, age, sex, KPS, number of metastatic sites, haemoglobin, and corrected calcium. (i) The 
omnibus test of model co-efficient was significant demonstrating that the new model offered an 
improvement over the old model (ii) Of the 132 patients, 104 had complete data available for all 
parameters and were therefore included in the analysis. (iii) Results of the Cox-regression analysis.  
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4.6 Validation of LIMD1 staining and correlation with clinico-pathological 
outcome data in a further cohort of patients. 
 
LIMD1 staining and its correlation with OS and PFS was validated by staining TMAs 
containing tumour samples generated from a clinical trial evaluating the role of upfront 
pazopanib prior to nephrectomy in mccRCC (Powles, Sarwar et al. 2016). This cohort 
of patients differed from those in the GSK cohort, as all patients received an upfront 
TKI. Histospots of 2mm derived from the same tumour were represented on the TMAs 
in duplicate, although for some tumours histospots were missing. The TMAs containing 
biopsy samples were of very poor quality as little tissue was left after staining the TMA 
blocks as part of the clinical trial protocol and therefore could not be used for IHC.   
 
63 of the 100 patients evaluable for the clinical benefit of pazopanib underwent 
nephrectomy and patients with missing tumour samples or no tumour represented on 
the histospots were excluded, which left 56 tumours evaluable for IHC. Staining was 
undertaken as for the GSK cohort, with controls included as before and an identical 
scoring system used as for that described in the GSK cohort. Staining was reviewed by 
Professor Michael Sheaff of Barts Health NHS Trust and established to be specific and 
valid for analysis. Dr. Scott Shepherd and myself double scored all TMAs. The intraclass 
correlation coefficient for single measures was excellent at 0.834, demonstrating that the 
scoring system was again reliable and reproducible.  
4.6.1 Correlation of LIMD1 staining and OS and PFS in the PANTHER cohort !
Correlation of LIMD1 staining and OS in the PANTHER cohort, validated the findings 
of the GSK cohort, with no association between LIMD1 staining and OS demonstrated 
(Log Rank test p=0.541) (Figure 4.9). A similar result was obtained when LIMD1 
staining and PFS was correlated in the PANTHER cohort (Log Rank test p=0.541) 
(Figure 4.10) 
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(i)
(ii)
(iii)
!
Case Processing Summary 
LIMD1 cut off <100 
versus >100 Total N 
N of 
Events 
Censored 
N Percent 
.00 35 27 8 22.9% 
1.00 21 15 6 28.6% 
Overall 56 42 14 25.0% 
Means and Medians for Survival Time 
LIMD1 cut off <100 
versus >100 
Mean Median 
Estimate Std. Error 
95% Confidence Interval 
Estimate Std. Error 
95% Confidence Interval 
Lower 
Bound Upper Bound 
Lower 
Bound Upper Bound 
.00 25.379 2.807 19.877 30.882 22.675 3.707 15.409 29.941 
1.00 28.343 2.297 23.840 32.846 35.163 7.479 20.503 49.822 
Overall 27.431 2.144 23.229 31.633 26.980 4.686 17.796 36.164 
 !
 
(iv)
OS PANTHER 
 
Figure 4.9 Loss of LIMD1 does not correlate with OS in ccRCC  
Kaplan-Meier plot of cumulative OS in patients in the PANTHER cohort. OS is defined as time from 
randomisation to date of death or last follow up in the case of censored patients.  (i) Summary of cases 
included in the analysis (ii) Kaplan-Meier plots of cumulative OS in patients with ccRCC tumours with 
no/low total LIMD1 staining versus OS in patients with tumours with LIMD1 staining, (iii) Estimated 
means and medians for survival time in the two groups. (iv) Comparison of cumulative OS with Log 
Rank, Breslow and Tarone-Ware Chi-Square test in the two groups. All analysis was undertaken using 
SPSS version 24.  
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(i)
(ii)
(iii)
Means and Medians for Survival Time 
LIMD1 cut off <100 
versus >100 
Mean Median 
Estimate Std. Error 
95% Confidence Interval 
Estimate Std. Error 
95% Confidence Interval 
Lower 
Bound Upper Bound 
Lower 
Bound Upper Bound 
.00 14.980 2.481 10.116 19.843 9.004 1.260 6.535 11.474 
1.00 13.877 2.233 9.501 18.253 9.399 .989 7.460 11.338 
Overall 15.419 1.966 11.565 19.273 9.136 .637 7.887 10.384 
 !
!
Case Processing Summary 
LIMD1 cut off <100 
versus >100 Total N 
N of 
Events 
Censored 
N Percent 
.00 35 27 8 22.9% 
1.00 21 15 6 28.6% 
Overall 56 42 14 25.0% 
 
Correlation LIMD1 PFS PANTHER
(iv)
 
Figure 4.10 Loss of LIMD1 does not correlate with PFS in ccRCC  
Kaplan-Meier plot of cumulative PFS in patients in the PANTHER cohort. PFS is defined as time from 
randomisation to date of death or last follow up in the case of censored patients.  (i) Summary of cases 
included in the analysis (ii) Kaplan-Meier plots of cumulative PFS in patients with ccRCC tumours with 
no/low total LIMD1 staining versus OS in patients with tumours with LIMD1 staining, (iii) Estimated 
means and medians for survival time in the two groups. (iv) Comparison of cumulative PFS with Log 
Rank, Breslow and Tarone-Ware Chi-Square test in the two groups. All analysis was undertaken using 
SPSS version 24.  
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4.7 Correlation of Ajuba expression with clinico-pathological indices 
 
The association between Ajuba staining and clinico-pathological outcome data was 
characterised using the TMAs generated from the GSK study (Ravaud, Hawkins et al. 
2008) Staining patterns were as described previously in control tissue TMAs and in 
healthy renal tissue and ccRCC. Staining in ccRCC tissue was predominantly nuclear 
with some limited cytoplasmic staining (Figure 4.11). As before, a TMA consisting of 
histospots derived from a range of pre-invasive/invasive tumours were included as 
positive/negative control and stomach tissue as a further positive control when staining 
the GSK trial TMAs. Primary antibody was omitted from one of the TMA slides as a 
further negative control. Professor Mike Sheaff reviewed all staining, which he felt to be 
specific and agreed that the optimum antibody concentration for the TMA staining was 
as before 1:50. As before, only nuclear staining was scored and the TMAs were double 
scored by Dr Scott Shepherd and myself, blinded to each others scoring and clinico-
pathological outcome data, although agreement on how scoring should be undertaken 
had been reached. Histospots without any tumour were excluded and a score for each 
tumour generated based on the mean staining score for histospots from the same 
tumour as a function of the percentage of positively staining tumour cells and the 
intensity of nuclear staining (scored as before from 0-3) throughout the histospot. Such 
a system was used in preference to the ARIOL automated system to ensure consistency 
with the LIMD1 scoring.  
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(i) (ii)
Ajuba staining TMAs GSK
 
 
Figure 4.11 IHC staining of tumour histospots for Ajuba 
TMA histospots derived from a phase II clinical trial were stained immunohistochemically for Ajuba 
using an optimised manual staining protocol and Ajuba antibody concentration 1:50. Histospots were 
represented on the TMAs in triplicate. (i) Low level nuclear Ajuba staining (ii) High level nuclear Ajuba 
staining. Scale bar shown for size comparison 
4.7.1 Intra-class correlation coefficient analysis to assess inter-observer scoring 
agreement for Ajuba 
 
The intra-class correlation coefficient analysis was calculated to assess the inter-observer 
scoring agreement for Ajuba. Excellent intra-class correlation of 0.943 for single 
measures between the two scorers was observed (Figure 4.12), suggesting that scoring 
was robust and reproducible. 
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Correlation Scott Kate Ajuba 
IHC 
(i) (ii)
(iii)
Case Processing Summary 
 n % 
Cases Valid 103 100 
Excluded 0 0 
Total 103 100.0 
 !
Reliability Statistics 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based on 
Standardized 
Items N of Items 
.967 .967 2 !
Intra-class Correlation Coefficient 
 
Intra-class 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower 
Bound 
Upper 
Bound Value df1 df2 Sig 
Single Measures 
 
.935 .906 .956 29.911 102 102 .000 
Average 
Measures 
.967 .951 .977 29.911 102 102 .000 !  
 
Figure 4.12 Excellent intra-class correlation is observed for Ajuba scoring in the 
GSK TMA histospots 
Ajuba histospot staining was double scored by Dr Scott Shepherd and by myself. Staining was 
predominantly nuclear and only nuclear staining scored. Histospots containing no tumour were excluded 
from analysis and only areas of tumour scored. Appropriate positive and negative controls were included. 
Both the proportion of positively staining tumour cells and intensity of nuclear staining was scored and a 
score generated by multiplying the intensity of staining by the percentage of tumour cells with positive 
staining. (i) Scoring undertaken by Dr Shepherd and myself was correlated with 103 valid cases included. 
(ii) Cronbach’s alpha value was estimated at 0.964 suggesting excellent internal consistency. (iii) The 
intra-class correlation coefficient was 0.967 for average measures, indicating excellent agreement between 
both scorers.  
 
4.7.2 Correlation of Ajuba staining with tumour stage and grade 
 
Next the relationship between Ajuba staining and tumour stage and grade was examined 
Tumours were sub-divided into those with absent or low Ajuba staining (mean 
histospot score≤100) versus those with moderate or high Ajuba staining (mean 
histospot score >100). Analysis using alternative cutoffs for high versus low staining, 
e.g. score less than the median versus score greater than the median did not change the 
outcome of statistical analysis, including OS and PFS analysis and therefore to ensure 
consistency with the LIMD1 data, this cutoff was chosen. Tumour grade did not 
correlate with Ajuba staining, (Χ2 test for trend p=0.785), however tumour stage did 
correlate with Ajuba staining (Χ2 test for trend p=0.037*), with a significantly greater 
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proportion of stage 4 tumours (75%) demonstrating reduced Ajuba staining compared 
to stage 1 tumours (40%) (Figure 4.13).  
Absent/low+
Ajuba+staining+
Moderate/high+
Ajuba+staining+
Grade+1+ 3/7$(43%)$ 4/7$(53%)$
Grade+2+ 28/41$(68%)$ 13/41$(32%)$
Grade+3+ 20/26$(77%)$ 6/26$(23%)$
Grade+4+ 5/12$(42%)$ 7/12$(58%)$
Absent/low+
Ajuba+staining+
Moderate/high+
Ajuba+staining+
Stage+1+ 6/15%(40%)% 9/15%(60%)%
Stage+2+ 10/14%(71%)% 4/14%(29%)%
Stage+3+ 22/33%(67%)% 11/33%(33%)%
Stage+4+ 27/36%(75%)% 9/36%(25%)%
A(i) A(ii)
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Figure 4.13 Ajuba staining correlates with tumour stage but not grade in ccRCC 
samples obtained from the GSK study 
Tumours were divided in to those with no or low Ajuba staining and those with moderate or high Ajuba 
staining based on the mean staining intensity throughout the histospots derived from the same tumour. A 
(i) Bar chart illustrating the relative number of tumours with no/low Ajuba staining versus those with 
moderate/high Ajuba staining for each ccRCC tumour grade. A (ii) Table illustrates the relative frequency 
of no/low Ajuba staining versus moderate/high Ajuba staining for each ccRCC tumour grade. B (i) Bar 
chart illustrating the relative number of tumours with no/low Ajuba staining versus those with 
moderate/high Ajuba staining for each ccRCC tumour stage. B (ii) Table illustrates the relative frequency 
of no/low Ajuba staining versus moderate/high Ajuba staining for each ccRCC tumour stage. The χ2 test 
for trend was calculated using Prism version 6 
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4.7.3 Ajuba staining does not correlate with OS  
 
Univariate analysis was undertaken dividing tumours using the cutoffs described. A total 
of 100 patients were included in the analysis, 21 results were censored, (patients lost to 
follow up or still alive at time of last follow up).  
 
Absent/low Ajuba staining did not correlate with OS in the GSK cohort.  The median 
estimated OS in patients with tumours with absent/low Ajuba staining was 345 days 
compared to 379 days in patients with tumours with moderate/high Ajuba staining 
(Log-rank p=0.480) (Figure 4.14).  
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(i)
(ii)
(iii)
Case Processing Summary 
Ajuba nuclear 
staining Total n 
n of 
Events 
Censored 
n Percent 
.00 66 51 15 22.7% 
1.00 34 28 6 17.6% 
Overall 100 79 21 21.0% !
 
Overall Comparisons 
 
Chi-
Square df Sig. 
Log Rank (Mantel-
Cox) 
.499 1 .480 
Breslow 
(Generalized 
Wilcoxon) 
.022 1 .883 
Tarone-Ware .124 1 .725 
 !
(iv)
 
Figure 4.14 Loss of Ajuba does not correlate with OS in ccRCC  
Kaplan-Meier plot of cumulative OS in patients in the GSK cohort. OS is defined as the time from 
randomisation to date of death or last follow up in the case of censored patients.  (i) Summary of cases 
included in the analysis (ii) Kaplan-Meier plots of cumulative OS in patients with ccRCC tumours with 
absent/low versus moderate/high Ajuba staining (iii) Estimated means and medians for survival time in 
the two groups. (iv) Comparison of cumulative OS with Log Rank, Breslow and Tarone-Ware Chi-Square 
test in the two groups. All analysis was undertaken using SPSS version 24.  
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4.7.4 On multi-variate analysis, low/absent Ajuba staining does not correlate 
with overall survival  
 
As before multivariate Cox regression analysis adjusting the regression model for KPS 
(KPS<80% or ≥80%), number of metastatic sites at screening (≤2 versus ≥2), 
haemoglobin (<normal/≥ normal), corrected serum calcium (≤10 or >10mg/dl), age 
and sex was undertaken. The adjusted multi-variate analysis demonstrated that loss of 
total staining for Ajuba was not statistically significant HR=1.373 (95% CI 0.774-2.435, 
p=0.279), however the validated prognostic markers of KPS (HR=3.804 (95% CI 
1.817-7.963, p=<0.0001***), corrected calcium ((HR=1.931, (95% CI 1.070-4.553) 
p=0.029*), number of metastatic sites (HR=2.183, (95% CI 1.254-3.802, p=0.006*) 
were statistically significant and correlated as we would predict with worse OS (Figure 
4.15). This demonstrates the validity of the multivariate model and statistical analysis.    
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OS Ajuba staining
Omnibus Tests of Model Coefficients 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-square df Sig. Chi-square df Sig. Chi-square df Sig. 
437.230 40.628 7 .000 32.695 7 .000 32.695 7 .000 
 !
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Event 65 48.9% 
Censored 18 13.5% 
Total 83 62.4% 
Cases dropped Cases with missing 
values 
50 37.6% 
Cases with negative 
time 
0 0.0% 
Censored cases 
before the earliest 
event in a stratum 
0 0.0% 
Total 50 37.6% 
Total 133 100.0% 
 !
(i)
(ii)
(iii)
Risk Factor Significance Hazard Ratio 
(HR) 
95% CI for 
HR (lower) 
95% CI for 
HR (upper) 
KPS (<80% versus >80%) <0.0001 3.804 1.817 7.963 
No of metastatic sites (>2 versus ≤2) 0.006 2.183 1.254 3.802 
Hb <N versus Hb>N 0.056 1.681 0.987 2.857 
Corrected Ca >10 versus ≤10  0.029 1.931 1.070 4.553 
Age 0.100 1.029 0.995 1.064 
Sex 0.779 1.092 0.494 1.697 
No/low Ajuba staining versus 
moderate/high Ajuba staining 
0.279 1.373 0.774 2.435 
 
Figure 4.15 Multi-variate Cox-regression analysis demonstrates that no/absent 
Ajuba staining does not correlate with OS. There is a correlation between OS 
and number of metastatic sites, KPS, and corrected calcium.  
Cox-regression analysis of OS in the GSK cohort was undertaken using SPSS version 24 to include 
nuclear Ajuba staining, age and sex and KPS, number of metastatic sites, haemoglobin and corrected 
calcium (i) The omnibus test of model co-efficient was significant demonstrating that the new model 
offered an improvement over the old model (ii) Of the 133 patients, 83 had complete data for all 
parameters and were therefore included in the analysis. (iii) Results of the Cox-regression analysis.  
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4.7.5 Ajuba staining does not correlate with PFS 
 
The relationship between PFS and staining for Ajuba was examined. Absent/low Ajuba 
staining does not correlate with PFS with an estimated PFS of 59 days versus 72 days 
for patients with moderate/high Ajuba staining in the GSK cohort (Log Rank (Mantel-
Cox) p=0.367) (Figure 4.16). 
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(i)
(ii)
(iii)
Case Processing Summary 
Ajuba nuclear staining Total n n of Events 
Censored 
n Percent 
.00 66 66 0 0.0% 
1.00 34 34 0 0.0% 
Overall 100 100 0 0.0% !
Means and Medians for Survival Time 
Ajuba nuclear 
staining 
Mean Median 
Estimate Std. Error 
95% Confidence Interval 
Estimate Std. Error 
95% Confidence 
Interval 
Lower Bound Upper Bound 
Lower 
Bound 
Upper 
Bound 
.00 113.833 12.198 89.926 137.741 59.000 8.575 42.192 75.808 
1.00 96.000 13.595 69.354 122.646 72.000 29.155 14.857 129.143 
Overall 107.770 9.281 89.579 125.961 62.000 13.077 36.369 87.631 
 !
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox) .812 1 .367 
Breslow (Generalized 
Wilcoxon) 
.345 1 .557 
Tarone-Ware .466 1 .495 !
(iv)
 
Figure 4.16 Loss of Ajuba does not correlate with PFS in ccRCC 
Kaplan-Meier plot of cumulative PFS in patients in the GSK cohort. PFS is defined as the time from 
randomisation to date of death or last follow up in the case of censored patients. (i) Summary of cases 
included in the analysis (ii) Kaplan-Meier plots of cumulative PFS in patients with ccRCC tumours with 
absent/low versus moderate/high Ajuba staining (iii) Estimated means and medians for survival time in 
the two groups. (iv) Comparison of cumulative PFS with Log Rank, Breslow and Tarone-Ware Chi-
Square test in the two groups. All analysis was undertaken using SPSS version 24.  
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4.7.6 Low/absent staining for Ajuba is not statistically significant for PFS on 
multi-variate analysis  
 
Again multivariate Cox Regression analysis for PFS adjusting the regression model for 
the parameters previously described was undertaken. All patients had progressed at the 
cut-off date for PFS analysis and 83 patients were included in each analysis with no 
cases censored. Low/absent Ajuba staining was not statistically significant on multi-
variate analysis for PFS (HR 1.062, 95% CI 0.642-1.754, p=0.815).  Increasing age and 
elevated corrected calcium were associated with shorter PFS, HR 1.049, 95% CI 1.019-
1.080 p=0.001**, and HR 1.730, 95% CI 1.008-2.976, p=0.047* respectively. KPS, 
haemoglobin, the number of metastatic sites and sex did not correlate with PFS (Figure 
4.17)  
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(i)
(ii)
(iii)
Case Processing Summary 
 n Percent 
Cases available in 
analysis 
Event 83 62.4% 
Censored 0 0.0% 
Total 83 62.4% 
Cases dropped Cases with missing 
values 
50 37.6% 
Cases with negative 
time 
0 0.0% 
Censored cases 
before the earliest 
event in a stratum 
0 0.0% 
Total 50 37.6% 
Total 133 100.0% !
Omnibus Tests of Model Coefficients 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-square df Sig. Chi-square df Sig. Chi-square df Sig. 
551.777 27.335 7 .000 23.909 7 .001 23.909 7 .001 
 !
Risk Factor Significance Hazard Ratio 
(HR) 
95% CI for 
HR (lower) 
95% CI for 
HR (upper) 
KPS (<80% versus >80%) 0.051 2.041 0.996 4.183 
No of metastatic sites (>2 versus ≤2) 0.275 0.801 0.801 2.980 
Hb <N versus Hb>N 0.216 1.359 0.836 2.210 
Corrected Ca >10 versus ≤10  0.047 1.730 1.008 2.976 
Age 0.001 1.049 1.019 1.080 
Sex 0.641 1.138 0.661 1.960 
No/low Ajuba staining versus 
moderate/high Ajuba staining 
0.815 1.062 0.642 1.754 
PFS Ajuba staining
 
Figure 4.17 Multi-variate Cox-regression analysis demonstrates that no/absent 
Ajuba staining does not correlate with PFS. There is a correlation between age 
and PFS 
Cox-regression analysis of PFS in the GSK cohort was undertaken using SPSS version 24 to include 
Ajuba nuclear staining, age and sex and KPS, number of metastatic sites, haemoglobin, and corrected 
calcium. (i) The omnibus test of model co-efficient was significant demonstrating that the new model 
offered an improvement over the old model (ii) Of the 132 patients, 83 had complete data available for 
all parameters and were therefore included in the analysis (iii) Results of the Cox-regression analysis.  
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4.8 Correlation of WTIP expression with clinico-pathological indices  
 
WTIP staining was correlated with clinico-pathological outcome data using the TMAs 
generated from the GSK trial. Staining patterns were as described previously with both 
nuclear and cytoplasmic staining observed (Figure 4.18). As before, a TMA consisting 
of histospots derived from a range of pre-invasive/invasive tumours were included as 
positive/negative control as well as gastric tissue as a further positive control. Primary 
antibody was omitted from one of the TMA as a further negative control. All staining 
was reviewed by Professor Sheaff who felt that staining appeared specific and agreed 
that the optimal antibody concentration was as before 1:100. TMAs were double scored 
by Dr Scott Shepherd and myself, blinded to each others scoring and clinico-
pathological outcome data, although agreement on how scoring should be undertaken 
had been reached. Histospots without any tumour were excluded and a score for each 
tumour generated based on the mean staining score for histospots from the same 
tumour as a function of the percentage of positively staining tumour cells and the 
intensity of nuclear staining (scored as before from 0-3) throughout the histospot. 
Separate scoring of both the nuclear and cytoplasmic compartments was undertaken. 
Again, such a system was used in preference to the Ariol automated system to ensure 
consistency with the LIMD1 and Ajuba scoring.  
(i) (ii)
WTIP staining TMA
 
 Figure 4.18 IHC staining of tumour histospots for WTIP 
TMA histospots derived from a phase II clinical trial (GSK trial) were stained immunohistochemically for 
WTIP using an optimised manual staining protocol and WTIP antibody concentration 1:100. Histospots 
were represented on the TMAs in triplicate. (i) Strong cytoplasmic staining for WTIP in ccRCC histospot 
(ii) Strong nuclear WTIP staining in ccRCC histospot. Scale bar corresponding to 200µm is shown for 
size comparison.  
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4.8.1 Intra-class correlation coefficient analysis to assess inter-observer scoring 
agreement for WTIP 
 
Intra-class correlation coefficient analysis to assess inter-observer scoring agreement for 
WTIP was undertaken. Excellent intra-class correlation of 0.972 for single measures 
between the two scorers for cytoplasmic staining was observed (Figure 4.19A) 
suggesting that scoring was robust and reproducible.  
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B(i) (ii)
(iii)
Intraclass correlation coefficient nuclear WTIP
Case Processing Summary 
 N % 
Cases Valid 81 100.0 
Excluded 0 .0 
Total 81 100.0 
 !
Reliability Statistics 
Cronbach's 
Alpha 
N of 
Items 
.985 2 !
Intraclass Correlation Coefficient 
 
Intraclass 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower 
Bound 
Upper 
Bound Value df1 df2 Sig 
Single Measures .961 .913 .980 64.744 79 79 .000 
Average 
Measures 
.980 .955 .990 64.744 79 79 .000 !
A (i) (ii)
(iii) Intraclass Correlation Coefficient 
 
Intraclass 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower 
Bound 
Upper 
Bound Value df1 df2 Sig 
Single Measures .972 .957 .982 70.060 80 80 .000 
Average 
Measures 
.986 .978 .991 70.060 80 80 .000 !
Case Processing Summary 
 N % 
Cases Valid 81 100.0 
Excluded 0 .0 
Total 81 100.0 
 !
 
 
Figure 4.19 Excellent intra-class correlation is observed for WTIP scoring in the 
GSK TMA histospots 
WTIP histospot staining was double scored by Dr Scott Shepherd and by myself, after review by 
Professor Sheath. Histospots containing no tumour were excluded from analysis and only areas of tumour 
scored. Appropriate positive and negative controls were included. Both the proportion of positively 
staining tumour cells and intensity of nuclear staining was scored and a score generated by multiplying the 
intensity of staining by the percentage of tumour cells with positive staining. (i) Scoring undertaken by Dr 
Shepherd and myself was correlated with 81 valid cases included. (ii) Cronbach’s alpha value was 
estimated at 0.986 and 0.985 for cytoplasmic and nuclear staining respectively suggesting excellent internal 
consistency. (iii) The intra-class correlation coefficient for average measures was 0.986 and 0.980, 
respectively for cytoplasmic and nuclear staining respectively indicating excellent agreement between 
scoring.  
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4.8.2 WTIP staining and correlation with overall survival 
 
Next the relationship between WTIP staining and overall patient survival was examined.  
A mean score for nuclear and cytoplasmic staining in each tumour based on the mean 
score throughout the histospots derived from the same tumour was calculated. 
Tumours were sub-divided into those with absent/low WTIP staining (score ≤100) 
versus those with moderate/high nuclear WTIP staining (score >100). Again, analysis 
using alternative cutoffs for high versus low staining, e.g. score less than the median 
versus score greater than the median did not change the outcome of statistical analysis 
and to ensure consistency with the LIMD1 and WTIP data, univariate analysis was 
undertaken subdividing tumours using these cutoffs.  
 
For the cytoplasmic staining, a total of 97 patients were included in the analysis, 22 
results were censored, (patients lost to follow up or still alive at time of last follow up).  
 
Absent/low cytoplasmic WTIP staining did not correlate with OS in the GSK cohort.  
The median estimated OS in patients with tumours with absent/low cytoplasmic WTIP 
staining was 322 days compared to 362 days in patients with tumours with 
moderate/high WTIP staining (Log-rank p=0.138) (Figure 4.20). For nuclear WTIP 
staining, the median estimated OS in patients with tumours with absent/low 
cytoplasmic WTIP staining was 362 days compared to 338 days in patients with tumours 
with moderate/high nuclear WTIP staining (log-rank p=0.453) (Figure 4.21).  
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Case Processing Summary 
WTIP 0-1 
versus>1 Total n 
n of 
Events 
Censored 
n Percent 
.00 31 21 10 32.3% 
1.00 66 54 12 18.2% 
Overall 97 75 22 22.7% !
Means and Medians for Survival Time 
Cytoplasmic WTIP 
0-1 versus>1 
Mean Median 
Estimate Std. Error 
95% Confidence Interval 
Estimate Std. Error 
95% Confidence Interval 
Lower 
Bound Upper Bound 
Lower 
Bound 
Upper 
Bound 
.00 583.463 104.283 379.067 787.858 322.000 130.413 66.390 577.610 
1.00 392.138 33.946 325.604 458.673 362.000 40.773 282.085 441.915 
Overall 451.299 43.281 366.468 536.130 351.000 53.988 245.184 456.816 
 !
(i)
(ii)
(iii)
 
Overall Comparisons 
 
Chi-
Square df Sig. 
Log Rank (Mantel-
Cox) 
2.198 1 .138 
Breslow 
(Generalized 
Wilcoxon) 
.012 1 .913 
Tarone-Ware .358 1 .550 !
(iv)
 
Figure 4.20 Loss of cytoplasmic WTIP does not correlate with OS in ccRCC  
Kaplan-Meier plot of cumulative OS in patients in the GSK cohort. OS is defined as the time from 
randomisation to date of death or last follow up in the case of censored patients.  (i) Summary of cases 
included in the analysis (ii) Kaplan-Meier plots of cumulative OS in patients with ccRCC tumours with 
absent/low versus moderate/high WTIP staining (iii) Estimated means and medians for survival time in 
the two groups. (iv) Comparison of cumulative OS with Log Rank, Breslow and Tarone-Ware Chi-Square 
test in the two groups. All analysis was undertaken using SPSS version 24.  
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(i)
(ii)
(iii)
Case Processing Summary 
Nuclear WTIP 0 
versus 1 Total n 
n of 
Events 
Censored 
n Percent 
.00 58 46 12 20.7% 
1.00 36 27 9 25.0% 
Overall 94 73 21 22.3% !
Means and Medians for Survival Time 
Nuclear WTIP 0 
versus 1 
Mean Median 
Estimate Std. Error 
95% Confidence Interval 
Estimate Std. Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
.00 474.780 58.540 360.041 589.519 362.000 55.070 254.063 469.937 
1.00 390.244 49.988 292.267 488.221 338.000 48.836 242.282 433.718 
Overall 447.377 43.346 362.419 532.335 345.000 52.965 241.188 448.812 
 !
 
Overall Comparisons 
 
Chi-
Square df Sig. 
Log Rank (Mantel-
Cox) 
.562 1 .453 
Breslow 
(Generalized 
Wilcoxon) 
.050 1 .822 
Tarone-Ware .199 1 .655 
 !
(iv)
 
Figure 4.21 Loss of nuclear WTIP does not correlate with OS in ccRCC  
 
Kaplan-Meier plot of cumulative OS in patients in the GSK cohort. OS is defined as time from 
randomisation to death or date of last follow up in the case of censored patients. (i) Summary of cases 
included in the analysis (ii) Kaplan-Meier plots of cumulative OS in patients with ccRCC tumours with 
no/low total nuclear WTIP staining versus OS in patients with tumours with no/low nuclear WTIP 
staining, (ii) Estimated means and medians for OS in the two groups. A (iii) Comparison of cumulative 
OS with Log Rank, Breslow and Tarone-Ware Chi-Square test in the two groups. All analysis was 
undertaken using SPSS version 24.  
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4.8.3 Correlation of cytoplasmic WTIP staining and OS 
 
Multivariate Cox regression analysis adjusting the OS regression model for KPS 
(KPS<80% versus ≥80%), number of metastatic sites at screening (≤2 versus ≥2), 
haemoglobin (<normal versus≥ normal), corrected serum calcium (≤10 versus 
>10mg/dl), age and sex was undertaken. Interestingly, the adjusted multi-variate 
analysis demonstrated that absent/low level cytoplasmic staining for WTIP was 
associated with longer survival (HR=0.438, 95% CI 0.222-0.862, p=0.017*), in contrast 
to the univariate model where survival was similar between the groups of patients with 
no/low and moderate/high cytoplasmic staining. Again, the validated prognostic 
markers of KPS (HR=3.367, 95% CI 1.538-7.371, p=0.002**), corrected calcium 
(HR=1.247, 95% CI 1.093-3.521, p=0.024*), number of metastatic sites (HR=1.852, 
95% CI 1.247-3.322, p=0.039*) and Hb<N (HR 2.088, 95% CI 1.199-3.636, p=0.009**) 
correlated with worse OS as we would predict, again demonstrating the validity of the 
statistical analysis and multivariate model (Figure 4.22).  
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Case Processing Summary 
 n Percent 
Cases available in 
analysis 
Event 61 45.9% 
Censored 19 14.3% 
Total 80 60.2% 
Cases dropped Cases with missing 
values 
53 39.8% 
Cases with negative 
time 
0 0.0% 
Censored cases 
before the earliest 
event in a stratum 
0 0.0% 
Total 53 39.8% 
Total 133 100.0% !
Omnibus Tests of Model Coefficients 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-square df Sig. Chi-square df Sig. Chi-square df Sig. 
400.469 43.231 7 .000 36.347 7 .000 36.347 7 .000 
 !
(i)
(ii)
(iii)
Risk Factor Significance Hazard Ratio 
(HR) 
95% CI for 
HR (lower) 
95% CI for 
HR (upper) 
KPS (<80% versus >80%) 0.002 3.367 1.538 7.371 
No of metastatic sites (>2 versus ≤2) 0.039 1.852 1.247 3.322 
Hb <N versus Hb>N 0.009 2.088 1.199 3.636 
Corrected Ca >10 versus ≤10  0.008 1.247 1.247 4.444 
Age 0.070 1.030 0.998 1.063 
Sex 0.580 0.839 0.452 1.559 
Absent/low cytoplasmic WTIP 
staining versus moderate/high 
cytoplasmic WTIP staining 
0.017 0.438 0.222 0.862 
Variables in the Equation 
 B SE Wald df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
Lower Upper 
Haemoglobin at time 
of randomisation 
-.737 .283 6.757 1 .009 .479 .275 .834 
Ca at time of 
randomisation 
-.855 .324 6.978 1 .008 .425 .225 .802 
Karnofsky 
Performance status 
1.214 .400 9.221 1 .002 3.367 1.538 7.371 
Number of metastatic 
sites 
-.616 .299 4.249 1 .039 .540 .301 .970 
Age at randomisation -.029 .016 3.287 1 .070 .971 .941 1.002 
Male/female -.175 .316 .307 1 .580 .839 .452 1.559 
Cytoplasmic WTIP 0-
1 versus>1 
-.826 .346 5.699 1 .017 .438 .222 .862 !
 
 
Figure 4.22 Multi-variate Cox-regression analysis demonstrates that absent/low 
cytoplasmic WTIP staining correlates with OS.  
 
Cox-regression analysis of OS in the GSK cohort was undertaken using SPSS version 24 to include 
LIMD1 staining, age nd sex and KPS, number of metastatic sites, haemoglobin, and corrected calcium. 
(i) The omnibus test of odel co-efficient was significant demonstrating that the new model offered an 
improvement over the old model (ii) Of the 133 patients, 80 patients had complete data available for all 
parameters and were therefore included in the analysis, 0 patients were censored. (iii) Results of the Cox-
regression analysis. 
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4.8.4 Correlation of nuclear WTIP staining and OS  
 
Multivariate Cox regression analysis for nuclear WTIP staining and OS was undertaken, 
adjusting the regression model for the parameters previously described. This 
demonstrated that absent/low nuclear WTIP staining did not correlate with OS (HR 
1.441, 95% CI 0.822-2.532, p=0.202), however the validated MSKCC components of 
KPS, Haemoglobin and elevated corrected calcium were significantly associated with 
worse OS (Figure 4.23).  
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(i)
(ii)
(iii)
 
Omnibus Tests of Model Coefficients 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-square df Sig. Chi-square df Sig. Chi-square df Sig. 
400.469 43.231 7 .000 36.347 7 .000 36.347 7 .000 
 
 !
nuclear WTIP and OS
Case Processing Summary 
 N Percent 
Cases available in 
analysis 
Event 61 45.9% 
Censored 19 14.3% 
Total 80 60.2% 
Cases dropped Cases with missing 
values 
53 39.8% 
Cases with negative 
time 
0 0.0% 
Censored cases 
before the earliest 
event in a stratum 
0 0.0% 
Total 53 39.8% 
Total 133 100.0% 
 !
 
 
Figure 4.23 Multi-variate Cox-regression analysis demonstrates that absent/low 
nuclear WTIP staining does not correlate with OS.  
Cox-regression analysis of OS in the GSK cohort was undertaken using SPSS version 24 to include 
LIMD1 staining, age and sex and KPS, number of metastatic sites, haemoglobin, and corrected calcium 
which are components of the validated MSKCC score for predicting OS in metastatic RCC. (i) The 
omnibus test of model co-efficient was significant demonstrating that the new model offered an 
improvement over the old model (ii) Of the 133 patients, 80 patients had complete data available for all 
parameters and were therefore included in the analysis, no patients were censored. (iii) Results of the 
Cox-regression analysis.  
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4.8.5 Correlation of cytoplasmic and nuclear WTIP staining and PFS 
 
Cox regression analysis was undertaken adjusting the regression model for the 
parameters described. In the adjusted multivariate model, this demonstrated that neither 
absent/low cytoplasmic nor absent/low nuclear WTIP staining was associated with 
differences in PFS compared to moderate/high expression, HR=1.245, 95% CI 0.701-
2.214, p=0.455 and HR=0.800, 95% CI 0.497-1.287, p=0.358 respectively. Elevated 
corrected calcium and increasing age were statistically significant in both multivariate 
models (Figures 4.24 and 4.25)  
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(i)
(ii)
(iii)
Omnibus Tests of Model Coefficients 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-square df Sig. Chi-square df Sig. Chi-square df Sig. 
528.115 23.797 7 .001 20.874 7 .004 20.874 7 .004 !
Case Processing Summary 
 n Percent 
Cases available in 
analysis 
Event 80 60.2% 
Censored 0 0.0% 
Total 80 60.2% 
Cases dropped Cases with missing 
values 
53 39.8% 
Cases with negative 
time 
0 0.0% 
Censored cases 
before the earliest 
event in a stratum 
0 0.0% 
Total 53 39.8% 
Total 133 100.0% 
 !
Risk Factor Significance Hazard Ratio 
(HR) 
95% CI for 
HR (lower) 
95% CI for 
HR (upper) 
KPS (<80% versus >80%) 0.071 2.018 0.942 4.322 
No of metastatic sites (>2 versus ≤2) 0.211 1.391 0.830 2.331 
Hb <N versus Hb>N 0.308 1.297 0.787 2.138 
Corrected Ca >10 versus ≤10  0.024 1.961 1.093 3.521 
Age 0.010 1.040 1.009 1.070 
Sex 0.865 1.048 0.609 1.801 
No/low cytoplasmic WTIP staining 
versus moderate/high cytoplasmic 
WTIP staining 
0.455 1.245 0.701 2.214 
 
Figure 4.24 Multi-variate Cox-regression analysis demonstrates that absent/low 
cytoplasmic WTIP staining does not correlate with PFS. There is a correlation 
between age and PFS 
Cox-regression analysis of PFS in the GSK cohort was undertaken using SPSS version 24 to include 
cytoplasmic WTIP staining, age and sex and KPS, number of metastatic sites, haemoglobin, and corrected 
calcium. (i) The omnibus test of model co-efficient was significant demonstrating that the new model 
offered an improvement over the old model (ii) Of the 133 patients, 80 had complete data available for 
all parameters and were therefore included in the analysis, no patients were censored. (iii) Results of the 
Cox-regression analysis.  
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Case Processing Summary 
 n Percent 
Cases available in 
analysis 
Event 77 57.9% 
Censored 0 0.0% 
Total 77 57.9% 
Cases dropped Cases with missing 
values 
56 42.1% 
Cases with negative 
time 
0 0.0% 
Censored cases 
before the earliest 
event in a stratum 
0 0.0% 
Total 56 42.1% 
Total 133 100.0% !
Omnibus Tests of Model Coefficients 
-2 Log 
Likelihood 
Overall (score) Change From Previous Step Change From Previous Block 
Chi-square df Sig. Chi-square df Sig. Chi-square df Sig. 
502.612 23.013 7 .002 20.071 7 .005 20.071 7 .005 !
(i)
(ii)
(iii)
Risk Factor Significance Hazard Ratio 
(HR) 
95% CI for 
HR (lower) 
95% CI for 
HR (upper) 
KPS (<80% versus >80%) 0.076 2.024 0.930 4.406 
No of metastatic sites (>2 versus ≤2) 0.254 1.353 0.805 3.631 
Hb <N versus Hb>N 0.415 1.236 0.743 2.055 
Corrected Ca >10 versus ≤10  0.042 1.767 1.020 3.067 
Age 0.012 1.039 1.007 1.008 
Sex 0.996 1.002 0.562 1.788 
No/low nuclear WTIP staining versus 
moderate/high nuclear WTIP staining 
0.358 0.800 0.497 1.287 
 
 
Figure 4.25 Multi-variate Cox-regression analysis demonstrates that absent/low 
nuclear WTIP staining does not correlate with PFS. There is a correlation 
between age and PFS 
Cox-regression analysis of OS in the GSK cohort was undertaken using SPSS version 24 to include WTIP 
staining, age and sex and KPS, number of metastatic sites, haemoglobin, and corrected calcium. (i) The 
omnibus test of model co-efficient was significant demonstrating that the new model offered an 
improvement over the old model (ii) Of the 133 patients, 77 had complete data available for all 
parameters and were therefore included in the analysis, no patients were censored. (iii) Results of the 
Cox-regression analysis.  
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4.9 Staining of the TMAs for other hypoxically regulated proteins 
 
The tumour suppressor VHL is a key component of an ubiquitin-ligase complex, 
targeting HIF1α for ubiquitylation and degradation. VHL loss is an early event that is 
near ubiquitous in both hereditary and sporadic ccRCC (Gossage, Eisen et al. 2015). 
Kroeger et al found that that high HIF2α nuclear expression was associated with lower 
grade and stage ccRCC tumours, whilst high cytoplasmic HIF2α was associated with a 
more aggressive ccRCC phenotype.  Such tumours were also more likely to have 
positive lymph nodes and distant metastases (Kroeger, Seligson et al. 2014).  HIF1α is 
frequently over-expressed in ccRCC and although Lidgren et al reported that high 
HIF1α expression in ccRCC was associated with better prognostic indicators, other 
studies have demonstrated worse survival in association with elevated HIF1α (Lidgren, 
Hedberg et al. 2005) (Minardi, Lucarini et al. 2015). Given the critical role of LIMD1 in 
the regulation of the hypoxic response and the contribution of HIF in driving 
tumourigenesis in ccRCC, the GSK ccRCC TMA was stained for VHL, HIF1α and 
HIF2α and staining correlated with staining for LIMD1 
4.9.1 VHL staining of control normal kidney tissue and ccRCC tissue 
 
In order to assess the specificity of the VHL antibody and determine an optimal 
antibody concentration for subsequent staining of the ccRCC TMAs, normal kidney 
tissue was stained using the automated Ventana discovery system with antigen 
visualisation using the avidin-biotin peroxidase method. VHL staining was felt to be 
specific and as expected stained the cytoplasm of the proximal and distal tubules with 
little staining of the glomeruli. After review by Dr Giorgia Trevisan, an antibody 
concentration of 1:100 was felt to give the best staining resolution without unacceptable 
background staining. In addition the TMA containing a range of pre-invasive and 
malignant histospots was stained in order to check expected staining patterns prior to 
staining the ccRCC TMAs. Normal renal tissue and the control TMA described were 
used as positive controls and the primary antibody omitted when staining one of the 
TMAs as a negative control. Of the 120-ccRCC samples, ten, 8.3% demonstrated VHL 
staining (Figure 4.26). As the proportion of tumour samples demonstrating staining for 
VHL was so low, it was not possible to correlate staining for VHL with that of other 
LAW proteins.  
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(i) (ii)
(iii)
VHL staining, normal, ccRCC control
 
Figure 4.26: VHL staining of control normal kidney tissue and ccRCC tissue 
IHC was undertaken using a semi-automated system with VHL antibody concentration 1:100 
(Discovery, Ventana Medical Systems, Tucson AZ), with visualisation using the Avidin-biotin 
peroxidase method. (i) paraffin embedded normal kidney tissue with staining of the proximal and distal 
tubules but no staining of the glomerulus, (ii) ccRCC histospot demonstrating strong positive cytoplasmic 
staining, (iii) ccRCC histospot demonstrating negative staining  
4.9.2 HIF-2α staining of normal kidney and clear cell renal cell carcinoma 
 
IHC for HIF2α was performed using the automated Ventana Discovery system. As 
before the tissue microarray containing a range of pre-invasive/malignant histospots 
was stained in order to establish antibody specificity/confirm expected staining patterns 
and placental tissue also stained as a further control tissue. Staining was reviewed by Dr 
Giorgia Trevisan and felt to be specific, with no staining of the kidney glomeruli and 
positive cytoplasmic and nuclear staining in the proximal and distal convoluted tubules 
as expected (Figure 4.27). An antibody concentration of 1:100 was felt to provide the 
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greatest specificity and allow the discrimination of differences in staining 
intensity/pattern with little associated non-specific staining.  
 
Figure 4.27.  HIF2α staining of normal kidney tissue and ccRCC 
IHC for HIF2α was undertaken using a semi-automated system (Discovery, Ventana Medical Systems, 
Tucson AZ), with antibody concentration 1:100 and visualisation using the Avidin-biotin peroxidase 
method. (i) Paraffin embedded normal kidney tissue stained with HIF2α demonstrating cytoplasmic 
staining and strong nuclear staining of the tubules. (ii) Paraffin embedded ccRCC tumour demonstrating 
strong nuclear and cytoplasmic HIF2α staining. (iii) Paraffin embedded ccRCC demonstrating weak 
patchy cytoplasmic and nuclear staining. (iv) Paraffin embedded HIF2α demonstrating neither 
cytoplasmic nor nuclear staining.  
 
Representative cytoplasmic and nuclear HIF2α staining in ccRCC tissue is shown in 
(Figure 4.27). Unfortunately, staining of the TMAs for HIF2α using the Novus 
Biologicals antibody was only successful if staining was undertaken immediately after 
the paraffin embedded sections were cut as it appeared that HIF2α antigen degradation 
was taking place. One of the TMAs had been sectioned in its entirety and therefore only 
two out of the three TMA slides could be stained. The TMAs were scored by Dr 
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Trevisan. The degree of reactivity was evaluated using a 3-point scale (0=negative, 
1=positive, 2=strongly positive) and the percentage of tumour cells staining recorded. 
As before a mean score for staining was calculated based on the mean staining of all 
histospots derived from the same tumour. Given the findings of Kroeger et al, that sub-
cellular HIF-2α localisation impacts on cancer-specific survival and tumour 
characteristics, cytoplasmic and nuclear HIF2α staining were scored separately and 
correlated with LIMD1 staining (Kroeger, Seligson et al. 2014).  
 
Positive nuclear HIF2α staining was seen in 37 of the 73-ccRCC tumours evaluable 
(51%) and positive cytoplasmic staining in 38 of the 73-ccRCC tumours evaluable 
(52%). Of the tumours that expressed HIF2α in the cytoplasm, 31/38 (82%) had 
concomitant nuclear HIF2α staining and of the tumours that expressed HIF2α in the 
nucleus, 32/37 (86%) had concomitant cytoplasmic HIF2α staining.  
 
For each tumour, the mean score for cytoplasmic and nuclear HIF2α staining was 
correlated with the mean score for LIMD1 staining using a manual scoring system. 
Calculation of the two-tailed Spearman correlation demonstrated no association 
between cytoplasmic HIF2α staining and LIMD1 (p=0.5077) nor was a correlation 
between nuclear HIF2α staining and staining for LIMD1 observed (p=0.6533). (Figure 
4.28). In addition, there was no correlation between cytoplasmic or nuclear HIF2α 
staining and Ajuba staining, nor with WTIP staining, data for which is not shown. 
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Figure 4.28 Correlation of HIF2α and LIMD1 staining 
Mean HIF2α staining for all histospots from the same tumour as a function of staining intensity and 
proportion of tumour cells staining positively was plotted against mean LIMD1 staining. (i) Mean 
cytoplasmic HIF2α staining plotted again mean LIMD1 staining (ii) mean nuclear HIF2α staining plotted 
against mean LIMD1 staining. All analysis was undertaken in Prism 6. The two-tailed Spearman 
correlation is shown. 
4.9.3 HIF1α  staining of normal kidney and clear cell renal cell carcinoma 
 
IHC for HIF1α using the automated Ventana system was unsuccessful and manual IHC 
was undertaken using an optimised protocol. After staining healthy renal tissue, placenta 
and tonsil tissue with a range of antibody dilution, optimal HIF1α antibody 
concentration was defined as 1:100. Staining in the RCC samples was predominantly 
cytoplasmic although some nuclear staining was observed. All staining was reviewed by 
Dr Giorgia Trevisan and felt to be specific.  
  Chapter 4: Results   
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Figure 4.29 HIF1α staining of placenta, ccRCC and renal tissue 
RCC samples represented in triplicate on tissue microarrays were stained using a manual IHC protocol using HIF1α 
antibody concentration 1:100, with visualisation using the Avidin-biotin peroxidase method. (i) Placenta tissue was 
included as a positive control (ii) ccRCC tumour demonstrating cytoplasmic HIF1α staining, (iii) HIF1α staining in 
renal tissue, with both cytoplasmic and nuclear staining  
 
A total of 110 ccRCC tumours were scorable, with 20 (18%) demonstrating nuclear 
staining and 35 (32%) cytoplasmic staining. Generally, more cytoplasmic than nuclear 
staining was observed. As before, a mean score per tumour was calculated as a function 
of the mean staining intensity throughout the histospots from the same tumour and 
percentage of tumour cells staining positively, all scoring was undertaken by Dr 
Trevisan and endothelial cells were not scored.  
 
All tumours with positive nuclear staining had only low levels of staining detectable and 
generally only in a small proportion of tumour cells: in tumours with positive HIF1α 
staining the mean nuclear staining of the tumours was 10% which is less than that 
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observed by other investigators (Ioannou, Mylonis et al. 2010). Staining for LIMD1 and 
both cytoplasmic and nuclear HIF1α was correlated.  
 
Calculation of the two-tailed Spearman correlation demonstrated no association 
between cytoplasmic HIF1α staining and LIMD1 (p=0.0974) nor correlation between 
nuclear HIF1α staining and staining for LIMD1 (p=0.635) (Figure 4.30). However, as 
described the number of tumours staining positively for HIF1α particularly in the 
nuclear compartment was less than might have been expected and immunoassay for 
HIF1α can be difficult with specificity issues and variability in sensitivity with the use of 
different antibodies (Ioannou, Mylonis et al. 2010). There was no correlation between 
staining for Ajuba nor for WTIP and HIF1α staining, data for which is not shown.  
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Figure 4.30 Correlation of HIF1α and LIMD1 staining 
Mean HIF1α staining for all histospots from the same tumour as a function of staining intensity and 
proportion of tumour cells staining positively was plotted against mean LIMD1 staining. (i) Mean 
cytoplasmic HIF1α staining plotted again mean LIMD1 staining (ii) mean nuclear HIF1α staining plotted 
against mean LIMD1 staining. All analysis was undertaken in Prism 6. The two-tailed Spearman 
correlation is shown 
 !
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4.10 Summary 
 
Barts Cancer Institute forms part of The Experimental Cancer Medicine Network, a 
network that aims to facilitate the translation of basic scientific discovery into an 
understanding of what drives tumourigenesis and resistance to therapeutics in vivo as 
well as develop novel treatments for patients with cancer. Access to patient tissue from 
two prospective clinical trials with detailed five-year clinico-pathological outcome data 
represents a very valuable resource.  
 
LIMD1, Ajuba and WTIP IHC staining were undertaken in ccRCC TMAs generated 
from a prospective phase II clinical trial of the EGFR-2 tyrosine kinase inhibitor 
lapatinib versus hormone therapy in patients who had progressed through first line 
cytokine therapy. Histospots were double scored by observers blinded to clinico-
pathological outcome data and each other’s scores, to ensure that scoring was valid and 
reliable. Excellent intra-class correlation between scorers was observed.  For each 
patient an overall score was calculated based on the mean staining of all tumour 
histospots derived from that patient. For each of the three LAW proteins, tumours were 
divided into those expressing absent/low protein levels and those expressing 
moderate/high protein levels.  
  
Often in studies investigating potential biomarkers, univariate and multivariate analysis 
is not undertaken. Therefore, for all three proteins, OS and PFS was correlated with 
levels of LIMD1, Ajuba and WTIP and in the multivariate analysis, the model modified 
to incorporate age, sex and components of the MSKCC score, a validated scoring 
system for OS in mccRCC. The clinical trial investigators also used these parameters in 
their multivariate analysis (Ravaud, Hawkins et al. 2008).  
 
Tumour stage and grade were correlated with levels of LIMD1 staining and Ajuba 
staining. An association between loss of Ajuba staining and tumour stage was observed 
but no correlation between LIMD1 staining and tumour grade or stage and Ajuba 
staining and tumour stage.  In both univariate and multivariate analysis, levels of 
LIMD1, Ajuba and WTIP did not correlate with OS or PFS. On multivariate analysis, 
components of the MSKCC score and increasing age correlating with OS, 
demonstrating the validity of the multivariate model. On multivariate analysis, increasing 
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age also corresponded with reduced PFS. The correlation of LIMD1 staining and OS 
and PFS, was assessed using a further cohort of patients enrolled in a clinical trial 
investigating the role of upfront pazopanib prior to nephrectomy in patients with 
mccRCC. Again no correlation between LIMD1 staining levels and OS or PFS was 
observed.  
 
Hypoxic deregulation is a critical mediator of tumourigenesis in ccRCC and LAW 
proteins, in particular LIMD1 have been shown to play a critical role in the regulation of 
HIF1α levels. TMA histospots were therefore stained for the hypoxic markers, HIF1α, 
HIF2α and VHL and staining correlated with LIMD1 levels. No correlation was 
observed between staining for LIMD1/Ajuba/WTIP and HIF1α nor HIF2α.  
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4. 11 Discussion 
 
4.11.1 IHC staining of ccRCC clinical trial TMAs 
 
Staining for LIMD1 was re-optimised using an automated protocol, as manual IHC 
staining was no longer effective when performed with a new batch of antibody. This 
established very similar staining in a range of normal tissues/tumours and in ccRCC 
samples to that observed using the initial staining protocol, such that LIMD1 staining in 
the trial ccRCC TMAs was felt to be specific and valid. IHC protocol re-optimisation 
was not necessary when staining the trial ccRCC TMAs for Ajuba and WTIP as staining 
was consistent with that observed previously.  Difficulties in the establishment of 
antibody specificity for IHC particularly for antigens not previously characterised is 
discussed in Chapter 3.   
 
4.11.2 Correlating TMA staining with clinico-pathological outcome data 
 
The use of TMAs for IHC analysis provides a number of advantages but there are 
limitations to such an approach. TMAs allow for the simultaneous, high-throughput 
analysis of multiple specimens that have been processed in the same manner and 
subjected to the same experimental conditions.  Samples are therefore directly 
comparable and scoring between samples can be compared in a semi-quantitative way 
(Barrette, van den Oord et al. 2014). If cores are taken from pathologist-identified 
regions of interest as was the case for the TMAs described, staining can be reliably 
scored by individuals without expert training in pathology (Camp, Neumeister et al. 
2008). Limited tissue is required for each TMA spot, of particular benefit in a clinical 
trial setting where multiple potential biomarkers may be stained and archived 
‘remaining’ tissue, often limited in its availability is frequently used (Barrette, van den 
Oord et al. 2014). 
 
Ideally TMAs should include multiple samples of the same tumour taken from as many 
histologically divergent sites as possible and such an approach can potentially overcome 
limitations associated with tumour heterogeneity, (Jensen, Riber-Hansen et al. 2011).  
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Intra-tumoural heterogeneity in ccRCC has been well characterised and represents an 
important potential barrier in the identification of tumour biomarkers (Fisher, Larkin et 
al. 2012) (Gulati, Martinez et al. 2014). In practice obtaining tissue from multiple 
tumour sites is not always possible, nor is it feasible or often appropriate to re-biopsy 
patients where tissue availability is limited. Insufficient samples from known spatially 
separated tumour regions represented in the PANTHER TMA were included as most 
of the tissue from the biopsy samples had been used up for the initial trial analysis and 
therefore assessment of inter-tumour heterogeneity for LIMD1 was not possible. 
 
 In our analysis, histospots were included in duplicate or triplicate, enabling the 
calculation of a mean score for staining and given the small size of the spots, minimising 
error in scoring. Since all TMAs were stained simultaneously for each marker, 
differences in staining intensity in association with variable haematoxylin 
counterstaining which can affect the interpretation of staining were overcome.  In 
addition, the intra-class scoring correlation was used to demonstrate that there was 
excellent consistency between independent scorers and that IHC scores were therefore 
valid for analysis. Scorers were also blinded to clinico-pathological outcome data to 
minimise the likelihood for conscious or unconscious bias 
 
Where possible TMA blocks were freshly cut prior to IHC staining although this was 
not possible for one TMA block in the GSK cohort where the block had been cut in its 
entirety. We were therefore unable to stain one of the three TMA slides for HIF-2α, as 
antigen degradation appeared to have occurred and staining for HIF2α in this slide was 
consistently negative. The loss of antigenicity in TMA FFPE tissue sections negatively 
impacts on staining validity (Yaziji and Barry 2006). Retention of endogenous water in 
tissue sections results in antigen degradation, as does exposure to high humidity during 
storage (Xie, Chung et al. 2011). Optimal tissue processing and storage is therefore 
essential. All TMA blocks were appropriately stored and processed with adherence to 
trial protocol Good Laboratory Practice (GLP). Although TMAs were created at the 
same time, they were predominantly derived from archived tumour samples of varying 
ages, many of which are likely to have been processed in different laboratories, where 
sample processing may not have been standardised. Nonetheless all hospital laboratories 
should adhere to GLP standards and practices should be similar. A recent European 
white paper on retrospective studies using archived tissues concluded that 
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improvements in tissue preservation and storage methods which standardised the 
degree of molecular degradation alongside standard operating processes make the use of 
archived tissue a valuable and acceptable approach within clinical trials. 
 
4.11.3 Using archived tissue for correlation with clinico-pathological outcome 
data 
Analysis of multiple tumour regions in primary ccRCC samples and metastatic sites 
reveals substantial intra-tumour heterogeneity with spatially separated sub-clones 
associated with distinct driver mutations and somatic copy number alterations 
(Gerlinger, Rowan et al. 2012, Gerlinger, Catto et al. 2015). Therefore as ccRCC 
tumours develop and metastasise, significant differences in tumour genotype/phenotype 
may be observed. Using archived tumour tissue for prognostic/predictive biomarker 
correlation may therefore not be representative of the tumour genotype/phenotype at 
the time of study enrolment, the time point at which PFS/OS correlation is undertaken. 
In the PANTHER cohort, tumour samples were either biopsy specimens taken at the 
point of clinical trial enrolment or at nephrectomy after neo-adjuvant pazopanib and 
therefore the issue of variation in length of time between tumour archive and study 
enrolment in patients was overcome. This was not the case for patients enrolled in the 
Phase II trial comparing lapatinib with hormonal treatment where time between study 
enrolment and tumour archive is likely to be highly variable. Most clinical studies do 
however make use of archived tissue and use of such tissue is felt to be valid in such 
analyses (Simon, Paik et al. 2009).  
 
Simon et al propose a number of guidelines for biomarker study design using archived 
specimens and where possible these guidelines were followed. They stipulate that 
adequate amounts of archived tissue from sufficient patients are available to adequately 
power statistical analysis (this was the case for our study), that the potential biomarker 
should be analytically and pre-analytically validated for use with archived tissue (LIMD1 
and Ajuba staining had been validated in previous studies using archived tissue) 
(Spendlove, Al-Attar et al. 2008, Shi, Chen et al. 2016)), that the plan for biomarker 
evaluation should be specified prior to the performance of biomarker assays on archived 
tissue (this was not the case) and in addition results should be validated using specimens 
from one or more similar studies (the staining for the GSK cohort was validated using 
the PANTHER tissue) (Simon, Paik et al. 2009).  
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4.11.4 Defining cutoffs for potential biomarkers 
 
Defining appropriate cutoffs for potential biomarkers is an essential but difficult aspect 
of biomarker assessment. IHC is generally quantified using an ordinal scale using the 
percentage of stained tumour cells, staining intensity or a combination of both 
parameters such as the Allred score (Allred, Clark et al. 1993, Harvey, Clark et al. 1999), 
although automated quantitative systems such as the Ariol system may also be used for 
quantification (Bolger, Heffron et al. 2006) and such systems are discussed in Chapter 3.  
 
In order to translate a continuous or ordinal diagnostic variable in to a meaningful 
stratification, appropriate cutoff determination is necessary (Mazumdar and Glassman 
2000). For the initial IHC described in chapter 3, the TMAs were scored using an 
automated Ariol system and a score generated for IHC comparison. Scanning the 
clinical trial TMAs however did not seem to correlate well with the manual scores, 
perhaps as the histospots, particularly in the GSK cohort were small and some 
histospots were not intact. In addition, some background staining was present in some 
histospots, which could be overlooked when scoring was undertaken manually. 
Automated analysis and expert pathologist scoring is considered to be equivalent 
(Turbin, Leung et al. 2008).    
 
For this analysis, a manual scoring system generating a combined score for each tumour 
was used based on the mean staining for all histospots derived from the tumour and 
where appropriate scoring both nuclear and cytoplasmic compartments separately using 
validated scoring systems were possible. Patients were then stratified in to those with 
no/low staining versus moderate/high staining. Spendlove et al used a similar 
stratification in their breast cancer cohort for LIMD1 staining with absent/weak nuclear 
LIMD1 staining strongly correlated with adverse prognostic indicators (Sharp, Al-Attar 
et al. 2008) and scoring system was based on this published scoring system. 
  
Using mean or median values for defining cut-offs is frequently described (Budczies, 
Klauschen et al. 2012). Re-analysis of the correlation of low versus high staining for 
LAW proteins with clinico-pathological outcome data when cutoffs were changed, e.g. 
characterising low staining as staining less than the median was not possible as staining 
scores were too clustered. In addition when patients were stratified using a greater 
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number of staining intensities, for example stratifying patients in to four groups, too few 
samples for some staining intensities were included for data analysis to be meaningful. 
For Ajuba and WTIP staining where scores were less clustered, changing the cut offs 
e.g. to less than the median versus greater than the median did not change the outcome 
of the analysis, suggesting that this was a true result.    
 
Other methods for cut-off determination are described in the literature, and underlying 
algorithms for determining such cut-offs are often unclear (Budczies, Klauschen et al. 
2012). Established methods frequently involve the use of receiver operating 
characteristic (ROC) curves, a graphical plot that illustrates the performance of a binary 
classifier system as its discrimination threshold is varied, generally by minimising p 
values, or techniques to maximise combinations of test sensitivity and specificity using 
area under the curve calculations (Perkins and Schisterman 2006). X-tile is a validated 
software tool application, specialised to the analysis of survival data, which makes use of 
a minimal p-value approach for cut-off optimisation (Camp, Dolled-Filhart et al. 2004). 
Specifically, it generates plots that provide an assessment of every possible way of 
dividing a population into low, medium and high-level marker expression and showing 
the resulting population subsets alongside an associated Kaplan-Meier curve. Such 
analysis can provide additional information about the biological nature of a marker, such 
as whether there is a linear distribution related to survival. Given that it is statistically 
invalid to test multiple divisions and accept the best P value, initial divisions are defined 
in a ‘training set’ and then a separate patient cohort ‘validation set’ used for division 
validation (Camp, Dolled-Filhart et al. 2004). Other systems have also been developed 
such as Cutoff Finder, a freely available web application bundle that makes use of an R 
package, which offers 5 different methods for cutoff optimisation. This includes a 
number of methods, including stratification according to the distribution of the marker 
under investigation, or subdivision according to an outcome or survival variable 
(Budczies, Klauschen et al. 2012).   
 
For IHC staining with LIMD1, tumour staining was fairly uniform throughout each 
histospot and using a system such as X-tile, where multiple cut-offs for staining are 
defined would not be possible.  
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4.11.5 Correlation of LAW staining with clinico-pathological outcome data 
 
For a preliminary analysis assessing LAW staining and correlating with clinico-
pathological outcome data we had access to two very valuable resources with clinical 
trial samples and detailed outcome data. For an early preliminary analysis, following the 
guidelines of Simon et al listed is rarely feasible. However, as described, where possible 
these guidelines were followed.  
 
Tumour samples were missing for some patients, which became more of an issue as the 
TMAs were cut further. In the GSK cohort, where the bulk of IHC staining was 
undertaken, despite the enrolment of 460 patients in the trial, tissue from only 130 
patients archived locally was available for analysis. In addition, it was not possible to 
obtain data as to which arm of the trial, lapatinib or placebo, patients had been 
randomised to and it was therefore unclear if patients in the two groups were similarly 
balanced with respect to arm randomisation.  The clinical trial was however negative, 
demonstrating no difference in PFS or OS in patients randomised to either lapatinib or 
placebo and therefore the absence of this data is unlikely to have affected the overall 
analysis.  
 
Advice regarding statistical analysis of the data was obtained.  On multivariate analysis 
components of the validated MSKCC score, KPS, number of metastatic sites, 
haemoglobin concentration and corrected calcium were predictive of OS but not PFS as 
would be predicted. This suggests that the patient population from which samples were 
derived was representative of a typical cohort of patients with metastatic ccRCC and 
that the multivariate analysis was valid. This also implies that patient characteristics were 
similar in those whose tumours expressed high or low LAW levels and that the missing 
data, i.e. treatment arm information and EGFR status, did not significantly impact on 
the overall analysis.  IHC analysis of LIMD1 staining in a further cohort of patients 
enrolled in a clinical trial, stratifying patients using the cutoffs described also did not 
show any difference in OS or PFS, further validating this analysis.  
 
Given that ccRCC tumours are likely to demonstrate 3p LOH and a significant 
proportion 14q LOH it would be expected that many tumours would express less 
LIMD1 and/or Ajuba than normal renal tissue.  It was hypothesised that clinico-
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pathological outcome data in patients with tumours with absent/low LIMD1 expression 
would be worse, as had been demonstrated by Spendlove et al in breast carcinoma: this 
however was not the case (Spendlove, Al-Attar et al. 2008). The same hypothesis was 
also made for Ajuba. Changing the cutoff values to the mean/median or stratifying by 
all staining intensities was not possible for LIMD1 for the reasons described.  
 
It is therefore possible that a statistically significant association was not identified 
because of too small a number of patients in one of the groups, for LIMD1 staining of 
the GSK cohort, 43 samples had no/low LIMD1 staining compared to 87 samples with 
moderate high LIMD1 staining. However visual inspection of the areas under the curve, 
do not look significantly different and if there had been a very significant difference in 
OS/PFS between the two cohorts, we would have expected to see a statistically 
significant difference despite the imbalance in numbers between the two groups. 
Changing the cutoff values for Ajuba and WTIP however did not affect the association 
between staining and tumour grade/stage and PFS and OS.   
 
 In the study described by Thiesen et al CNAs of LIMD1 were identified in 28 of the 48 
ccRCC tumours analysed (58.3%) with interestingly a correlation between lower tumour 
grade and loss, with 21 of the 26 (80%) grade 1 tumours demonstrating CNA compared 
to only 5 of the 20 (25%) grade 3 tumours. This suggests that loss of LIMD1 at least as 
identified by CNA could in fact be associated with a less aggressive tumour phenotype 
(Thiesen, Steinbeck et al. 2017). This could also fit, given our knowledge of the role of 
LIMD1 in the regulation of HIF1α, with the observation that HIF1α overexpression in 
ccRCC is often considered a positive prognostic indicator: HIF1α is often considered a 
tumour suppressor gene and that loss of HIF1α expression is common and may 
contribute to tumourigenesis (Kroeger, Klatte et al. 2013). In a recently published small 
cohort of 28 patients with ccRCC, loss of LIMD1 staining was common compared to 
MAT control tissue and more frequently observed in stage 1 tumours, 20.2% compared 
to 6% of stage 3 tumours, again corroborating the study by Thiesen et al and suggesting 
that LIMD1 loss may be more important in the pathogenesis of early tumours (Sur, 
Maurya et al. 2017).   
 
One of the most consistently validated prognostic stratification approaches is the 
differentiation of ccRCC tumours into clear cell type A (ccA) and clear cell type B (ccB) 
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subtypes. Interestingly patients with ccA type tumours have a significant survival 
advantage compared to those with ccB type tumours of 8.6 versus 2 years in those with 
localised tumours (Brannon, Reddy et al. 2010).  For ccA type tumours, the 
overexpression of HIF signalling components is observed, whilst for ccB type tumours, 
genes that regulate EMT, the cell cycle and wound healing are typically deregulated 
(Brannon, Reddy et al. 2010).  
4.11.6 Correlation of LIMD1 staining with established markers of hypoxic 
deregulation 
 
Correlation of LIMD1 staining in the GSK TMAs with staining for HIF2α in both the 
nuclear and cytoplasmic compartments demonstrated no significant association.  
 
Most tumours demonstrated no HIF1α staining with fewer tumours staining positively 
than might have been expected (Klatte, Seligson et al. 2007, Minardi, Lucarini et al. 
2015).  HIF1α IHC is often difficult, with considerable variation in antibody sensitivity 
and specificity described (Ioannou, Mylonis et al. 2010). In vitro work described in 
chapter 5, demonstrated that LIMD1 loss was associated with increased HIF1α activity 
in vitro in two ccRCC lines as assessed using a HIF1α reporter assay. In the RCC48 cell 
line, HIF1α was also up-regulated in hypoxia in association with LIMD1 loss.  
 
Given that staining was less than expected, with many tumours demonstrating no 
HIF1α staining, it is difficult to assess the correlation between LIMD1 and HIF1α 
protein levels in this cohort. 
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4.12 Future Work 
 
In chapter 3, the loss of LAW is demonstrated in a significant proportion of ccRCC 
samples and the relationship between LAW proteins described. LAW staining and 
staining for markers of hypoxic deregulation are described and further IHC for CD31 
and VEGF-R suggested. Further experiments characterising assessing LAW mRNA 
levels and copy number are suggested as well as in vitro work to further correlate sub-
cellular localisation of LAW.  
 
Sur et al stained 28 ccRCC tumours for LIMD1 expression and found that lower stage 
tumours were more likely to demonstrate loss of LIMD1 expression than higher stage 
tumours (Sur, Maurya et al. 2017).  IHC was done of entire slides. TMA are considered 
to be a validated and appropriate method to assess tissue expression of a particular 
marker as a means of assessing expression of that marker in the tissue as a whole 
(Simon, Paik et al. 2009). Tumour heterogeneity can however be problematic and it 
would be interesting to score larger sections, ideally from spatially separated regions of 
the tumour to validate our staining findings.   
 
The correlation of IHC staining for LAW with markers of hypoxic deregulation was 
difficult to characterise. As described, it was not possible to stain for HIF2α on TMAs 
that had been pre-cut a while previously limiting the number of tumour samples 
possible for analysis. It would be worthwhile to attempt to stain the recently cut 
commercially available TMAs described in chapter 3 for HIF2α, although some antigen 
degradation may also have occurred in these samples. Given the difficulties of IHC for 
HIF1α, characterisation of HIF1α mRNA levels by RT-PCR and correlation with 
staining for LAW as assessed by IHC may be a more meaningful analysis.  
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Chapter 5 
Characterisation of the in v i t ro  effects of LIMD1 loss on 
tumourigenesis in ccRCC 
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5.1 Introduction 
 
Members of the Ajuba family function as protein adapters. Their high affinity cores 
enable the specific binding of multiple proteins simultaneously with subsequent 
regulation of a number of different pathways/processes (Kadrmas and Beckerle 2004). 
With both nuclear and cytoplasmic localisation domains, Ajuba family proteins function 
as signal transducers, mediating communication between the nucleus and the cytoplasm 
(Kadrmas and Beckerle 2004).  
 
In Chapters 3 and 4, expression of LIMD1, Ajuba and WTIP was characterised in 
ccRCC samples and matched adjacent tissue, the relationship between the family 
members described and expression correlated with known markers of hypoxic 
deregulation. LIMD1, Ajuba and WTIP expression was also correlated with clinico-
pathological outcome data.  
 
In vitro work has identified a number of roles for Ajuba proteins.  In drosophila, Djub is 
the sole orthologue of the Ajuba subfamily of LIM proteins and functions as an 
essential negative regulator of the conserved Hippo signalling pathway, a critical 
regulator of organ size, and cell cycle control, de-regulation of which is implicated in 
tumourigenesis in multiple tumour types (Huang, Wu et al. 2005). LIMD1 interacts with 
the retinoblastoma protein to inhibit E2F1-mediated transcription and LIMD1 loss 
results in the up-regulation of pro-tumourigeneic E2F1-driven transcription (Sharp, 
Munoz et al. 2004). LIMD1 is also a critical regulator of HIF-1 activity, acting as a 
molecular scaffold, bridging an association between the prolyl hydroxylases and VHL 
and targeting HIF1α for degradation via the proteasome (Foxler, Bridge et al. 2012). 
LIMD1, Ajuba and WTIP localise to cytoplasmic P-bodies, sites of miRNA/mRNA 
interaction, where they facilitate interactions between the core miRISC and the 
EIF4E/m7GTP cap structure of mRNA, thereby blocking mRNA translation initiation 
(James, Zhang et al. 2010, Bridge, Shah et al. 2017). 
 
In ccRCC, Ajuba family members have not been characterised previously in vivo or in 
vitro The effects of LIMD1 loss on tumourigenesis were characterised using paired 
ccRCC cell lines that were LIMD1 proficient or expressed low levels of LIMD1.  
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CRISPR-Cas-9 mediated genetic editing enables the targeted and efficient modification 
of eukaryotic species (Hsu, Lander et al. 2014) and has only been successfully applied to 
a few primary human cell types (Hendel, Bak et al. 2015). A CRISPR-Cas-9 gene editing 
system was used to knockout LIMD1 and Ajuba in renal proximal tubular epithelial cells 
(RPTEC), the likely cell of origin of ccRCC. Targeted deletion of a tumour suppressor 
in primary cells enables the specific investigation of the effects of loss on 
tumourigenesis, in the absence of the deregulation of other genes/pathways.  
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5.2 Chapter Aims 
 
1. To generate lentivirally transduced ccRCC cell lines with stable effective LIMD1 
knockdown (shLIMD1), LIMD1-knockdown with concomitant LIMD1-rescue 
(rrLIMD1) and a control cell line (scr) for use in further in vitro assays 
 
2. To transduce renal proximal tubular epithelial cells (RPTEC) with a B 
lymphoma Mo-MLV insertion region 1 homolog (BMI-1) construct  
 
3. To utilise a CRISPR-Cas-9 gene editing system to achieve knockout of LIMD1 
and Ajuba in BMI-1 transduced RPTEC cell lines 
 
4. To characterise the effects of LIMD1 loss on tumourigenesis using the 
lentivirally transduced cell lines 
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5.3 Lentiviral transduction of RCC11 and RCC48  
 
RCC11 and RCC48 cell lines were transduced with a lentiviral construct to achieve 
knockdown of LIMD1 (shLIMD1), knockdown of LIMD1 with concomitant rescue 
(rrLIMD1) and to generate a non-targeting control cell line (scr). 
 
The RCC11 line was selected for use in in vitro assays, as it expresses high levels of HIF-
1α and HIF-2α.  In addition, the wild type cell line expresses high levels of LIMD1 and 
moderate levels of Ajuba and WTIP (Figures 3.1 and 5.1).  
 
In contrast the RCC48 cell line, expresses high levels of HIF-2α but lower levels of 
HIF1α and could therefore be considered representative of an aggressive ‘hypoxically 
deregulated’ ccRCC line, in ccRCC tumourigenesis there is often a switch from HIF1-α 
to HIF2-α overexpression associated with increasing tumourigenesis (Koh, Lemos et al. 
2011). The RCC48 cell line expressed high levels of LIMD1 and WTIP with low Ajuba 
(Figure 5.1). Knockdown of LIMD1 in the RCC48 cell line therefore enabled the 
investigation of the effects of LIMD1 loss in a cell line that could be considered 
representative of an aggressive, ‘hypoxically deregulated’ ccRCC line where there was 
still moderate levels of expression of WTIP (Figure 5.1). This is in contrast to the 
RCC11 line, where knockdown of LIMD1 would still leave cells expressing moderate 
levels of Ajuba and WTIP (Figures 3.1 and 5.1). It was felt important that in cells 
where LIMD1 knockdown had been achieved, expression of either Ajuba or WTIP 
remained: in mammalian cells depletion of all 3 LAW proteins in the dog kidney 
epithelial cell line, MDCK results in cell death (Das Thakur, Feng et al. 2010). Blots 
kindly provided by Dr Katherine Bridge (Figure 5.1).  
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(i) (ii)
(iii)
  
Figure 5.1. Expression levels of LIMD1, Ajuba, WTIP, HIF1α and HIF2α in a 
panel of ccRCC lines 
(i) Immunoblot of HIF1α, HIF2α and WTIP in a panel of ccRCC lines with β-actin as loading control. 
(ii) Immunoblot of Ajuba in a panel of ccRCC lines with β-actin as loading control. (iii) Immunoblot of 
LIMD1 in a panel of ccRCC lines with β-actin control as loading control. Blots kindly provided by Dr 
Katherine Bridge of the Sharp lab.    
 
RCC11 and RCC48 cell lines were transduced with a lentiviral construct containing  (1) 
a LIMD1 shRNA, construct, (2) a non-targeting scr construct, or (3), a rrLIMD1 
construct, with concomitant LIMD1 knockdown and rescue.  All three lentiviral 
constructs expressed a puromycin resistance marker. Immunoblot confirmed high levels 
of LIMD1 expression in the non-targeting control (scr) and the rrLIMD1 lines with low 
levels of LIMD1 expression in the shLIMD1 line confirming successful lentiviral 
transduction (Figure 5.2).  
 
  Chapter 5: Results   
! 258!
rrLIMD1'U6# shLIMD1' pUbiC# Flag/His# SV40# Puro#
5’# ##3’#
U6# shLIMD1' pUbiC# Flag/His# SV40# Puro#
5’# ##3’#
U6# Scr' pUbiC# Flag/His# SV40# Puro#
5’# ##3’#
shLIMD
1#
rrLIMD
1#
shScr#
RC
C4
8%s
hL
IM
D1
%
RC
C4
8%
sc
r%%
RC
C4
8%%
rrL
IM
D1
%
α0LIMD1%
α0β0ac3n%
75%%%
%
37%
  
!!!
R
C
C
11
 s
hL
IM
D
1 
R
C
C
11
sc
r  
R
C
C
11
 rr
LI
M
D
1 
kDa!
50'!
37'!
LIMD1 
β-actin 
α"LIMD1(
α"β"ac,n(
RC
C1
1(s
cr(
RC
C1
1(s
h(L
IM
D1
((
kDa(
(((75(
50(
37(
RC
C1
1(r
r(L
IM
D1
((
RC
C4
8%r
r%L
IM
D1
%%
α-LIMD1%
α-β-ac1n%
RC
C4
8%s
cr%
RC
C4
8%s
h%L
IM
D1
%%
kDa%
%%%75%
50%
37%
A B
 
Figure 5.2. Successful lentiviral transduction of RCC11 and RCC48 ccRCC lines 
to create LIMD1 knockdown (shLIMD1), concomitant knockdown and rescue 
(rrLIMD1) and non-targeting control (scr) cell lines 
RCC11 and RCC48 cells were plated in 6-well plates at a seeding density of 1x105 cells/well. At 24 hours, 
the media was changed and concentrated virus added directly to the media. Media was changed at 48 
hours and puromycin selection started at 96 hours.  Once confluent, cells were passaged. Expression of 
LIMD1 in the scr and rrLIMD1 lines and knockdown of LIMD1 in the shLIMD1 line was confirmed by 
immunoblotting. (A) Immunoblot of LIMD1 and β-actin control in the RCC 11 line, (B) Immunoblot of 
LIMD1 and β-actin control in the RCC48 line.   
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5.4 Renal Proximal tubular epithelial cells (RPTEC) were effectively transduced 
with a BMI-1 construct  !
The literature predominantly supports the idea that ccRCC arises from renal proximal 
tubular epithelial cells (Frew and Moch 2015). One critical step in the development of a 
cancerous cell is the acquisition of an unlimited replicative lifespan, defined as 
immortalisation. ccRCC lines are very heterogeneous, with different cell lines likely to 
show deregulation of multiple separate genes and signalling pathways. The effects of 
deletion of a gene of interest in two separate cell lines may therefore be associated with 
significantly different experimental outcomes making generalisations about the effects 
of deletion of a particular gene of interest with respect to tumourigenesis difficult. The 
use of a primary cell line for in-vitro experiments overcomes these difficulties and 
provides an effective platform for investigating the effects of loss of a TSG on early 
tumourigenesis and transformation.  RPTEC immortalisation was attempted by 
transducing RPTEC cells with a BMI-1 construct.  
 
The transcription factor Myc can induce telomerase expression in normal human 
mammary epithelial cells (MEC) and normal human diploid fibroblasts through the 
induction of the expression of hESTs (hTRT/TP2), the limiting subunit of telomerase 
(Wang, Xie et al. 1998). B lymphoma Mo-MLV insertion region 1 homolog (BMI-1) is a 
polycomb ring finger containing protein, originally identified as a c-Myc cooperating 
oncoprotein. The hTERT promoter contains several c-Myc binding sites which can 
induce telomerase activity and bypass senescence in normal human mammary epithelial 
cells and some fibroblast cell lines (Dimri, Martinez et al. 2002) (Wang, Xie et al. 1998). 
 
Other mechanisms drive immortalisation in MEC cells with BMI-1 acting independently 
of c-Myc binding sequences to upregulate hTERT expression, with the RING finger of 
BMI-1 and a conserved helix turn-helix-turn domain inducing telomerase with resultant 
MEC immortalisation (Dimri, Martinez et al. 2002). BMI-1 also can regulate cell 
proliferation in both MEC and fibroblasts. In BMI-1 deficient fibroblasts the tumour 
suppressors p16 and p19Arf, negative regulators of the cell cycle are markedly up-
regulated. Overexpression of BMI-1 permits fibroblast immortalisation, by down-
regulating p16 an inhibitor of CDK4 activity and p19ARF protein levels, a cell signal 
checkpoint that triggers a p53 dependent response that induces growth arrest and/or 
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apoptosis (Park, Park et al. 2002). This in combination with H-ras overexpression leads 
to neoplastic transformation of fibroblasts (Jacobs, Kieboom et al. 1999). BMI-1 over-
expression also down-regulates p16 and p19ARF protein levels in MEC driving cell 
proliferation (Dimri, Martinez et al. 2002).   
 
RPTEC lines can only be passaged a limited number of times prior to senescing, 
potentially reducing their usefulness for in vitro assays. RPTECs were transduced with a 
BMI-1 construct with the aims of increasing the number of times the cells could be 
passaged prior to senescing and in order to generate a cell line with a greater potential 
for malignant transformation. In combination with the deletion of LAW proteins, it was 
anticipated that this would result in a cell line with a phenotype that more closely 
resembled that of a ccRCC line.  
 
RPTECs were transduced with a BMI-1 construct containing a puromycin resistance 
gene. Following puromycin selection and passage, immunoblotting confirmed 
significant up-regulation of BMI-1 expression confirming that BMI-1 transduction had 
been successful (Figure 5.3).   
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Figure 5.3. Successful lentiviral transduction of RPTECs with a BMI-1 construct 
RPTEC cells were plated in 6-well plates at a seeding density of 1x105 cells/well. At 24 hours, the media 
was changed and concentrated virus added directly to the media. Media was changed at 48 hours and 
puromycin selection started at 96 hours. Non-transduced RPTEC and BMI-1 transduced RPTEC were 
lysed and immunoblotted for BMI-1 and β-actin. A (i), A (ii). Representative images of non-transduced 
and transduced RPTEC. No difference in cell morphology was observed and both cell lines grew well. B 
Immunoblot demonstrated a significant increase in BMI-1 in the BMI-1 transduced RPTEC compared to 
non-transduced control.  
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5.5 Use of a CRISPR-Cas-9 gene editing system to knockout LIMD1 and Ajuba 
in BMI-1 transduced RPTEC 
 
Cas-9-mediated gene editing enables the targeted and efficient modification of 
eukaryotic species (Hsu, Lander et al. 2014). In particular the use of the CRISPR system 
can be used to target virtually any genomic location with the use of a short RNA guide 
(Hsu, Lander et al. 2014). Using a CRISPR-Cas-9 system, complete and permanent 
cleavage of a gene of interest is possible such that no transcription of that gene will 
occur, with little in the way of off-target effects (Hsu, Lander et al. 2014).  
 
An Edit-R DharmafectTM Duo CRISPR-Cas-9 gene editing system containing a 
blasticidin resistance construct was used to target LIMD1 and AJUBA in RPTECs. 
Three separate guide-RNA sequences directed against different encoding regions of 
LIMD1 and AJUBA were used to maximise the likelihood of successful gene editing. 
Guide-RNAs directed against WTIP were not available.  
  
Reasonable transfection efficiency of around 20% was achieved using a Dharmafect 
transfection system as indicated by the mKATE transfection control (Figure 5.4A). 
Following transfection, and transient blasticidin selection, the BMI-1 transduced 
RPTEC were allowed to recover and were passaged. Immunoblot for AJUBA and 
LIMD1 in the heterogeneous population demonstrated excellent knockout of AJUBA 
and LIMD1 in the knockout lines compared to proficient control (Figure 5.4B). 
Unfortunately, despite repeated attempts, single colony selection of both cell lines was 
not possible, as cells did not survive being plated singly.   
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Figure 5.4. A CRISPR-Cas-9 system was used to successfully knockout Ajuba 
and LIMD1 in BMI-1 transducted RPTEC 
 BMI-1 transduced RPTEC cell lines were seeded in to a 24-well plate at a seeding density of 5x104 
cells/well and at 24 hours transfected using an optimised DharmaFECTTM Duo CRISPR Transfection 
system. Three crRNAs complementary to the genomic target sequence for LIMD1, and three for 
AJUBA, were utilised. An mKate2 fluorescent reporter with a blasticidin resistance marker and an hCMV 
promoter element was used to assess transfection efficiency at 48 hours. At 48 hours the transfection mix 
was removed and cells transiently selected with blasticidin for 72 hours before being allowed to recover 
and cells passaged.  (A) A transfection efficiency of approximately 20% was achieved as assessed using 
the mKate2 fluorescent reporter. B Immunoblot of the cell lysate demonstrates very low levels of Ajuba 
expression in the AJUBA (Bi) and LIMD1 (Bii) knockout lines compared to control following transient 
blasticidin selection and passage. RCC45 immunoblot is shown alongside for comparison.  
5.6 Assessing the effects of LIMD1 loss on tumourigenesis in ccRCC in v i tro 
 
Hanahan and Weinberg proposed six critical capabilities acquired during the multistep 
development of cancer (Hanahan and Weinberg 2011). These capabilities include 
sustained proliferative signalling, evasion of growth suppressors, resistance to cell death, 
replicative immortality, induction of angiogenesis and activation of invasion and 
metastases. Underlying these capabilities is genomic instability, generating the genetic 
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diversity that drives the acquisition of such characteristics (Hanahan and Weinberg 
2011).  
 
The lentivirally transduced RCC11 and RCC48 lines were used to investigate the effects 
of LIMD1 loss on tumourigenesis, specifically the effects of LIMD1 loss on migration 
as a marker of invasion, sustained proliferative signalling as assessed by clonogenic 
assay, changes in cell cycle, indicative of changes in responsiveness to the negative 
regulators of cell cycle progression, and changes in angiogenesis as assessed by VEGFa 
ELISA and HIF1α reporter assay.  
 
5.6.1  LIMD1 loss does not affect the migration of RCC11 and RCC48 cells as 
assessed by scratch assay 
 
A simple scratch assay was used to study cell migration in vitro. This method is based on 
the observation that in a confluent cell monolayer, creation of a ‘scratch’ will result in 
cells at the edge of the gap moving to close the ‘scratch’, mimicking to some extent 
migration of cells in vivo (Liang, Park et al. 2007). Tumour cell migration and invasion is 
a clinically relevant end point as tumour metastasis impacts significantly on patient 
survival with 90% of cancer related patient deaths attributable to metastatic spread.  
Four replicates for each experiment were carried out and three biological repeats 
undertaken. The mean results for each biological repeat was compared in the RCC11 
and RCC48 cell lines at 24 and 48 hours. The Student’s t-test was used to compare the 
rate of wound healing in the different lines. Loss of LIMD1 was not associated with a 
difference in the rate of wound healing in the RCC11 cell line  at either time point 
(Figure 5.4). At 24 hours, Student’s t-test p=0.136 for shLIMD1 compared to scr and 
p=0.947 for rrLIMD1 compared to shLIMD1 lines and at 48 hours, Student’s t-test 
p=0.114 for  shLIMD1 compared to scr and p=0.333 for rrLIMD1 compared to 
shLIMD1 lines.    
A similar result was observed in the RCC48 cell line.  At 24 hours, Student’s t-test 
p=0.165, for shLIMD1 compared to scr lines and p=0.737 for rrLIMD1 compared to 
shLIMD1 lines whilst at 48 hours, Student’s t-test p=0.157 for shLIMD1 compared to 
scr and p=0.747 for rrLIMD1 compared to shLIMD1 lines. Excellent knockdown of 
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LIMD1 was confirmed by immunoblot in the shLIMD1 line, with high levels of 
LIMD1 expression in the scr and rrLMD1 lines (Figures 5.5 and 5.6) 
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Figure 5.5. LIMD1 depletion does not affect cell migration in RCC11 cells as 
assessed by scratch assay  
All cell lines were grown to confluency in a 6-well plate, a scratch made with the tip of a p200 prior to 
serum starvation with RPMI media containing 1% FCS: puromycin selection was maintained throughout. 
Four repeats were carried out for each scratch assay and three biological repeats undertaken. A Images of 
representative scratch at baseline and at 24 and 48 hours of RCC11 scr, shLIMD1 and rrLIMD1 cell lines. 
B Immunoblot of cells plated concurrently and lysed at 48 hours demonstrates high levels of LIMD1 
expression in the scr and rrLIMD1 lines with excellent knockdown in the shLIMD1 line. C The mean 
result for each of the three experimental repeats is shown with error bars representing standard deviation. 
Statistical analysis shown is Student’s t test. All analysis was conducted using Prism version 6. 
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Figure 5.6. LIMD1 depletion does not affect cell migration in RCC48 cells as 
assessed by scratch assay 
All cell lines were grown to confluency, a scratch made with the tip of a p200 prior to serum starvation 
with RPMI media containing 1% FCS, puromycin selection was maintained throughout. Four repeats 
were carried out for each scratch assay and three biological repeats undertaken. A Images of 
representative scratch at baseline and at 24 and 48 hours of RCC48 scr, shLIMD1 and rrLIMD1 cell lines. 
B Immunoblot of cells plated concurrently and lysed at 48 hours demonstrates high levels of LIMD1 
expression in the scr and rrLIMD1 lines with excellent knockdown in the shLIMD1 line. C The mean 
result for each of the three experimental repeats is shown with error bars representing standard deviation. 
Statistical analysis shown is Student’s t test. All analysis was conducted using Prism version 6. 
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5.6.2 LIMD1 depletion increases the number of RCC11 and RCC48 colonies 
formed in a clonogenic assay 
 
Clonogenic assays are widely used assays for testing the effects of drugs/genes on the 
proliferative characteristics and growth of cells in vitro (Franken, Rodermond et al. 
2006). A clonogenic survival assay determines the ability of a single cell to proliferate 
indefinitely, and thereby retain its ability to form a large colony or clone (Franken, 
Rodermond et al. 2006). The clonogenic potential of the lentiviral transduced RCC11 
and RCC48 cell lines expressing LIMD1 or LIMD1 depleted was assessed. Identical 
numbers of cells were seeded in to a 6-well plate, and the plating efficiency (PE) 
calculated for each biological repeat ((Number of colonies counted/number of cells 
plated) before normalising the PE for the shLIMD1 and rrLIMD1 lines to that of the 
scr control. Six replicates were plated for each experiment, with four biological repeats 
undertaken.  
 
The LIMD1 depleted RCC11 and RCC48 cell lines (shLIMD1) formed increased 
colonies compared to scr control as assessed by manual counting after crystal violet 
staining, Student’s t-test p=0.0215* for RCC11 seeded at 200 cells/well. For RCC48 
cells, Student’s t-test p=0.0031** and p=0.0131* when seeded at 200 cells/well and 300 
cells/well respectively (Figures 5.7 and 5.8). 
 
 The crystal violet was subsequently solubilised, an alternative method for characterising 
clonogenic assays (Franken, Rodermond et al. 2006). Increased absorbance was 
observed in the shLIMD1 lines compared to scr control.  This did not quite meet 
statistically significant in the RCC48 lines seeded at 300 cells/well, Student’s t-test 
p=0.1014, but was statistically significant in the RCC48 seeded at 200 cells/well, 
Student’s t-test p<0.0001***, and for RCC11 seeded at 100 cells/well, Student’s t-test 
p=0.0124* (Figures 5.7 and 5.8).  
 
An increased number of colonies was consistently observed in the rrLIMD1 control 
compared to shLMD1 line for each biological repeat, however as variability was 
observed in the mean number of colonies for each experiment, the shLIMD1 and 
rrLIMD1 data were normalised to the scr control. The resulting error bars for the 
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rrLIMD1 line were large and comparison of the shLIMD1/rrLIMD1 lines did not meet 
statistical significance.  
 
In the RCC11 line, comparison of the LIMD1 depleted shLIMD1 (RCC11 shLIMD1) 
and rrLIMD1 lines did not meet statistical significance as assessed by both manual 
counting and reading the absorbance of the solubilised crystal violet, Student’s t-test, 
p=0.219 and p=0.1397 respectively (Figure 5.7). In the RCC48 line, comparison of the 
LIMD1 depleted shLIMD1 and rrLIMD1 lines also did not meet statistical significance 
as assessed by both manual counting and reading the absorbance of the solubilised 
crystal violet, Student’s t-test, p=0.0627 and p=0.3608 respectively for cells seeded at 
200 cells/well and p=0.1565 and p=0.1562 respectively for cells seeded at 300 cells/well 
(Figure 5.8).   
 
Taken together the increased colony formation observed in both cell lines in association 
with LIMD1 knockdown compared to proficient control, suggests that LIMD1 loss 
increases clonogenic survival in both cell lines. 
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Figure 5.7. LIMD1 depletion increases RCC11 colony formation  
 
A Representative images of colonies in the RCC11 scr, shLIMD1 and rrLIMD1 cell lines at 20 days: 100 
cells of the three lentiviral transduced cell lines were seeded in to one well of a 6-well plate with six 
replicates for each cell line plated and cells were maintained in puromycin selection. B Knockdown of 
LIMD1 in the shLIMD1 cell line and expression in the scr and rrLIMD1 lines was confirmed at the end 
of the assay by Western Blot analysis. C (i) Results are representative of three separate biological repeats, 
quantifying colony number by manual counting after fixation and staining with crystal violet C (ii) The 
crystal violet was extracted and quantified by absorbance. Error bars represent standard deviation n=6, 
results are normalised to the scr control.  Statistical analysis shown is Student’s t test. All analysis was 
conducted using Prism version 6. 
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Figure 5.8. LIMD1 depletion increases RCC48 colony formation 
 
 A Representative images of colonies in the RCC11 scr, shLIMD1 and rrLIMD1 cell lines at 20 days: 200, 
or 300 of the three lentiviral transduced cell lines were seeded in to one well of a 6-well plate with six 
replicates for each cell line plated at each seeding density, cells were maintained in puromycin selection 
throughout. B Knockdown of LIMD1 in the shLIMD1 cell line and expression in the scr and rrLIMD1 
lines was confirmed at the end of the assay by Western Blot analysis. C (i) Results are representative of 
three separate biological repeats quantifying colony number by manual counting after fixation and staining 
with crystal violet, results are normalised to the scr control. C (ii) The crystal violet was extracted and 
quantified by absorbance. Error bars represent standard deviation n=6, results are normalised to the scr 
control. Statistical analysis shown is Student’s t test. All analysis was conducted using Prism version 6.  
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5.6.3 Loss of LIMD1 increases VEGFa secretion in RCC11 and RCC48 lines as 
assessed by ELISA 
 
Analysis of IHC staining in the ccRCC histospots demonstrated an inverse correlation 
between LIMD1 and VEGFa staining, contrary to the correlation expected. It was 
hypothesised that this may be related to a ‘steal’ effect whereby tumours with higher 
VEGF levels in turn secrete more VEGF to promote neo-vascularisation, thereby 
resulting in paradoxically lower VEGF staining within the tumours, but increased neo-
angiogenesis, a similar observation to that observed by Kluger et al (Kluger, Siddiqui et 
al. 2008). Given this observation and the role of VEGFa as a potent mediator of 
angiogenesis in ccRCC, VEGFa secretion was assessed in paired LIMD1 expressing and 
LIMD1 depleted RCC11 and RCC48 cells.  
 
In the RCC11 line in both normoxia and after incubation in 1% O2 for 20 hours, 
increased VEGF secretion was observed in the shLIMD1 line compared to scr control, 
Student’s t-test p=0.0418* and p=0.0434* respectively (Figure 5.9 (Ai)). A similar 
result was observed in the RCC48 line, with increased VEGF secretion in the shLIMD1 
line compared to scr control: this was statistically significant in normoxia but not in 
hypoxia, Student’s t-test p=0.0328* and p=0.0503 respectively (Figure 5.9 (Aii)). All 
assays were undertaken in duplicate and two biological repeats performed. The assay 
was not undertaken in the rrLIMD1 line, as insufficient ELISA kit was available.   
 
 The results of the ELISA suggests that loss of LIMD1 is associated with increased 
VEGF secretion in vitro, potentially contributing to increased angiogenesis and 
consistent with a role of LIMD1 in the regulation of the hypoxic response. This also 
supports the hypothesis that the positive correlation observed between staining for 
LIMD1 and VEGFa in tumour samples could be as result of increased VEGFa 
secretion in tumours with low LIMD1 expression, a ‘steal’ effect that results in those 
tumours having paradoxically less VEGFa staining.  
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Figure 5.9 LIMD1-depletion increases VEGF secretion as assessed by ELISA in 
RCC11 and RCC48 cells 
RCC11 and RCC48 cells were seeded at 2x105 cells/well in to a 6-well plate to ensure 50-60% confluency 
at 36 hours. At 16 hours, RCC11 and RCC48 cells were incubated in a hypoxic chamber at 1% O2 for 20 
hours prior to lysis. Cells were also left for a further 20 hours in normoxia, (20% O2) prior to lysis. A 
commercially available VEGF ELISA kit from was used to assess VEGF secretion and optical density 
read using a Wallac 1420 Multilabel counter plate reader. Control standards were used to determine 
VEGF levels. All ELISAs were measured in duplicate. Results are representative of two separate 
biological repeats. (Ai) Increased VEGF secretion is demonstrated in the RCC11 shLIMD1 cells relative 
to the scr control in both normoxia and hypoxia (Aii) Increased VEGF secretion is demonstrated in the 
RCC48 shLIMD1 cells relative to the scr control incubated in normoxia but not hypoxia. (B (i)) and B 
(ii).  Excellent knockdown of LIMD1 was observed in the shLIMD1 line upon immunoblot with high 
levels of LIMD1 expression in the scr line in both RCC11 (B (i)) and (B (ii)) RCC48 lines. Statistical 
analysis shown is Student’s t test with error bars demonstrating the standard deviation. All analysis was 
conducted using Prism version 6. 
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5.6.4 HIF1α luciferase dual-reporter assay 
 
LIMD1 functions as an adapter protein, binding PHDs and VHL simultaneously and 
targeting HIF1α for degradation via the proteasome. LIMD1 depletion is associated 
with HIF1α upregulation in HEK-293-T cells (Foxler, Bridge et al. 2012).  
Luciferase dual-reporter assays are widely used to study transcriptional activation (Dyer, 
Ferrer et al. 2000). The two different types of luciferases commonly used have distinct 
substrate requirements, which produce different wavelengths of fluorescence, thus 
enabling quantification from a single sample. In this assay, cells were simultaneously 
transfected with a thymidine kinase-Renilla (TK-Renilla) luciferase reporter, thymidine 
kinase is constitutively expressed, and a pGL3- (6x) HRE-firefly luciferase plasmid, 
where the promoter response element for HIF1-α had been cloned upstream of the 
pGL3 basic firefly luciferase plasmid. Differences in transfection efficiency were 
accounted for by normalising the luminescence obtained for the experimental reporter 
HRE plasmid or Vo plasmid to the luminescence for the constitutive Renilla reporter. 
The normalised reporter luminescence in the shLIMD1 cell lines were then normalised 
to the scr control. Three biological repeats were carried out, with each assay conducted 
in triplicate. This enabled a functional read out of the effect of LIMD1 loss on the 
activation of a HIF1α reporter construct in both RCC11 and RCC48 cell lines.  
In the RCC11 line, normalised luminescence and therefore HIF1α activity was greater in 
the shLIMD1 line in hypoxia compared to the scr control, Student’s t-test p=0.03459*, 
this did not meet statistical significance in normoxia, Student’s t-test p=0.3299. In 
RCC48, normalised luminescence and therefore HIF1α activity was greater in the 
shLIMD1 line in normoxia compared to the scr control, Student’s t-test p=0.0040**, 
this did not meet statistical significance in hypoxia, p=0.0790 but a trend towards 
significance was observed. Excellent knockdown was observed in the shLIMD1 lines, 
compared to scr control as assessed by immunoblot (Figure 5.10).  
Figure 5.10. LIMD1 depletion increases HIF1α activity as measured by a HIF1α 
reporter assay 
3.5x105 of each cell line was seeded in to a 24-well plate, with each co-transfection carried out at 24 hours 
in triplicate. Cells were co-transfected with either 200 ng of the pGL3- (6x) HIF1 HRE-firefly 
luciferase or 200 ng of the pGL3Vo firefly luciferase in combination with 30 ng of the TK-Renilla 
luciferase reporters.  After seven hours one plate was transferred to the hypoxic workstation for sixteen 
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hours incubation and the second plate remained in normoxia. The luminescence was read according to 
the manufacturers instructions (Promega). Differences in transfection efficiency were accounted for by 
normalising the luminescence obtained for the experimental reporter, Firefly or Vo, to the luminescence 
for the constitutive reporter, Renilla. A (i) Increased HIF1α reporter activity is demonstrated in RCC11 
shLIMD1 compared to RCC11 scr in hypoxia. A (ii) Increased HIF1α reporter activity is demonstrated 
in RCC48 shLIMD1 compared to RCC11 scr in both normoxia and hypoxia. Excellent knockdown of 
LIMD1 was observed in the shLIMD1 line upon immunoblot with high levels of LIMD1 expression in 
the scr line in both RCC11 (B (i)) and (B (ii)) RCC48 lines. Analysis was undertaken in Prism 6. 
Statistical analysis shown is Student’s t test with error bars representing standard deviation, three 
biological repeats were undertaken. 
5.6.6 Changes in cell cycle associated with loss of LIMD1 in RCC11  
 
The loss of responsiveness to negative regulators of cell cycle progression, and/or the 
acquisition of independence from mitogenic signals is a critical change in the cell cycle 
associated with malignant transformation (Hanahan and Weinberg 2011). Fluorescence-
associated cell sorting (FACS) is a tool used to analyse cell cycle distributions, providing 
a clear picture of the proportions of cells in each of the cell cycle phases.  
Cell cycle phase was assessed in the RCC11 lentivirally transduced cell lines and 
comparison of the scr and shLIMD1 lines undertaken. Cells of similar early number 
passage number were used, media changed concurrently in the different lines and PI 
staining of cells that were approximately 50% confluent, undertaken. Three biological 
repeats were undertaken with each experiment conducted in triplicate. Fluorescence was 
read using the FACS Caliber B machine with the YG-610/20 excitation-emission filters. 
The appropriate gates were set around the G0/G1, S and T2/M phase peaks and 
analysis undertaken using Flowjo 7.6.5 software. Representative cell cycle phase peaks 
and gating is shown in Figure 5.11A. For each biological repeat, the mean for the 
proportion of cells in each cell cycle phase was calculated. The mean and standard 
deviation for the biological repeats is shown in Figure 5.11B. There was no difference 
in the proportion of cells in each phase of the cell cycle in association with loss of 
LIMD1.    
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Figure 5.11. LIMD1 depletion does not affect cell cycle phase as assessed by 
propidium iodide staining and FACS sorting 
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RCC11 scr/shLIMD1 cells were seeded in to 6-well plates such that cell confluency was approximately 
50% 24 hours post seeding. Cells were lysed and counted, then permeabilised and fixed prior to staining 
with propidium iodide. Fluorescence was read using a Fluorescence Activated Cell Sorter (FACS Caliber 
B) using the YG-610/20 excitation-emission filters with the appropriate gates set around the G0/G1, S 
and G2/M phase peaks. Results were analysed using Flowjo 7.6.5 software. Three biological repeats were 
undertaken with each experiment conducted in triplicate. Fluorescence was read using the FACS Caliber 
B machine with the YG-610/20 excitation-emission filters. (A) Representative cell cycle phase peaks and 
gating for RCC11scr, RCC11 shLIMD1 and RCC11 rrLIMD1. (B) For each biological repeat, the mean 
for the proportion of cells in each cell cycle phase was calculated and plotted using Prism 6. The mean 
and standard deviation for the biological repeats is shown. (C). Cells plated concurrently were also lysed 
and immunoblotted for LIMD1 and β-actin as loading control, high levels of LIMD1 expression were 
confirmed in the scr and rrLIMD1 lines with excellent knockdown in the shLIMD1 line.  
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5.7 Summary 
 
In vitro work has identified a number of roles for LAW protein members including the 
regulation of the Hippo signalling pathway, a critical regulator of organ size and cell 
cycle control, de-regulation of which is implicated in tumourigenesis in multiple tumour 
types (Huang, Wu et al. 2005), LIMD1 interacts with the retinoblastoma protein to 
inhibit E2F1-mediated transcription (Sharp, Munoz et al. 2004) and functions as a 
critical regulator of HIF-1 activity, bridging an association between the prolyl 
hydroxylases and VHL and targeting HIF1α for degradation via the proteasome (Foxler, 
Bridge et al. 2012). In addition, LIMD1, Ajuba and WTIP localise to cytoplasmic P-
bodies, sites of miRNA/mRNA interaction, where they facilitate interactions between 
the core miRISC and the EIF4E/m7GTP cap structure of mRNA, thereby blocking 
mRNA translation initiation (James, Zhang et al. 2010) 
 
In ccRCC, the effects of LAW protein loss on tumourigenesis have not been 
characterised. The effects of LIMD1 loss on tumourigenesis were investigated further. 
A lentiviral transduction system was used to generate non-targeting siRNA (scr) control, 
LIMD1 knockdown (shLIMD1), and LIMD1 knockdown with concomitant rescue 
(rrLIMD1) in RCC11 and RCC48 lines, chosen as they are representative of aggressive,  
‘hypoxically’ deregulated ccRCC lines. Using these lentiviral lines, in vitro assays 
demonstrated that LIMD1 loss did not affect migration using a scratch assay as a 
marker of invasion, nor were changes in cell cycle observed, indicative of changes in 
responsiveness to the negative regulators of cell cycle progression as assessed by FACS 
analysis.  
VEGFa ELISA and HIF1α reporter assay however suggested that LIMD1 loss in these 
cell lines was associated with greater hypoxic deregulation with increased VEGFa 
secretion and increased activity of a HIF1α reporter assay. Immunoblot of the 
lentivirally transduced RCC48 cell lines incubated in hypoxia also demonstrated 
increased HIF1α levels in association with LIMD1 knockdown.  
 
CRISPR-Cas-9 mediated genetic editing enables the targeted and efficient modification 
of eukaryotic species (Hsu, Lander et al. 2014) and has only been successfully applied to 
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a few primary human cell types (Hendel, Bak et al. 2015). RPTEC lines were 
successfully transduced with a BMI-1 construct with the aim of increasing replicative 
lifespan and of generating cell lines that in combination with LAW protein loss more 
closely resembled that of a ccRCC line. A CRISPR-Cas-9 gene editing system was used 
to successfully knockout LIMD1 and AJUBA in the BMI-1 transduced RPTEC. Single 
cell selection however was not possible and it was therefore not possible to use such 
cells in further in vitro assays.  
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5.8 Discussion 
 
In this chapter the use of a CRISPR-Cas-9 system to selectively delete LIMD1 and 
AJUBA in the primary renal cell line RPTEC, transduced with a BMI-1 construct was 
demonstrated.  The effects of LIMD1 depletion on several critical features of 
tumourigenesis were characterised: sustained proliferative capacity using a clonogenic 
assay, the activation of invasion and metastases using a migration assay, sustained 
proliferative signalling through FACS analysis and the induction of angiogenesis using a 
VEGFa ELISA and HIF1α reporter assay.   
5.8.1 BMI-1 transduction of RPTEC 
 
BMI-1 can induce telomerase activity and bypass senescence in some cell lines such as 
mammary epithelial cells (MECs) and fibroblasts and mechanisms for this have been 
described (Dimri, Martinez et al. 2002) (Jacobs, Kieboom et al. 1999). However, for 
most epithelial cells, senescence cannot be overcome by the ectopic expression of 
telomerase alone, through for example BMI-1 or hTERT overexpression, and in many 
such cells alterations in the pRb pathway are also necessary. In a study by Lundberg et al, 
human airway epithelial cells were directly immortalised through both the successive 
introduction of the Simian Virus 40 Early Region (SV40T) and hTERT (Lundberg, 
Randell et al. 2002) and such an approach has also been used to successfully immortalise 
RPTEC using two lentiviral vectors carrying hTERT and SV40T, flanked by loxP sites 
(Kowolik, Liang et al. 2004).  
 
Immunoblotting for hTERT was undertaken in an attempt to quantify differences in 
hTERT expression in association with RPTEC BMI-1 transduction but immunoblots 
were of poor quality and it was difficult to assess whether BMI-1 transduction up-
regulated hTERT expression. BMI-1 transduction did not seem to increase the 
replicative capacity of RPTEC, with cells undergoing senescence after a similar number 
of passages compared to the non-transduced cells. It is therefore likely that in the 
RPTECs, BMI-1 transduction alone was not sufficient for immortalisation. This limited 
the use of the RPTECs for subsequent in vitro experiments as cell stocks underwent 
senescence after a few passages.  
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5.8.2 Use of the CRISPR-Cas-9 system to generate LIMD1 and Ajuba RPTEC 
knockouts 
 
Systems such as homologous recombination-mediated targeting can generate knockin 
and knockout animal models, however recombination events occur extremely 
infrequently. RNA interference with small interfering (siRNA) or short hairpin RNAs 
(shRNAs) can provide good knockdown, which in the case of siRNA is transient or 
more permanent with an shRNA system.  Very good knockdown with a lentiviral 
shRNA system was consistently achieved, with such a system however, levels of 
knockdown are variable and never complete. In addition, the lentiviral constructs used 
were large and sites of gene integration cannot be predicted and could vary from one 
cell to another, which could have unpredictable downstream consequences on the 
expression of other genes.  
 
Use of CRISPR-Cas-9-mediated genetic editing enables the targeted and efficient 
modification of eukaryotic species (Hsu, Lander et al. 2014). In particular the use of the 
CRISPR system can be used to target virtually any genomic location with the use of a 
short RNA guide (Hsu, Lander et al. 2014). Using a CRISPR-Cas-9 system, complete 
and permanent cleavage of a gene of interest is possible such that no-transcription of 
that gene will occur with little in the way of off-target effects (Hsu, Lander et al. 2014). 
Given frequent 3p and 14q LOH in ccRCC, we would expect functional LIMD1 and 
Ajuba to be reduced in many ccRCC lines compared to primary renal lines such as 
RPTEC. Therefore, a system that results in biallelic permanent cleavage of LIMD1 or 
Ajuba allows for the clear investigation of the effects of gene loss on tumourigenesis.  
The Edit-R DharmaFECTTM Duo CRISPR-Cas-9 system was used to successfully 
knock out LIMD1 and Ajuba in the BMI-1 transduced RPTEC.  
CRISPR-Cas-9 technology has only been successfully applied to a few primary human 
cell types and predominantly cells with greater replicative potential such as human 
embryonic stem cells (Hendel, Bak et al. 2015). Reasons for the frequent lack of efficacy 
of CRISPR-Cas-9 technology in primary cells are not fully known, but some 
contributing factors include low transfection efficiencies, the requirement for multiple 
passages/proliferation, the harsh selection conditions generally required to achieve an 
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edited primary cell population and DNA repair fidelity (Hsu, Lander et al. 2014, Chu, 
Rios et al. 2015).  
 
The use of synthesised guide RNAs is often considered to be a superior method for 
inducing higher levels of gene editing using a CRISPR-Cas9 system compared to for 
example a lentiviral construct (Hendel, Bak et al. 2015). sgRNA mediated DNA cleavage 
is also increased by increasing the number of sgRNAs included: three sgRNAs were 
used for both LIMD1 and Ajuba to increase the likelihood of successful gene editing 
(Hendel, Bak et al. 2015). The use of a synthesised guide RNA system effectively 
induces targeted indels indicative of mutagenic non-homologous end joining and gene 
disruption, with off-target gene disruption close to background (Hendel, Bak et al. 
2015). Excellent knockdown of Ajuba and LIMD1 was observed in the heterogeneous 
RPTEC population suggesting that this system resulted in successful biallelic gene 
editing in a significant proportion of cells.   
 
FACS sorting with enrichment of cells that still express the transiently expressed 
mKATE2 expression plasmid two to three days days post transfection can enrich the 
cell population that has undergone CRISPR-Cas-9 mediated gene editing further but 
given the excellent knockdown in the heterogeneous population, and likely significant 
loss of cells associated with this approach, FACS sorting was not undertaken.  
 
The use of single cell selection ensures that the cell population used is clonal and clearly 
defined. Single cell selection of the RPTEC in order to generate cells derived from a 
clonal population was however not possible, despite BMI-1 transduction.  BMI-1 
transduction did not appear to increase the number of times the cells could be passaged 
prior to senescing.  
 
5.8.3. Single cell selection of primary cells 
 
Single cell selection of primary cells is often difficult. Chu et al used a lentiviral CRISPR-
Cas-9 system to knockout Muc01 in human epithelial cells (Chu, Rios et al. 2015). They 
were able to effectively grow these cells such that cells demonstrated near unlimited 
proliferation but did not undergo transformation. Cells were grown with the addition of 
a Rho-kinase (ROCK) inhibitor and using modified Schlegel culture conditions, where 
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cells are cultured on an irradiated fibroblast feeder layer containing specialised media 
additives (Chu, Rios et al. 2015).  Such an approach allows near unlimited proliferation 
and the passage of numerous epithelial cell types without loss of primary characteristics 
and transformation (Liu, Ory et al. 2012). Of note single cell selection was not 
undertaken by Chu et al, but the use of modified Schlegel culture conditions in 
combination with puromycin selection in order to select for cells that had undergone 
lentiviral transduction, allowed for the selective enrichment of transduced cells.  Cells 
grown from the heterogeneous population were then used to establish Muc01 knockout 
(Chu, Rios et al. 2015).  
 
A search of the literature, failed to identify any articles detailing successful single cell 
selection of RPTECs. Seeding cells into a large tissue dish with the aim of single cell 
selecting colonies was unsuccessful, as colonies failed to grow. The use of conditioned 
media can also increase the likelihood of single cell selection of primary cells.  Here cells 
are cultured in media supplemented with 25-50% media from cultured cells no more 
than 70% confluent. In the study by Liu et al, the use of modified Schlegel culture 
conditions, in combination with a ROCK inhibitor, caused many normal and tumour 
epithelial cells such as primary prostate and mammary cells to proliferate indefinitely in 
vitro (Liu, Ory et al. 2012).  
 
It had been hoped that given the excellent LIMD1 and Ajuba knockdown in the 
CRISPR-Cas-9 heterogeneous RPTEC population, the heterogeneous population could 
be used for further in vitro experiments to investigate the effects of LIMD1 and Ajuba 
loss, but the senescence of these cell lines after a few additional passages meant that this 
was not possible. The use of a ROCK inhibitor and or modified Schlegel conditions 
may have been more successful in the RPTECs, allowing cell number to be bulked up 
quickly within a relatively low number of cell passages.   
CRISPR-Cas-9 mediated gene editing in primary cells represents a particular challenge 
and has not been described in ccRCC.  This work demonstrates that the Edit-RTM 
CRISPR-Cas9 gene-engineering platform can be used successfully to delete genes in 
RPTECs. Modification of the cell immortalisation protocol and techniques for bulking 
up cell number after CRISRP-Cas-9 mediated gene editing within a relatively few 
number of cell passages, could enable heterogeneous cell populations or single cell 
selected cells to be used in further in vitro assays.   
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5.8.4 In v i tro work to characterise the effects of LIMD1 loss on cell migration 
 
Simple scratch assays were undertaken in both lentiviral-transduced RCC11 and RCC48 
lines, to assess the effects of LIMD1 loss on migration.  It was hypothesised that 
LIMD1 depletion through HIF1α stabilisation might up-regulate pro-migratory 
cytokines such as VEGF, with consequent increased cell migration and wound healing.  
Loss of LIMD1 however did not increase cell migration as assessed by scratch assay in 
either line.  
 
Migration is defined as the directed movement of cells on a substrate, by definition 
within a 2-dimensional (2-D) context, without any obstructive networks. Invasion, 
however is associated with the movement of cells through a 3-dimensional (3-D) matrix 
with associated restructuring of the 3-D environment, for example invasive cancer cells 
must interact and re-shape the extracellular matrix (ECM) and both migration and 
invasion are critical components of tumourigenesis (Liang, Park et al. 2007). Scratch 
assays are simple, 2-D assays that are inexpensive and easy to interpret but have some 
limitations. In particular it is hard to control the precise scratch area and therefore 
guarantee equivalence between control and experimental scratches (Liang, Park et al. 
2007).  With practice however, it was observed that initial scratch areas were of similar 
size and initial scratches that differed significantly in size from that observed typically 
were excluded from analysis.  
A long-term wound-healing assay, defined as greater than 24 hours cannot distinguish 
between increased healing as a consequence of increased cell proliferation and increased 
cell motility. It had been observed that loss of LIMD1 did not affect the rate of cell 
growth in either cell line when grown in standard conditions with RPMI supplemented 
with 10% FCS. In the wound healing assays, cells were serum starved and grown in 1% 
FCS such that wound healing was more likely to be a function of cell migration and not 
as a result of increased cell proliferation.  
Wound healing was assessed at 24 and 48 hours but wound healing was also initially 
assessed at 12 hours and no differences between the cell lines observed. The use of 
automated video microscopy in time-lapse experiments can enable the distinction 
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between cell migration and cell division and automated cell tracking algorithms exist 
that can enable the recording of several cell types simultaneously (Kramer, Walzl et al. 
2013).  
Scratching can damage the matrix underneath the cells and cells at the edge of the 
scratch are more likely to be damaged. This can result in dysfunction in their migration 
and the release of unidentified factors that may affect the migration of other cells. 
Proprietary inserts can overcome this by generating a consistent wound gap between 
cells and minimising the likelihood of cell damage at the wound interface. The inserts 
create an exclusion zone when cells are seeded, and the cell density adjusted such that 
cells are fully confluent (Kramer, Walzl et al. 2013). However for all cell types, 
particularly given the consistency of the scratch size, damage to the matrix underneath 
and cells at the scratch assay should have been fairly consistent.  
Although our results did not show any difference in cell migration in association with 
LIMD1 loss, assays were only carried out in two cell lines, and further migration assays 
for example measuring three-dimensional migration or transwell migration assays could 
characterise this further.  
5.8.5 Increased cell proliferation is observed in association with LIMD1 loss in 
ccRCC 
 
The two-dimensional clonogenic assay demonstrated an increase in colony formation in 
association with LIMD1 loss suggesting that LIMD1 down-regulation may give rise to 
more transformed cancer cell phenotype with an increase in the cells ability to retain a 
proliferative capacity indefinitely.  
Colony assays are simple semi-quantitative assays that are easy to read and for many 
years were considered the gold standard for the analysis of the proliferative/malignant 
potential of individual cells and their ability to resist treatment (Franken, Rodermond et 
al. 2006). The assay assesses the ability of individual cells to produce progeny, 
specifically to produce a clone defined as more than 50 cells. Typically clonogenic assays 
evaluate the ability of a single cell to resist treatment and grow into a colony after 
treatment with a chemotherapeutic agent but clonogenic assays are also used to evaluate 
the transforming effect of oncogenes or to investigate the effects associated with the 
  Chapter 5: Discussion   
! 285!
loss of a tumour suppressor protein (Franken, Rodermond et al. 2006).  
Two separate methods were used to evaluate the number of colonies formed, a 
subjective manual counting approach and a more objective approach where the 
absorbance of the solubilised crystal violet was read. For both approaches, loss of 
LIMD1 was associated with increased colony formation in both cell lines. Other more 
quantitative approaches involve the use of an Image-J plug in to automatically assess 
clonogenic assay area as a function of the total well area (Guzman, Bagga et al. 2014).  
Three-dimensional (3-D) colony assays measure the ability of cells to form colonies in 
three-dimensions, typically in soft agar. The transformations associated with this 
phenotype include a loss of contact inhibition and anchorage independence, i.e. cells can 
grow over one another, features considered critical for in vivo carcinogenesis. 3-D assays 
are often considered to represent a more stringent assay for the assessment of 
clonogenicity and in addition, the environment in the centre of the colony may be 
hypoxic or deficient in nutrients and therefore more closely resemble the in vivo 
environment (Hoffman 1991). Multiple attempts at 3-D colony assays in the lentiviral 
transduced RCC11 and RCC48 lines were unsuccessful and it is unclear as to why this 
was the case.  
Both assays have some limitations in that cells that form colonies are actively dividing 
and are therefore considered to represent those that have the greatest potential for self-
renewal and are more likely to represent the cancer stem cell population. However, cells 
that are reversibly non-dividing in G0 are not assessed by such an assay and such cells 
may still have the potential for clonogenic growth (Hoffman 1991). In addition, the 
disaggregation of cells necessary for plating results in loss of normal cell interactions and 
such interactions may be a critical component of tumourigenesis (Hoffman 1991).  
Both 2-D and 3-D colony assays have however correlated with the capacity for 
tumourigenesis in a number of studies in vivo and as such provide a good validated in 
vitro model (Niell, Soloway et al. 1983) (Freedman and Shin 1974).   
5.8.6 VEGF ELISA 
 
Correlation of VEGFa and LIMD1 staining immunohistochemically demonstrated a 
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positive correlation with tumours with increased LIMD1 staining also demonstrating 
increased VEGFa staining. VEGFa is a marker of hypoxic deregulation, up-regulated by 
HIF and a critical driver of ccRCC (Pouyssegur, Dayan et al. 2006) as well as 
representing a validated prognostic indicator in ccRCC (Patard, Rioux-Leclercq et al. 
2009).  
It had been hypothesised that LIMD1 and VEGFa staining would correlate negatively 
in ccRCC samples in vivo, with increasing VEGFa expression contributing to increasing 
angiogenesis. However an unexpected positive correlation was observed and it was 
hypothesised that this could be related to a ‘steal’ effect, whereby tumours with higher 
VEGFa levels in turn secrete more VEGFa to promote neo-vascularisation, thereby 
resulting in paradoxically lower VEGF staining within the tumours, but increased neo-
angiogenesis Kluger et al had observed a similar relationship (Kluger, Siddiqui et al. 
2008).  
 
ELISA assays are sensitive, highly reproducible assays, which alongside the 
incorporation of standard controls enable the accurate quantification of the antigen or 
antibody of interest. As for the cell cycle analysis, cells analysed were of similar passage 
number and confluency, with media changed at the same time across cell lines to ensure 
consistency. Given the hypoxic microenvironment of ccRCC in vivo and the hypoxic 
deregulation that occurs during tumourigenesis, cells were incubated both in normoxia 
(20% O2) and in hypoxia (1% O2).  
 
In both cell lines, VEGFa secretion was increased in the RCC11 and RCC48 cell lines in 
association with LIMD1 loss in both normoxia and hypoxia, although this did not quite 
meet statistical significance in the RCC48 line in hypoxia (Figure 5.9).  In keeping with 
this observation, work by Foxler et al in HEK-293 cells, a human embryonal kidney 
derived cell line, demonstrated that depletion of endogenous LIMD1 induces the 
expression of endogenous HIF-1 targeted genes including VEGF as assessed by mRNA 
levels (Foxler, Bridge et al. 2012).  
 
This would suggest that LIMD1 loss is not only associated with increasing VEGFa 
secretion as assessed by ELISA, but also fit with our hypothesis that the positive 
correlation observed in vivo was as a consequence of a ‘steal’ effect, whereby tumours 
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with greater LIMD1 in turn secreted more VEGFa, resulting in a paradoxical decrease 
in VEGFa staining within the tissue. 
5.8.7 HIF1-α reporter assay and HIF1-α expression in hypoxia 
 
Loss of LIMD1 in the RCC11 line was associated with an increase in HIF1α activity in 
hypoxia but not normoxia as assessed by an HRE-assay. In the RCC48 cell line, an 
increase in HIF1α activity was observed in normoxia in association with LIMD1 loss 
but not in hypoxia.  
Loss of LIMD1 has been shown to result in the up-regulation of HIF1-α in both 
normoxia and hypoxia. In hypoxia, PHD2 is still active and can result in HIF1α 
degradation.  LIMD1 depletion results in reduced PHD2 activity with consequent 
HIF1α up-regulation (Foxler, Bridge et al. 2012).  
Although the results of the HIF1α reporter assay were inconsistent, increased HIF1α 
activity was observed in both cell lines (Figure 5.9).  Error bars were however large in 
some of the assays and given the trend observed, further biological repeats may well 
result in the differences becoming statistically significant.  
5.8.8 Changes in cell cycle associated with loss of LIMD1 in the ccRCC lines 
 
Hanahan and Weinberg described the critical changes in cell cycle associated with 
malignant transformation: the loss of responsiveness to negative regulators of cell cycle 
progression and/or the acquisition of independence from mitogenic signals (Hanahan 
and Weinberg 2011). FACS has become a standard tool to analyse cell cycle 
distributions, providing a clear picture of the different proportion of cells in each of the 
cell cycle phases.  
Work in the RCC11 line did not show differences in the proportion of cells in 
G1/S/G2 in association with loss of LIMD1 (Figure 5.10) suggesting that LIMD1 loss 
was not associated with changes in cell cycle as assessed with this assay.  
FACS analysis provides a snapshot of the cell cycle distribution at any given point in 
time. Factors such as culture conditions can have a significant effect on cell cycle 
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progression: cells should be sub-confluent at around 50% when analysis is undertaken 
as over-confluency can lead to cell-cell contact and contact inhibition, although this is 
less critical for transformed cells (Schorl and Sedivy 2007). Media should also be 
changed regularly and at the same time for different cell lines undergoing analysis such 
that nutrient availability is consistent across lines (Schorl and Sedivy 2007).  
Cells cycle can be synchronised, through for example arresting cells in G0, by growing 
cells to confluency and then subjecting cells to serum deprivation, although this is less 
critical for cells that are already transformed. A more accurate method for the 
determination of the fraction of cells in S phase is to pulse label an asynchronous 
culture with BrdU for 15-60 minutes before immediately harvesting for analysis.  With 
this method, cells at the very beginning and end of S phase are captured which is often 
missed with standard FACS analysis (Schorl and Sedivy 2007).    
The cell lines analysed with FACS were of a similar passage number, confluency was 
consistent at the time of analysis at around 50% and media was changed at the same 
time across the cell lines. Where possible, variables that might have affected cell cycle 
were kept constant.  
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5.9 Future work 
 
5.9.1 Immortalisation of RPTEC 
 
A comprehensive search of the literature did not identify any publications where a 
CRISPR-Cas-9 system had been used to successfully knockout gene expression in 
RPTEC. The use of CRISPR-Cas9 systems in primary cells is particularly difficult but 
provides a very powerful tool since primary cells provide a better model to investigate 
the effects of loss of function mutations on tumourigenesis.  
 
BMI-1 transduction alone did not appear to result in RPTEC immortalisation, which 
limited their proliferative capacity, and cells that had undergone gene editing using the 
CRISPR-Cas-9 system underwent senescence before they could be used in in vitro assays. 
RPTECs immortalisation could be attempted through the successive introduction of the 
Simian Virus 40 Early Region (SV40T) and hTERT, which has been shown to 
effectively immortalise RPTECs without causing transformation (Kowolik, Liang et al. 
2004) .  
 
Single cell selection of BMI-1 transduced RPTECs was not possible after successful 
gene editing of LIMD1 and Ajuba using a CRISPR-Cas-9 mediated deletion system.  
Single cell selection of primary cells is difficult and although effective immortalisation 
may increase the likelihood of success this is not guaranteed. After single cell plating, 
the use of conditioned media where media is supplemented with 25-50% media 
obtained from cells that are approximately 70% confluent may increase the likelihood of 
success.  
 
Given that it was not possible, to use the heterogeneous LIMD1 and AJUBA deleted 
RPTEC population in further in vitro assays effective immortalisation may overcome this 
limitation. However, alongside single cell selection using conditioned media, other 
strategies to improve growth of the CRISPR-Cas-9 LIMD1 and Ajuba knockdown lines 
to enable the use of the heterogeneous population in in vitro assays could include the use 
of a Rho-kinase (ROCK) inhibitor and modified Schlegel culture conditions.  
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Having successfully used a CRISPR-Cas-9 system in a primary cell line, the use of such 
an approach in ccRCC cells is likely to be much easier, with issues such as single cell 
selection much easier to overcome. Using such a system, RCC45 and RCC12 cells 
demonstrated excellent transfection efficiencies, and the protocol could be easily 
optimised for a ccRCC line.  
 
After single cell selection, the CRISPR-Cas-9 transduced cells should be subjected to a 
mismatch detection assay using the T-7 endonuclease assay (T7-EI) in order to confirm 
the presence of indels secondary to gene editing. Here genomic DNA spanning the 
crRNA target site is PRC amplified and analysed using the T7-EI mismatch detection 
assay and then run on a 2% agarose gel, with gene editing indicated by the presence of 
cleaved bands under the primary PCR product. Sanger sequencing can then be 
performed on the PCR products, to confirm whether PCR products are wild type, 
homozygous or heterozygous.  
 
5.9.2 Further assays to investigate the in v i tro  effects of LIMD1 loss on 
tumourigenesis 
 
5.9.2.1 Measuring the effects of LIMD1 loss on Clonogenic potential 
 
RCC11 and RCC48 ccRCC lines were successfully lentivirally transduced to generate scr 
control lines, shLIMD1, and rrLIMD1 lines. A number of critical components of 
tumourigenesis as described by Hanahan and Weinberg were then investigated 
(Hanahan and Weinberg 2011).  
Increased proliferative capacity was confirmed by increased colony formation in 
association with LIMD1 loss as assessed in a 2-D format. 3-D colony assays are 
however considered a more stringent assay, cells by definition must have lost of contact 
inhibition and be anchorage independence, features considered critical for in vivo 
carcinogenesis.  
It is unclear why the 3-D assays undertaken were unsuccessful but such an approach 
would be worth optimising. In addition more sophisticated 3-D culture enables the 
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creation of an environment that more closely mimics that observed in vivo, for example 
with the inclusion of cells from the tissue microenvironment and of the basement 
membrane through for example the inclusion of laminin-rich basement membrane 
extracellular matrix (Matrigel). Recently, a novel automated method to measure 
clonogenic survival and proliferation of cells in a 3D matrix consisting of matrigel and 
more closely representing physiological in vivo growth conditions has been described 
(Eke, Hehlgans et al. 2016).  
5.9.2.2 Measuring the effects of LIMD1 loss on migration and invasion 
 
The scratch assay demonstrated that loss of LIMD1 was not associated with changes in 
migration. The use of more than one migration assay confirming the same result would 
provide additional evidence that LIMD1 loss was not associated with changes in cell 
migration. 2-D assays can be adapted to more closely mimic the in-vivo environment, for 
example coating plates with collagen or basal membrane extract, (Matrigel) prior to 
seeding. In the transwell migration assay cells are seeded in to one chamber separated by 
a porous membrane through which cells transmigrate. Cells are generally seeded into the 
upper compartment, and can then migrate vertically through pores of the membrane to 
the lower compartment containing an attractant or higher serum content.  A variant of 
this, the transwell invasion assay assesses the effects of the ECM on invasion. A thin 
layer of ECM is overlaid on the porous filter prior to seeding cells which occludes the 
membrane pores and blocks non-invasive cells from migration. The IncuCyte® system 
for example enables the real-time visualisation and assessment of cell morphology in 
scratch wound assays without disrupting plates inside a tissue culture incubator.  
 
5.9.2.3 Changes in cell cycle associated with loss of LIMD1 
 
FACS analysis of the LIMD1 proficient and LIMD1 depleted RCC11 and RCC48 lines, 
was not associated with changes in cell cycle. We did not however synchronise cells 
prior to FACS analysis.  Although such an approach is often not required in 
transformed cells, cell synchronisation particularly in combination with BrdU 
incorporation would enable the more accurate determination of cell cycle phase 
progression in these cell lines.  
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5.9.2.4 Characterising HIF in association with loss of LIMD1 
 
Given the critical role of HIF2α in tumourigenesis in ccRCC it would be interesting to 
evaluate the effects of LIMD1 loss using a HIF2α reporter assay. RNA sequencing 
(RNA-Seq) uses high-throughput sequencing methods to provide an insight into the 
transcription of a cell and could be used to identify differences in the expression of 
genes associated with hypoxic deregulation in association with loss of LIMD1 in the cell 
lines described.  
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6.1 Introduction 
 
There is a need to selectively target cancer cells whilst minimising drug-associated 
toxicity in healthy cells. Multiple effective anti-cancer drugs have been identified but a 
particular challenge is to target cancer cells with drugs at concentrations that will not 
have significant effects on healthy non-cancerous tissue. Given that deletion/mutation 
of tumour suppressors is associated with a loss of function phenotype, targeting such 
genes represents a particular challenge.  
 
Two genes are synthetically lethal if mutation/deletion of either gene is compatible with 
viability but mutation/deletion of both genes results in cell death, for example targeting 
BRCA1/2 mutated breast and ovarian cancer through PARP inhibition (Kaelin 2005, 
Yap, Sandhu et al. 2011). By targeting tumour cells that already have loss of function of 
at least one tumour suppressor, a synthetically lethal approach can be used to identify 
drugs that kill cells in a genotype-specific manner, targeting the protein products of 
genes that are synthetically lethal in association with such cancer-causing mutations 
(Kaelin 2005).  
 
There is an unmet need to develop strategies by which choice of treatment is influenced 
by the particular characteristics of the tumour, maximising drug therapeutic effect for an 
individual patient. Predictive biomarkers provide information on the likely benefit of a 
particular treatment for an individual patient. In metastatic ccRCC however no 
predictive biomarkers have been consistently validated (Gulati, Martinez et al. 2014). 
25% of ccRCC tumours demonstrate inherent resistance to targeted TKI therapy and 
resistance will almost invariably develop in the remainder of tumours (Chowdhury, 
Larkin et al. 2008). 
 
49.3% of ccRCC tumours demonstrated reduced LIMD1 staining compared to matched 
adjacent tissue and in vitro, reduced LIMD1 staining was observed in ten out of twelve 
ccRCC lines compared to the control RPTEC line. Reduced LIMD1 staining did not 
correlate with the clinico-pathological indices of tumour grade, stage, PFS and OS. 
Nonetheless, LIMD1 loss could represent a predictive biomarker and tumours 
demonstrating reduced LIMD1 staining could be selectively targeted using a synthetic 
lethal approach.   
  Chapter 6: Introduction   
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A synthetic lethality screen was undertaken in the ccRCC cell line RCC11 and drug 
sensitivities in control RCC11 scr cells were compared with drug sensitivities in an 
RCC11 cell line where LIMD1 levels had been significantly downregulated using a 
knockdown lentiviral vector system (RCC11 shLIMD1).  The drug library consisted of 
584 FDA-approved drugs either already in clinical use as cancer-therapeutic drugs, or 
previously evaluated within a clinical trial setting as showing potential cancer-therapeutic 
effects. Such an approach should spare LIMD1-proficient cells, minimising damage to 
healthy normal cells and enabling the selective targeting of tumour cells with loss/low 
LIMD1 expression, through the targeting of an as yet uncharacterised protein product 
of a gene within the LIMD1-low/deficient cells.  
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6.2 Aims and Objectives 
 
The aims of this chapter are: 
 
1. To screen a drug library of 584 cancer-therapeutic drugs using a paired LIMD1 
proficient ccRCC cell line (RCC11 scr) and an RCC11 cell line where LIMD1 
had been significantly knocked down using a lentiviral system (RCC11 
shLIMD1), in order to identify drugs that may demonstrate synthetic lethality in 
association with LIMD1 loss/downregulation.  
 
2. To validate the results of the drug screen in the RCC11 scr/shLIMD1 cell lines 
and in a further ccRCC line, RCC48, using paired LIMD1 proficient RCC48 scr 
cells and LIMD1 low, RCC48 shLIMD1 cells  
 
3. To validate the results of the drug screen in LIMD1 proficient and deficient 
HELA and A549 lines, where biallelic LIMD1 inactivation had been undertaken 
using a CRISPR-Cas-9 gene editing system 
 
4. To establish whether reduced LIMD1 expression is associated with differences 
in sensitivity to the VEGF-TKI sunitinib and the mTOR inhibitor everolimus, 
drugs commonly used for the treatment of metastatic ccRCC  
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6.3 A drug screen was undertaken to identify cancer-therapeutic drugs that 
demonstrated synthetic lethality in association with LIMD1 loss.  
 
Short-term cell viability assays were undertaken to assess the effects of LIMD1 
depletion on the sensitivity of the ccRCC line RCC11 to a range of cancer-therapeutic 
drugs using a drug library obtained from the Institute of Cancer Research (ICR), with 
each drug represented in the drug library once. RCC11 was selected as it expresses high 
levels of LIMD1, Ajuba and WTIP and relatively high levels of both HIF1α and HIF2α, 
and is therefore representative of a relatively aggressive, hypoxically deregulated tumour 
line. LIMD1 depleted RCC11 cells would still be Ajuba and WTIP proficient.   
 
The assay was performed simultaneously in the 2 lentiviral transduced cell lines RCC11 
scr (control cells transduced with non-targeting siRNA (scr)) and RCC11 shLIMD1 
(transduced with an shLIMD1 construct to generate effective LIMD1 knockdown). 
Early passage cells of identical passage were used for all assays, and cells were seeded in 
the absence of puromycin, and at a density to ensure confluency of between 90 and 
95% on day 6, considered optimal for control wells in 2-dimensional drug viability 
assays. Cells were drugged at 24 hours and 72 hours such that the final drug 
concentration of the drug library compounds was 1µM and appropriate controls 
included. In addition, cells taken out of puromycin selection 24 hours prior to seeding 
were simultaneously plated in to six-well plates to achieve a confluency of 90-95% on 
day 6, and lysed and Western blotted to establish good LIMD1 expression in the scr 
control with effective knockdown of LIMD1 in the shLIMD1 RCC11 cell lines. 
Consistently high levels of LIMD1 expression were observed in the scr line, with 
excellent knockdown in the shLIMD1 line (Figure 6.1).  
 
Drug assays were read at day 6 using the ATP-based assay, Cell-Titre GloTM. The ‘Z 
score’ method was used to compare the relative cell killing for each drug between the 
scr and shLIMD1 plates. This method excludes control measurements altogether under 
the assumption that most compounds are inactive and can serve as controls. The 
scoring system rescales the output of the Cell-Titre GloTM assay relative to the within 
plate variation by subtracting the median of the plate values from each drug assay result 
and dividing the difference by the median absolute deviation calculated from all 
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measurements within the plate. This generates a readout whereby the more negative the 
Z-score the greater the degree of cell killing relative to the plate as a whole and the more 
positive the Z-score the greater the cell viability relative to the plate as a whole and 
represents a validated method for the analysis of the results of a drug screening platform 
(Malo, Hanley et al. 2006). 
 
The outputs of the Z-scores were plotted graphically using Prism 6. Comparison of the 
Z-scores for the RCC11 scr and RCC11 shLIMD1 cell lines enables the identification of 
drugs that are associated with more cell death in association with LIMD1 loss but not in 
the scr control, drugs that may demonstrate synthetic lethality in association with 
LIMD1 loss (Figure 6.1).  
 
For most drugs there was little difference between the Z-scores for the scr and the 
shLIMD1 drug screens and excellent agreement between the first and the second 
experimental repeats.  Plotting Z-scores for the drug screen in the RCC11 scr line 1st 
repeat against Z-scores for RCC11 scr in the 2nd repeat demonstrated excellent 
concordance, p<0.0001*** and in the RCC11 shLIMD1 line, p<0.0001***, for 
concordance.  (Figures 6.1A and 6.1B). This demonstrates that the drug assay repeats 
were consistent and suggests that where possible, inferential errors causes by procedural 
factors such as the format of the assay, inconsistent pipette delivery and unintended 
differences in compound concentration related to the evaporation of media were 
minimised.  
 
Drug screen hits were likely to represent a true result when both drug screen repeats 
identified the same drug as a ‘hit’ compound.  Drugs that demonstrated an increase in 
cell killing in the RCC11 shLIMD1 compared to the LIMD1-proficient RCC11 scr in 
both repeats, were designated ‘hit’ compounds, and are listed in Table 6.1 alongside 
their relative Z-scores. 
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Figure 6.1: Synthetic lethality screen with drug library of 584 FDA cancer 
approved drugs. 
RCC11 scr and shLIMD1 matched cells were plated at 1000 cells/well and 1200 cells/well respectively 
into 96-well plates. Cells were taken out of puromycin selection 24 hours prior to plating.  Drugging with 
a compound library of 584 cancer approved drugs and negative controls of media only and media 
supplemented with 0.1% DMSO was undertaken 24 hours and 72 hours after seeding to result in a final 
drug concentration of the drug library compounds of 1µM. Sunitinib control wells with a final drug 
concentration of between 1-3µM were also included. Cell viability was assessed after 6 days using Cell 
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Titer-Glo Luminescent Cell Viability Assay (Promega).  The ‘Z score’ method was used to compare the 
relative cell killing for each drug between the scr and shLIMD1 plates whereby the median of the plate 
values was subtracted from each drug assay result and then divided by the median absolute deviation 
calculated from all measurements within the plate. All plots were undertaken using Prism 6. 
A. Graphical output of Z-scores from the 1st and 2nd drug screen repeats in 
matched LIMD1 proficient/low LIMD1 expressing RCC11 cells. (A (i)) Z-scores for 
the drug screen in the RCC11 (scr) line 1st repeat plotted against the 2nd repeat demonstrate excellent 
concordance (p<0.0001).) (A (ii)) Z-scores for the drug screen in the RCC11 shLIMD1 1st repeat plotted 
against the 2nd repeat demonstrate excellent concordance (p<0.0001).  
B (i) B (ii) Scatter plots of Z-scores for drug screen. Comparison of the Z-scores for 
RCC11 scr versus RCC11 shLIMD1 cell lines with both drug screens represented 
C. Western blot of LIMD1 expression.  Western blot analysis demonstrates high levels of 
expression of LIMD1 in the RCC11 scr cell line, with excellent LIMD1 knockdown in the RCC11 
shLIMD1 cell line.  
 
6.3.1 Pazopanib and irinotecan were identified as ‘drug hits’ in both repeats of 
the synthetic lethality screen 
The two drugs identified as possible hits in both repeats of the drug screen were 
pazopanib and irinotecan with increased cell death observed in the RCC11 shLIMD1 
cell line compared to RCC11 scr control (Figure 6.2).  The difference in Z-score for 
these ‘hit’ compounds was small at around -1 and typically larger differences in Z-score 
are considered significant in a drug synthetic lethality drug screening platform (Malo, 
Hanley et al. 2006). However, both drugs have an established role in the treatment of 
renal cell carcinoma (Shamash, Powles et al. 2005, Sternberg, Davis et al. 2010) and 
differences were consistent between repeats. In addition, most treatments for ccRCC 
result in stable disease or a partial response at best and therefore smaller differences in 
Z score may be more significant in ccRCC compared to other tumour types (Escudier, 
Szczylik et al. 2012).  
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Drug Z score 
(scr) 
1st repeat 
Z score 
(shLIMD1) 
1st repeat 
Z score 
(scr) 
2nd repeat 
Z score 
(shLIMD1) 
2nd repeat 
 
Pazopanib -0.4529 -1.1557 -1.18077 -2.7898 
 
Irinotecan -0.4737 -1.3670 -0.1814 -1.193 
 
 
Figure 6.2: Two replicates of synthetic lethality screen with drug library dosing 
at 1µM demonstrate increased cell death with pazopanib and irinotecan 
treatment in the RCC11 shLIMD1 lines compared to RCC11 scr control  
Results of synthetic lethality drug screen demonstrating ‘positive hits’, with increased cell death in both 
replicates of the RCC11 shLIMD1 cell line compared to scr control. The ‘Z score’ method was used to 
compare the relative cell killing for each drug between the scr and shLIMD1 plates.   
6.3.2 The synthetic lethality drug screen was repeated with a drug concentration 
of 2µM 
The drug library had been stored in the -20°C freezer for over one year and it was 
unclear whether over this time period the potency of some of the drugs had diminished 
through degradation. The drug screen was therefore repeated a third time as described 
with the aim of drugging the cells at 24 and 72 hours with 2µM of the screen drugs 
within the library. Unfortunately due to evaporation of diluent within the library 
particularly from the plate edges, there was insufficient drug available to drug at 72 
hours and drugging was therefore only carried out at 24 hours. Graphical representation 
of the Z-scores for this drug screen in the RCC11scr and RCC11 shLIMD1 lines is 
shown in Figure 6.3.   
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Figure 6.3: Graphical output of Z scores from the synthetic lethality drug screen 
with drugging with 2µM of the drug library 
RCC11 scr and shLIMD1 matched cells were plated in 96 well plates. Drugging with a compound library 
of 584 cancer approved drugs and negative controls of media only and media supplemented with 0.1% 
DMSO was undertaken at 24 hours with final drug concentration of 2µM. Sunitinib control wells with a 
final drug concentration of between 1-3µM were also included. Cell viability was assessed after 6 days 
using the Cell Titer-Glo Luminescent Cell Viability Assay (Promega). The ‘Z score’ method was used to 
compare the relative cell killing for each drug between the scr and shLIMD1 plates. This rescales the 
output of the Cell-Titre GloTM assay relative to the within plate variation by subtracting the average of the 
plate values from each drug assay result and dividing the difference by the standard deviation calculated 
from all measurements within the plate. All plots were undertaken using Prism 6. 
A. Scatter plot of Z-scores for drug screen. Comparison of the Z-scores in RCC11 scr versus RCC11 
shLIMD1 with cells drugged with 2µM of the drug library 24 hours post seeding. B. Western blot of 
LIMD1 expression.  Western blot analysis demonstrates high levels of expression of LIMD1 in the 
RCC11 scr cell line, with excellent LIMD1 knockdown in the RCC11 shLIMD1 cell line.  
 
6.3.3: Irinotecan was identified as a ‘drug hit’ in the RCC11 shLIMD1 line in the 
2µM synthetic lethality screen as well as two additional drugs, selumetinib and 
dorzolamide !
The third drug screen resulted in fewer drug compounds with very negative Z-scores 
(Figure 6.3), probably as a result of less cell killing secondary to drugging only at 24 
hours. The screen did however also identify irinotecan as a potential ‘selectively lethal’ 
hit in association with LIMD1 loss: the Z-score for the shLIMD1 line was -4.811 
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compared to -1.1953 in the scr control (Figure 6.4), consistent with irinotecan 
demonstrating synthetic lethality in association with LIMD1 loss.  
 
Within this screen, pazopanib resulted in increased cell death in the RCC11 scr cell line, 
Z-score -2.2946 versus 0.687 in the shLIMD1 line, the opposite effect to that observed 
in the first two drug screens. Two additional ‘drug hits’ were identified, the drug 
selumetinib, known to function as an orally available, potent, non-ATP selective MEK-
1/2 inhibitor with demonstrated efficacy in K-Ras mutated non-small cell lung 
carcinoma (Janne, Shaw et al. 2013) and dorzolamide, a carbonic anhydrase inhibitor 
widely used in the treatment of glaucoma and ocular hypertension (Balfour and Wilde 
1997). For selumetinib, in the 2µM drug screen, the Z-score in the shLIMD1 line was -
3.4752 compared to 0.2496 in the scr control and for dorzolamide, the Z score was -
1.7139 in the shLIMD1 line compared to scr control. Neither drug was identified as ‘hit’ 
compounds in the 1µM drug screens in association with LIMD1 loss (Figures 6.3 and 
6.4). 
 
Drug Z score 
scr  
2µM drug 
screen 
Z score 
shLIMD1 
2µM drug 
screen 
Z score 
scr  
1µM drug 
screen 
1st repeat 
Z score 
shLIMD1 
1µM drug 
screen 
1st repeat 
Z score 
scr  
2nd drug 
screen 
2nd repeat 
Z score 
shLIMD1 
2nd drug 
screen 
2nd repeat 
Selumetinib 
(AZD6244) 
0.2496 -3.475 -0.872 -1.190 -3.740 0.441 
Dorzolamide 0.2605 -1.714 -0.050 0.576 0.450 0.176 
Pazopanib -2.2946 0.688 0.453 -1.156 -1.181 -2.790 
Irinotecan -1.1953 -4.811 -0.474 -1.367 -0.181 -1.245 
 
Figure 6.4 Results of ‘drug hits’ from synthetic lethality screen with final drug 
concentration 2µM, alongside Z-scores from 1st and 2nd drug screen  
Results of synthetic lethality drug screen demonstrating ‘positive hits’ with increased cell death in the 
shLIMD1 cell line compared to scr control with the drug library with drugging at 2µM at 24 hours, 
alongside Z-scores for the 1st and 2nd repeats of the drug screen with drugging at 1µM at 24 and 72 hours. 
The ‘Z score’ method was used to compare the relative cell killing for each drug between the scr and 
shLIMD1 plates.  
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6.4 Validation of hits from the synthetic-lethality drug screen 
 
Short-term cell viability assays across a range of drug concentrations were undertaken to 
assess the effects of LIMD1 depletion on the sensitivity of the RCC11 and RCC48 cell 
lines to the ‘drug hits’ identified in the drug screen. The assay was performed 
simultaneously with early passage RCC11 and RCC48 cells transduced with a non-
targeting control construct (scr), or knockdown LIMD1 construct (shLIMD1) in a 96- 
well plate format. As before, cells were taken out of selection 24 hours prior to seeding 
and seeded at a density associated with 90-95% confluency on day 6 in the control wells.  
Cells were also seeded in to a 6-well plate for lysis on day 6 to assess relative LIMD1 
expression by immunoblot. Cells were drugged in triplicate at 24 and 72 hours for each 
drug concentration of between 0.1µM and 60µM and relative cell viability assessed on 
day 6 using the ATP based Cell-Titre GloTM assay.  
 
6.4.1 Validation of the carbonic anhydrase inhibitor dorzolamide as a drug hit 
from the synthetic lethality screen. 
 
Drugging with dorzolamide up to a concentration of 60µM resulted in almost no cell 
death in either the RCC11 or RCC48 cell lines (Figure 6.5). Although dorzolamide was 
identified as a ‘hit’ in the 2µM drug screen with a Z-score of -1.7139 in the RCC11 
shLIMD1 screen compared to 0.265 in the RCC11 scr screen, almost no cell death was 
seen in either cell line in the 1st or 2nd drug screen at 1µM and further validation with 
dorzolamide was not undertaken (Figure 6.2). The failure of validation of drugs 
identified as ‘hits’ in a drug-screening platform is near universal. A review article by 
Carnero suggested that one marketable drug emerges from screening one million 
compounds and that only one in twenty drugs identified in a compound library as 
‘screening hits’ are subsequently validated as ‘active hits’ (Carnero 2006). 
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Figure 6.5: The carbonic anhydrase inhibitor dorzolamide is not associated with 
cell death in either RCC11 or RCC48 cell lines 
RCC11 scr/shLIMD1 lines and RCC48 scr/shLIMD1 lines were taken out of puromycin selection and 
plated into the same 96-well plate at a seeding density associated with 90-95% confluency on day 6 and 
exposed to a range of dorzolamide concentrations between 0.1µM and 60µM 24 hours and 72 hours after 
seeding, with drugging in triplicate at each drug concentration.  Cells were simultaneously plated for 
Western blot analysis to assess knockdown on day 6. Cell viability was assessed on day 6 using the ATP-
based Cell-Titer Glo™ assay. All graphs were generated in Prism version 6, with error bars demonstrating 
SEM.   
(A (i) Representative dorzolamide dose-response curve, RCC11 scr/shLIMD1, (A (ii)) Representative 
dorzolamide dose-response curve, RCC48 scr/shLIMD1. (B (i)) Western blot analysis demonstrates high 
levels of expression of LIMD1 in the RCC11 scr cell line, with good LIMD1 knockdown in the RCC11 
shLIMD1 cell line. (B (ii)) Western blot analysis demonstrates high levels of expression of LIMD1 in the 
RCC48 scr cell line, with good LIMD1 knockdown in the RCC11 shLIMD1 cell line.  
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6.4.2 Validation of selumetinib as a drug hit from the synthetic lethality screen. 
 
Drugging with selumetinib up to a concentration of 60µM was not associated with cell 
death in RCC48 cells (Figure 6.6). In the lentiviral-transduced RCC11 scr/shLIMD1 
cell lines, inconsistent results were observed with some repeats of the drug assay 
demonstrating increased drug sensitivity in the scr line and other repeats increased 
sensitivity in the shLIMD1 line, with little cell killing in either cell line up to a drug 
concentration of 60µM (Figure 6.6). Good knockdown of LIMD1 was observed in all 
repeats of the validation experiment (Figure 6.6).  In addition selumetinib sensitivity 
was inconsistent between repeats of the drug screen at 1µM in the RCC11 cells: 
increased sensitivity was observed in the shLIMD1 cell line in the 1st repeat but 
increased sensitivity in the scr RCC11 cell line in the 2nd repeat (Figure 6.4).  Given the 
inconsistency of the drug screen results and conflicting results of the initial validation 
attempts, selumetinib was not felt to represent a true hit from the drug screen.  
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Figure 6.6: Inconsistent dose responses are observer in the RCC11 scr/shLIMD1 
cell lines drugged with selumetinib and little cell death in RCC48 cells drugged 
with up to 60µM selumetinib 
RCC11 scr/shLIMD1 lines and RCC48 scr/shLIMD1 lines were plated in the same 96 well plate at a 
seeding density associated with 90-95% confluency on day 6 and exposed to a range of selumetinib 
concentrations between 0.1µM and 60µM 24 and 72 hours after seeding, with drugging in triplicate at 
each drug concentration.  Cells were also plated for Western blot analysis to assess knockdown on day 6. 
Cell viability was assessed on day 6 using the ATP-based Cell-Titer Glo™ assay. All graphs were 
generated in Prism version 6, with error bars demonstrating the SEM.  
 (A (i)-A (ii)) Selumetinib dose-response curve, RCC11 scr/shLIMD1, B Selumetinib dose-response 
curve, RCC48 scr/shLIMD1. (B (i)) Western blot analysis demonstrates high levels of expression of 
LIMD1 in the RCC11 scr cell line, with excellent LIMD1 knockdown in the RCC11 shLIMD1 cell line. 
(B (ii)) Western blot analysis demonstrates high levels of expression of LIMD1 in the RCC48 scr cell 
line, with excellent LIMD1 knockdown in the RCC11 shLIMD1 cell line.  
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6.4.3 Validation of the multi-targeting tyrosine kinase inhibitor pazopanib as a 
drug hit from the synthetic lethality screen 
 
The multi-tyrosine kinase inhibitor pazopanib is an established first-line treatment for 
metastatic ccRCC, targeting VEGF, PDGF and c-Kit tyrosine kinases (Motzer, Hutson 
et al. 2013) (Sternberg, Davis et al. 2010). However, treating both the RCC11 
scr/shLIMD1 and RCC48 scr/shLIMD1 cell lines with drug concentrations up to 
60µM was associated with little cell death in either cell line, particularly for the RCC11 
cell line (Figure 6.7).  For both cell lines, no difference in relative cell death between 
the scr/shLIMD1 cell lines over a range of drug concentrations was observed. Excellent 
LIMD1 knockdown in the shLIMD1 line and high LIMD1 expression in the scr control 
was consistently observed (Figure 6.7).  
 
The results of the drug screen repeats were also inconsistent, with the drug screen at 
2µM demonstrating increased sensitivity to pazopanib in the scr line compared to 
shLIMD1 line (Z-score for scr line -2.2946 versus 0.68764 for shLIMD1) (Figure 6.4). 
Drugging the paired cell lines with sunitinib, a TKI also targeting VEGF, PDGF and c-
KIT tyrosine kinases, demonstrated no difference in drug sensitivity between the 
scr/shLIMD1 cell lines, results of which are shown later in this chapter, (Figure 6.13).  
 
Sunitinib and pazopanib have broadly similar tyrosine kinase targets, although some 
differences are noted which could explain some of the relative differences in drug 
sensitivity in different cell lines (Gotink and Verheul 2010). The lack of sensitivity of 
both cell lines to pazopanib but sensitivity to sunitinib is however surprising. Given the 
inconsistent results, and dose-response curves demonstrating no difference in sensitivity 
to sunitinib in paired RCC11 scr/shLIMD1 and RCC48 scr/shLIMD1 lines (Figure 
6.13), pazopanib was not felt to represent a true ‘hit’ and was not validated further.  
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Figure 6.7. The multi-targeting targeting tyrosine kinase inhibitor pazopanib is 
not associated with significant cell death in RCC11 or RCC48 cell lines 
RCC11 scr/shLIMD1 lines and RCC48 scr/shLIMD1 lines were plated in the same 96-well plate at a 
seeding density associated with 90-95% confluency on day 6 and exposed to a range of pazopanib 
concentrations between 0.1µM and 60µM 24 and 72 hours after seeding, with drugging in triplicate at 
each drug concentration.  Cells were also plated for Western blot analysis to assess knockdown on day 6. 
Cell viability was assessed on day 6 using the ATP-based Cell-Titer Glo™ assay. All graphs were 
generated in Prism version 6, with error bars demonstrating the SEM.  (A (i)) Representative pazopanib 
dose-response curve, RCC11 scr/shLIMD1. (A(ii)) Representative pazopanib dose-response curve 
RCC48 scr/shLIMD1. (B (i)) Western blot analysis demonstrates high levels of expression of LIMD1 in 
the RCC11 scr cell line, with excellent LIMD1 knockdown in the RCC11 shLIMD1 cell line. (B (ii)) 
Western blot analysis demonstrates high levels of expression of LIMD1 in the RCC48 scr cell line, with 
excellent LIMD1 knockdown in the RCC11 shLIMD1 cell line.  
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6.5 Validation of irinotecan as a drug hit from the synthetic lethality screen in 
ccRCC lines 
 
The efficacy of chemotherapy in RCC has been disappointing and it has been suggested 
that this in part may be because renal cancer cells produce large amounts of a multidrug 
resistance protein leading to the efflux of cytotoxic drugs (Tobe, Noble-Topham et al. 
1995). Relative tumour hypoxia and impaired drug delivery are also likely to contribute.  
 
With the development of effective multi-targeting tyrosine kinase inhibitors, the role of 
chemotherapy in the treatment of RCC is less well defined. However, topoisomerase-I 
inhibitors do demonstrate efficacy in vitro and in vivo, with irinotecan demonstrating 
activity in renal xenografts (Miki, Nonomura et al. 1998)  and topetecan resulting in 
increasing apoptosis in RCC cell lines compared to 5-FU (Ramp, Mahotka et al. 2001).  
Irinotecan efficacy has also been demonstrated in vivo. In a phase II trial of patients with 
metastatic RCC progressing after treatment with interferon alpha, a 61% symptomatic 
response rate was observed to combination chemotherapy with irinotecan, cisplatin and 
mitomycin C (Shamash, Powles et al. 2005) and activity of irinotecan alone has also 
been described (Fizazi, Rolland et al. 2003).  
 
The drug screen contained a further topoisomerase-I inhibitor topetecan. No obvious 
differences in topetecan sensitivity between the RCC11 scr/shLIMD1 lines were 
observed with Z-values of -5.189 and-5.790 respectively for the first screen and -6.177 
and -6.318 for the second screen respectively with the drug library at 1µM. Significant 
cell death was however observed in both scr/shLIMD1 lines and it may be that this 
drug concentration did not allow for the resolution of differences in drug sensitivity 
which may have been observed with drugging at lower drug concentrations. Another 
explanation may be that differences in drug sensitivity observed with irinotecan in the 
RCC11scr/shLIMD1 lines may not be related to the effects of the drug on 
topoisomerase-I. A number of topoisomerase-II inhibitors, etoposide, doxorubicin, 
daunorubicin and mitoxantrone were included in the screen. No differences in 
sensitivity to these drugs were observed between the scr and shLIMD1 cell lines.  
 
Short-term cell viability assays in the paired RCC11 scr and RCC11 shLIMD1 and 
RCC48 scr and RCC48 shLIMD1 cell lines plated simultaneously and exposed to 
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increasing irinotecan concentrations were undertaken.  Increased drug sensitivity in both 
shLIMD1 cell lines compared to scr control was observed, with a greater effect 
observed in the RCC48 cell line in association with LIMD1 loss (Figures 6.8 and 6.9). 
 
There was some variation in the degree of cell killing at any particular irinotecan 
concentration between biological repeats of the assay. This variation may have been 
related to slight differences in final drug concentration between repeats due to for 
example media evaporation effects, drug dilution reproducibility and slight differences 
in rates of cell growth associated with cell passage/cell confluency of cells at time of 
seeding.  Cells of similar passage were seeded for biological repeats and similar 
confluency/cell titre-GloTM readings for the control cells treated with DMSO alone were 
observed between experiments. In addition for the RCC11 cells the dose-response 
curves tailed off and drugging with 80 or 100µM of irinotecan did not result in 
increased cell death (data not shown). Drug treatment of RCC aims to reduce tumour 
burden or stabilise disease and complete response is unusual. Given that the dose-
response curves did not consistently result in close to 100% cell death at the highest 
drug concentrations, calculation of the drug IC50 was difficult and therefore a drug 
concentration of 0.5µM was selected and sensitivity to irinotecan compared.  
 
At this drug concentration increased cell death in association with LIMD1 loss was 
observed in the RCC11 shLIMD1 compared to RCC11 scr control but this did not meet 
statistical significance, Student’s T test p=0.1161 (Figure 6.8). This difference was 
however significant in the RCC48 shLIMD1 line compared to RCC48 scr control, 
Student’s T test p=0.0016* (Figure 6.9). 
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Figure 6.8: Drugging with irinotecan is associated with increased cell death in 
RCC11 cells with reduced LIMD1 expression (shLIMD1) compared to scr control 
RCC11 scr/shLIMD1 lines were plated in a 96 well plate at a seeding density associated with 90-95% 
confluency on day 6 and exposed to a range of irinotecan concentrations between 0.1µM and 60µM 24 
and 72 hours after seeding, with drugging in triplicate at each drug concentration.  Cells were also plated 
for Western blot analysis to assess knockdown on day 6. Cell viability was assessed on day 6 using the 
ATP-based Cell-Titer Glo™ assay. All graphs were generated in Prism version 6, with error bars 
demonstrating the SEM.  (A (i))-A (ii)) Irinotecan dose-response curves, RCC11 scr/shLIMD1. B. An 
irinotecan concentration of 0.5µM was selected and relative sensitivity of RCC11 cells with high LIMD1 
versus low LIMD1 expression (scr versus shLIMD1) assessed. Sensitivity to irinotecan for the shLIMD1 
lines at 0.5 µM is shown relative to the scr control cells with error bars representing the SEM for the 3 
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biological repeats of the experiment. P value represents Students t-test value. Analysis was undertaken 
using Prism 6.  
C. Immunoblot demonstrating high levels of LIMD1 expression in the scr control with good knockdown 
in the shLIMD1 cell lines.  
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Figure 6.9: Drugging with the topoisomerase-I inhibitor irinotecan is associated 
with increased cell death in RCC48 cells with reduced LIMD1 expression 
(shLIMD1) compared to scr control 
RCC48 scr/shLIMD1 lines were plated in a 96 well plate at a seeding density associated with 90-95% 
confluency on day 6 and exposed to a range of irinotecan concentrations between 0.1µM and 60µM 24 
  Chapter 6: Results   
! 314!
and 72 hours after seeding, with drugging in triplicate at each drug concentration.  Cells were also plated 
for Western blot analysis to assess knockdown on day 6. Cell viability was assessed on day 6 using the 
ATP-based Cell-Titer Glo™ assay. All graphs were generated in Prism version 6, with error bars 
demonstrating the SEM.  (A (i))-A (ii)) Irinotecan dose-response curves, RCC48 scr/shLIMD1. B. An 
irinotecan concentration of 0.5µM was selected and relative sensitivity of RCC48 cells with high LIMD1 
versus low LIMD1 expression (scr versus shLIMD1) assessed. Sensitivity to irinotecan for the shLIMD1 
lines at 0.5 µM is shown relative to the scr control cells with error bars representing the SEM for the 3 
biological repeats of the experiment. P value represents Students t-test value. Analysis was undertaken 
using Prism 6. C. Immunoblot demonstrating high levels of LIMD1 expression in the scr control with 
good knockdown in the shLIMD1 cell line 
 
6.6 Validation of irinotecan as a drug hit from the synthetic lethality screen in 
non-ccRCC lines in association with LIMD1 loss 
 
Dr Daniel Foxler of the Sharp group had used a CRISPR-Cas-9 system to biallelically 
inactivate LIMD1 in the lung adenocarcinoma line, A549 and in HELA cells. Cell 
viability in CRISPR-Cas-9 LIMD1-/- cells and LIMD1 proficient Cas-9 control cells 
exposed to increasing irinotecan concentration was compared. It was hypothesised that 
as the CRISPR-Cas-9 LIMD1 knockout cell lines expressed no LIMD1, in comparison 
to the RCC11/RCC48 shLIMD1 lines where some LIMD1 expression remained, a 
greater difference in cell viability between the Cas-9 LIMD1 proficient and CRISPR-
Cas-9 LIMD1 deficient cell lines might be observed.  
 
Increased sensitivity to irinotecan in the LIMD1-/- HELA/A549 CRISPR-Cas 9 cells 
compared to LIMD1 proficient controls was observed in all three biological repeats of 
the irinotecan dose-response assays in both cell lines (Figures 6.10 and 6.11). Again 
some variation in the degree of cell killing at any particular irinotecan concentration 
between biological repeats of the assay in both proficient and deficient cell lines was 
observed. Cells of similar passage were seeded for biological repeats and similar 
confluency/cell titre-GloTM readings for the control cells treated with DMSO alone were 
observed between experiments.  
 
A concentration of 2µM irinotecan was selected and irinotecan sensitivity in both the 
A549 LIMD1-/- and HELA LIMD1-/- cells compared to proficient control. This 
concentration was selected as differences in irinotecan drug sensitivity in the LIMD1 
  Chapter 6: Results   
! 315!
deficient compared to proficient A549 and HELA cells was greatest at this drug 
concentration. Again, calculation of the drug IC50 was not possible, as at the highest 
irinotecan drug concentrations, cell death close to 100% was not consistently observed.  
Pooled analysis of the biological repeats demonstrated a significant increase in 
sensitivity to irinotecan with on average a 25% increase in cell death in the LIMD1 
deficient A549 cells compared to proficient control drugged with 2µM irinotecan, 
Student’s T test, p=0.0232* (Figure 6.11). This figure was even greater in HELA cells, 
where 60% more cell death occurred in the LIMD1 deficient HELA cells compared to 
proficient control at this drug concentration, Student’s T test p=0.0196* (Figure 6.11).   
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Figure 6.10: The topoisomerase-I inhibitor irinotecan is associated with 
increased cell death in LIMD1 deficient compared to matched LIMD1-proficient 
control A549 cells 
A549 CRISPR/Cas-9 LIMD1+/+ and CRISPR/Cas-9 LIMD1-/- cells were plated simultaneously in a 96- 
well plate at a seeding density associated with 90-95% confluency on day 6 and exposed to a range of 
irinotecan concentrations between 0.1µM and 60µM 24 and 72 hours after seeding, with drugging in 
triplicate at each drug concentration. Cells were also plated for Western blot analysis to assess LIMD1 
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expression on day 6. Both cell lines were plated simultaneously on the same 96 well plate and exposed to 
a range of irinotecan concentrations between 0.1µM and 60µM 24 hours after seeding, with drugging in 
triplicate at each drug concentration. Cell viability was assessed on day 6 using the ATP-based Cell-Titer 
Glo™ assay. All graphs were generated in Prism version 6, with error bars demonstrating the SEM.  
(A(i))-A(iii)) Irinotecan dose-response curves, for A549 LIMD1+/+ and A549 LIMD1-/- lines. B. An 
irinotecan concentration of 2µM was selected and the relative sensitivity of HELA and A549 LIMD1-/- 
cells generated by a CRISPR-Cas-9 LIMD1 knockout system compared to CRISPR-Cas-9 LIMD1+/+ 
control assessed. Sensitivity to irinotecan at 2µM is shown relative to the CRISPR-Cas-9LIMD1+/+ 
control cells with error bars representing the SEM for the 3 biological repeats. P value represents Students 
t-test value. All analysis was undertaken using Prism 6. C. Immunoblot demonstrating high levels of 
LIMD1 expression in the A549 LIMD1+/+ control with no LIMD1 expression in the A549 LIMD1-/-. 
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Figure 6.11: The topoisomerase-I inhibitor irinotecan is associated with 
increased cell death in LIMD1 deficient compared to matched LIMD1-proficient 
control HELA cells 
HELA CRISPR/Cas-9 LIMD1+/+ and CRISPR/Cas-9 LIMD1-/- cells were plated simultaneously in a 96 
well plate at a seeding density associated with 90-95% confluency on day 6 and exposed to a range of 
irinotecan concentrations between 0.1µM and 60µM 24 and 72 hours after seeding, with drugging in 
triplicate at each drug concentration. Cells were also plated for Western blot analysis to assess LIMD1 
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expression on day 6. Cell viability was assessed on day 6 using the ATP-based Cell-Titer Glo™ assay. All 
graphs were generated in Prism version 6, with error bars demonstrating the SEM.  (A(i))-A(iii)) 
Irinotecan dose-response curves, for HELA LIMD1+/+ and HELA LIMD1-/- lines. B.  An irinotecan 
concentration of 2µM was selected and the relative sensitivity of HELA LIMD1-/- cells generated by a 
CRISPR-Cas-9 LIMD1 knockout system compared to CRISPR-Cas-9 LIMD1+/+ control assessed. 
Sensitivity to irinotecan at 2µM is shown relative to the CRISPR-Cas-9LIMD1+/+ control cells with error 
bars representing the SEM for the 3 biological repeats. P value represents Students t-test value. All 
analysis was undertaken using Prism 6. C. Immunoblot demonstrating high levels of LIMD1 expression 
in the HELA LIMD1+/+ control with no LIMD1 expression in the HELA LIMD1-/-. 
6.7 Levels of endogenous LAW expression correlate with sensitivity to irinotecan 
in a panel of ccRCC cell lines. 
 
LAW expression was evaluated in a panel of ccRCC cell lines with Western Blotting and 
is described in chapter 3. Given the overlapping functions of LAW family members 
particularly in the regulation of the hypoxic response and microRNA silencing, the 
relationship between expression of LAW family members and sensitivity to irinotecan 
was explored.  
 
Five ccRCC cell lines were selected, two with high levels of expression of all three 
family members, RCC11 and CAKI2, and three with lower levels of expression of LAW 
family members, RCC4, RCC12 and RCC912 (Figure 6.12B). Irinotecan dose-response 
was characterised in these cell lines by Ms Kathryn Davidson.  As before, cells were 
seeded into 96- well plates such that they were at between 90-95% confluency on day 6 
in the control wells containing DMSO 0.1% only. Drugging at a range of irinotecan 
concentrations was undertaken at 24 and 72 hours and the plates read on day 6 using an 
ATP based assay (Cell-Titer-Glo™). Cell lines with low levels of endogenous LAW 
expression RCC4, RCC12 and RCC912 demonstrated increased sensitivity to irinotecan 
compared to CAKI2 and RCC11, cell lines that express high levels of LAW proteins, 
suggesting that loss of LAW expression is associated with increased irinotecan 
sensitivity in ccRCC (Figure 6.12A).   
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Figure 6.12. Levels of endogenous LAW expression correlates with sensitivity to 
irinotecan in a panel of ccRCC cell lines 
RCC4, RCC11, RCC12, CAKI2 and RCC912 cells were plated in a 96 well plate at a seeding density 
associated with 90-95% confluency on day 6 and exposed to a range of irinotecan concentrations between 
0.1µM and 60µM 24 and 72 hours after seeding, with drugging in triplicate at each drug concentration. 
Cell viability was assessed on day 6 using the ATP-based Cell-Titer Glo™ assay. All graphs were 
generated in Prism version 6, with error bars demonstrating the SEM.  (A) Irinotecan dose-response 
curves, for RCC4, RCC11, RCC12, CAKI2 and RCC912 cell lines. B. Immunoblot demonstrating levels 
of LAW expression in a panel of ccRCC cell lines with β-actin included as a loading control.  
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6.8 LIMD1 loss does not affect the sensitivity of RCC11 or RCC48 to the tyrosine-
kinase inhibition sunitinib or the mTOR inhibitor temsirolimus 
 
Short-term cell viability assays were undertaken to assess the effects of LIMD1 
depletion on the sensitivity of the ccRCC lines RCC11 and RCC48 to the multi-tyrosine 
kinase inhibitor sunitinib. Sunitinib is a TKI which acts predominantly to inhibit VEGF, 
PDGF and c-kit tyrosine kinases and is used first-line in the treatment of ccRCC 
(Albiges, Choueiri et al. 2015). The effects of LIMD1 depletion on sensitivity to 
temsirolimus, an mTOR inhibitor used after the failure of TKI were also characterised 
(Albiges, Choueiri et al. 2015). 
 
Work by del Peurto-Nevado et al, demonstrated that phosphorylated KDR staining 
(phosphorylated VEGFR2) is a predictor of clinical benefit to sunitinib-based therapy 
and hence that active angiogenesis predicts response to therapy (del Puerto-Nevado, 
Rojo et al. 2014). Given the known function of LIMD1 in the regulation of the hypoxic 
response, the effects of LIMD1 loss on sunitinib sensitivity were investigated. In the 
RCC11/RCC48 cell lines, loss of LIMD1 was not however associated with differences 
in sensitivity to the multi-TKI pazopanib (Figure 6.7).  
 
As before, the assay was performed in the RCC11/48 scr and shLIMD1 lentiviral 
transduced cell lines plated simultaneously in the same 96-well plates. Cells were taken 
out of puromycin selection 24 hours prior to seeding and seeded at the cell densities 
previously described. Cells were also plated in a 6-well plate and lysed on day 6 to check 
for LIMD1 expression in the scr control and LIMD1 knockdown in the shLIMD1 line. 
Drug assays were read at day 6 using the Cell-Titre GloTM. LIMD1 depletion did not 
affect the sensitivity of either cell lines to sunitinib when compared to control LIMD1 
proficient cell lines (Figures 6.13 and 6.14).  
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Figure 6.13 LIMD1-depletion does not affect the sensitivity of RCC11 to the 
multi-tyrosine kinase inhibitor sunitinib 
 
RCC11 scr/shLIMD1 cells were plated in to a 96 well plate at a seeding density association with 90-95% 
confluency on day 6. Cells were also plated for Western blot analysis to assess LIMD1 knockdown on day 
6. Scr/shLIMD1 cells were plated simultaneously on the same 96 well plate and exposed to a range of 
sunitinib concentrations between 0.1µM and 10µM 24 and 72 hours after seeding, with drugging in 
triplicate at each drug concentration. Cell viability was assessed on day 6 using the ATP-based Cell-Titer 
Glo™ assay. All graphs were generated in Prism version 6, with error bars demonstrating the SEM.  (A 
(i)-A (iii)) Sunitinib dose-response curve, RCC11 scr/shLIMD1, B Expression of LIMD1 in the scr line 
and knockdown of LIMD1 in the shLIMD1 line was confirmed by Western Blotting 
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Figure 6.14 LIMD1-depletion does not affect the sensitivity of RCC48 to the 
multi-tyrosine kinase inhibitor sunitinib 
RCC48 scr/shLIMD1 cells were plated in to a 96 well plate at a seeding density association with 90-95% 
confluency on day 6. Cells were also plated for Western blot analysis to assess LIMD1 knockdown on day 
6. Scr/shLIMD1 cells were plated simultaneously on the same 96 well plate and exposed to a range of 
sunitinib concentrations between 0.1µM and 10µM 24 and 72 hours after seeding, with drugging in 
triplicate at each drug concentration. Cell viability was assessed on day 6 using the ATP-based Cell-Titer 
Glo™ assay. All graphs were generated in Prism version 6, with error bars demonstrating the SEM.  (A 
(i)-A (iii)) Sunitinib dose-response curve, RCC11 scr/shLIMD1, B Expression of LIMD1 in the scr line 
and knockdown of LIMD1 in the shLIMD1 line was confirmed by Western Blotting 
 
Temsirolimus is a serine-threonine kinase inhibitor targeting mTOR (Mackenzie, Rini et 
al. 2011). The mTOR pathway is a convergence point for multiple signalling pathways, 
including the PI3K/Akt pathways, the insulin-like growth factor pathways and the 
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MAP-kinase pathways and mTOR functions to elicit the response of tumour cells to 
numerous growth and survival signals. Phosphorylation of the downstream targets of 
mTOR, S6K and 4EBP1 results in increased translation of a range of specific proteins 
that allow cell cycle progression and increased translation of components of the 
hypoxia-inducible pathway, in particular HIF1α (Mackenzie, Rini et al. 2011). 
Temsirolimus demonstrates OS benefit versus IFN-α in poor-prognosis metastatic RCC 
patients (Hudes, Carducci et al. 2007) and retrospective data suggests some efficacy after 
progression with VEGFR inhibitors (Mackenzie, Rini et al. 2011).  
The assay was undertaken as described for sunitinib in the RCC11 and RCC48 
scr/shLIMD1 lines. LIMD1 depletion did not affect the sensitivity of either cell line to 
temsirolimus when compared to control LIMD1 proficient cell lines (Figures 6.14 and 
6.15).  
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Figure 6.14 LIMD1-depletion does not affect the sensitivity of RCC11 cells to the 
multi-tyrosine kinase inhibitor temsirolimus 
 
RCC111 scr/shLIMD1 cells were plated in to a 96 well plate at a seeding density association with 90-95% 
confluency on day 6. Cells were also plated for Western blot analysis to assess LIMD1 knockdown on day 
6. Scr/shLIMD1 cells were plated simultaneously on the same 96 well plate and exposed to a range of 
sunitinib concentrations between 5µM and 40µM 24 and 72 hours after seeding, with drugging in 
triplicate at each drug concentration. Cell viability was assessed on day 6 using the ATP-based Cell-Titer 
Glo™ assay. All graphs were generated in Prism version 6, with error bars demonstrating the SEM.  (A 
(i)-A (iii)) Temsirolimus dose-response curve, RCC11 scr/shLIMD1, B Expression of LIMD1 in the scr 
line and knockdown of LIMD1 in the shLIMD1 line was confirmed by Western Blotting 
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Figure 6.15 LIMD1-depletion does not affect the sensitivity of RCC48 to the 
multi-tyrosine kinase inhibitor temsirolimus 
 
RCC48 scr/shLIMD1 cells were plated in to a 96 well plate at a seeding density association with 90-95% 
confluency on day 6. Cells were also plated for Western blot analysis to assess LIMD1 knockdown on day 
6. Scr/shLIMD1 cells were plated simultaneously on the same 96 well plate and exposed to a range of 
sunitinib concentrations between 5µM and 40µM 24 hours after seeding, with drugging in triplicate at 
each drug concentration. Cell viability was assessed on day 6 using the ATP-based Cell-Titer Glo™ assay. 
All graphs were generated in Prism version 6, with error bars demonstrating the SEM.  (A (i)-A (iii)) 
Temsirolimus dose-response curve, RCC11 scr/shLIMD1, B Expression of LIMD1 in the scr line and 
knockdown of LIMD1 in the shLIMD1 line was confirmed by Western Blotting 
 
  Chapter 6: Summary   
! 327!
6.9 Summary 
 
Ten out of twelve ccRCC lines characterised in vitro demonstrated reduced LIMD1 
expression compared to LIMD1 proficient primary cells (RPTEC) and 49.3% of ccRCC 
samples compared to MAT in vivo (results shown in Chapter 3).  Consequently the 
selective targeting of tumours demonstrating LIMD1 loss/down-regulation represents 
an attractive novel therapeutic approach and the identification of a drug demonstrating 
synthetic lethality in association with loss of this tumour suppressor would enable the 
selective targeting of a significant proportion of ccRCC tumours with relative sparing of 
non-tumour LIMD1 proficient cells.    
 
A synthetic lethality screen was undertaken in paired RCC11 proficient (scr) compared 
to RCC11 deficient (shLIMD1) cell lines using a compound library of 584 FDA 
approved drugs with demonstrated anti-cancer activity or evaluated as potential anti-
cancer drugs. This identified a number of ‘hits’ that resulted in increased cell death in 
the LIMD1 deficient compared to proficient cells. With the exception of the 
topoisomerase-I inhibitor irinotecan, validation of the ‘hits’ from the drug screen across 
a range of drug concentrations in RCC11scr/RCC11 shLIMD1 cells was not successful.   
 
In both RCC11 shLIMD1 and RCC48 shLIMD1 cell lines and in the non-ccRCC cell 
lines, HELA and A549, where LIMD1 had been deleted using a CRISPR-Cas-9 gene 
editing system, dose-response curves demonstrated increased irinotecan sensitivity in 
the LIMD1 low/deficient cell lines compared to LIMD1 proficient control.  
 
In a panel of five ccRCC cell lines, two with high levels of LAW expression, CAKI2 and 
RCC11, and three with lower levels of LAW expression, RCC4, RCC12 and RCC912, 
increased sensitivity to irinotecan was observed in cell lines with low LAW expression 
compared to cell lines with high LAW expression. Taken together, this indicates that 
LAW expression levels and in particular LIMD1 loss may act as a predictive biomarker 
for irinotecan sensitivity in ccRCC lines and perhaps non-ccRCC lines in vitro, although 
further validation is required. 
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The sensitivity of the paired RCC11scr/shLIMD1 cell lines and RCC48 scr/shLIMD1 
cell lines to the multi-TKI sunitinib used in the first line treatment of ccRCC, and the 
mTOR inhibitor temsirolimus, used after failure of primary TKI therapy demonstrated 
no differences in sensitivity to either drug in association with LIMD1 loss compared to 
the LIMD1 proficient cells.    
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6.10 Discussion 
 
6.10. 1 Drug screening platforms in oncology 
 
This chapter demonstrates the use of a drug-screening platform to identify drugs with 
established anti-cancer activity, which may act in a synthetically lethal manner in 
association with LIMD1 loss. Irinotecan was validated as a ‘drug hit’ across a range of 
concentrations in two ccRCC and two non-ccRCC cell lines and an association between 
lower LAW expression and increased irinotecan sensitivity was observed in a panel of 5 
ccRCC lines. Given our observation that loss of LIMD1 is a feature of 50% of ccRCC 
cell lines in vitro and reduced LIMD1 expression is observed in 49.3% of ccRCC 
tumours, targeting LIMD1 low/deficient or LAW low/deficient tumours with 
irinotecan may represent an attractive biomarker driven treatment strategy.  
 
In oncology, drug screening offers a powerful tool for identifying novel anti-cancer 
drugs or identifying novel uses for existing anti-cancer drugs (Sharma, Haber et al. 
2010).  A key challenge in drug candidate screening is the accurate determination of 
human efficacy: toxicity and lack of clinical efficacy are the commonest causes of drug 
failure during drug development (Kola 2008) with fewer than 10% of novel cancer 
drugs identified in drug screening platforms progressing successfully through clinical 
development (Arrondeau, Gan et al. 2010). In addition, nearly 3% of all drugs that make 
it into the clinical setting are subsequently withdrawn due to adverse side effects (Kola 
and Landis 2004).    
 
The use of drug-libraries containing FDA-approved drugs with known cancer-
therapeutic efficacy and clearly identified toxicity profiles overcomes many of these 
problems and such an approach is likely to lead to a much higher hit rate. More recently, 
synthetically lethal approaches have been utilised to identify novel therapeutic drugs, or 
characterise the role of drugs within biomarker driven populations, such as the use of 
PARP inhibitors in patients with breast and ovarian cancers in association with BRCA1 
or BRCA2 mutations (Yap, Sandhu et al. 2011). Such an approach is particularly 
attractive as it minimises toxicity to healthy, non-cancer cells (Chan and Giaccia 2011).  
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6.10.2 Two-dimensional drug screening platforms. 
 
The use of a two dimensional drug-screening platform has a number of advantages. 
Such assays are amenable to automated/semi-automated high throughput screening, 
which can reduce screening cost and time and particularly with automated platforms can 
quickly generate accurate screen information, allowing a potential drug to be quickly 
evaluated as a drug of interest or disregarded as unlikely to demonstrate efficacy (Chen, 
Huang et al. 2011). Such early-stage in vitro cell-based assays, can provide a multitude of 
information on relevant biological end-points, including drug sensitivity, proliferation, 
motility, differentiation, cell shape, metabolism and protein expression/localisation 
(Chen, Huang et al. 2011).  
 
However, there are a number of limitations to such an approach. In our assays in a 96- 
well plate, only 800-2500 cells per well were plated and cells were plated manually. 
Seeding density may have a significant impact on the end point of drug sensitivity with 
small variations in seeding density significantly impacting on drug sensitivity. Errors may 
be caused by poor pipette delivery, and unintended differences in compound 
concentrations as a result of evaporation of the solvent. In addition, systematic across-
plate and within-plate column or row biases, typically known as edge effects are 
common (Malo, Hanley et al. 2006). When using 2µM of the drug library, drugging at 24 
and 72 hours could not be undertaken due to insufficient drug availability, particularly 
for drugs at the edges of the plates, where presumably greater evaporation had taken 
place. 
 
Once technical and procedural efficiencies have been optimised, the only way to 
minimise variability further is to take averages (the mean or median) across replicate 
measurements. Excellent reproducibility between the two repeats of the drug screen at 
1µM (Figure 6.1) was observed, however without further repeated measurements, 
activity estimates are difficult to quantify. In addition, further replicate measurements 
can provide estimates of variability and therefore be used in power analysis, to 
determine the likely probability of detecting a ‘true hit’ (Malo, Hanley et al. 2006). 
Increasing the number of replicates will reduce the number of false positives, without 
increasing the number of false negatives (Malo, Hanley et al. 2006).   
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Using a single drug dose has a number of limitations. The topoisomerase-I inhibitor 
topetecan resulted in significant death and very negative Z-scores in both RCC11 scr 
and shLIMD1 lines. Topetecan may still demonstrate synthetic lethality in association 
with LIMD1 loss in this cell line but the toxicity observed in both lines at this drug 
concentration with almost all cells killed may have obscured any association and it 
would be relevant to conduct a topetecan dose-response curve with the 
RCC11scr/shLIMD1 lines.  
 
Drugging with the drug library was undertaken at 24 and 72 and cell viability output 
read on day 6 using an ATP based Cell-Titer Glo™ assay. Different drugs within the 
library will have different pharmacokinetics and the optimal timing of both dosing and 
reading output is likely to vary from one drug to another. By varying both the dosing 
schedules and timing of output reading, different ‘hits’ from the screen may well have 
been identified.  
 
Another limitation is that the drug screen was undertaken in one paired cell line alone. 
This line was selected as it is VHL mutated, expresses high levels of all 3 LAW family 
members, high HIF1α and moderate HIF2α. It was therefore felt that to be 
representative of an aggressive ‘hypoxically deregulated’ ccRCC LIMD1 tumour 
phenotype. In addition, given that all 3 LAW family members are expressed, lentiviral 
knockdown of LIMD1 allowed for the effects of LIMD1 loss alone on drug sensitivity 
to be investigated.  
 
6.10.3 Statistical analysis of two-dimensional drug-screening platforms. 
 
Statistical analysis of the assay performance is critical in assessing such screen data. 
Recent articles have expressed concern about a lack of reproducibility of drug testing 
methodology and suggested standardisation of laboratory protocols (Hatzis, Bedard et 
al. 2014). The screen undertaken used the commonly held assumption that the data 
from the screen is normally distributed and a log transformation was then applied to 
achieve a better fit to the normal distribution. A more robust Z-score method was then 
calculated for each compound, which normalises each compound to the median value 
and median absolute deviation as opposed to the mean and the standard deviation. Such 
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an approach is commonly used and in particular is attractive as it diminishes the effects 
of outliers on the final analysis result (Chung, Zhang et al. 2008).  
 
Another method is to use the B score, sometimes considered a more robust analogue of 
the Z score (Brideau, Gunter et al. 2003). This method applies a two-way median polish 
to account for row and column effects of the plate, and the resulting residuals within 
each plate are divided by their median absolute deviations to standardise for plate-to 
plate variability.  This approach has the advantage that it is non-parametric and 
therefore makes minimal distribution assumptions, minimises measurement biases 
related to position and is resistant to statistical outliers (Malo, Hanley et al. 2006, 
Mpindi, Swapnil et al. 2015).  
 
Mpindi et al concluded that for high throughput screening experiments with high hit 
rates, it is best to scatter controls throughout the plate and normalise using a polynomial 
least squares fit method, to reduce edge effects (Mpindi, Swapnil et al. 2015). For the 
drug library described most controls were within column seven of twelve on the 96-well 
plate and given that the library was already plated prior to use, it would not have been 
possible to change the location of the control wells.  
 
6.10.4 Three-dimensional assays to more closely mimic the in-v ivo  environment.  
 
2-D in vitro assays offer a number of advantages, but as outlined, do not provide 
sufficient data for understanding drug performance in vivo (Astashkina, Mann et al. 
2012). In particular an in vitro assay should produce reliable, biomedically relevant 
information that mimics the phenotype of cells within the target tissue (Mazzoleni, Di 
Lorenzo et al. 2009).  By using a more in vivo-like, three-dimensional environment, a 
more robust screening platform that more closely resembles the in vivo environment can 
be created. For example cells grown in 2D versus 3D environments demonstrate 
significant differences in cell morphology, proliferation, gene expression, signalling and 
differentiation (Schmeichel and Bissell 2003). Organotypic, organ/explant and 3-D 
cultures can overcome some of these limitations (Astashkina, Mann et al. 2012). High 
throughput methods for 3-D models can be employed although are less straightforward 
than for 2-D models. For example using 3D microarray culture for drug assays, where 
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microarray spots are printed on a modified glass microscope slide or chip (Meli, Jordan 
et al. 2012).   
 
6.10.5 Genomic heterogeneity and its impact on drug screening 
 
Genomic heterogeneity has a significant impact on drug sensitivity and in ccRCC this 
may related to both intra-patient and inter-patient heterogeneity, reflecting heterogeneity 
both within the primary tumour and within metastatic deposits (Gerlinger, Catto et al. 
2015). In non-small cell lung cancer (NSCLC) for example, the EGFR TKIs gefitinib 
and erlotinib, demonstrate significant efficacy in patients with activating EGFR 
mutations, however only around 10% of patients with adenocarcinomas have such 
mutations (Kris, Natale et al. 2003). In metastatic ccRCC, driver mutations not shared 
by the primary tumour may drive metastatic spread and contribute to resistance to 
targeted therapy (Gerlinger, Rowan et al. 2012).  
 
6.10.6 Irinotecan as a drug demonstrating synthetic lethality in association with 
LIMD1 loss 
 
Despite the limitations of the drug screen outlined, the identification of irinotecan as a 
potential hit appears to represent a true result. The difference in irinotecan drug 
sensitivity between the RCC11 scr and shLIMD1 line did not quite meet statistical 
significance when validated across a range of drug concentrations (Figures 6.8 and 
6.10) but the differences were statistically significant in the RCC48 shLIMD1 cells 
compared to RCC48 scr line (Figures 6.9 and 6.10) and in both the HELA CRISPR-
Cas-9 LIMD1 and A549 CRISRP-Cas-9 LIMD1 proficient and deficient cell lines, 
where LIMD1 loss was consistently associated with increased irinotecan sensitivity 
(Figures 6.11, 6.12).  Additional work undertaken by Miss Katy Davidson demonstrated 
that in the RCC lines CAKI2 and RCC11 where LAW expression is high, reduced 
sensitivity to irinotecan is observed compared to the RCC lines RCC4, RCC12 and 
RCC912, where LAW expression is low (Figure 6.13).  
 
Irinotecan is a semisynthetic analogue of captothecin that causes S-phase specific cell 
killing through its interaction with cellular Topo-I-DNA complexes (Xu and Villalona-
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Calero 2002). Specifically, topoisomerases cleave and reseal the phosphodiester 
backbone of DNA by forming covalent enzyme-DNA linkages, allowing the passage of 
single and double strand DNA breaks through the nick. Topo-1 binds to single strand 
DNA breaks and the Topo-1 DNA complex leads to irreversible arrest of the 
replication fork and cell death upon collision with the advancing replication form, as 
well as signalling the presence of DNA damage to an S-phase checkpoint mechanism 
and G2 arrest/delay (Solary, Bertrand et al. 1994, Webb and Ebeler 2003).  Multiple 
mechanisms determine irinotecan sensitivity, including cellular drug accumulation, 
related to active drug efflux, levels of Topo-1 expression, variations in enzyme levels 
involved in the conversion of irinotecan to its more active form SN-38, alterations in 
cellular response to drug-Topo-1-DNA complex formation and variations in the 
activation of the transcription factor NFκB by DNA damage (Xu and Villalona-Calero 
2002).  
 
It is difficult to know why increased irinotecan sensitivity is seen in association with 
LIMD1 loss/depletion. Several studies have identified an association between hypoxia 
and chemo-resistance in a number of tumour types, mediated through the Ajuba 
signalling pathway. In hepatocellular carcinoma (HCC), under conditions of hypoxia, 
HCC cells are highly resistant to topoisomerase inhibitors including the active 
metabolite of irinotecan, SN38 (Cai, Liu et al. 2014). It had previously been 
demonstrated that HIF1 plays a critical role in chemo-resistance in HCC cells (Jiao and 
Nan 2012, Tong, Li et al. 2013). Dai et al however showed that the Yes-Associated 
Protein (YAP), an oncoprotein closely correlated with the development of HCC (Xu, 
Yao et al. 2009) played a critical role in mediating resistance to SN38, with hypoxia 
inhibiting LATS1 mediated phosphorylation of YAP in a HIF1 independent manner, in 
turn inducing YAP nuclear translocation and YAP accumulation with subsequent 
activation of its downstream target genes, (Dai, Zhuang et al. 2016) including genes that 
promote tumour progression and or metastasis (Zeng and Hong 2008). Notably in 
association with nuclear YAP translocation in hypoxia, HCC cells were much less 
sensitive to SN38 in hypoxia compared to normoxia, and this effect was abrogated upon 
YAP depletion (Dai, Zhuang et al. 2016).  In addition, Dai et al used statins, which 
inhibit the mevalonate metabolic pathway and are used to treat hypercholesterolaemia to 
inhibit YAP nuclear translocation which in turn re-sensitised HCC cells to SN38 in 
hypoxia (Dai, Zhuang et al. 2016).  
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The Ajuba LIM proteins are negative regulators of the Hippo signaling pathway (Das 
Thakur, Feng et al. 2010). Ajuba, LIMD1 and WTIP strongly associate with LATS1/2 
and in mammalian cells antagonise the phosphorylation of YAP (Das Thakur, Feng et 
al. 2010).  Work by Zhao et al has demonstrated that in sub-confluent non-contacted 
cells, Ajuba LIM proteins are predominantly cytosolic, whilst YAP is nuclear and cells 
proliferate but once confluent, YAP is phosphorylated and is translocated to the cytosol 
whilst Ajuba proteins are recruited to adherens junctions (Zhao, Wei et al. 2007) 
potentially releasing LATS and enabling Hippo pathway mediated YAP phosphorylation 
with subsequent cell inactivation and growth arrest. Therefore LAW depletion can 
potentially increase active YAP, with increased YAP nuclear translocation and 
downstream oncogene target activation. Given the observation of reduced sensitivity to 
SN38 in association with nuclear YAP translocation in HCC, it might however be 
hypothesised that LAW depletion might reduce irinotecan sensitivity in ccRCC, the 
opposite of the results observed. 
 
One explanation for increased irinotecan sensitivity in LIMD1 depleted cells may come 
from work by Chen et al in colorectal cell lines. In a study evaluating multi-drug 
resistance (MDR) in the colorectal carcinoma cell lines Colo205 and HCT-8, established 
by exposure of the primary cell lines to increasing doses of 5-fluorouracil (5-FU) over a 
year, LIMD1 expression was found to be increased in the MDR cell lines compared to 
their respective parental cell line.  LIMD1 siRNA constructs transfected into these 
MDR cell lines were able to abrogate some aspects of the MDR phenotype, almost 
completely re-sensitising the cells to 5-FU and significantly increasing the proportion of 
cells undergoing apoptosis compared to the MDR cell lines. The authors had previously 
demonstrated that resistance of these MDR cell lines was mediated through the 
expression of the multidrug transporter gene MRP1 (ABCC1). The association between 
LIMD1 upregulation and multi-drug resistance was not explored but the authors 
hypothesised that this was related to the function of LIMD1 as an adapter-linker 
protein, shuttling between the nucleus and cytoplasm and perhaps contributing to 
increasing cell drug efflux (Chen, Zhu et al. 2014).  
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6.11 Future work 
 
6.11.1 Further experiments to investigate the role of irinotecan as a potentially 
synthetic lethal drug in association with LIMD1 loss 
 
Further experiments are required to investigate the role of irinotecan as a potentially 
synthetic lethal drug in association with LIMD1 loss. We have looked at a small panel of 
five ccRCC cell lines and correlated irinotecan sensitivity with LAW expression. This 
should be extended to include a larger panel with variable LAW expression. In addition 
we have cell lines in which a CRISPR-Cas-9 system has been used to selectively delete 
Ajuba and WTIP expression and this will provide a useful screening platform to further 
investigate the effects of loss of LAW on irinotecan sensitivity and assess if 
Ajuba/WTIP loss results in a similar phenotype. Additional assays measuring irinotecan 
effects on cell growth can also be undertaken such as colony assay formation, which 
determines the ability of a cell to proliferate indefinitely and thereby retain its 
reproductive ability to form a large colony or clone (Riss, Moravec et al. 2004). Short-
term cell viability assays, using an ATP based assay of cell viability, such as Cell Titer-
Glo™ or the MTT assay which measures the ability of cells to convert MTT into a 
purple coloured formazan product as a result of reduced NADH activity (Riss, Moravec 
et al. 2004) rely predominantly on mitotic linked death for differences in cell viability to 
be observed but many drugs may affect proliferation/cell cycle block but have no 
impact on clonogenic capacity after drug-withdrawal (Citrin 2016),  this may be of 
particular relevance for RCC where disease stabilisation/control is often the main aim 
of treatment.  
 
Irinotecan is a known inhibitor of topoisomerase-I but it is not clear that in this screen 
differences in sensitivity associated with LIMD1 loss were as a consequence of 
topoisomerase-I activity.  The expression of topoisomerase-I in the paired LIMD1 
proficient/deficient cell lines should be compared. Although we attempted to 
characterise expression, difficulties with optimising the antibody for Western Blot 
analysis meant that levels were not characterised. mRNA levels could also be compared 
using RT-PCR.  
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The topoisomerase-I inhibitor topetecan was associated with significant cell death in 
both RCC11 scr and RCC11 shLIMD1 lines in the drug screen with similar Z-scores in 
both cell lines. This however, as outlined, does not mean that topetecan does not 
potentially demonstrate synthetically lethal in association with LIMD1 loss and dose-
response assays should be undertaken in paired LIMD1 proficient/deficient cell lines. 
Validation with topetecan would strongly suggest that the mechanism of synthetic 
lethality is related to topoisomerase-I inhibition. In addition, by using siRNAs to 
knockdown topoisomerase I and assays where topoisomerase-I is knocked down and 
re-expressed in LIMD1 deficient/proficient cell lines, with and without irinotecan 
drugging, topoisomerase-I as a likely target for synthetic lethality in association with 
LIMD1 loss can be further investigated. 
 
No topoisomerase-II inhibitors were identified as hits in the synthetic lethality screen. 
Topoisomerase II cuts both strands of a double stranded DNA molecule in an ATP-
dependent manner to repair double strand breaks (Nitiss 2009). Topoisomerase-II 
inhibitors act to increase levels of covalent topoisomerase II-cleaved DNA complexes 
acting either as therapeutic poisons or inhibitors, through the disruption of the catalytic 
turnover of the complex (Burden and Osheroff 1998). Given the limitations of a drug 
screen and the high potential for missing drug therapeutic hits, it would be relevant to 
carry out drug-response curves in paired LIMD1 proficient/deficient ccRCC lines with 
topoisomerase-II inhibitors.  
 
Other relevant assays include the assessment of topoisomerase-I activity in the paired 
LIMD1 proficient/deficient cell lines. Topoisomerase I facilitates the relaxation of 
supercoiled DNA, which has a different electrophoretic mobility from DNA that is 
completely relaxed, i.e. not supercoiled. Using E.coli plasmid DNA, which is negatively 
supercoiled, the amount of active topoisomerase-I can be determined on an agarose gel 
with ethidium bromide staining (Nitiss, Soans et al. 2012).  
 
Given the effects of topoisomerase-I activity on cell cycle, with the Topo1-DNA 
complex initiating activation of an S-phase checkpoint mechanism and G2 arrest/delay 
(Solary, Bertrand et al. 1994) it would be interesting to investigate the effects of 
irinotecan on cell cycle in the LIMD1 proficient/deficient cell pairs using for example 
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propidium iodide staining and FACS analysis. In addition, given that abnormal cellular 
replication is associated with the accumulation of replication-associated double strand 
DNA breaks (DSB) and the close association between cell cycle control and the DNA 
damage response pathway (Shaltiel, Krenning et al. 2015), it would be relevant to look at 
phosphorylation of H2AX (γH2Ax), considered one of the earliest indications of a DSB 
(Paull, Rogakou et al. 2000), in combination with cell cycle analysis.  
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 Final Discussion 
 
Representing 5% and 3% of all adult malignancies in men and women respectively 
(Levi, Ferlay et al. 2008, Ljungberg, Campbell et al. 2011) (Rathmell and Godley 2010), 
the incidence of RCC is continuing to increase particularly in the Western World where 
environmental factors such as hypertension and obesity increase relative risk (Ljungberg, 
Campbell et al. 2011). RCC incidence trends worldwide have started to show signs of 
plateau and more strikingly, cancer mortality rates have levelled or shown signs of 
decline in some western countries (Ljungberg, Campbell et al. 2011). Whilst this is in 
part related to an increase in the proportion of small tumours diagnosed incidentally and 
a downward shift in tumour stage, all stage mortality has started to fall (Gill, Aron et al. 
2010, Ljungberg, Campbell et al. 2011). Nonetheless, the prognosis for many patients 
with metastatic RCC remains poor (Heng, Xie et al. 2013).  
 
The commonest RCC subtype, ccRCC represents around 80% of all RCC types (Frew 
and Moch 2015). Greater understanding of tumour biology has shown that beyond the 
seminal genetic alteration of VHL, ccRCC tumours are extremely heterogeneous. 
Notably, three of the most commonly deregulated genes PBRMI, BAP1 and SETD2 are 
located close to VHL on chromosome 3p and mutation of BAP1 or SETD2 is 
associated with worse clinico-pathological outcomes (Hakimi, Pham et al. 2013, Sato, 
Yoshizato et al. 2013, Frew and Moch 2015). Indeed ccRCC cancers are increasingly 
referred to as ‘diseases of chromosome 3p.’ 
 
The sequential use of TKIs that target angiogenesis and/or mTOR inhibitors can 
significantly improve progression free survival and overall survival in metastatic ccRCC 
such that median overall survival now stands at around 40-months (Heng, Xie et al. 
2013) and novel therapies may increase this further. Despite this progress, durable 
responses are exceedingly rare.  Some of the escape mechanisms, particularly cMET 
upregulation and FGF activation have driven the development of novel targeting 
strategies that target these pathways with cabozantinib targeting both cMET and VEGF 
TKI pathways and lenvatinib inhibiting VEGF and FGF pathways (Karakashev and 
Reginato 2015).    
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The paucity of durable responses to targeted therapies stimulated interest in the 
development of immune modulators for effective targeting of RCC.  Observations that 
circulating cytokines, chemokines and tumour infiltrating lymphocytes were commonly 
observed in ccRCC confirmed a complex interaction between the tumour and host 
immune system (Porta, Bonomi et al. 2007). RCC can effectively subvert the host 
immune response, particularly through the increased expression of immunosuppressive 
cytokines and the upregulation of immuno-suppressive T-regulatory cells (Noessner, 
Brech et al. 2012). Complex feedback mechanisms involving immune checkpoint 
molecules inhibit immune system activation of both the innate and adaptive systems 
(Topalian, Drake et al. 2015). RCC can up-regulate cell surface immune checkpoint 
ligands that block T cell function in response to inflammation, a process known as 
adaptive immune resistance (Noessner, Brech et al. 2012). 
 
The use of high dose IL-2 confirmed that modulating the immune response in 
metastatic RCC could be used to effect tumour response, although durable responses 
are observed in only a small subset of patients and in clinical trials this did not translate 
to an increase in overall OS. In addition toxicity is very significant (Coppin, Porzsolt et 
al. 2005). Checkpoint blockade with PD-1 and PDL-1/2 blocking drugs alone or in 
combination with CTLA-4 blockade offers an exciting new therapeutic avenue 
(Topalian, Drake et al. 2015). Results from the Checkmate 214 Study presented at 
ESMO in September 2017 demonstrated a significant improvement in PFS for poor and 
intermediate prognosis patients with PDL-1 positive tumours receiving combination 
immunotherapy with nivolumab, a PD-1 inhibitor, and ipilumimab, a CTLA-4 inhibitor, 
compared to VEGF-targeted therapy with sunitinib (22.8 months versus 5.9 months) 
(Rexer, Steiner et al. 2017).  
 
Despite these successes, many patients present with primary resistance to VEGF 
targeted therapies and immunotherapy and most initial responders will ultimately 
develop progressive disease (Powles, Chowdhury et al. 2011, Escudier, Porta et al. 
2014). The use of clinical prognostic groups such as the Heng criteria stratifies patients 
into prognostic groups but does not predict response to therapy (Heng, Xie et al. 2013). 
Robust predictive biomarkers are required to help clinicians identify drugs 
demonstrating maximal benefit for individual patients whilst minimising toxicity.  
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Many potential biomarkers have been identified in ccRCC but most do not help patient 
selection.  Most biomarkers were assessed after patients had started treatment and most 
targeted therapies for metastatic RCC were approved on the basis of clinical trials of an 
unselected patient population and not using a molecularly stratified biomarker guided 
approach (Gulati, Martinez et al. 2014).  Much of the published biomarker data is 
retrospective, based on small studies and results from such studies are often 
contradictory.   
 
A further difficulty in the identification of biomarkers is tumour heterogeneity, 
particularly of relevance in the development of drug resistance, where drug selection 
pressures may facilitate the faster growth of drug resistance clones, ultimately resulting 
in further metastasis and treatment failure. (Gerlinger, Rowan et al. 2012)   
 
LIMD1 is a 3p21.3 encoded tumour suppressor with a range of established functions 
including the regulation of the hypoxic response through HIF1α regulation (Foxler, 
Bridge et al. 2012), and regulation of miRNA silencing (Bridge, Shah et al. 2017). Given 
LIMD1’s critical role in the regulation of pathways commonly deregulated in ccRCC 
and location on 3p, it was hypothesised that loss could be an important driver of 
tumourigenesis in ccRCC. Recent work by Thiesen et al has demonstrated that CNA of 
LIMD1 are common, occurring in 58.3% of ccRCC tumours analysed and occurring 
independently of CNA at other 3p loci (Thiesen, Steinbeck et al. 2017).   
 
Ajuba and WTIP are closely homologous LIM-domain proteins with overlapping roles 
identified (Kadrmas and Beckerle 2004): both for example play a role in the regulation 
of the hypoxic response and microRNA silencing (Foxler, Bridge et al. 2012, Bridge, 
Shah et al. 2017). Ajuba is an important regulator of the Hippo signalling pathway, 
deregulation of which is frequently implicated in tumourigenesis (Das Thakur, Feng et 
al. 2010, Tanaka, Osada et al. 2015). All three proteins have not been characterised in 
ccRCC.  
 
Initial work demonstrated that LIMD1 loss was common both in vitro and in vivo, in 88% 
of cell lines and in 49% of ccRCC samples compared to matched adjacent tissue. Even 
higher rates of Ajuba loss were observed: in 92% of cell lines analysed and in 76% of 
ccRCC samples.  Interestingly WTIP loss was not common either in vitro, or in vivo.  In 
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vitro, 33% of cell lines demonstrated less WTIP staining and in vivo 63% of tumours 
actually demonstrated an increase in total WTIP staining. Subcellular WTIP localisation 
however did appear to be relevant with 49% of tumours demonstrating no nuclear 
staining compared to matched control tissue.  
 
Staining tissue samples derived from a large clinical trial failed to demonstrate any 
association between LIMD1 levels and tumour grade/stage, nor was an association 
between staining and PFS or OS observed. For Ajuba an association between tumour 
stage and reduced staining was observed, whilst for WTIP no association between 
staining and tumour stage/grade or PFS/OS was observed. Thiesen et al demonstrated 
that CNA alterations of LIMD1 were more commonly observed in lower grade tumours 
(Thiesen, Steinbeck et al. 2017).  
 
Although LIMD1, Ajuba and WTIP levels did not appear to be prognostic in this 
cohort with the exception of Ajuba staining and tumour stage, loss of expression could 
still be predictive of response to therapy. The concept of synthetic lethality is being 
exploited in oncology to identify drugs that specifically target cancer cells. In cancer cells 
where a particular cancer-specific gene inactivation has occurred, targeting a second 
gene may result in cancer-specific cell death whilst sparing non-cancerous cells (Nijman 
2011).  
 
Using a drug library containing 584-cancer therapeutic drugs, paired LIMD1 proficient 
and deficient ccRCC lines were screened for drugs that demonstrated synthetic lethality 
in association with LIMD1 loss. This identified irinotecan as a potential synthetically 
lethal drug hit, associated with increased death in the LIMD1 deficient compared to 
proficient control and further validated as demonstrating increased cell death in 
association with LIMD1 loss in two ccRCC lines across a range of drug concentrations 
as well as in HELA cells and a lung adenocarcinoma line, A549. Using a panel of 6 
ccRCC lines, ccRCC lines with reduced LAW expression demonstrated increased 
sensitivity to irinotecan compared to those expressing higher levels of LAW proteins.  
 
Sequencing strategies in mccRCC remain to be fully defined and the paradigm for 
treating ccRCC is constantly being re-evaluated. Given the molecular complexity of this 
tumour type, a ‘one size’ fits all approach is not appropriate and our understanding of 
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this complex tumour type is increasing all the time. Chemotherapy currently plays a 
relatively limited role in the treatment of metastatic ccRCC: most ccRCC tumours 
demonstrate a degree of chemotherapy resistance (Tobe, Noble-Topham et al. 1995, 
Karakashev and Reginato 2015) and novel targeted agents that are associated with 
superior efficacy have largely replaced such a treatment modality. Nonetheless, 
chemotherapy does have a limited role particularly for aggressive tumour types with 
sarcomatoid differentiation and a study evaluating combination chemotherapy with 
irinotecan, cisplatin and mitomycin-C demonstrated a response rate of 64% (Shamash, 
Powles et al. 2005).  
 
Based on our data so far, it could be hypothesised that loss of LAW family members 
could increase sensitivity to irinotecan chemotherapy in ccRCC and perhaps in other 
tumour types. Irinotecan is an attractive drug to investigate further in a clinical setting in 
association with loss of LAW family members, as it is a commonly used chemotherapy 
drug with a well-understood toxicity profile. In addition in several colorectal cell lines, 
LIMD1 upregulation is associated with chemotherapy resistance and this resistance was 
abrogated by transfection with siRNA LIMD1 constructs (Chen, Zhu et al. 2014).  
 
This data presented is preliminary and significant further in vitro validation is required as 
well as further experiments to determine the potential mechanism associated with 
synthetic lethality in association with LIMD1 loss. Moving forward, animal studies with 
in vivo xenografts analysis demonstrating a reduction in tumour volume in LIMD1 
knockout/low-expressing xenografts compared to control would be required and 
patient derived xenografts (PDX) models could be used to demonstrate that 
endogenous LIMD1 levels determine irinotecan sensitivity in vivo. Funding has been 
obtained for such work.  
 
 Perhaps given the efficacy of novel targeted agents including immunotherapy agents, if 
irinotecan is evaluated in a clinical setting, a more rational approach would be to 
combine it with VEGF-targeting agents such as sunitinib or to give it in combination 
with a drug targeting the PD-1/PDL-1 axis such as nivolumab in patients stratified for 
low LAW expression. Another approach could be to target patients with reduced LAW 
expression who had progressed through multiple lines of therapy including VEGF 
targeting drugs and immunotherapy agents. It would be important to investigate genetic 
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heterogeneity with respect to LAW expression in such a patient cohort and what effect 
this heterogeneity had on sensitivity to irinotecan: the use of circulating blood 
biomarkers such as circulating tumour cells and cell-free plasma DNA may however 
provide a non-invasive real time surrogate for tissue based biomarkers and overcome 
some of the issues associated with tumour heterogeneity.  
 
Given the need for effective biomarker identification and paucity of both prognostic 
and predictive biomarkers that have been externally validated in ccRCC, our preliminary 
results are encouraging and with further validation experiments and clinical trial 
evaluation could represent a further stratified approach for the treatment of mccRCC. 
Given our validation of the drug screen demonstrating increasing response to irinotecan 
in HELA and the lung adenocarcinoma line A549 as well as in ccRCC lines in 
association with LIMD1 loss, such an approach could suggest that LIMD1 loss could 
predict the response to a target therapy independently of the tumour histology.  
Targeted therapy for such mutations/molecular markers are being evaluated in ‘Basket 
trials’, screening patients across tumour types for targetable mutations/deregulated 
pathways and treating with drugs targeting such pathways. 
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